
Academic and Clinical Perspectives Ontario Centre Of Excellence In Environmental Health

Chronic Complex Conditions

**Myalgic Encephalomyelitis/Chronic Fatigue Syndrome,
Fibromyalgia Environmental Sensitivities/Multiple Chemical Sensitivity**

*Funded by Ontario Ministry of Health and Long Term Care
and Ontario Trillium Foundation*

Compendium 3/4 of the Business Case for an OCEEH

Acknowledgments to Volunteer Reviewers

Medical Advisory Committee:

Lynn Marshall MD, FAAEM, LMCFP
Kathleen Kerr MD, Dip Env Health, MCFP
Riina Bray BSc, MAsc, MD, FCFP, MHSc
Dona Bowers MD, FCFP- Somerset West CHC, Medical Project Coordinator

Expert Reviewers:

Jennifer Armstrong BSc, MD, DIBEM, FAAEM- Medical Director, Ottawa Environmental Health Clinic
Alison Basted MD, FRCPC- Medical Director, Complex Chronic Disease Program, B.C. Women's Hospital and Health Centre
Howard Hu ScB, MD, MPH, ScD, Dean, Dalla Lana School of Public Health, U. of Toronto
Margaret Parlor, Statistical Analyst, President National ME/FM Action Network

**John Molot MD FCFP
October 2013**

Table of Contents

Executive Summary	6
I Accumulating Evidence of Chronic Complex Conditions Relatedness to the Environment	
▪ Introduction	13
▪ Environmental Health	15
▪ Chronic Complex Conditions	15
▪ Genetics and the Environment	17
▪ Epigenetics	18
▪ Early and Late Exposures	18
▪ Body Burden	21
▪ Linking Divergent Chronic Conditions and the Environment	22
○ Detoxification	22
○ Cellular Organelles	22
○ Oxidative Stress	23
○ Changes in Cell Function	23
○ Systemic inflammation	23
▪ Reductionism, Systems Biology and Systems Medicine	23
▪ Summary	24
II Increasing Prevalence and Awareness of Three Chronic Complex Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia (FM), and Environmental Sensitivities/Multiple Chemical Sensitivity (ES/MCS)	
▪ Introduction	26
▪ ME/CFS	26
▪ FM	34
▪ ES/MCS	40
For each:	
○ Description and Prevalence, including Women and Children	
○ Diagnostic Criteria	
○ Pathological Mechanisms	
○ Comorbidity	
○ Management Strategies	
○ Disability and Prognosis	
▪ Functional Status	48
▪ Psychologization	49
▪ Interventions and Prognosis for ME/CFS, FM, and ES/MCS	51
▪ Summary	52
III Need for Environmental Health Education and Government-funded Canadian Environmental Health Clinics	
▪ Current Medical Education	54

▪ Jurisdictional Review of Community Health Centres	55
▪ Ontario College of Family Physicians Consideration of a Centre of Excellence in Environmental Health	56
▪ Government-funded Canadian Environmental Health Clinics	
○ British Columbia	57
○ Nova Scotia	58
○ Ontario	59
▪ Summary	63
IV Ontario Centre of Excellence in Environmental Health- Principles	
▪ Meaning of Centres of Excellence	64
▪ Networks of Centres of Excellence	65
▪ Integration of Primary Care and Public Health in the OCEEH	66
▪ Evidence-based Practice of Medicine	67
▪ Hub and Spokes Model	70
▪ Jurisdictional Review of Expert Centres	71
▪ Patient- and Person-centred Care	71
○ Chronic Care Model	71
○ Self-management	72
○ Patients' Needs and Preferences	72
○ Ongoing Relationships with Staff	73
▪ Interprofessional Team	74
○ Interprofessional Collaboration	74
○ Shared Decision-making	74
○ Individualized Treatment Program	75
▪ Summary	75
V Function and Overview of Services in Hub and Spokes	
▪ Evolution	77
▪ The Hub	77
○ Association with a Teaching Hospital	77
○ Association with Academia	79
○ Location	79
○ Physical Requirements	79
○ Responsibilities	80
○ Staff Required for Clinical Services	80
○ Staff Required for Hub Administrative Support	81
○ Staff Required for Research	81
○ Assessment, Treatment and Research	82
○ Specialized Equipment and Space	82
▪ The Spokes	83
○ Responsibilities	83
○ Staff Required for Spokes Clinical Support	84
○ Staff Required for Spokes Administrative Support	84
○ Education of Staff	84
○ Physical Requirements	85

▪ Integration of Responsibilities of Hub and Spokes	85
○ Health Services	85
○ Social Services and Policy Advancement	86
○ Education	86
○ Research	86
▪ Assessments	87
○ Introduction	87
○ Laboratory Assessments	87
○ Additional Laboratory Tests	88
○ Experts' Opinions	88
○ Assessments of Function	90
○ Neuropsychological Testing	91
○ Other Medical Tests	92
○ Potential Diagnostic Tests	92
▪ Treatment	92
○ Present Guidelines and Treatment	92
○ Future Guidance	93
○ Organ Dysfunction	94
○ Central Nervous System	94
- Biofeedback	94
- Neural Biofeedback	95
○ Gastrointestinal System	95
○ Immune System	96
○ Endocrine System	97
○ Treatment on a Cellular Level	98
○ Specifics for ME/CFS	98
○ Specifics for FM	99
○ Specifics for ES/MCS	100
○ Lowering the Xenobiotic Load	101
▪ Summary	101

VI Building the OCEEH

▪ Introduction and Steps Required	103
▪ Create the Foundation	104
○ Increase EHC Clinical Staff	104
○ Begin Training of Fellows	104
○ Organize Research Projects for Fellows	104
○ Organize Workshop of Experts to Develop GRADE Recommendations	104
○ Upgrade and Refine Methods for Data Gathering	104
○ Develop Specific Hub Agreements	105
○ Prepare Education Program for Spokes	105
○ Accreditation in Environmental Health	106
○ Develop Updated Hospital Guidelines	106
▪ Expand the Foundation	106
○ Begin Education of Spoke Health Care Providers	106

○ Develop Education Modules for Medical Students/Residents	107
○ Develop Education Modules for Nursing and Other Health Professionals	107
○ Organize Workshop of Experts to Set Research Agenda, Evaluative Criteria and Initiate Research Collaborations	107
○ Develop Programs for University Health Sciences	107
○ Develop Education Modules for Patients	108
○ Develop Modules for Self-management	108
○ Develop Safe Rooms in spokes	108
○ Create Temporary Lodging for Patients Attending Hub	108
○ Initiate Programming	109
○ Begin Provision of Care in Spokes	109
○ Develop teleconference and e-consultation Services for Consultation in Remote Areas	110
○ Further Develop Research Agenda and Research Associates	110
○ Apply for Research Funding	110
○ Initiate Research Programs	110
○ Create an OCEEH Website	111
▪ Maintenance and Expansion	111
▪ Summary	111

References 113

Appendices

Appendix A- Overlapping Diagnoses for 23 Chronic Conditions Cohorts

Appendix B- ES/MCS Status Report: Advances in Knowledge and Current Service Gaps

Appendix C- SEEDS of Health

Tables

Table 1- CIHR Funding for Chronic Health Conditions	14
Table 2- Chemical Pollutants Most Frequently Linked to Early Exposures and Later Chronic Diseases	19
Table 3- Comparison of ME/CFS diagnostic Criteria	30
Table 4- Oxidative Stress Biomarkers	89
Table 5- First Steps to Building the OCEEH	12 & 112
Table 6- Next Steps in Building the OCEEH	12 & 112

Figures

Figure 1- Determinants of Health	17
Figure 2- Functional Status of EHC Patients vs Canadian Norms	48
Figure 3- Exhaustion	60
Figure 4- Adaptation	

Executive Summary

Introduction

Whereas previously there was little evidence of specific association between many environmental exposures and health problems, now there is mounting evidence of links influenced by genetics and epigenetics in all the chronic complex conditions that have been studied. Understanding is accumulating of potentially related mechanisms and relationships.

While the science is plentiful and dense to read, the implications are very important.

This report includes the following sections.

1. Sections I-II:

A broad-based scoping, but non-systematic, review of the scientific literature related to environmental associations with chronic complex health conditions (Section I) and focused on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia (FM), and Environmental Sensitivities/Multiple Chemical Sensitivity (ES/MCS) (Section II).

The literature reviewed was, in most part, published by the United States National Library of Medicine in Medline, supplemented on occasion by credible reports by government agencies, professional associations and environmental/patient support organizations.

2. Section III-VI:

An overview of what might be developed to build the Centre of Excellence on the foundation of the Environmental Health Clinic to prevent chronic environmentally linked conditions, and to care for people with ME/CFS, FM and ES/MCS as close to home as possible, as well as broad expansion of education/health promotion and research (Sections III-VI).

I Accumulating Evidence of Chronic Complex Conditions Relatedness to the Environment

Chronic complex conditions are the leading cause of death and disability worldwide. Almost 80% of Ontarians over the age of 45 have a chronic condition, and 70% of them have more than one. Although poorly managed single conditions can be complex, multimorbidity usually contributes to continuing functional decline, poor quality of life, disability and high personal and system health care costs.

Environmental health, according to Public Health Ontario, encompasses the assessment and control of the physical, chemical, biological, social and behavioural factors in the environment that influence health and disease occurrence. According to the World Health Organization, factors in the environment have both direct pathological and often indirect effects on health and wellbeing from housing, urban development, land use and transport.

While there are genetic susceptibility factors, environmental factors influence 70 to 90% of chronic disease risk. Pollution exposure influences epigenetic change, which increases genes' susceptibility to turn on and off in response to environmental factors. That then increases the

risk, particularly in those individuals with genetic susceptibility factors, to develop environmentally-linked diseases, such as allergies, autoimmune disorders, asthma, diabetes, cardiovascular disease, neuropsychological development disorders and autism in children, as well as progressive neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases.

Chronic conditions such as ME/CFS, FM, and ES/MCS appear to also be linked to the environment in these ways and are increasing in prevalence. These conditions commonly overlap with each other and other chronic conditions and are challenging to manage. However, in spite of high rates of unmet health needs and high rates of disability, with considerable health care dollars being spent, there is almost no focus on research to be able to diagnose, treat and prevent these conditions more efficiently.

Toxic chemicals/agents enter the body not only from exogenous sources (air, water, diet, drugs, consumer products and radiation) but also from endogenous processes, including byproducts of our natural metabolism, inflammation, existing diseases, infections, and gut flora. Thus, the relevant 'environment' is the body's internal chemical environment, i.e. what's inside it.

The common pathological mechanisms of all these diseases and conditions include a burden to detoxification systems, damage to cellular organelles (metabolic subunits), including the energy-generating mitochondria, as well as oxidative stress, reduced cell function, with increased cell death or proliferation, and systemic inflammation, which makes other chronic conditions (multimorbidity) more likely.

The traditional reductionist approach to understanding and treating chronic complex conditions is inadequate because of dysfunction of multiple organ systems and comorbidity.

A systems medicine approach, that includes environment as a determinant of health, recognizes the interactions of organs, cells, genetics and epigenetics, oxidative stress and systemic inflammation in response to exposure to environmental agents.

II Increasing Prevalence and Awareness of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia (FM) and Environmental Sensitivities/Multiple Chemical Sensitivity

The 2010 Canadian Community Health Survey (CCHS) reported that the number of Canadians who had a diagnosis by a health professional of ME/CFS, FM and ES/MCS has increased markedly since 2005. The prevalence of CFS increased by 23%, FM by 13% , and ES/MCS by 34%.

ME/CFS affects from 0.5 to 3 percent of the population and recovery rates are quite low - around 6%. The dominating complaint is severe, chronic fatigue present for at least 6 months, 3 months in children, which is made worse by exertion, is not substantially relieved by rest, and the post-exertion recovery time is prolonged. It affects women six times the rate of men and it is unknown how often it occurs in children. There are various definitions, which influence estimates of prevalence, diagnosis and guidelines for treatment. Two day cardiopulmonary exercise testing repeated 24 hours after the first test demonstrates reduction in maximal aerobic

capacity, aerobic threshold and increased oxidative stress, and so exercise should be at an individual's own pace. There are extensive alterations in gene expression with at least 7 different genetic subtypes and there is significant comorbidity, including with FM and ES/MCS. Treatment is currently symptom-based and individualized. There is a lack of evidence on the comparative effectiveness of individual therapies.

FM is a chronic, widespread pain disorder, present for at least 3 months. Prevalence ranges from 2-6 percent, with females 6-9 times more commonly affected than men. In children, it is more common in prepubertal or adolescent girls.

FM is thought to be a nervous system disorder, with activation of NMDA and TRPV1 receptors. There is evidence for oxidative stress, reduced mitochondrial function and systemic inflammation. It is frequently comorbid with ME/CFS, ES/MCS and other chronic conditions and there is significant disability. The majority of those who work do so part-time. Multiple treatments including pregabalin and duloxetine medications, physical therapies and exercise are suggested. Many patients find pharmacotherapy is not helpful or discontinue it due to side effects.

ES/MCS has been described as multisystem symptoms triggered by exposure to diverse chemicals at levels not formerly bothering the patients and not affecting most people. Published consensus criteria for the diagnosis have been validated by the Ministry of Health-funded Environmental Hypersensitivity Research Unit (EHURU) at the University of Toronto in collaboration with the Environmental Health Clinic at Women's College Hospital.

ES/MCS affects 2.4-3.4 percent of the Canadian population, women being more affected than men. This may be due to being more responsive to their environment via both the limbic and immune systems, having a greater body burden of chemical exposures, and having less efficient detoxification systems compared to men.

Sensitization of the nervous system to chemicals and subsequent increased sensitivity has been demonstrated in animal models and there is evidence that ES/MCS patients are genetically predisposed to have inferior enzyme systems for detoxification. Because they are less capable of efficiently detoxifying, oxidative stress occurs, which can sensitize TRPV1 receptors. These receptors are widespread and are found in the brain, eye, bladder lining, mast cells, stomach lining, intestines, larynx and bronchial tubes. They are capsaicin (hot pepper) sensitive. Capsaicin sensitivity has been documented in ES/MCS.

ES/MCS is frequently comorbid with ME/CFS and FM and they all are also frequently comorbid with other common conditions, such as chronic headache, chronic migraine headache, irritable bowel syndrome (IBS), allergies, asthma and autoimmune disorders. (APPENDIX A-Overlapping Diagnoses for 23 Chronic Conditions Cohorts)

ES/MCS patients have problems accessing common community resources that most persons take for granted, including communities of worship, grocery stores, shopping centres, community meetings, public libraries, restaurants, movies, use of public transportation, the homes of extended family members and friends, offices of dentists and medical doctors, public parks,

classes at their local universities, and most significantly, access to work. Others' lack of understanding and refusal to make accommodations in the workplace have denied spatial access. (APPENDIX B- ES/MCS Status Report) People with ME/CFS and FM may also have access issues because of lack of energy and reduced activity levels.

Patients with ME/CFS, FM and ES/MCS are stigmatized by their condition and have difficulty accessing appropriate, effective health care.

Earlier diagnosis of these three conditions can reduce referral costs and investigations, and interventions may prevent the onset of comorbidity, leading to a better quality of life for the individual and net savings for the healthcare sector.

III Need for Environmental Health Education and Government-funded Canadian Environmental Health Clinics

Systems-based health training recognizing environment as a determinant of health is lacking in medical schools and there is a lack of connection to public health. There is an absence of education about ME/CFS, FM and ES/MCS, except for annual Environmental Health Clinic or Ontario College of Family Physicians Environmental Health Days, and presentations and Mainpro-C workshops at professional conferences for practising physicians who choose to attend. The Jurisdictional Review of Community Health Centres revealed that most physicians and nurse practitioners are not comfortable diagnosing or treating these disorders.

A feasibility study by the OCFP in 2008 concluded that an adequately funded Environmental Health Centre is long overdue. Presently, the Environmental Health Clinic at Women's College Hospital provides much less clinical service than the Nova Scotia Environmental Health Centre and the planned provision of assessment, treatment and research by the newly established Complex Chronic Diseases Program at British Columbia Women's Hospital and Health Centre.

Nevertheless, the EHC has made an important start with clinical programs, resources, education of health professionals, crucial foundational research, and partnerships for health promotion with the Ontario College of Family Physicians, the Canadian Partnership for Children's Health and Environment and the Canadian Coalition for Green Health Care (APPENDIX B- ES/MCS Status Report). The EHC has developed tools to educate patients in easy-to-understand language how overload of the body's systems can occur, and employ an innovative "Weed, SEEDS and Feed" framework for organizing complex treatments (APPENDIX C- SEEDS of Health).

IV OCEEH-Principles

A medical centre of excellence delivers comprehensive, evidence-based or –informed care, which is multidisciplinary, and yields best quality outcomes and high patient satisfaction. In particular, the OCEEH will utilize and integrate individual and population based approaches: primary care, preventive medicine and public health. It will provide service for environmentally linked illnesses, focused on ME/CFS, FM and ES/MCS, including health services, social services and policy enhancement, research, education and health promotion.

Guidance for assessment and treatment of ME/CFS, FM and ES/MCS will be developed by experienced physicians and researchers in a 3- day clinical forum/workgroup. Based on available evidence, best and promising practices will be classified using the GRADE system. The strength of the recommendations will be determined by four key factors: (1) balance between desirable and undesirable effects; (2) quality of evidence; (3) patients' values and preferences and (4) costs. These collaborators will be encouraged to keep connected to evaluate promising practices with respect to efficacy and adverse effects.

The present level of available treatment is clearly insufficient to induce significant recovery and reduction of disability, especially as measured by ability to return to work. As it is beyond the scope of this review to rate the quality of evidence available for the assessment, diagnosis and treatment of these chronic, complex, environmentally linked conditions, the recommendations relied upon for diagnosis and therapy at present are limited to the information contained in the Mainpro-C modules, accredited by the College of Family Physicians of Canada.

A three-day research forum /workgroup will be held with experienced clinicians and researchers to establish a research agenda, evaluative mechanisms and encourage collaboration in carrying it out through applying for study grants.

In order to fill the gap in care for people with ME/CFS, FM or ES/MCS, the proposed model for the OCEEH includes a central provincial Hub and ever-widening Spokes providing services as close to home as possible. The Hub will develop education about these disorders and train health care providers in the Spokes. Ongoing research in Hub and Spokes will play a key role.

Treatment will be made available according to GRADE recommendations. Emphasis will be on the provision of education and supportive interventions by health care staff to increase patients' skills and confidence in managing their health problems, including regular assessment of progress and problems, goal setting, and problem-solving support, in a patient- and person-centered manner.

Individual care will be delivered by an interprofessional team collaborating with the patient in shared decision-making. Treatment programs will be individualized because of the uniqueness of each individual's determinants of health and the likelihood of multimorbidity.

The OCEEH will also contribute to the integration of primary care, preventive medicine and public health in communities across Ontario.

V Function and Services in the Hub and Spokes

The model of the OCEEH contains a central Hub and multiple Spokes, expanding across the province. The Hub will be an academic, tertiary healthcare centre, providing specialized investigation and treatment to people referred primarily from primary and secondary healthcare providers, including the physicians in the Spokes. Physical requirements include being reasonably accessible to those patients with ES/MCS, although home visits or teleconferencing may be held initially. The Hub must have close and direct affiliation with a teaching hospital and will be associated with academia. It will be responsible for the provision of health and social

services, education, knowledge transfer, guiding and conducting research, and policy development. Multiple trained medical and other clinical staff will be required. Specialized equipment and space that cannot be shared may also be required.

Health professionals in the Spokes will utilize a comprehensive clinical history, including the environmental exposure history and chronological functional inquiry and will be capable of making the diagnoses and initiating recommended treatments for ME/CFS, FM and ES/MCS. The Spokes will provide generally safe facilities (having a fragrance-free policy and using non-toxic cleaning and laundry products) and a "safe room" with air filtration for severely environmentally sensitive patients or contingencies. They will make use of the environmental exposure history in everyday practice to identify patients at risk for developing chronic conditions linked to the environment. They will work with the Hub to engage in innovative research, including evaluating assessment and treatment tools, and will provide education programs in collaboration with Department of Clinical Public Health at the Dalla Lana School of Public Health, University of Toronto. Eventually, all physicians and nurse practitioners in Ontario will be aware of the environment as a determinant of health and will be able to practise systems-based medicine.

The Hub and Spokes will integrate the responsibilities of individual and public health services, social services and policy enhancement, research, education and health promotion.

VI Building the OCEEH

In order to provide the highest quality of health care for people with ME/CFS, FM and ES/MCS, the Hub must be built before the Spokes, although collaboration with interested spokes may be started as early as possible. The Spokes may be in Community Health Centres and Family Health Teams and will eventually spread to other primary health care practitioners around the province.

The Hub must update the tools presently being used, develop guidance for assessment and treatment, develop and start to participate in research and refine and provide the teaching program for the Spokes, and eventually for all primary health care and public health practitioners in Ontario.

Building the OCEEH requires the steps in Table 5- Creating and Expanding the Foundation and Table 6- Initiating, Maintaining and Expanding the Program. Creating and expanding the foundation, as first steps, should take about 1-2 years.

Table 5 First Steps to Building the OCEEH

Create the Foundation	Expand the Foundation
Immediate increase of EHC medical staff to 4 FTEs, including a Medical Director	Begin education of Spoke health care providers, starting with an introductory course
Begin training of Fellows to expand medical staff	Develop education modules and case-based training for medical students, residents, Spoke providers and primary care providers
Organize research projects for Fellows and clinical staff	Develop education modules for nursing and other health professionals
Organize workshop (preferably 3 days) of clinical and research experts to develop GRADE recommendations, and advise re “promising” practices	Organize workshop (preferably 3 days) of clinical and research experts to set research agenda, including evaluation strategies, and initiate research collaborations
Upgrade and refine methods for data gathering	Develop programs for University Sciences (humanities, natural and social science, environmental policy and urban planning)
Develop specific Hub agreements with the university(ies) and teaching hospital(s)	Develop education modules for patients
Prepare education program for Spokes	Develop modules for self-management
Develop university certificate in Environmental Health, and apply for CFPC special practice designation	Develop safe rooms in Spokes
Develop updated hospital guidelines	Create temporary lodging for patients attending the Hub

Table 6 Next Steps in Building the OCEEH

Initiate Programming	Maintenance and Expansion
Begin provision of care in Spokes, and provide support consultations	Gather research data
Develop teleconference and e-consultation service for provision of consultations in remote areas by Hub and Spokes	Refine assessments and treatment protocols
Further develop Research Agenda and Research Associates	Disseminate knowledge
Initiate research programs; case studies and research protocols	Network
Apply for Research Funding	Continue research in Hub and Spokes
Create a website	Expand Spoke availability in Ontario

I Accumulating Evidence of Chronic Complex Conditions Relatedness to the Environment

▪ Introduction

There is an increasing prevalence of multiple chronic illnesses, which cannot be adequately accounted for by genetics. The rise is due in part to the aging population and changing behaviours associated with the Western lifestyle, notably poor diet and lack of exercise. The Western lifestyle has also contributed to a significant increase in chemical pollution exposures from outdoor and indoor air, food, water, and consumer products.

The burden of chemical pollution impacts on the ability of cells to metabolize internal waste and external toxins and leads to oxidative stress, reduced cell function, cell death (apoptosis) or proliferation, and chronic systemic inflammation. Having a genotype for poor detoxification is a risk factor and genetic predisposition to develop chronic illness can in turn be enhanced by epigenetic changes elicited by environmental pollutant exposures. All these entities have been demonstrated in environmentally linked illnesses, which include neurological,^{1 2} cardiovascular,^{3 4} respiratory,^{5 6} immunologic^{7 8} and endocrine disorders.^{9 10}

As will be outlined, these same abnormalities are also more likely to be found in patients with three chronic complex conditions: myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM) and environmental sensitivities/multiple chemical sensitivity (ES/MCS). These conditions are commonly occurring and overlapping, but the underlying mechanisms are not yet clear.

Unfortunately, the resources to assess, diagnose, treat and provide support for the more than 550,000 patients with these entities in Ontario are lacking. According to the Canadian Community Health Survey (2010), the prevalence of one or more of ME/CFS, FM and ES/MCS (1,415,000) is slightly less than heart disease or diabetes (Table 1). In addition to commonly overlapping with each other, these conditions also have high rates of co-morbidity with other conditions, such as migraine, headaches, arthritis, stroke and cancer (Appendix A- Overlapping Diagnoses for 23 Chronic Conditions Cohorts- used with permission of author).

In spite of frequent patients' reports (CCHS) of high rates of consulting health care practitioners in search of relief, high rates of unmet needs, and high rates of disability, high amounts of health care dollars are being spent while research dollars are few (Table 1). Because underlying mechanisms for ME/CFS, FM and ES/MCS are not yet well understood, treatment based on etiology has yet to develop. Better management of poorly managed individual conditions and better management of these conditions overlapping with other chronic health problems could make the co-morbid conditions easier to manage as well.

The Environmental Health Clinic at Women's College Hospital is a unique provincial multidisciplinary clinic, established in 1996 by the Ministry of Health to provide comprehensive assessments for physician-referred people with chronic, complex conditions that were commonly overlooked in the Ontario health care system. Initially services were focused on environmental sensitivities/multiple chemical sensitivity (ES/MCS)¹¹, but myalgic encephalomyelitis/chronic

fatigue syndrome (ME/CFS) and fibromyalgia (FM) were added in 1998, as these conditions were commonly observed clinically to overlap.¹²

Table 1 Canadian Institutes of Health Research Funding for Chronic Health Conditions

(Data extracted from CIHR funding databases using keyword searches, Margaret Parlor, Statistical Analyst, President, National ME/FM Action Network- used with permission of author)

Medical Condition Keyword	Per patient funding Apr 2010 to Mar 2013	Canadians affected CCHS 2010
Parkinson	\$399.49	39,000
Alzheimer	\$237.71	111,500
Muscular Dystrophy	\$157.87	26,000
Epilepsy	\$78.89	134,500
Multiple Sclerosis	\$73.09	108,500
Tourette	\$53.54	18,000
Crohn	\$47.47	102,500
Cerebral Palsy	\$44.07	36,000
Diabetes	\$38.93	1,841,500
Spina Bifida	\$26.61	35,000
Heart Disease	\$25.25	1,431,500
Dystonia	\$20.26	15,500
Bronchitis, Emphysema, COPD	\$9.12	805,000
Asthma	\$6.90	2,246,500
Arthritis	\$5.85	4,454,000
Fibromyalgia	\$1.38	439,000
Chronic Fatigue Syndrome	\$0.35	411,500
Multiple Chemical Sensitivities	\$0.01	800,500

There is mounting evidence of environment and health links influenced by genetics and epigenetics in all chronic complex conditions, and accumulating understanding of potentially related mechanisms and relationships.

This report includes the following sections.

1. Sections I-II:

A broad-based scoping, but non-systematic, review of the scientific literature related to environmental associations with chronic complex health conditions (Section I) and focused on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia (FM), and Environmental Sensitivities/Multiple Chemical Sensitivity (ES/MCS) (Section II).

The literature reviewed was, in most part, published by the United States National Library of Medicine in Medline, supplemented on occasion by credible reports by government agencies, professional associations and environmental/patient support organizations.

2. Section III-VI:

An overview of what might be developed to build the Centre of Excellence on the foundation of the Environmental Health Clinic to prevent chronic environmentally linked conditions, and to care for people with ME/CFS, FM and ES/MCS as close to home as possible, as well as broad expansion of education/health promotion and research (Sections III-VI).

▪ Environmental Health

The World Health Organization (WHO) defines health as;

*“a state of complete physical, mental and social well-being and not merely the absence of disease”.*¹³

As stated in 1989, by the European Charter and Commentary emerging from the first WHO Pan-European Meeting of Environment and Health Ministers, environmental health is:

*“those aspects of human health and disease that are determined by factors in the environment ...both the direct pathological effects of chemicals, radiation and some biological agents, and the effects (often indirect) on health and wellbeing of the broad physical, psychological, social and aesthetic environment which includes housing, urban development, land use and transport. It also refers to the theory and practice of assessing and controlling factors in the environment that can potentially affect health.”*¹⁴

According to Public Health Ontario, environmental health encompasses the assessment and control of the physical, chemical, biological, social and behavioural factors in the environment that influence health and disease occurrence.¹⁵

To summarize, environmental exposures are one of several determinants of health, linked to the community, the home location, occupation, food/beverage choices and various actions, such as wearing scented products, smoking or taking medications.

To promote environmental health and improve the health care for people with poorly recognized chronic, complex conditions ME/CFS, FM, and ES/MCS, the Ontario Ministry of Health and Long-Term Care established the Environmental Health Clinic (EHC) at Women's College Hospital in 1996.¹⁶ Unfortunately funding for this incubator program has not expanded to meet the needs. Presently, the wait list is over one year and patients are limited to two follow-up appointments. Building on the EHC and expanding services to meet the provincial need is the context of this report.

▪ Chronic Complex Conditions

Chronic illnesses are conditions that traditionally last one year or more and require ongoing medical attention and/or limit activities of daily living.¹⁷ Common chronic conditions include cardiovascular and cerebrovascular disease, cancer, diabetes, metabolic syndrome, obesity, neurodegenerative disorders, chronic lung and kidney disease, and immune dysfunction such as autoimmune diseases, allergies and asthma.

According to the World Health Organization (WHO), chronic diseases have overtaken infectious diseases as the leading cause of death and disability worldwide.¹⁸ Non-communicable diseases now account for 59% of the world's 57 million annual deaths, and 46% of the global burden of disease and the prevalence and resulting number of related deaths are expected to increase substantially due to population growth and aging, and environmental risk factors. Escalating rates of neurocognitive, metabolic, autoimmune and cardiovascular diseases cannot be ascribed

only to genetics, lifestyle, and nutrition. Early life and lifelong ongoing pollutant exposures and bioaccumulation also contribute to the cause of chronic disease.^{19 20 21 22}

The picture for Ontario is similar. Chronic disease is most frequent among older Ontarians. According to the 2003 Canadian Community Health Survey, almost 80% of Ontarians over the age of 45 or 3.7 million people were living with a chronic condition. Chronically ill Ontarians are also likely to have more than one chronic disease; 70% of them over the age of 45 have multiple conditions.²³

The co-occurrence of multiple diseases in the same individual is called multimorbidity. When there are multiple morbidities, chronic disease is considered complex, although there are other factors at play. For example, social, cultural, environmental situations and finances may account for the different consequences of identical health conditions in different different people (Figure 1).²⁴ A single condition (e.g. schizophrenia) in a person living on the street is complex, whereas well-controlled diabetes, hypertension and hyperlipidemia in a married employed man is not.²² Chronic complex disease (CCD) requires the attention of multiple health care providers or facilities²⁵ and possibly community (home)-based care.²⁶

Because of the high and increasing prevalence of these disorders, economists and health planners are already questioning the sustainability of our medical and social systems, due to the massive impact of the aging population.²⁷ In a study of approximately 3000 patients, it was found that the health care utilization and cost were significantly increased among patients with multimorbidity.²⁸ In Ontario, chronic diseases account for 55% of direct and indirect health costs, which includes years of healthy life lost from premature death and lost productivity from disability as well as direct health care costs.²⁹

What is important to the individual is that comorbid illnesses have an additive or even synergistic and significantly negative impact on quality of life.³⁰ The major consequences of multimorbidity are continuing functional decline, disability, poor quality of life, and high personal health-care costs.^{31 32 33 34} The Health Council of Canada reports that 50% of people with multimorbidity report moderate or severe disability in daily living.³⁵ There is an increasing trend of multimorbidity in younger patient demographics.³⁶ The impact of multimorbidity from the patient perspective has been explored, indicating that individuals feel the current system is not addressing the basic needs of their health problems.^{37 38 39 40}


Chronic complex diseases and conditions also have a significant impact on family members and healthcare providers, who are frequently inadequately trained to understand the complex interrelationships of comorbid illnesses.^{41 42} Physicians do not yet have guidelines to treat multimorbidity.⁴³ Specialists are usually responsible for a single disease among many. Applying guidelines for each individual disease simultaneously provides uncertain benefit and potential harm.^{44 45 46} What is good for an individual condition may not be good for patients with multiple conditions.^{47 48}

Chronic illnesses are frequently comorbid because they share common risk factors and conditions. The concept of multiple determinants of health comes from the realization that there

are multiple complex factors which combine or interact to impact on individuals and population groups.³⁵

Whether people are healthy or not is determined by their circumstances and environment. The World Health Organization states that factors such as where we live, the state of our environment, genetics, our income and education level, and our relationships with friends and family all have considerable impacts on health.⁴⁹

Figure 1



Source: Health Canada, “Health and Environment: Critical Pathways,” *Health Policy Research Bulletin*, Issue 04, October 2002, p. 3.

▪ **Genetics and the Environment**

Although many experts argue about how quickly genetic evolution can occur, there is general consensus that very little change in the human genome will occur in just two or three generations (60 years). Clearly, genetic transformation and evolution are not majorly contributing to the rapid and significant changes in health patterns that have recently emerged.⁵⁰ Genetics might predict susceptibility, but environmental factors are thought to cause 70 to 90% of chronic disease risk.⁵¹

The human genome was categorized from 1990-2003⁵² and poses protective and susceptibility factors to human health. As the World Health Organization stated, “*Most diseases involve many genes in complex interactions, in addition to environmental influences*”,⁵³ and they quote evidence re genetic polymorphisms influencing or protecting from cancer, cardiovascular disease and diabetes and many other chronic conditions.

In addition, the science of epigenetics and how environmental stimuli influence genes to turn on and off their expression of metabolic enzymes, is in its infancy and is evolving rapidly.^{54 55 56}

Disease is often the result of vulnerable genes being triggered by specific determinants. Mounting evidence suggests that without activation, some disease processes will not develop, and removal of the initiating trigger may allow developing illness to abate or subside.⁵⁷

▪ Epigenetics

Expression or silencing of genes occurs by removing or replacing their coverings, i.e. modifying the epigenome. The epigenome is the wrappings (chromatin and histone) around our DNA. It covers and protects the DNA, but most importantly, it activates and deactivates individual genes. The term epigenetics is used to describe any process that refers to changes in the genome, which alters gene activity and expression without actually changing the DNA or genomic sequence itself.^{58 59 60 48 49}

Emerging evidence suggests that air pollutants can influence epigenetic changes^{61 62 63} and these changes are even more likely to occur with genetic predisposition to poor detoxification.⁶⁴ In fact, there are numerous studies demonstrating that epigenetic changes are triggered by oxidative stress.^{65 66 67 68 69 70 71 72 73}

Mounting evidence suggests that inappropriate epigenetic changes and subsequent misinterpretation of the genetic code is linked to numerous chronic illnesses. A large number of animal studies provide evidence that supports the role of environmental epigenetics in disease susceptibility.⁷⁴ These studies show that there are many agents that provoke epigenetic changes, including heavy metals, pesticides, diesel exhaust, tobacco smoke and other environmentally toxic and persistent chemicals.^{75 76}

In particular, epigenetic modulation by ambient air pollution can play a role in regulating the expression of genes important in the pathogenesis of inflammation in asthma.^{77 78} Ambient air pollutants can affect DNA methylation and result in changes in chromatin structure.⁷⁹

For example, living in a more polluted North American city such as Fresno California (high particulate matter and ozone) is associated with epigenetic changes which contribute to impairment in regulatory T cell function seen in asthmatics.⁸⁰ In a longitudinal cohort study of non-smoking women in New York City, polyaromatic hydrocarbons (PAH) exposure during pregnancy, derived largely from traffic-related air pollutants, was measured using personal air monitors. This study also demonstrated that the prevalence of asthma (>25%) was among the highest in the US. Prenatal PAH exposure was associated with epigenetic changes, in particular with genes involved in the pathogenesis of asthma.^{81 82}

The resulting acquired susceptibility from epigenetic change is expected to interact with environmental factors and with genetic susceptibility to increase risk for environmental disease.⁸³

▪ Early and Late Exposures

In 2011, the Canadian Environmental Law Association, the Ontario College of Family Physicians and the Environmental Health Institute of Canada produced an extensive scoping review of the literature.⁸⁴ Their main findings include:

- The in utero and perinatal environment all play major roles in the risk of later life disease
- There is more and more confirmation for the role of early life exposures to environmental contaminants and a lifelong vulnerability to chronic disease.
- The following chronic diseases or conditions were studied, and were found to be associated with early life environmental chemical exposures:
 - cardiovascular disease
 - cardiac birth defects
 - low birth weight
 - obesity
 - type 2 diabetes
 - Alzheimer's disease
 - Parkinson's disease
 - developmental neurotoxicity
 - cancer (breast, prostate, testicle)
 - respiratory disease (asthma).

In addition, this review found the same agents were associated with these conditions (Table 2), and subsequently colleagues in the Canadian Partnership for Children's Health and Environment were able to mount a public information campaign targeted towards parents. They translated the research findings into "Top 5 tips: Creating Healthy Home Environments for Kids" that was widely distributed as a brochure and fact cards, translated into multiple languages, and a video (www.healthyenvironmentforkids.ca).

Table 2

Chemicals/Pollutants Most Frequently Linked to Early Exposures and Later Chronic Diseases

- **Air pollution/Tobacco smoke**
- **Lead**
- **Mercury**
- **Bisphenol A**
- **Phthalates**
- **Organophosphate pesticides**
- **POPs (e.g. organochlorine pesticides, dioxins, PCBs, PBDEs, polyvinyl chloride)**
- **VOCs**

Cooper K, Marshall L - used with permission of the authors

The World Health Organization declared chronic disease to be the number one healthcare challenge of the 21st century.⁸⁵

For instance, the incidence of allergies has been increasing.^{86 87 88} The prevalence of food allergy in children under the age of 18 increased by 18% percent from 1997 to 2007⁸⁹ and the prevalence of peanut allergy has doubled.⁹⁰ Anaphylactic reactions, which are severe and potentially life-

threatening allergic reactions, have increased as well.^{91 92} The increase in incidence of allergies impacting the respiratory system has been related to pollution exposure.^{93 94}

The prevalence of autoimmune disorders is increasing, and the increase is associated with environmental exposures, such as solvents^{95 96} and air pollution.⁹⁷

There has been a sharp increase in the global prevalence, morbidity and mortality associated with asthma over the last 40 years, particularly in children.⁹⁸ Up to 37% of teenagers are affected by asthma symptoms, making it one of the most common chronic diseases in childhood.⁹⁹ Approximately 300 million people worldwide currently have asthma and its prevalence increases by 50% every decade.¹⁰⁰ Pollution influences the development of asthma.^{101 102}

Long term exposure to pollution outdoors is linked with diabetes,^{103 104} and considered a risk factor for its development.^{105 106 107 108} Chemical exposure is related to both type 1^{109 110 111} and type 2 diabetes,^{112 113} and a 2010 animal study even linked it to developing obesity.¹¹⁴ Persons with diabetes are particularly susceptible to the acute effects of air pollution,^{115 116} increasing the risk for complications requiring hospitalization.¹¹⁷

The number of heart attack-related hospitalizations has increased steadily.¹¹⁸ The American Heart Association has established a link between air pollution exposure, in particular particulate matter, with cardiovascular morbidity and mortality.^{119 120} Chronic exposure to particulate air pollution enhances the risk of developing cardiovascular disease.^{121 122 123} Living near traffic increases the risk for heart attack,¹²⁴ doubles the risk for death¹²⁵ and women are at greater risk.¹²⁶ Overall mortality is higher in the most polluted cities.¹²⁷ Living in areas with higher outdoor pollution reduces the long term chances of surviving a stroke.¹²⁸

Multiple studies have also found detrimental cardiovascular effects from environmental air pollutants due to the exacerbation of known risk factors, including atherosclerosis and increased blood pressure.^{129 130 131 132 133 134 135}

People who are genetically poor detoxifiers are also more susceptible to the cardiovascular and respiratory effects of air pollution.^{136 137} In particular, having such an abnormality has been shown to have an adverse impact on the effects of pollution exposure by modifying heart rate variability,^{138 139} lengthening of the QT interval on electrocardiograms,¹⁴⁰ contributing to the risk of endothelial inflammation caused by traffic particles,¹⁴¹ and increasing homocysteine levels,¹⁴² all of which are risk factors for heart disease. Having an abnormal genotype for detoxification can adversely affect lung function, including increasing the risk of ozone-induced asthma^{143 144} and wheezing.^{145 146}

The brain is especially vulnerable to chemical exposures. Accumulating evidence links air pollution exposure to central nervous system (CNS) oxidative stress, pathology and disease.¹⁴⁷^{148 149} Epidemiology studies have shown that exposure to high levels of air pollution is associated with a deficit in neuropsychological development in children,^{150 151 152 153 154} behavioural deficits,¹⁵⁵ autism^{156 157 158} and cognitive decline in the elderly.^{159 160 161 162 163 164}

Human studies have also revealed that individuals living in highly polluted cities show Alzheimer's disease (AD)-like and Parkinson's disease (PD)-like pathology, when compared to individuals living in cities with less pollution.^{165 166} More specifically, high levels of air pollution are associated with elevated markers of neurodegenerative disease in humans, including tau phosphorylation, diffuse β amyloid plaque deposition, and a synuclein aggregation.^{167 168 169} Parkinson's and late onset Alzheimer's, are also associated with poor detoxification genotypes.^{170 171 172 173 174} Trichloroethylene, a chlorinated solvent widely used as a degreasing agent in industry, is a common environmental contaminant and an exposure risk factor for the development of Parkinson's disease.^{175 176 177} The epidemiological and toxicological evidence is also repeatedly identifying both occupational and ambient exposure to pesticides as a significant factor.^{178 179 180 181 182 183 184 185 186}

Human reports also revealed that air pollution causes oxidative stress, neuroinflammation, and microglial activation in the brain.¹⁸⁷ Consistent with human reports, animal studies have found that exposure to air pollution causes lipid peroxidation,¹⁸⁸ DNA damage,¹⁸⁹ elevated cytokines,¹⁹⁰ protein nitration and chemokine increases,^{191 192} aggregated alpha synuclein¹⁹³ and activation of microglia.^{194 195 196}

Preliminary evidence exists for abnormal detoxification genotypes contributing to susceptibility to developing progressive multiple sclerosis.¹⁹⁷

▪ **Body Burden**

There are distinctions between external exposures, how much actually enters the body and accrued internal bioaccumulation. Some agents are rapidly metabolized and excreted and do not remain in the human body. Other compounds may remain in the human body for a period of time depending on the efficiency of inherent detoxification mechanisms, which vary from one individual to another, some people having more effective detoxification mechanisms than others.^{198 199} They can also vary with the chemical properties of the agent. Some compounds are poorly excreted and tend to bioaccumulate in tissues. Repeated or continuous exposure will offset the ability of the body to lower the accrued amount.

North Americans carry as many as 212 contaminants in their bodies and women have higher levels of many of these chemicals than men.²⁰⁰ The exposures in utero are due to contaminants crossing the placenta. Toxic chemicals/agents enter the body not only from exogenous sources (air, water, diet, drugs, consumer products and radiation) but also from endogenous processes, including byproducts of our natural metabolism, inflammation, existing diseases, infections, and gut flora.²⁰¹ Thus, the relevant 'environment' is the body's internal chemical environment, i.e. what's inside it.²⁰²

All our daily and accumulated exposures to volatile and semivolatile organic compounds (VOCs SVOCs), by-products of indoor chemistry, outdoor pollutants such as ozone and particulate matter, and numerous additives and pesticides found in food add to the burden of our natural detoxification systems.

Chronic illnesses are increasing and 'relatively new' illnesses, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM) and environmental

sensitivities/multiple chemical sensitivity (ES/MCS) are increasingly reaching our awareness. According to the Statistics Canada Canadian Community Health Surveys in 2005 and 2010, these newer conditions are also increasing in prevalence.²⁰³ The simultaneous occurrence of the rise in pollution and resulting increase in body burden is associated with the increasing prevalence of chronic illness, which suggests that these phenomena are potentially linked.

▪ **Linking Divergent Chronic Conditions and the Environment**

Biologically, these chronic illnesses and conditions are distinct, but there are common, overlapping pathological mechanisms. These include a burden to detoxification systems, damage to cellular organelles, oxidative stress, changes in cell function, and systemic inflammation.

○ **Detoxification**

The liver is a major organ for detoxification. It breaks down toxic agents and converts oil soluble products into more water soluble metabolites, which can be efficiently eliminated from the body by the kidneys.²⁰⁴ This degradation, or biotransformation, is primarily accomplished by two liver enzyme systems called Phase I and II.²⁰⁵ Waste products can be eliminated from the body through bile and stool, urine, and sweat.²⁰⁶

Every cell is naturally equipped with a detoxification system to deal with internal wastes, and that same system is used to detoxify and eliminate foreign chemicals (xenobiotics) which are potentially harmful. Xenobiotics are encountered by humans on a daily basis and undergo metabolism and detoxification to produce numerous metabolites, some of which also have the potential to cause toxic effects.²⁰⁷ Waste that cannot be completely degraded or easily eliminated by the cell must be altered in order to remove it from the body. When the cell is unable to rapidly detoxify waste or toxic foreign substances, damage can occur.

○ **Cellular Organelles**

Cells obtain energy by combining glucose with oxygen. This critical role in energy metabolism is performed by cell organelles (cell subunits that perform specific functions) called mitochondria.²⁰⁸ Mitochondria are specialized subunits which are fundamental to cell life and cell death. They consume about 98% of the oxygen we inhale.²⁰⁹ That we must breathe oxygen to stay alive is simply the consequence of the demand of our mitochondria for oxygen.

Mitochondria are the source of the energy, strength and vitality for every cell. As the powerhouse of cells, they provide energy for cell division, production or destruction of proteins and other substances, cell signaling, and transportation of large molecules across the cell membrane. Depending on the cell's energy requirements, there are hundreds or thousands of well-functioning mitochondria traveling around the cell, distributing readily available energy wherever it is needed. Metabolically, this is where the action is inside a cell. The byproducts of this metabolism are toxic waste products, to be destroyed or eliminated, but unfortunately, the mitochondria sit in the middle of it all.

These byproducts are called reactive oxygen species or oxidants or free radicals. They are electronically unstable molecules capable of stripping electrons from any other molecules they

meet in an effort to achieve stability. Doing so creates more unstable molecules which can then attack their neighbours in domino-like chain reactions.

Free radicals are produced in small amounts under normal physiological conditions, derived from essential metabolic processes. They are the waste products of the energy produced by mitochondria. When their production is increased, or their detoxification is inadequate, molecular damage occurs inside cells. This damaging process is called oxidative stress.

- **Oxidative Stress**

Oxidative stress represents an imbalance between the production of reactive oxygen species and the ability to neutralize or detoxify them. It refers to any of the resulting various pathologic changes seen in living cells in response to excessive levels of reactive oxygen species. We can observe the imbalance directly by measuring the levels of oxidants or free radicals, or we can assume it is occurring by finding low levels of antioxidants.²¹⁰

We know oxidative stress is occurring when we find evidence of damage and destruction inside cells.^{211 212 213 214} Oxidative stress damages DNA,²¹⁵ especially mitochondrial DNA,²¹⁶ lipids from cell and organelle membranes²¹⁷ and various proteins,²¹⁸ and we can measure the resulting by-products of this damage in blood or urine.^{219 220 221 222 223}

- **Changes in Cell Function**

Oxidative stress and DNA damage can cause significant changes in cell function. The mitochondria are most likely to be damaged because they produce free radicals as waste products of their production of energy, and are immersed in them, making them highly vulnerable to attack. In research labs, we can assess mitochondrial function by stimulating cell activity and measuring the levels of substances normally used by working mitochondria. When the mitochondria are activated, and are functioning well, there is a marked reduction in these substances as they get used up.^{224 225}

- **Systemic Inflammation**

The literature robustly demonstrates pollution leads to oxidative stress and systemic inflammation, which in turn contributes to the onset and exacerbation of cardiovascular disease,^{226 227} chronic obstructive lung disease,²²⁸ and neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases.^{229 230} It worsens symptoms, increases medication use, decreases function and increases health care utilization and mortality.²³¹ Those with an abnormal genotype for detoxification tend to be more susceptible to developing such chronic illnesses.

- **Reductionism, Systems Biology and Systems Medicine**

The principle of reductionism is the belief that complex systems can be understood by studying their most fundamental parts.²³² It is the way we attempt to explain complex phenomena; we try to define the functional properties of the individual components of complex systems. Reductionism dominates traditional medical science and affects the way we diagnose, treat, and prevent diseases.²³³ The natural inclination of medical practitioners is to isolate the single factor that is most responsible for the observed abnormality and to treat that factor. Implicit within this practice is the approach that every disease has a potential single target for medical treatment. For

example, the target in infection is the bacteria; for cancer, it is the tumour. The disease becomes the central focus, not the whole person biologically participating in and affected by the disease. With the reductionist approach alone, we cannot completely understand the mechanisms of abnormal chronic, complex medical conditions by looking at how the individual parts work in isolation.^{234 235 236}

Chronic diseases and conditions are commonly comorbid, and involve multiple organ systems. On a cellular level, they include genetics, epigenetics, oxidative stress, systemic inflammation and influences from the environment. They develop over time because of the complex interactions and imbalances among all the different systems involved.²³⁷ Furthermore, a person's sleeping habits, diet, living conditions, age, sex, other co-morbid illnesses, and emotional stress may all have contributed to the onset, continuation, and exacerbation of his or her disease process. It is now widely recognized that chronic diseases arise as a result of a complex interaction of environmental and genetic risk factors.²³⁸

Systems biology is the study of the behavior of complex biological organization and processes.²³⁹ Defining it is difficult. It involves the application of experimental, theoretical, and computational techniques to the study of biological organisms at all levels, from the molecular, through the cellular, to the organ, organism, and populations. Its aim is to understand biological processes as integrated systems instead of as isolated parts.²⁴⁰ Most major universities in Canada, the United States, Europe and Asia now have education and research departments in systems biology.²⁴¹

Chronic illness is about the failure of multiple systems. Systems medicine is the application of systems biology approaches to medical research and medical practice.²⁴² A systems medicine approach that recognizes the interactions between all the components responsible for human clinical dysfunction is required to better understand and manage chronic disease, rather than perceiving the disease as a single abnormal mechanism occurring in isolation, and then trying to treat it accordingly.²⁴³

The increasing awareness of chronic complex conditions ME/CFS, FM, and ES/MCS has revealed they have not had a single body system on which medical specialists for that system could focus. Hence, endocrinologists, infectious disease specialists, rheumatologists, allergists, respiratory physicians et cetera seldom have sufficient management strategies for these conditions. Collaboration among various health care professionals to manage the failure of multiple systems in these conditions may also point the way to more effectively manage other chronic complex conditions.

▪ Summary

Chronic complex conditions are the leading cause of death and disability worldwide. Almost 80% of Ontarians over the age of 45 have a chronic condition, and 70% of them have more than one. As does poor management of a single condition, multimorbidity contributes to continuing functional decline, disability, poor quality of life and high personal health care costs.

The physical environment is one of the multiple determinants of health, but environmental health encompasses the assessment and control of the physical, chemical, biological, radiological, social and behavioural factors in the environment that influence health and disease occurrence.

Environmental factors are thought to cause 70 to 90% of chronic disease risk. Pollution exposure influences epigenetic change, which increases genes' susceptibility to turn on and off in response to environmental factors, and then increases the risk to develop environmentally linked conditions, particularly in those individuals with genetic susceptibility factors.

Exposure to pollution, particularly in early life, increases the risk for developing environmentally-linked diseases, such as allergies, autoimmune disorders, asthma, diabetes, cardiovascular disease, neuropsychological developmental disorders and autism in children, and progressive neurodegenerative disorders, such as Parkinson's and Alzheimer's.

Chronic conditions such as ME/CFS, FM, and ES/MCS appear to also be linked to the environment in these ways and are increasing in prevalence. These conditions commonly overlap with each other and other chronic conditions and are challenging to manage. However, in spite of high rates of unmet health needs and high rates of disability, with considerable health care dollars being spent, there is almost no focus on research to be able to diagnose, treat and prevent these conditions more efficiently.

Toxic chemicals/agents enter the body not only from exogenous sources (air, water, diet, drugs, consumer products and radiation) but also from endogenous processes, including byproducts of our natural metabolism, inflammation, existing diseases, infections, and gut flora. Thus, the relevant 'environment' is the body's internal chemical environment, i.e. what's inside it.

The common pathological mechanisms of all these diseases and conditions include a burden to detoxification systems, damage to cellular organelles (metabolic subunits) including the energy-generating mitochondria, as well as oxidative stress, reduced cell function, with increased cell death or proliferation, and systemic inflammation, which makes other chronic conditions (multimorbidity) more likely.

The traditional reductionist approach to understanding and treating chronic complex conditions is inadequate because of dysfunction of multiple organ systems and comorbidity.

A systems medicine approach, that includes environment as a determinant of health, recognizes the interactions of organs, cells, genetics and epigenetics, oxidative stress and systemic inflammation in response to exposure to environmental agents.

II Increasing Prevalence and Awareness of Three Chronic Complex Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Fibromyalgia, and Environmental Sensitivities/Multiple Chemical Sensitivity

▪ Introduction

The 2010 Canadian Community Health Survey (CCHS) reported that the number of Canadians reporting a diagnosis of ME/CFS, fibromyalgia and ES/MCS has increased markedly since 2005. The prevalence of CFS increased by 23%, FM by 13%, and MCS by 34%. The numbers are increasing perhaps because the incidence is increasing- these illnesses usually do not resolve and more people get added to the total; and more doctors are now making the correct diagnosis. On the other hand, one can also argue that the numbers are likely underestimated because some doctors don't know how to make the diagnoses and others refuse to accept the legitimacy of these illnesses. Nevertheless, the numbers are significant in that these people frequently have a significant reduction in quality of life. In fact, 69% of the patients assessed at the Environmental Health Clinic at Women's College Hospital are no longer able to work.²⁴⁴

Thus far, these conditions do not have readily available clinical biological markers for diagnosis.

Although individually unique, ME/CFS, FM and ES/MCS display the same overall pattern as the above reviewed chronic complex diseases. They are increasing in prevalence. They overlap with each other and other chronic conditions. Please see APPENDIX A- Overlapping Diagnoses for 23 Chronic Conditions Cohorts. They demonstrate abnormal genotypes, oxidative stress, reduction in number and function of mitochondria, systemic inflammation and multimorbidity.

▪ Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

○ ME/CFS Description and Prevalence, including Women and Children

The description of ME/CFS has continued to evolve over the past 20 years because of the multiple complicating symptoms, which add to the difficulty of nailing it down precisely.^{245 246 247 248 249 250} Severe chronic fatigue is the dominating complaint. It is made worse by exertion, is not substantially relieved by rest, and the post-exertion recovery time is prolonged. The fatigue is commonly both physical and cognitive.^{251 252} ME/CFS affects up to three percent of the population, may follow an infection, and usually does not go away.²⁵³

ME/CFS affects women at six times the rate of men.²⁵⁴ Moreover, women exhibit more severe fatigue, worse physical functioning, more bodily pain, poorer emotional functioning and significantly greater impairment of work activities.^{255 256}

ME/CFS also occurs in children, especially adolescents. The prevalence is considerably lower than among adults²⁵⁷ and the prognosis is better.²⁵⁸ However, they report significantly more illness impairment, especially in school attendance, than those with other chronic conditions such as juvenile idiopathic arthritis and emotional disorders.²⁵⁹

In children and adolescents, ME/CFS occurs at a developmentally vulnerable time, which adds to the disability. It affects self-concept, autonomy, body image, socialization, sexuality and academic problems, which have a significant psychosocial impact.²⁶⁰ Those affected report difficulty explaining their illness to peers and being believed, and they experience bullying.²⁶¹

ME/CFS is relatively common in young people (prevalence 0.4% to 2.0%)^{262 263 264} and is very disabling, as 45% report more than 50% school absences with a mean time out of school estimated at more than one academic year.²⁶⁵

One recent study assessed the impact of adolescent ME/CFS on the parents.²⁶⁶ They described anger and frustration as consequences of struggling to access health care for their children. The anger and frustration was attributed to their interactions with the medical profession, feeling helpless and not knowing where to turn to for support and practical advice. Furthermore, the parents described problems with judgmental blaming attitudes by physicians, which made them feel abandoned and disrespected. They specifically described doctors as blaming their parenting.

○ **ME/CFS Diagnostic Criteria**

The diagnosis of ME/CFS is made by comparing the patient's symptom pattern with the diagnostic criteria, and then eliminating other conditions which would display these symptoms.

There are no definitive laboratory tests or physical findings²⁶⁷ but what distinguishes it from other causes of chronic fatigue is that minimal exertion will exacerbate the fatigue, and the recovery time is pathologically prolonged. Sometimes it can take days or weeks to recover, instead of minutes or hours.

Various diagnostic criteria and management guidelines for ME/CFS have been published:

- Oxford criteria²⁷⁰
- National Institute of Health and Clinical Excellence (NICE) guidelines²⁶⁸
- Carruthers BM. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Clinical Case Definition and Guidelines for Medical Practitioners. An Overview of the Canadian Consensus Document²⁶⁹
- Centers for Disease Control and Prevention (USA).²⁷⁰
- Myalgic encephalopathy (ME) and chronic fatigue syndrome (CFS): management guidelines for general practitioners. (Australia) ISBN 0 7308 9334 0²⁷¹
- International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS.). ME/CFS: A Primer for Clinical Practitioners²⁷²

These management guidelines differ somewhat in their approach. One reason for this is that they use different definitions to define the illness. The Canadian criteria emphasize the importance of managing/pacing activity including exercise. Management guidelines in England (NICE), Canada (Carruthers) and Australia use the Canadian criteria. The difference in definitions is of great importance in order to establish the most effective therapeutic recommendations.

The various definitions of ME/CFS require other symptoms and patterns, including chronic pain such as recurrent headaches and fibromyalgia, disturbed or less than refreshing sleep, cognitive complaints, gastrointestinal complaints and sensitivities to foods, medications, odours and/or

chemicals. There are multiple system complaints and the immune system appears to be playing a role.^{273 274 275}

The Oxford Criteria²⁷⁶ were developed in 1991. Two broad syndromes can be defined:

1. Chronic fatigue syndrome (CFS):

- A syndrome characterized by fatigue as the principal symptom.
 - A syndrome of definite onset that is not life long.
- i. The fatigue is severe, disabling, and affects physical and mental functioning.
 - ii. The symptom of fatigue should have been present for a minimum of 6 months during which it was present for more than 50% of the time.
 - iii. Other symptoms may be present, particularly myalgia, mood and sleep disturbance.
 - iv. Certain patients should be excluded from the definition. They include:
 - a. Patients with established medical conditions known to produce chronic fatigue (eg severe anaemia). Such patients should be excluded whether the medical condition is diagnosed at presentation or only subsequently. All patients should have a history and physical examination performed by a competent physician.
 - b. Patients with a current diagnosis of schizophrenia, manic depressive illness, substance abuse, eating disorder or proven organic brain disease. Other psychiatric disorders (including depressive illness, anxiety disorders, and hyperventilation syndrome) are not necessarily reasons for exclusion.

2. Post-infectious fatigue syndrome (PIFS)

This is a subtype of CFS which either follows an infection or is associated with a current infection (although whether such associated infection is of aetiological significance is a topic for research). To meet research criteria for PIFS patients must:

- i. fulfil criteria for CFS as defined above, and
- ii. should also fulfil the following additional criteria:
- iii. There is definite evidence of infection at onset or presentation (a patient's self-report is unlikely to be sufficiently reliable).
- iv. The syndrome is present for a minimum of 6 months after onset of infection.
- v. The infection has been corroborated by laboratory evidence.

In reporting studies it should be clearly stated which of these two syndromes is being studied.

The fatigue described in this paper describing the Oxford criteria does not consider the exacerbation of symptoms and the prolonged recovery time. This difference in the description of the fatigue is critical, and has contributed to the conflict in the medical literature regarding the effect of graded exercise therapy (GET). Studies which use the Oxford criteria tend to show clinical improvement. But the Oxford Criteria also encompass those who have depression or unexplained chronic fatigue. In other words, the subjects in many of the studies supporting the effectiveness of graded exercise do not necessarily meet the criteria used by the later consensus definitions for ME/CFS.

In the medical literature, the most common definition used is the CDC (1994) definition by Fukuda.²⁷⁷

1. Clinically evaluated, unexplained persistent or relapsing chronic fatigue that is of new or definite onset (i.e., not lifelong), is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction in previous levels of occupational, educational, social, or personal activities.
2. The concurrent occurrence of **four or more** of the following symptoms:
 - substantial impairment in short-term memory or concentration;
 - sore throat;
 - tender lymph nodes;
 - muscle pain;
 - multi-joint pain without swelling or redness;
 - headaches of a new type, pattern, or severity;
 - unrefreshing sleep; and
 - post-exertional malaise lasting more than 24 hours.

These symptoms must have persisted or recurred during 6 or more consecutive months of illness and must not have predated the fatigue.

The Canadian Expert Consensus Panel, constituted by Health Canada, published the first diagnostic ME/CFS criteria for clinical use in 2003.²⁷⁸ Dr. Alison Basted, formerly an EHC Staff Physician and now Medical Director of the Complex Chronic Diseases Program in Vancouver was a member of this Panel. In contrast to the Fukuda Criteria, this newer clinical case definition made it compulsory that, to be diagnosed with ME/CFS, a patient must become symptomatically ill after minimal exertion. It also clarified other neurological, neurocognitive, neuroendocrine, autonomic, and immune manifestations of the condition. This new definition narrowed and specified the characteristic of the fatigue in this syndrome. It also expanded the number and variety of symptoms required for the diagnosis of ME/CFS.

The following outlines the Canadian case criteria for the clinical diagnosis of ME/CFS:²⁷⁹

1. New onset, unexplained, persistent physical and mental fatigue that substantially reduces activity
2. Post-exertional malaise or fatigue with pathologically slow recovery
3. Sleep dysfunction
4. Pain in muscles and joints
5. Neurologic/cognitive manifestations
6. At least 1 symptom in 2 or more categories:
 - a. autonomic e.g. orthostatic hypotension, palpitations, irritable bowel syndrome
 - b. neuroendocrine e.g. low temp, premenstrual syndrome
 - c. immune manifestations e.g. lymphadenopathy, allergy
7. Illness persisting at least 6 months (3 months in children); onset usually distinct, but can be gradual

Table 3 Comparison of ME/CFS Diagnostic Criteria

Case Definition of Fukuda		Oxford Criteria	Case Definition of Canadian Consensus Document	
Requires the Presence of Profound Fatigue , Defined as Follows:	Also Requires four or More of the Following Features :	Requires the Presence of Severe Disabling Fatigue as the Main Symptom and Further Defined as Follows:	Requires the Presence of the Following Features :	Also Requires one Symptom From two of the Following Categories :
Symptom duration of ≥ 6 mo Causes a substantial reduction in occupational, personal, social, or educational activities Unrelieved with rest Other medical or psychiatric conditions excluded	Post-exertional malaise lasting >24 hr Impaired memory or concentration Non-refreshing sleep Muscle pain Pain in multiple joints without signs of inflammation Headaches of new type or severity Sore throat Tender cervical or axillary lymph nodes	Symptom duration of ≥ 6 mo Affects both physical and mental functions Symptoms are present $\geq 50\%$ of the time Definite onset and not lifelong Other medical or psychiatric conditions excluded	Symptom duration of ≥ 6 mo for adults and ≥ 3 mo for children New onset of unexplained, persistent, or recurrent physical or mental fatigue that substantially reduces activity levels Post-exertional malaise Sleep dysfunction Pain in muscles and joints Neurologic/cognitive manifestations Other medical or psychiatric conditions excluded	Autonomic manifestations (e.g. orthostatic intolerance, lightheadedness, extreme pallor, nausea, irritable bowel syndrome, urinary freq., bladder dysfunction, palpitations with or without cardiac arrhythmias, exertional dyspnea) Neuroendocrine manifestations (e.g. loss of thermostatic stability, intolerance of extremes of heat and cold, marked weight change, loss of adaptability, worsening of symptoms with stress) Immune manifestations (e.g. tender lymph nodes, recurrent sore throat, recurrent flulike sx's, general malaise, new sensitivities to food, medications, or chemicals)

In August, 2013, the United States Health and Human Services proposed to contract (sole source) with the Institute of Medicine (IOM) to develop “clinical diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome”. However, patient groups objected, and so the process was on hold temporarily, but now will proceed in spite of a letter from 35 of the leading researchers and clinicians to Health and Human Services Secretary Kathleen Sebelius to say they had reached a consensus on using the Canadian Consensus Criteria.²⁸⁰

○ ME/CFS Pathological Mechanisms

ME/CFS has often been documented following exposure to an acute pathogen.²⁸¹ For instance, long-term fatigue, CFS/ME, or both have been reported after infectious mononucleosis,²⁸² viral meningitis²⁸³ and giardia.²⁸⁴ In addition, higher titres of several well-known pathogens have been detected in patients with CFS/ME. One of the most well-studied microbes in this syndrome is Epstein-Barr virus since patients often have higher titers of IgM to the EBV viral capsid antigen.²⁸⁵ Also, antibodies against cytomegalovirus and human herpes virus-6, and Parvovirus B19 have been detected more often in some ME/CFS patients.^{286 287}

On the other hand, the species and prevalence of any one microbe identified in a particular cohort varies from one study to the other, limiting their utility for inferring causation. However, this observed association with infection may be significant because there is evidence that intracellular microbes such as EBV, HHV-6 and CMV can directly interfere with the expression of human genes, contributing to dysregulation of vitamin D receptors, potentially leading to the changes in the endocrine and immune function seen in ME/CFS.^{288 289 290} Some evidence also exists for the possibility that chronic intracellular infection, such as mycoplasma, contributes to ME/CFS.^{291 292}

But there is no trial evidence that antibiotic treatment is effective. Similar observations have been made for Gulf War syndrome that antibiotic treatment is ineffective.²⁹³ Others have argued that pulsed, low dose antibiotics are required (Marshall protocol)²⁹⁴ for ME/CFS, but there is no evidence in the medical literature that antibiotic therapy was found to be generally effective, although patients have reported it may help in some cases.²⁹⁵

A systematic review of the medical literature reveals that the weight of available evidence points towards a reduced physiological exercise capacity in ME/CFS, when compared to sedentary controls.²⁹⁶ Pacing self-management provides a modest improvement in symptom severity in daily functioning.²⁹⁷

There are several studies of ME/CFS which have used cardiopulmonary exercise testing. The first results from these studies were mixed. Some found that the exercise capacity of ME/CFS patients was normal,^{298 299 300} while others found a reduced^{301 302 303 304} capacity. However, repeating the exercise test on the following day demonstrates significant exertional malaise and prolonged recovery in patients with ME/CFS.³⁰⁵ Healthy subjects score the same the next day but ME/CFS patients do worse, with evidence for reductions in maximal aerobic capacity (VO₂ max) and anaerobic threshold.^{306 307} ME/CFS patients have impaired mitochondrial energy metabolism.^{308 309 310 311} With exertion, they reach the anaerobic threshold within two minutes. Because they can't replace the mitochondrial energy fast enough, their exercise capacity test scores are even worse 24 hours later.^{312 313 314 315} Their oxidative stress levels rise faster and stay high longer. This explains why minimal exertion aggravates the fatigue with subsequent prolonged recovery time. It explains why there are many practitioners, experienced in treating these patients, who have witnessed that graded exercise therapy (GET) according to a fixed schedule may be harmful, rather than helpful for ME/CFS.³¹⁶

There is increasing evidence in ME/CFS, similar to fibromyalgia, for the role of central sensitization³¹⁷ and even more robust evidence for oxidative stress.^{318 319 320 321 322 323 324} There is also evidence for change in muscle cell function due to oxidative stress in ME/CFS.³²⁵

Exercise studies on ME/CFS patients show that there is reduced muscle excitability³²⁶ and impaired recovery³²⁷ with simultaneous increases in oxidative stress.^{328 329} ME/CFS patients produce more metabolic byproducts from exercise compared to normal individuals³³⁰ and they have subsequent reduced mitochondrial function.^{331 332 333}

This distinct pattern of fatigue in ME/CFS is important from a therapeutic standpoint. Patients with ME/CFS have great difficulty responding to pre-formatted graded exercise programs, as recommended by some practitioners.³³⁴

Thus far, TRPV1 receptor abnormalities have not been directly measured in any ME/CFS studies, although these patients demonstrate increased gene expression of these receptors after moderate exercise.³³⁵ Like other environmentally linked illnesses, there is evidence for systemic inflammation.^{336 337 338}

In a quantitative PCR genetic analysis of ME/CFS patients' blood compared to controls, differential expression of 88 genes was noted in the ME/CFS patients, 85 of which were upregulated and 3 downregulated. Authors were then able to identify 7 different subtypes of ME/CFS with differences in symptom profiles, severity and Short Form-36 scores.³³⁹

The present available guidelines for the assessment and treatment of ME/CFS are conflicting. What is necessary is to test consensus definitions for validation of their criteria. Using the two day consecutive cardiopulmonary exercise test may help settle the argument as ME/CFS patients show substantially decreased function on the second day compared to normals. This test is potentially an objective, sensitive and specific biomarker for ME/CFS.

○ **ME/CFS Comorbidity**

ME/CFS is comorbid with other entities, including irritable bowel syndrome, chronic tension-type headache, and interstitial cystitis,³⁴⁰ migraine,³⁴¹ metabolic syndrome,³⁴² major depressive disorder,³⁴³ and post traumatic stress disorder.³⁴⁴ ME/CFS is also frequently comorbid with FM and ES/MCS.³⁴⁵ Please see APPENDIX A-Overlapping Diagnoses for 23 Chronic Conditions Cohorts.

○ **ME/CFS Management Strategies**

Dealing with symptoms and life interruptions of chronic complex conditions can be very taxing and frightening indeed. Each person is an individual who has used various mechanisms to cope with the changes related to illness, and other challenging incidents in life. Diverse supportive strategies have been tried to strengthen people's ability to move forward in managing their illnesses and return to better function and quality of life.

One commonly chosen goal of treatment for chronic complex conditions is to improve the daily routines of life which influence health, such as diet, exercise, reduction of chemical exposures and sleep hygiene. The intervention described as cognitive behavioural therapy (CBT) supports the skills for improvement. It is important to distinguish the CBT used in traditional psychotherapy from that which is used as a treatment for chronic complex conditions such as ME/CFS.³⁴⁶ The latter uses some of the same tools and techniques as traditional CBT, but includes condition-specific strategies and should be considered as lifestyle enhancement therapy.

Problem-solving and goal setting are just some of the tools used to assist the patient in working towards an improved structured pattern of life. When necessary, the patient is taught to identify and challenge maladaptive thoughts and triggers which interfere with change.³⁴⁷

A Cochrane Database systematic review of 15 studies using the homework component of cognitive behavioral therapy (CBT) concluded that CBT homework is effective in reducing the symptoms of fatigue at post-treatment compared with usual care.³⁴⁸ However, the evidence at follow-up is limited to a small group of studies with inconsistent findings. At treatment end, 40% of the CBT group showed clinical improvement in contrast to only 26% in usual care, but changes were not maintained at a 1 to 7 month follow-up because people dropped out.

Exercise in the form of graded exercise or paced activity, was assumed to be an integral component of CBT. Ten studies attempted to increase activity and reduce rest time as part of the CBT intervention, which may explain the high dropout rate.

There is evidence from a four-arm trial that CBT with graded exercise (GET) can be more effective for ME/CFS than specialist medical care or adaptive pacing.³⁴⁹ There has also been a strong rebuttal.³⁵⁰ For example, the subjects included in the cited study met the criteria for the broad Oxford definition of ME/CFS, which can also capture those with chronic fatigue of another origin, and depression.

Although it is difficult to research the precise techniques, several modalities have been shown to help. For example, focused attention or self hypnosis might be helpful for chronic pain.^{351 352 353} Other mind-body approaches, including progressive muscle relaxation, meditation, laughter, mindfulness based approaches, guided imagery, yoga, and biofeedback, can be effective in chronic pain.³⁵⁴ Group delivered courses with healthcare professional input may have more beneficial effects than individual therapy for some patients.³⁵⁵

Motivational interviewing (MI) has also been tried. Specific MI techniques include:³⁵⁶

1. using reflective listening to express empathy and clarify the patient's perspectives, without evaluating or lecturing the patient about what *should* be done;
2. questioning discrepancies between current behavior and important goals and reflecting them to the patient, encouraging him or her to consider how changing current behavior might reduce this discrepancy (e.g., how reducing bed rest might further the patient's goal of increasing physical activity);
3. avoiding arguing with or confronting the patient about behavior change by "rolling with resistance"; and
4. supporting self-efficacy, the patient's belief that he or she is capable of successfully performing a specific behavior.

Incorporating specific motivational enhancement strategies into CBT adds to engagement and helps to facilitate change.^{357 358} In order to be successful in reaching health goals, patients must advance through the five stages of change:³⁵⁹

1. precontemplation
2. contemplation
3. preparation

4. action
5. maintenance

When used alone or in combination, according to the needs of the individual, all the above modalities may promote more successful outcomes in self-management for chronic complex conditions such as ME/CFS, including making positive changes in diet, exercise and pain management.^{360 361 362 363 364 365 366}

There is a lack of evidence on the comparative effectiveness of therapies alone or in combination with other treatments, and further studies are required to inform the development of effective treatment programs. One of the goals and measurement of success of self-management programs should be the maintenance of effective treatments.

○ **ME/CFS Disability and Prognosis**

A literature search of clinical follow-up of patients following a diagnosis of ME/CFS³⁶⁷ found that full recovery from untreated ME/CFS is rare, but the prognosis for an improvement in symptoms is less gloomy. The percentage of patients not working varies considerably, from 27 to 65%, and return to work at follow-up ranges from 8 to 30%. The observed wide range is because many studies included both chronic fatigue and chronic fatigue syndrome. The characteristic of the fatigue of ME/CFS is that minimal exertion exacerbates the fatigue, and recovery is prolonged. This defining characteristic is illustrated by the above mentioned reduced exercise capacity scores 24 hours post exertion, which is due to impaired mitochondrial function and increased oxidative stress.

Post exertional fatigue is a strong predictor of an inactive work status and full work incapacity in the long term.³⁶⁸ Thus, the prognosis for ME/CFS with respect to return to work is generally poor.³⁶⁹ The more severe the fatigue is, the worse the prognosis for recovery.³⁷⁰

There are some studies that suggest that cognitive behavioral therapy and graded exercise can improve the functional ability and return to work status for those with ME/CFS.³⁷¹ Most notable is the PACE trial, which has been criticized for flawed methodology.^{372 373 374 375 376 377 378} One reason these studies demonstrated improvement is because they used case criteria which did not restrict the subjects to those with post exertional fatigue. This criterion is required to meet the Canadian case criteria for the clinical diagnosis of ME/CFS. Pushing these patients to increase exercise is potentially harmful.^{379 380}

The majority of women with ME/CFS report some improvement in physical functioning over time, but the improvement is still far short of recovery. Furthermore, those who have a more negative outcome are more likely to have comorbid fibromyalgia.³⁸¹

▪ **Fibromyalgia**

○ **Description and Prevalence, including Women and Children**

Fibromyalgia is a chronic, widespread pain disorder, present for at least 3 months. It frequently follows tissue injury. Although pain is felt in muscle or joint areas, there has been no physical abnormality found in these tissues. Pain onset is usually insidious, sometimes beginning in a

localized area. It may initially be intermittent and progressively becomes more persistent. Pain may vary in location and intensity from day to day, and can be modulated by factors such as weather or stress. Cold and humid weather tends to be associated with increased symptoms. The most frequently reported sensory symptom in fibromyalgia is pressure induced pain.³⁸² Fibromyalgia also includes fatigue, non-restorative sleep, cognitive dysfunction and mood variability, as well as other bodily (somatic) symptoms.³⁸³

Prevalence rates for fibromyalgia in the United States vary from 2-6 percent of the population³⁸⁴ with a female-to-male ratio of 6:1.³⁸⁵ In Canada, the prevalence rate for fibromyalgia is 2-3 percent, with females affected six to nine times more commonly than males.^{386 387} In children, it is more common in prepubertal or adolescent girls,³⁸⁸ and estimates for the prevalence of juvenile fibromyalgia range from 1.3-6.2 percent.^{389 390 391} Juvenile fibromyalgia is similar to the adult presentation and is characterized by persistent and widespread musculoskeletal pain, sleep difficulty, fatigue, and mood disturbance. Patients with juvenile fibromyalgia experience substantial impairment in physical, school, social, and emotional functioning,^{392 393 394} and the majority of them continue to have ongoing symptoms and functional disability into late adolescence and early adulthood.³⁹⁵ There are few studies of treatment of juvenile fibromyalgia. Meta-analytic reviews of cognitive behavioral therapy (CBT) clinical trials arrive at different conclusions regarding the effectiveness of CBT on pain and function.^{396 397} Pain is reduced by only 14%, which is lower than the 30% reduction in pain thought to be clinically meaningful.³⁹⁸ However, these and other reviews indicate significant improvement in coping. Enhancing the ability to engage more in activities such as going to school, doing chores, going out with friends can be achieved without increasing the pain.³⁹⁹

○ **FM Diagnostic Criteria**

In 1990, the American College of Rheumatology (ACR) published the diagnostic criteria for fibromyalgia:⁴⁰⁰

- a history of widespread pain, which has been present for at least three months. The pain is considered widespread when all of the following are present:
 - pain in both sides of the body
 - pain above and below the waist.
 - axial skeletal pain (cervical spine, anterior chest, thoracic spine or low back pain) must be present.
 - palpation induces pain in at least 11 of 18 designated tender point sites.

A proliferation of studies followed publication of the 1990 criteria. According to Medline (US National Library of Medicine), 361 English-language original articles with “fibromyalgia” as a keyword were published in the 20 years before the criteria existed, compared with 3844 in the 20-year period after the publication.⁴⁰¹ The 1990 ACR criteria generated numerous benefits. Studies have begun to unravel the etiology and impact of the disorder, treatment strategies have improved, and patients have also benefited from increased recognition and diagnosis of the disorder. However, the ACR criteria have also been criticized. The most notable criticism has been regarding the use and interpretation of the tender-point count.^{402 403 404 405 406 407}

A strong argument for continuing to count tender points as part of the clinical evaluation is that it is a measure of severity.^{408 409} However, the number of tender points does not fully capture the

essence of the illness. For example, there is almost always accompanying fatigue, which is often severe.^{410 411} The 1990 ACR criteria also lack consideration of associated symptoms, which impact on function and level of disability.^{412 413}

In the early 2000's, Health Canada constituted an Expert Medical Consensus Panel representing clinicians, academic teachers and researchers to study fibromyalgia at the same time as their appointed panel studied ME/CFS. Their findings were published in 2003 and 2004 as a Clinical Working Case Definition of Fibromyalgia. They built upon a history of widespread pain and tender point examination by including additional clinical symptoms and signs. It was required that patients, in addition to the ACR criteria, report two or more symptoms from the following: neurological manifestations, neurocognitive manifestations, fatigue, sleep disturbance, autonomic and neuroendocrine manifestations and stiffness.⁴¹⁴ These criteria have been widely followed internationally and are posted on the Ontario College of Family Physicians' website.⁴¹⁵

In 2010, the ACR proposed new diagnostic criteria, which removed the requirement for tender points.⁴¹⁶ The criteria included measuring the severity of the widespread pain, fatigue, poor sleep restoration and cognitive complaints.⁴¹⁷ This encouraged doctors to quantify and follow symptom severity, although there was disagreement that this captured the essence of the condition.⁴¹⁸ The new criteria proposed two validated measurements to discriminate between patients with fibromyalgia and those with other non-inflammatory pain disorders: the widespread pain index (WPI), i.e., a count of number of painful body regions, and the Symptom Severity (SS) scale, a measure of cognitive symptoms, sleep, fatigue, and additional somatic symptoms.

In 2012, a multidisciplinary team, the Canadian Fibromyalgia Guidelines Committee (CFGF), representing healthcare professionals from relevant fields managing fibromyalgia patients, published evidence-based guidelines for the diagnosis, management and illness trajectory of persons with this disorder. Although there has been some debate over the contents, the diagnostic guidelines have been endorsed by the Canadian Rheumatology Association (CRA) and the Canadian Pain Society:⁴¹⁹

- the diagnosis is based clinically on the chief complaint of pain and associated symptoms of fatigue, sleep disturbance, cognitive changes, mood disorder and other somatic symptoms.
- there are no confirmatory tests for fibromyalgia.
- the examination of tender points to confirm a diagnosis is not required. The physical examination is within normal limits apart from tenderness of soft tissues. There is still some debate about the removal of the mandatory requirement of 11/18 tender points.⁴²⁰
- investigations should be limited to simple laboratory testing, unless the clinical picture suggests some other diagnosis.

The 2012 CFGF criteria include mood disorder in the syndrome of fibromyalgia. The guidelines state that mood disorder, including depression and/or anxiety, is present in up to three quarters of persons with fibromyalgia. The basis for this number comes from one study of 73 individuals seen in tertiary care centres.⁴²² However, community samples are less likely to be as impaired as tertiary-care samples.⁴²³ According to the 2010 Canadian Community Health Survey, only 25% of Canadians reporting a diagnosis of FM also reported a diagnosis of mood

disorder. The data derived exclusively from tertiary centres should not be used to estimate and emphasize the prevalence of psychiatric comorbidity among the general population of individuals with fibromyalgia.

A syndrome is a group of symptoms occurring together that are sufficiently common and distinctive to be characteristic and indicative of some underlying cause. Thus it can be argued that the increased comorbidity of mood disorders requires that they must be included in the syndrome. Non-pain related symptoms in the 2012 Canadian guidelines include sexual dysfunction and posttraumatic stress disorder. Yet, there is no mention of chronic rhinitis or chronic urticaria, which may also be associated with fibromyalgia.^{424 425 426}

Mood disorders are also more likely to be comorbid with other physical diseases such as allergy⁴²⁷ and asthma⁴²⁸ and impact on the severity of poor lung function⁴²⁹ They are considered risk factors for the incidence of diabetes and cardiovascular disease, affecting severity and outcomes.^{430 431} However, the increased comorbidity of mood disorders does not make them part of these diagnoses.

The guidelines state that mood disorders and fibromyalgia are likely distinct. But stating that mood disorders are also part of the syndrome of fibromyalgia may be misleading to clinicians and potentially harmful to patients. Furthermore, there is no mention of ES/MCS in these guidelines, despite the fact that the Canadian Community Health Survey found that 15% the patients with fibromyalgia report chemical sensitivities, and other authors have found more.^{432 433}
^{434 435 436 437 438} Patient organizations have raised considerable concern that the 2012 Canadian diagnostic criteria will lead to confusion, further deterioration in service for fibromyalgia patients, and an increase in stigma.⁴³⁹

○ **FM Pathological Mechanisms**

Fibromyalgia is considered to be a CNS disorder^{440 441 442} in which the processing of pain is abnormal⁴⁴³, involving central sensitization.⁴⁴⁴ This is the term used to describe an increased central nervous system response to a normal sensory input.⁴⁴⁵ It is thought due to activation of NMDA^{446 447 448} and TRPV1 receptors.^{449 450} These receptors are activated by oxidative stress,⁴⁵¹
⁴⁵² which has been demonstrated in fibromyalgia.⁴⁵³ In particular, TRPV1 receptors are activated by chemical exposures.^{454 455} The oxidative stress also contributes to the neuron malfunction in fibromyalgia by reducing mitochondrial function.⁴⁵⁶ There is evidence for systemic inflammation.^{457 458}

Genetic polymorphisms affecting the catechol-o-methyltransferase (COMT) enzyme may predispose to fibromyalgia through abnormal function of the hypothalamic-pituitary-adrenal (HPA) axis, including hyperactive adrenocortical trophic hormone (ACTH) release and adrenal hyperresponsiveness. These polymorphisms may affect ability to inactivate catecholamines and catecholamine-containing drugs.⁴⁵⁹

○ **FM Comorbidity**

Fibromyalgia is frequently comorbid with chronic fatigue and cognition complaints.^{460 461} Patients with fibromyalgia frequently complain of poor memory, severe enough to affect job performance and to lead to disability.⁴⁶² Sleep is also disturbed.⁴⁶³ Overnight polysomnograms

show abnormal alpha wave intrusion.⁴⁶⁴ They have less sleep efficiency, a higher proportion of stage 1 non-REM sleep, and twice as many arousals per hour of sleep.⁴⁶⁵

In particular, fibromyalgia is frequently comorbid with, and is impacted by, ME/CFS,⁴⁶⁶ ES/MCS,^{467 468} IBS,⁴⁶⁹ vulvodynia,⁴⁷⁰ cervical myofascial pain syndrome,⁴⁷¹ migraine headache,⁴⁷² elevated body-mass index (BMI),^{473 474} sleep apnea,^{475 476} chronic rhinitis,⁴⁷⁷ chronic urticaria,⁴⁷⁸ psoriasis,⁴⁷⁹ endometriosis,⁴⁸⁰ lupus and rheumatoid arthritis.⁴⁸¹ Please see APPENDIX A-Overlapping Diagnoses for 23 Chronic Conditions Cohorts.

○ **FM Management Strategies**

According to the 2012 Canadian Fibromyalgia Guidelines Committee (CFGC), similar to a treatment framework published in the United States by the Mayo Clinic,⁴⁸² the ideal management of FM will address pain as well as the composite of symptoms that comprise this syndrome.⁴⁸³ Specific points made by the CFGC include:

- Primary care physicians are encouraged to establish a diagnosis of fibromyalgia as early as possible without need for specialist confirmation.
- Ideal care is centered in primary care.
- Treatment plans should incorporate self-management techniques, goal setting and healthy lifestyles, with acknowledgement of psychological distress when present.
- Patient goals and their levels of achievement should be recorded as a useful strategy to follow outcome.
 - Tender point examination should not be used as an outcome measure.
- Treatment requires a multimodal approach.
- Self-management is facilitated by multi-component therapy.
- Attention should be paid to individual symptoms in a patient-tailored approach.
- Patients should be encouraged to identify specific goals regarding health status and quality of life at the initiation of treatment, with reevaluation of goals during follow-up
- Non-pharmacologic treatments have a positive effect with improvements in self-reported outcome measures including physical status.
 - Non-pharmacologic treatments appear more effective than most pharmacological interventions.
 - These include cognitive behavioural therapy, motivational interviewing, meditation, EMG-biofeedback therapy, imagery, hypnosis, mind-body therapies, transcranial magnetic stimulation, transcranial direct current stimulation, acupuncture, Tai Chi, Qigong, and hydrotherapy.
- Persons with fibromyalgia should participate in a graduated exercise program of their choosing.
- Pharmacologic treatments should be initiated in low doses with gradual and cautious upward titration to minimize side effects.
 - Only pregabalin and duloxetine have been approved by Health Canada for management of fibromyalgia. All other pharmacological treatments constitute "off label use".
 - Continued medication use requires diligent evaluation, with attention to the need for continued use and emergence of adverse effects.
- Clinical outcome can be measured by a simple narrative report of symptom status, without the use of specific questionnaires.

- Psychological counseling and cognitive behavioral therapy may be helpful for associated psychological distress, including fear of pain and activity.
- Any new symptom requires appropriate clinical evaluation and should not immediately be attributed to fibromyalgia.
- Other comorbid illnesses need to be addressed.

Other guidelines have been developed and can be compared to the ACR and CFGC guidelines.⁴⁸⁴ The European League Against Rheumatism (EULAR) gave cognitive behavioral therapy a much lower strength of recommendation.⁴⁸⁵ There were no recommendations provided for patient education or multi-component treatment, both of which are essential for management of chronic, complex conditions.

○ **FM Disability and Prognosis**

Patients with fibromyalgia report persistent widespread pain, fatigue, and substantial functional limitations, which may lead to high health resource use and lost productivity.⁴⁸⁶

Patients with fibromyalgia frequently complain of poor memory, severe enough to affect job performance and lead to disability. There are subsequent economic consequences for both patient and employer, as well as the healthcare system.⁴⁸⁷ Factors such as diminished productivity, temporary work disability, permanent work disability, or early retirement are responsible for up to 70-80% of the total cost of this disease,^{488 489 490} with a loss of 17 to 30 work days per year by patients with fibromyalgia.^{491 492} More than one third of women with fibromyalgia are disabled.⁴⁹³ The majority (70%) of those who work do it part-time.⁴⁹⁴ The economic burden increases with severity.

The Fibromyalgia Impact Questionnaire (FIQ) was developed to meet the need for comprehensive fibromyalgia patient evaluation. It is a validated questionnaire,⁴⁹⁵ which has been used to assess people in the community who have chronic pain⁴⁹⁶ to determine the impact of fibromyalgia on everyday life⁴⁹⁷ and to measure disability⁴⁹⁸ as well as outcomes in drug studies, exercise treatment, multidisciplinary approaches and treatment program evaluation. It is designed to quantify the overall impact of fibromyalgia over many dimensions using visual analog scales (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.). The average score for fibromyalgia is 50. Almost all patients with a score above 79 are disabled from work.⁴⁹⁹

Results from epidemiological research in several countries clearly demonstrate the socioeconomic burden of fibromyalgia and its comorbidities. These results highlight the urgent need for more research on pathophysiology and treatment challenges.⁵⁰⁰

Unfortunately, finding appropriate care for patients with fibromyalgia may be difficult. The majority of Ontario rheumatologists do not wish to be responsible for their care, and the new guidelines say patients with FM should be seen by family physicians, not rheumatologists, despite the fact that the American College of Rheumatology developed the criteria for the diagnosis of fibromyalgia. More than half of rheumatologists still believe that fibromyalgia is primarily a psychosomatic illness.⁵⁰¹

▪ **Environmental Sensitivities/Multiple Chemical Sensitivity (ES/MCS)**

○ **ES/MCS Description and Prevalence, including Women and Children**

The staff physicians at the Environmental Health Clinic at Women's College Hospital produced a 42-page Environmental Sensitivities/Multiple Chemical Sensitivities Status Report, Advances in Knowledge and Current Service Gaps dated October 31, 2010 and updated on February 17 and June 2, 2011. To meet the needs of non-English-speaking populations, the report has now been translated into French and German. A copy is provided (ATTACHMENT B- ES/MCS Status Report), and so not as much detail has been provided in this compendium as for ME/CFS and FM.

In 1994, the Ontario Ministry of Health funded an Environmental Hypersensitivity Research Unit (EHRU) at the University of Toronto, on the recommendation of the Ministry-appointed Ad Hoc Committee on Environmental Hypersensitivity Disorders, chaired by then Family Court Judge George M. Thomson (later Deputy Attorney General for Ontario and Canada).⁵⁰² The EHRU first clarified the distinguishing definitional characteristics, and then took blood samples from cases and controls that revealed genetic detoxification abnormalities in cases. These were considered likely ES/MCS susceptibility factors.⁵⁰³

ES/MCS is a chronic, polysymptomatic condition. Multiple systems are involved, but the system most likely to be provoked is the CNS. The term sensitization has been used in the research of brain function in animals for over 40 years. It is the progressive increase in the size of a response because of repeated stimulations.⁵⁰⁴ In immunology, it is called allergy. In psychology, it is the process of becoming highly sensitive to specific emotional events or situations (e.g. in social anxiety disorder). In ES/MCS, it is the sensitization of the brain to many substances at levels that previously had no relevance. The EHRU noted that 4 neurological symptoms were more common in cases than controls, discussed on p. 43.

One study reported the five most common symptoms with ES/MCS are tiredness/lethargy, difficulty concentrating, muscle aches, memory difficulties and long-term fatigue.⁵⁰⁵

Affected persons report recurrent flares of illness, with symptoms individual to them, when exposed to low levels of environmental chemicals (e.g., pesticides, solvents), common foods (e.g., milk, chocolate, wheat, sugar), multiple drugs, other ingestants (e.g., alcohol, chlorinated water)⁵⁰⁶ and electromagnetic devices.⁵⁰⁷ These flares can vary with the substance, dose, combination and frequency of exposures.

People are continuously exposed to electromagnetic fields (EMFs) in everyday life. Whether they can be harmful to human health continues to be a matter of great debate.

Some individuals experience symptoms in proximity to wireless systems, when using cordless or cell phones, when exposed to baby monitors or some types of artificial light, or in response to various other common electromagnetic exposures, such as cell phone towers. These individuals are being referred to the Environmental Health Clinic at Women's College Hospital with increasing frequency.

Self-reported electric and magnetic field hypersensitivity has been described for more than 25 years.⁵⁰⁸ Population surveys suggest that about 3 to 5% of the population report being symptomatic when near electrical devices.^{509 510} The most common symptoms are fatigue, dizziness, headache, and difficulties concentrating. Other symptoms frequently involve the skin (itching, burning, stinging), respiratory and gastrointestinal systems. The major features of this self-reported disorder are the onset or exacerbation of symptoms with proximity to electrical devices or power lines and telephone towers, and the reduction or disappearance of symptoms when the source is off, or not nearby. In the populations surveyed, claiming to be doctor-diagnosed with ES/MCS was the strongest predictor of also reporting being hypersensitive to EMFs.⁵¹¹

Some authors argue that robust evidence is lacking to support the theory that people can be sensitive to EMFs, basing their opinion on a review of more than 40 blind or double-blind provocation studies.^{512 513} They therefore attribute the EMF hypersensitivity to somatoform disorders.

However, the human brain can detect weak EMFs, as evidenced by changes in brain electrical activity.^{514 515} The medical literature describes other effects of EMFs,⁵¹⁶ such as risk of brain tumors, damage to sperm, behavioural problems in young children,⁵¹⁷ and damage to the blood-brain barrier. However, the literature also demonstrates that the level of evidence is weak,⁵¹⁸ and each issue remains controversial. More research is required and the OCEEH Hub can provide the leadership to network with other international projects in order to develop and promote the required studies,^{519 520} such as developing a working definition of electromagnetic field hypersensitivity (EHS), developing and validating a diagnostic tool (questionnaire) to characterize subjects with purported EHS, identifying subjects, who may be more at risk for testing, performing double-blind exposure challenges (applying the specific frequencies to which each of the participants report reactions), and developing management and treatment tools for patients who identify symptom provocation with EMF proximity.

Like those with ME/CFS and FM, more women are affected with ES/MCS than men. Of those affected with ES/MCS, 70 to 80% are women.^{521 522}

One common denominator of these three conditions is limbic system sensitization. There are sex differences in how the limbic system responds. Functional brain scans reveal that, when challenged, men and women activate different limbic structures following the same provocative stimuli.⁵²³ There are sensory differences which are related to limbic system function. Women have a higher prevalence of several pain-related conditions, including migraine headaches, temporomandibular joint disorders, carpal tunnel syndrome, Raynaud's disease, chronic widespread pain, osteoarthritis (OA), irritable bowel syndrome and pain related to autoimmune disorders (rheumatoid arthritis and other collagen vascular diseases).^{524 525} On average, women are more responsive to painful stimuli,⁵²⁶ and women also tend to have a heightened inflammatory response compared to men.⁵²⁷

Statistics gleaned from the National Health and Nutrition Environmental Survey (NHANES) in the US suggests that environmental pollution exposures affect women more than men.^{528 529 530} Women biologically handle chemicals differently compared to men. The enzyme systems for

detoxification are more active than men.^{531 532 533} Normal kidney clearance of chemicals is lower in females compared to males.^{534 535 536 537} Also, women retain more inhaled volatile organic compounds than men.^{538 539} This is likely because women have a higher percentage of body fat,⁵⁴⁰ which affects the distribution of chemicals that are not easily eradicated.^{541 542 543}

Given the higher domestic responsibilities relative to men, women also have greater exposure to chemical cleaners, detergents and fabric softeners. Women also use more cosmetics, skin care and scented products.

In summary, the prevalence of environmentally linked illnesses, as seen particularly well in ES/MCS, are more common in women because they are more responsive to their environment via both the limbic and immune systems, have a greater body burden of chemical exposures and less efficient detoxification systems compared to men.

Children, from embryo to the completion of adolescence, are often at a different and increased risk from environmental contaminants compared to adults because of differences in behavior and physiology.⁵⁴⁴ They have greater exposures relative to adults, immature detoxification systems, and still-maturing organ systems.^{545 546}

There has been a significant rise in chronic complex conditions in childhood. The number of children with developmental disabilities has increased by 17% over the last decade so that now one child in six is being diagnosed with one of attention deficit hyperactivity disorder (ADHD), cerebral palsy, autistic spectrum disorder, seizures, stammering or stuttering, mental retardation, moderate to profound hearing loss, blindness or learning disorders.⁵⁴⁷

The Environmental Working Group did two small studies of 10 American, Canadian and Dutch newborn babies in 2005⁵⁴⁸ and 2009,⁵⁴⁹ in which they measured the chemicals found in cord blood. In both studies, they found well over 200 chemicals in the newborn babies' circulation. More than 400 publications are available in the U.S. National Library of Medicine which confirm the presence of pollutants in newborn children. Sources of contaminants include outdoor and indoor air, food, water and consumer products.

In 2011, the Canadian Environmental Law Association, the Ontario College of Family Physicians and the Environmental Health Institute of Canada published an extensive scoping review of the literature.⁵⁵⁰ Their main findings were that there is increasing scientific confirmation for the role of early life (in utero and peri-natal) exposures to environmental contaminants and a lifelong vulnerability to chronic disease.

Children are particularly vulnerable to the effects of outdoor air pollution. Those living in urban areas exhibit higher rates of allergy and asthma compared with those from rural areas.^{551 552 553} There are several studies showing adverse effects of outdoor air pollutants on lung development in children of all ages.^{554 555 556 557} The more time kids spend outdoors and the closer they live to major roadways, the more likely they are to have reduced lung function growth by age 18.^{558 559} Children with a genetic predisposition to poor detoxification are more likely to have their pulmonary function growth affected by air pollution.^{560 561}

Several studies have also associated autism and prenatal and early life exposure to air pollution from traffic.^{562 563 564 565} Children with autism have shown a decreased ability to detoxify as well as an elevated body burden of xenobiotics.⁵⁶⁶ Furthermore, there may be an epigenetic predisposition inherited from the mother.⁵⁶⁷

○ ES/MCS Diagnostic Criteria

In the 1980s and 90s various criteria had been proposed for defining a case of MCS, also called environmental sensitivities or hypersensitivities, environmental illness, environmental intolerances, idiopathic environmental intolerances, or toxicant-induced loss of tolerance. There were 9 published definitions. Based on the previous work of Nethercott et al,⁵⁶⁸ a list of criteria that reflected an internationally *consistently observed pattern* of symptom presentation was agreed upon by 34 North American clinicians and researchers who collectively had experience with thousands of MCS patients.⁵⁶⁹

Part of the definitional challenge was, and is, related to the fact that symptoms and signs triggered by low level exposures to environmental agents vary among affected individuals and within individuals, depending on inciting agents as well as the doses, timing, and combinations of exposures. Also, while there can be abnormal physical and laboratory findings, the same findings are not *consistently* abnormal in all patients or in individual patients all the time.⁵⁷⁰

The 1999 consensus criteria were subsequently validated using a reproducible questionnaire.⁵⁷¹ A checklist of the criteria is posted on the Ontario College of Family Physicians website for use by practising clinicians.⁵⁷² The criteria include:

- symptoms are reproducible with (repeated chemical) exposure
- the condition is chronic
- low levels of exposure (lower than previously or commonly tolerated) result in manifestations of the syndrome
- the symptoms improve or resolve when the incitants are removed
- responses occur to multiple chemically unrelated substances
- (added in 1999): symptoms involve multiple organ systems

These criteria were validated by the Ministry of Health-funded Environmental Hypersensitivity Research Unit (EHRU) at the University of Toronto in collaboration with the Environmental Health Clinic at Women's College Hospital. Symptoms which most commonly distinguished patients with ES/MCS from controls were :⁵⁷³

- having a stronger sense of smell than others
- difficulty concentrating
- feeling dull or groggy
- feeling spacey

A systematic literature review published in 2005 confirmed that the most frequent system involved in ES/MCS is the central nervous system.⁵⁷⁴ It is noteworthy that this same observation was described in the 1985 report to the Ontario Ministry of Health by the Ad Hoc Committee on Environmental Hypersensitivity Disorders,⁵⁷⁵ which led to the creation and provincial funding of the Environmental Health Clinic at Women's College Hospital.

○ ES/MCS Pathological Mechanisms

In animal studies, stimulating the brain with electric currents causes seizures. Stimulating the brain for a few weeks at a very low intensity, too low to cause any type of convulsing (aka seizure or epilepsy), will eventually cause seizures in rats even though only a very low stimulation is applied.⁵⁷⁶ Their brains become sensitized to electricity, and the sensitivity lasts for months.^{577 578} This process is called kindling.

Chemicals can cause kindling too. Giving rats repeated low doses of chemicals, which can induce seizures at higher doses, eventually drops the threshold. Giving the rat the previously tolerated low dose would then induce a seizure, without any evidence that the substance had accumulated in the rats.^{579 580 581 582} With this discovery, researchers theorized that kindling, as a form of sensitization, provided a biological explanation for the ES/MCS phenomenon.^{583 584 585}

There is evidence to support the position that sensitization in the brain of rats can be induced by repeated low dose exposures to chemicals. Behavioural or neurochemical alterations can occur from sensitization to solvents, which are toxic at higher doses, such as 1,1,1, trichloroethane,⁵⁸⁶ toluene^{587 588} and formaldehyde⁵⁸⁹ as well as several different pesticides.^{590 591 592 593 594} Examples in animal experiments demonstrate that sensitization to a chemical leads to increased sensitivity to other, chemically unrelated substances.^{595 596 597 598 599}

Oxidative stress contributes to receptor excitability in kindling.⁶⁰⁰ Activating NMDA receptors on the cell membrane of neurons induces kindling.^{601 602} There are other receptors that can be stimulated by oxidative stress, notably the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor, and there is evidence in human studies that these receptors become sensitized in ES/MCS.

TRPV1 receptors are also receptors for capsaicin, which is the pungent ingredient in red-hot chilli peppers. The sensation of heat is created by capsaicin selectively binding to TRPV1 receptors.⁶⁰³ These receptors are widespread and are found in the brain,⁶⁰⁴ eye,⁶⁰⁵ lining of the bladder,^{606 607} mast cells,⁶⁰⁸ stomach lining,^{609 610} bowels,^{611 612} larynx⁶¹³ and bronchial tubes.⁶¹⁴ Because they are found in the pulmonary system, challenging these receptors with inhalations of capsaicin is used to study cough.^{615 616 617 618 619}

The capsaicin inhalation challenge test consists of inhaling different concentrations of capsaicin using a mouthpiece apparatus to control the amount. The total number of coughs provoked is counted over 10 minutes.⁶²⁰ This test is commonly used in clinical research because it induces cough in a safe, reliable, dose-dependent, and reproducible manner.⁶²¹ Well over 100 studies using the capsaicin challenge testing procedure were published over a 20 year period from 1984 to 2004.⁶²²

ES/MCS patients with respiratory symptoms, even without asthma, are hypersensitive to inhalation of capsaicin, when compared to controls, and this has been demonstrated by double-blind challenges.⁶²³ The ES/MCS patients coughed more and, the higher the dose, the more coughs provoked. Other challenge studies have reproduced the same results, demonstrating TRPV1 receptor hypersensitivity in patients with chemical sensitivities.^{624 625 626 627 628 629} These

patients also secrete more nerve growth factor (protein which promotes growth of sympathetic and sensory nerve cells) in the nasal secretions after capsaicin provocation challenge.⁶³⁰

This hypersensitivity explains how and why ES/MCS patients have multiple symptoms from multiple systems. The TRPV1 receptor is especially active in sensory neurons,^{631 632} and the brain,^{633 634 635} notably in the limbic system,⁶³⁶ where it facilitates long lasting sensitization.^{637 638} These receptors drive the excitation of neurons to enhance messaging between them.⁶³⁹

Why some people get sensitized to chemicals more easily than others is not clear. There are many factors including genetic susceptibility. There is evidence that ES/MCS patients are genetically predisposed to have inferior enzyme systems for detoxification.^{640 641} Because they are less capable of efficiently detoxifying,⁶⁴² oxidative stress occurs in ES/MCS patients.⁶⁴³ Oxidative stress can sensitize TRPV1 receptors.^{644 645 646 647} Although the TRPV1 receptor may be the major target for organic solvents in ES/MCS, there are likely others, such as NMDA receptors.^{648 649} There is also some evidence for systemic inflammation.⁶⁵⁰

Austin Bradford Hill developed the basis of modern epidemiological research, which attempts to establish scientifically valid causal connections between potential disease agents and disease. The Bradford Hill's Criteria of Causation outline conditions he thought were needed to establish the strength of a cause-and-effect relationship between two items.^{651 652} One of the criteria for observing cause, which goes beyond just a statistical association, is whether it makes scientific sense. This is known as the coherence of association. The cause-and effect interpretation of data should not seriously conflict with the generally known facts of the natural history and biology of the disease. Another criterion is plausibility. As stated by Bradford Hill, "*What is biologically plausible depends upon the biological knowledge of the day. In short, the association we observe may be one new to science or medicine and we must not dismiss it too light-heartedly as just too odd.*"

Using these cause and effect criteria, it has been argued by some that the etiology of ES/MCS is psychogenic⁶⁵³ and fails to meet Bradford Hill's criteria as a physical entity.⁶⁵⁴ These opinions were published 10 years ago before classical toxicology, i.e. the dose makes the poison, was modernized with recognition of non-monotonic dose responses to many chemicals and the demonstrated model of sensitization. In fact, there are many papers published demonstrating that this classical toxicology model is no longer tenable.

As stated by Bradford Hill: *All scientific work is incomplete - whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time.*

Genetic polymorphisms indicate that people with ES/MCS have more difficulty metabolizing and excreting commonly encountered environmental chemicals and medications in comparison with controls.^{655 656 657 658 659} Even in the absence of an abnormal detoxification polymorphism, oxidative stress occurs in ES/MCS patients.⁶⁶⁰

To summarize, patients with ES/MCS are more likely to have a genetic predisposition to poor detoxification, evidence of oxidative stress and sensitization of TRPV1 receptors. Up-regulation of these receptors occurs secondary to oxidative stress. Studies in animals have demonstrated that central nervous system sensitization to chemicals can occur from repeated and/or strong exposures to individual chemicals. These studies also demonstrated that sensitization to a chemical leads to the increased likelihood of sensitization to other, chemically unrelated substances.

○ **ES/MCS Comorbidity**

ES/MCS is frequently comorbid with ME/CFS and FM and they are also frequently comorbid with other common conditions, such as chronic headache, chronic migraine headache, irritable bowel syndrome (IBS), allergies, asthma and autoimmune disorders. See APPENDIX A- Overlapping diagnoses for 23 Chronic Condition Cohorts.

Patients with multimorbid chronic illness face challenges of self-management, with increased adverse events, high health care utilization and poor quality of care.^{661 662} This is no doubt influenced by the fact that medical care has traditionally focused on the prevention, diagnosis and treatment of single diseases.⁶⁶³

Most research studies focus on the effectiveness of disease-specific interventions, and patients with comorbidity or complex problems are often excluded from clinical trials.^{664 665 666} When they are included, it is difficult to know whether the overall effect of a trial can be extrapolated to individuals with comorbidities, i.e. whether the effect of the treatment is different in those with or without comorbidities.

Approximately 40% of people with ME/CFS also have ES/MCS,^{667 668 669} and 21% were found to have both in the Canadian Community Health Survey 2010. ES/MCS is frequently comorbid with FM,^{670 671 672} IBS,⁶⁷³ and major depressive disorder.^{674 675 676}

○ **ES/MCS Management Strategies**

Guidance for treating ES/MCS has come from experience by numerous clinicians internationally, outlined in the ES/MCS Status Report (APPENDIX B- ES/MCE Status Report: Advances in Knowledge and Current Service Gaps).

It is stated the cornerstones in clinical management of ES-MCS are:

- reduction of exposure to each person's unique environmental symptom triggers (e.g. some perfumes, cat dander) and toxins (e.g. formaldehyde emitted from particleboard, pesticides), once identified via exposure history and observation,
- enhancement of internal processing and elimination of chemicals,
- reduction in body burden of retained chemicals if necessary,
- relief of suffering with symptomatic treatments as needed,
- treatment of co-morbid conditions that can exacerbate or be exacerbated by ES-MCS, and
- encouragement to make changes in habits that would be likely to prevent further illness and promote health.

A survey of support groups and 917 participants was published, which rated the perceived efficacy of 101 treatments, and reported help:harm ratios for these treatments.⁶⁷⁷ For example, chemically free living space was rated the most beneficial treatment, with a help:harm ratio of 155:1, followed by chemical avoidance (119:1). Psychotherapy to help cope had a somewhat positive effect (6:1), but psychotherapy for MCS cure provided no help but no harm (1:1). Antianxiety/antidepressant medications worsened symptoms (0.3:1).

○ **ES/MCS Disability and Prognosis**

Illness related dysfunction from ES/MCS fluctuates on a continuum from mild to serious. It is an important health care issue because it often includes serious dysfunction, is poorly understood by providers and poses extensive financial and treatment obstacles for those who experience it. This can include loss of job, relationships, public access and personal comfort.⁶⁷⁸

There are many studies which have identified a common theme of lack of accessibility.⁶⁷⁹ At best, most patients with ES/MCS have difficulty accessing common community resources that most persons take for granted, including communities of worship, grocery stores, shopping centres, community meetings, public libraries, restaurants, movies, use of public transportation, the homes of extended family members and friends, offices of dentists and medical doctors, public parks, classes at local universities, and most significantly, access to work.^{680 681 682 683 684 685 686} (People with ME/CFS and FM may have difficulty with access based on lack of energy and reduced activity levels.)

Others' lack of understanding and refusal to make accommodations in the workplace have denied spatial access to those with ES/MCS.^{687 688} It is also almost impossible for many of those who are significantly impacted by ES/MCS to find suitable housing because buying and creating a place to live that does not provoke symptoms is only possible for those with the financial resources to do so.⁶⁸⁹ Reduced financial resources is partially as a result of a combination of reduced income, increased expenses, and lack of financial support from authorities, including difficulties receiving worker's compensation and disability benefits because they had difficulties establishing a medical diagnosis.⁶⁹⁰

There has been reluctance to accept ES/MCS as a pathological disorder. But the history of medicine shows that iconoclastic ideas have occurred with many other medical disorders. They invoke controversy, resistance, and sluggish knowledge translation.⁶⁹¹

The limited access to medical care because of the physical barriers of chemical exposures is complicated further because physicians are often unfamiliar with and/or do not believe in ES/MCS. They lack experts and resources to rule in or out other conditions. As a result, these patients describe unmet medical needs, delays in correct diagnosis, or treatment for the wrong condition.⁶⁹²

Persons with multiple chemical sensitivity seek medical treatment in a variety of contexts. Many hospitals and public facilities have initiated scent free policies,⁶⁹³ in part as a result of the EHC's work with the Canadian Coalition for Green Health Care. However, there are difficulties with cooperation and enforcing the policy. Healthcare providers need to be better informed to avoid iatrogenic harm due to medical exposures (for example from cleaning products, scented soaps,


pharmaceuticals, etc.). Preventing reactions not only helps the patient, but saves time and trouble for the staff.

▪ Functional Status

There is substantial comorbidity in patients with any of ME/CFS, FM or ES/MCS. These patients suffer more functional impairment and disability with comorbidity,⁶⁹⁴ just like those with other chronic illnesses. Those patients with all three diagnoses experience the greatest amount of disability, as demonstrated by the following graph (Figure 2 below) of 128 consecutive patients seen at the Environmental Health Clinic, Women's College Hospital.⁶⁹⁵ This is a graph of scores from the Medical Outcomes Study Short-Form Health Survey (SF-36).

The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It assesses functional status on 8 descriptively named subscales: physical functioning (PF), role limitations due to physical health problems (RL-P), bodily pain (BP), general health perceptions (GH), energy and fatigue (E/F), social functioning (SF), role limitations due to personal or emotional health problems (RL-E), and emotional well-being (EWB).⁶⁹⁶ Each has been shown to have high reliability and validity. The SF-36 has been documented in nearly 4,000 publications in articles describing more than 200 diseases and conditions.⁶⁹⁷ It has been used in general population surveys of Canadians,^{698 699} in a range of patient populations, including those with CFS,^{700 701 702} FM,^{703 704 705} and MCS,⁷⁰⁶ as well as in a comparative study of all 3 groups.⁷⁰⁷ Scoring results in scale ranges from 0 to 100, with higher values representing better function.

Figure 2 Functional Status (SF-36) of EHC Patients vs Canadian Norms



ES/MCS has been described as a stigmatized condition, both because people affected have to avoid seemingly harmless exposures or wear a mask⁷⁰⁸ and because of the psychologization of the condition, whereby they are perceived as liars or hypochondriacs.^{709 710} The veracity,

morality, and accuracy of patient symptom descriptions is questioned. Similarly, psychologization and disbelief are experienced by patients with ME/CFS and fibromyalgia.⁷¹¹

▪ Psychologization

Opinion articles still appear in respected medical journals in support of the psychogenesis of ME/CFS, FM and ES/MCS,⁷¹² despite the fact that the citations frequently used to support the argument are outdated.⁷¹³

Significant methodological errors also persist. For example, studies which positively demonstrate the efficacy of graduated exercise for ME/CFS often use case definitions which capture other fatigue-related conditions, such as depression and unexplained chronic fatigue. These latter conditions respond somewhat favorably to pre-programmed exercise, but ME/CFS does not.

ME/CFS patients do have an increased prevalence of current mood disorders, primarily major depression,^{714 715 716 717 718} but it is unclear whether the patients had these conditions before or after they became ill with ME/CFS. Some doctors use this fact to insist that ME/CFS is primarily a psychiatric illness.^{719 720 721 722 723}

Mood disorder has been added by the Canadian Fibromyalgia Guidelines Committee to the latest diagnostic criteria for FM with scant evidence from a tertiary care sample.

Because there are currently no generally recognized biological markers for ES/MCS and the pattern of sensitivities does not match the traditional toxicology paradigm, psychological theories to explain ES/MCS and psychotherapeutic treatments have been suggested since the 1980s.^{724 725} They were roundly criticized for poor methodology.⁷²⁶ For example, one early study of 50 cases concluded that because at least half the patients were still symptomatic even when avoiding chemical pollutants, ES/MCS cannot exist.⁷²⁷

Studies report associations of ES/MCS with panic disorder^{728 729} and major depression.^{730 731 732} However, association does not mean that there is a cause and effect relationship. In fact, mood disorders are also more likely to be comorbid with other physical diseases such as allergy⁷³³ asthma,⁷³⁴ diabetes⁷³⁵ and cardiovascular disease.⁷³⁶ Nevertheless, the theories of psychogenic etiology due to false attribution, i.e., panic disorder, chemical phobia and agoraphobia, continue to be offered in the medical literature.^{737 738 739 740 741 742} Some authors have opined that ES/MCS "is a belief characterized by an over-valued idea of toxic attribution of symptoms and disability, fulfilling criteria for a somatoform disorder and a functional somatic syndrome."⁷⁴³ These same authors postulate that to work with ES/MCS patients, "one must understand the dynamics of brainwashing, including the effects of iatrogenic influence and the individual's predisposition and susceptibility to it."⁷⁴⁴

Another recently published article refers to these patients as hermits.⁷⁴⁵ The authors claimed to have conducted a "literature review" of case reports of ES/MCS and compared their "recluse-like behaviour" resulting from environmental sensitivities to the behaviour of ancient hermits. The bias in this report is reflected by their "literature review", which only searched media articles, blog posts, and online books and forums in order to generate the following quotes: "This is not a

lifestyle I choose”, “I have no choice”, “Nobody would live like this if they had a choice”, and, “Do you think I would have given up a satisfying life ... if I had a choice?” Unfortunately, the authors used these quotes to conclude, without any substantiation, that ES/MCS patients have a compulsion to flee, like hermits. What was actually expressed in these case reports is the absence of choice due to symptom provocation in certain environments, and the subsequent negative impact on quality of life in order to maintain health.

If one wishes to study how individuals experience their own problems in the life situation in which they find themselves, interviews can offer a method to obtain such information. They are used as a means of understanding how people experience their world and to gain insight into their perceptions, experiences and emotions. However, the goal of the interview is to obtain nuanced descriptions of various aspects of the interviewee’s life-world, and to analyze the data according to qualitative research protocols. Qualitative content analysis of interview data should follow a set procedure: (a) audio review, (b) reading through transcriptions, (c) discussions among investigators regarding key elements of participants’ perceptions, (d) determination of conceptual themes, and (e) assignment of relevant responses to appropriate thematic constructs.⁷⁴⁶

In comparison to the lack of science and open bias apparent in the above article comparing ES/MCS patients to hermits, consider the results of a published interview study, in which ES/MCS subjects were first identified objectively by capsaicin inhalation challenge. The interviews were analyzed using qualitative content analysis, which revealed the following themes and suitable quotes:⁷⁴⁷

Limitations in one’s life situation

- *I simply can’t enter that shop, my eyes smart ...I have to leave immediately.*
- *We have someone who uses ... it’s the smell that makes me feel so bad and I avoid her ever since she got that perfume.*
- *We have relaxation exercises in that room in the morning and it ended up with me leaving; I couldn’t take part because we were supposed to lie down on the wall-to-wall carpet and my throat started to catch and I felt bad.*

Lack of understanding from others

- *You can be sitting at a meeting where people reek of strong perfume and an undertone of sweat. And it attracts a bit of attention when you have to inhale and all that and, well...I know that people have thought that I was being fussy.*
- *The staff come back from their breaks and smell of smoke and coffee and what-not and it’s...I haven’t told anyone that they’re causing me any problems...you’d just look like a whiner.*

In support of the psychogenic theory is the argument that we have been unable to demonstrate chemical sensitivity with double blind challenge studies. However, blinding the chemical challenge is impossible, without using another chemical to mask it. Nevertheless, a published, systematic review of all the challenge studies concluded that MCS cannot exist.⁷⁴⁸ There was no transparency of authors’ financial involvements in this systematic review. Furthermore, there was no explanation as to why several previously published challenge studies using capsaicin to demonstrate chemical sensitivity were not considered.

Based on a reductionist, psychogenic model, published suggestions for treatment have included cognitive behavioral therapy, relaxation therapy with deconditioning and psychotherapeutic medications.⁷⁴⁹ However, the level of evidence demonstrating any efficacy of these treatments for ES/MCS is almost non-existent since only a few case reports of improvement have been published in the past 30 years.^{750 751 752 753} Furthermore, the fact that relaxation therapies may possibly have a biological impact on patients with ES/MCS does not verify that it is a psychiatric illness. These techniques also have a positive effect on biological entities, such as asthma,^{754 755} hypertension and migraine,⁷⁵⁶ and can significantly lower blood glucose, cholesterol and hypertension.^{757 758 759 760 761}

While skeptics and proponents often frame the debate in a dualistic or reductionist manner, claiming that chemical intolerance is either completely psychogenic or completely toxicogenic, accumulating data strongly suggests that a multifactorial process underlies these conditions.⁷⁶² The Nova Scotia Environmental Health Centre integrates relaxation therapies with avoidance of chemical triggers, elimination diet for food sensitivities, low dose allergen therapy, intravenous therapy, and pacing and energy management strategies when necessary.⁷⁶³ This is consistent with the systems medicine model.

Although there is no objective evidence of direct psychogenesis, some people disbelieve patients reporting of symptoms of ME/CFS, FM or ES/MCS, diminish the significance of their symptoms and experiences, and dismiss even the possibility of the existence of the conditions.

▪ Interventions and Prognosis for ME/CFS, FM and ES/MCS

Thus far, treatments routinely used for ME/CFS and ES/MCS are consistent with their definitions. Patients with ME/CFS have fatigue that is exacerbated with minimal exertion, with prolonged recovery. Therefore, the patients are instructed how to pace activities with rest, with reported improvement in quality of life.⁷⁶⁴ Patients with ES/MCS have symptoms exacerbated by chemical exposures, which are relieved after they are no longer exposed. Treatment is the provision of support and education to maintain environmental control and avoidance, which seems to provide the highest patient satisfaction.⁷⁶⁵ There are more treatments available for fibromyalgia, but they are highly variable, and long-term prospective observational studies have found that patient outcomes are typically poor.^{766 767} Almost half the patients with fibromyalgia are likely to be dissatisfied with treatment.^{768 769}

The basic requirements for care of patients with ME/CFS, FM and ES/MCS are the same as those with other chronic diseases; to provide support, relieve symptoms, improve outcome and quality of life, increase function and independence, and decrease their use of the healthcare system other than periodic monitoring. It is not desirable that patients avoid physicians altogether because they may neglect to get timely treatment for other significant treatable conditions.

Many patients with FM and ES/MCS are at least partially disabled and unable to work, as are most patients with ME/CFS. Reduced physical functioning, which is common in all three of these conditions, is a predictor of work disability.⁷⁷⁰ The more time missed from work, the greater the likelihood of long-term disability.^{771 772} The present inadequacies in being able to

provide early diagnoses and the paucity of available treatments in the general medical community underline the need for more education and earlier interventions to preserve or even restore the ability to work.⁷⁷³ Patients with one of these conditions are more likely to develop one or both of the others, increasing disability. Both the number of comorbidities and disability are strongly associated with cost.⁷⁷⁴ Earlier diagnosis can reduce referral costs and investigations, and interventions may prevent the onset of comorbidity, all of which can lead to a net savings for the healthcare sector, and a better quality of life for the individual.

▪ Summary

The 2010 Canadian Community Health Survey (CCHS) reported that the number of Canadians stating they had a diagnosis of ME/CFS, FM and ES/MCS by a health professional has increased markedly since 2005. The prevalence of CFS increased by 23%, 13% for FM and 34% for ES/MCS.

ME/CFS affects up to three percent of the population and, although it may improve, it usually does not go away (around 6% recovery rate). Severe, chronic fatigue is the dominating complaint. It is made worse by exertion, is not substantially relieved by rest, and the post-exertion recovery time is prolonged. It affects women six times the rate of men. It also occurs in children.

There are various definitions for ME/CFS, which influence guidelines for treatment. Cardiopulmonary exercise testing repeated 24 hours later demonstrates reduction in maximal aerobic capacity, aerobic threshold and increased oxidative stress. There are extensive alterations in gene expression with at least 7 different subtypes of ME/CFS related to genetic upregulation (86 genes) or downregulation (3 genes).

There is significant comorbidity, including with FM and ES/MCS. There is a lack of evidence on the comparative effectiveness of therapies alone or in combination with other treatments, and further studies are required to inform the development of effective treatment programs.

FM is a chronic, widespread pain disorder, present for at least 3 months. Prevalence ranges from 2-6 percent, with females six to nine times more commonly affected. In children, it is more common in prepubertal or adolescent girls. The most recent (2012) diagnostic and management guidelines are endorsed by the Canadian Rheumatology Association (CRA) and the Canadian Pain Society, although there is wide international respect for the Canadian Clinical Working Case Definition of FM (2003).

FM is a nervous system disorder, with activation of NMDA and TRPV1 receptors. Genetic abnormalities affecting the catechol-o-methyl transferase enzyme may predispose to FM. There is evidence for oxidative stress, reduced mitochondrial function and systemic inflammation. It is frequently comorbid. Multiple treatments including pregabalin and duloxetine medications and exercise are recommended. There is significant disability, and the majority of those who work do so part-time.

The consensus criteria for the diagnosis of ES/MCS have been validated by the Ministry of Health-funded Environmental Hypersensitivity Research Unit (EHRU) at the University of Toronto in collaboration with the Environmental Health Clinic at Women's College Hospital.

The Ministry of Health also funded pioneering genetic research. There is evidence that ES/MCS patients are genetically predisposed to have inferior enzyme systems for detoxification. Because they are less capable of efficiently detoxifying, oxidative stress occurs, which can sensitize TRPV1 receptors.

Sensitization of the nervous system to chemicals and subsequent increased sensitivity has been demonstrated in animal models. This is more likely to occur due to oxidative stress, which activates TRPV1 receptors. These TRPV1 receptors are widespread and are found in the brain, eye, bladder lining, mast cells, stomach lining, intestines, larynx and bronchial tubes. They are capsaicin (hot peppers) sensitive. Capsaicin sensitivity has been documented in ES/MCS.

Women are more affected by ES/MCS than men. This may be due to being more responsive to their environment via both the limbic and immune systems, having more exposures and a greater body burden of chemical agents, and having less efficient detoxification systems compared to men. Clinical practitioners report children are affected, but the prevalence is unknown.

ES/MCS patients, because their symptoms are triggered by environmental exposures, have difficulties accessing common community resources that most persons take for granted, including communities of worship, grocery stores, shopping centres, community meetings, public libraries, restaurants, movies, use of public transportation, the homes of extended family members and friends, offices of dentists and medical doctors, public parks, classes at their local universities, and most significantly, access to work. Others' lack of understanding and refusal to make accommodations in the workplace have denied spatial access. People with ME/CFS and FM may have problems with access based on lack of energy and reduced activity levels.

ES/MCS is frequently comorbid with ME/CFS and FM and is also frequently comorbid with other common conditions, such as chronic headache, chronic migraine headache, irritable bowel syndrome (IBS), allergies, asthma and autoimmune disorders. People with multiple conditions and all 3 of these diagnoses experience the greatest amount of disability.

Patients with ME/CFS, FM and ES/MCS are stigmatized by their condition and have difficulty accessing health care. The basic requirements for care of these patients are the same as those with other chronic diseases; to provide support, relieve symptoms, improve outcome and quality of life, increase function and independence, and decrease their use of the healthcare system other than periodic monitoring.

Earlier diagnosis of these three chronic complex conditions, not only may lead to a better quality of life for affected individuals, but also can reduce referral costs and investigations. In addition, interventions may prevent the onset of comorbidity, leading to a net savings for the healthcare sector.

III Need for Environmental Health Education and Government-funded Canadian Environmental Health Clinics

▪ Current Medical Education

In the early 1990s, the Institute of Medicine advised doctors to be prepared to diagnose, prevent and treat environmentally related conditions because public trust in government and industry was declining and physicians were being looked upon by patients and community groups as reliable sources of information on environmental risks.^{775 776} In 1996, 24% of medical schools in the US had no required environmental content in their curriculum. Those schools which did averaged only a total of seven hours of instruction⁷⁷⁷ and 70% of the deans of those schools stated that there was minimal emphasis on environmental health.⁷⁷⁸ Environmental medicine was rated as an unimportant area of training by medical students⁷⁷⁹ and was described by physicians as the least important area in their practice.⁷⁸⁰ Even today, many doctors are still uninformed when questioned by their patients on possible environmental health effects.⁷⁸¹

It is difficult to teach public health effectively within a medical culture that values acute care of individual patients over population-based health protection, health promotion, and disease prevention.⁷⁸² Medical students lack interest in public health undergraduate medical training. Many find it a “waste of time” and irrelevant, which is unfortunate because many students feel they are able to function more effectively as clinicians after taking elective public health courses or a combined MD/MPH degree.⁷⁸³ Public health and preventive medicine need to be incorporated into the medical curriculum and taught by credible clinicians who are key role models and opinion leaders.⁷⁸⁴

A report of a survey, which was sent to 1000 physicians in Virginia, was published in 2011.⁷⁸⁵ The response rate was low, but there were 90 responses, most commonly from family practice and internal medicine. Although 97% of the respondents reported having patients with ES/MCS, only 6% had a treatment protocol for the condition. Only 30% had received any training regarding ES/MCS in medical school and it was not determined what type of training they had received. Only 13% reported currently considering chemicals when diagnosing health problems in new patients. These statistics are significant when one considers that some degree of ES/MCS occurs in up to 1 in 5 primary care patients presenting with diverse symptoms, yet it is rarely recognized by clinicians.⁷⁸⁶

There is an absence of education for management of patients with ME/CFS, FM and ES/MCS, except, as far as funding would allow for the staff physicians of the Environmental Health Clinic, for accredited rounds, annual Environmental Health Days, presentations at professional conferences, and the Mainpro-C programs produced for the Ontario College of Family Physicians (OCFP). Most nursing settings do not have an MCS protocol.⁷⁸⁷ Although there is elective training in the EHC, there is no formal education for medical students or residents. The criteria for the diagnoses of ME/CFS, FM and ES/MCS are available on the website of the OCFP. However, no other specialty has a particular interest in any of these patients. The majority of rheumatologists in Ontario do not even want to treat patients with FM.⁷⁸⁸ And, there are no specialized treatment centres in Ontario for children with these disorders.

▪ Jurisdictional Review of Community Health Centres

In April 2013, a questionnaire developed by this project's Medical Advisory Committee was sent to various community health centres (CHC's) in Ontario. There were 41 respondents, 80% by physicians and 20% by nurse practitioners. There is a clear lack of comfort in ability to diagnose and/or treat environmentally linked conditions. The following is an analysis of the results:

• **Diagnosis:**

- 73.2% were not comfortable with their ability to diagnose ME/CFS. Only 2.4% of respondents were totally comfortable with their ability to diagnose ME/CFS;
- 35.7% were not comfortable with their ability to diagnose fibromyalgia. Only 11.9% of respondents were totally comfortable.
- 92.7% of respondents were not comfortable with their ability to diagnose ES/MCS;
- 90.5% of respondents were not comfortable with their ability to diagnose sick building syndrome;

• **Treatment:**

- 23.8% of respondents were totally or somewhat comfortable with treating patients with ME/CFS;
- 50% of respondents were totally or somewhat comfortable with treating patients with fibromyalgia.
- 7.3% of respondents were totally or somewhat comfortable treating patients with ES/MCS;
- 2.6% of respondents were totally or somewhat comfortable treating patients with sick building syndrome; 80.6% were somewhat or very uncomfortable;

It is quite clear that there is a need for further education in the comprehension, diagnosis, treatment, and self-management of these disorders. The observed reluctance to make the diagnoses of these environmentally linked conditions is consistent with the medical literature.⁷⁸⁹
⁷⁹⁰ ⁷⁹¹ ⁷⁹² An early diagnosis can have a positive effect on severity and the prognosis for disability in ME/CFS and FM,⁷⁹³ ⁷⁹⁴ ⁷⁹⁵ but unfortunately this rarely happens.⁷⁹⁶ ⁷⁹⁷ The jurisdictional review results strongly suggest that these patients' needs are not being met.

Respondents were also asked to indicate which elements of environmental medicine should be included in pursuing further education on these chronic conditions, and to rank the importance as *absolutely*, *perhaps*, or *not interested*. The following results were obtained:

• **Furthering education (answered as 'absolutely'):**

- | | |
|--|-----|
| - diagnostic criteria | 93% |
| - effectiveness of various treatments | 92% |
| - self-management strategies | 90% |
| - history/physical manifestations | 87% |
| - expected course of disease progression | 83% |
| - complementary and alternative treatments | 76% |
| - etiology | 73% |

- | | |
|--|-----|
| - prevention strategies | 73% |
| - completion of insurance disability forms | 65% |
| - comorbidities | 59% |
| - impact of social determinants of health | 47% |

▪ **Ontario College of Family Physicians Consideration of a Centre of Excellence in Environmental Health**

In 2008, the Ontario College of Family Physicians (OCFP) was funded by the Ministry of Environment (Ontario) to determine the feasibility of establishing a Centre of Excellence in Environmental Health.⁷⁹⁸ The project was chaired by Ms. M. Janet Kasperski, who was the Chief Executive Officer of the OCFP.

The following are quotes from that publication:

- *The Ontario College of Family Physicians (OCFP) and our partners firmly believe that now is the time to invest in a comprehensive program to gather and synthesize the research regarding the impact of the environment on health and use the evidence to support healthy public policy and the education of healthcare professionals (family doctors, paediatricians, obstetricians, nurses, nurse practitioners and dieticians) so that they understand the impact that the environment plays in the health of the population.*
- *While it is vitally important for healthcare professionals to be knowledgeable regarding environmental health, policy makers also need to have easy access to credible information on which to base policy decisions. The Ontario College of Family Physicians (OCFP) and our partners have actively used the evidence we have gathered to support policy development. One concrete example relates to the OCFP's Pesticide Review paper that has been used to support Cosmetic Pesticide By-laws all across the country. The second relates to our urban sprawl paper and subsequent brochures that have been used to support the Greenbelt and Places to Grow legislative bills.*
- *Research indicates that family physicians are seen as the most trusted healthcare professionals to address these concerns; however, doctors report that their academic training did not prepare them adequately to answer the questions that their patients pose. The lack of access to peer-reviewed information on the environment and health further decreases their ability to provide the level of support that patients require.*
- *The Environmental Health Clinic at Women's College Hospital has been gathering the evidence regarding the assessment, diagnosis and treatment of environment induced conditions such as fibromyalgia, chemical sensitivities, chronic fatigue syndrome and the like. They have worked hard to develop tools to help family doctors to assess and manage environment induced conditions and have developed a well regarded educational series, as well as summer internships and practice placements to support learners and practising family doctors to gain experience in the treatment of these complex disorders.*

The following are a few quotes from those who contributed to the feasibility study:

- *The current system in Ontario for environmental research and education (knowledge synthesis, translation and transfer) is grossly inadequate to non-existent.*
- *Scientific back-up is absolutely critical. There is already a lot of science behind this kind of medicine. Because the science comes from here and there and another place, somehow, it gets lost. There is not one common voice. There is lots but we have to put Authority behind it to have a positive impact on future generations.*
- *There is a need to change the current way of thinking so that physicians pay more attention to lifestyle and environmental impacts on health.*
- *The time is now. The public understands that the health of themselves and especially that of their children and their children's children depends upon what we do today. The time is right for the establishment of the centre of excellence in environmental health.*

The feasibility study concluded that "An Environmental Health Centre, adequately funded, is long overdue."

▪ **Government-funded Canadian Environmental Health Clinics**

Along with the present Environmental Health Clinic at Women's College Hospital (EHC) in Toronto, there are two other publicly-funded clinics in Canada for patients with environmentally-linked chronic complex conditions.

There is an academic paediatric clinic in Edmonton that also sees children and adolescents with these conditions, but does not have government funding. It is a member of the Pediatric Environmental Health Specialty Units in the United States.⁷⁹⁹

○ **Complex Chronic Diseases Program (CCDP) at British Columbia Women's Hospital and Health Centre**

This program was established in fall, 2012 in Vancouver. Dr. Alison Bested, who was a staff physician at the EHC, is the Medical Director. The program is funded by Provincial Health Services Authority (PHSA) to assist persons with Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Tick-borne Illnesses e.g. Lyme disease.⁸⁰⁰

The CCDP has a consultative/research/educational model. It offers an integrative care approach, with an interdisciplinary team including: specialty medicine, nursing, social work, physiotherapy, and naturopathy. It will offer patients a variety of group sessions on the topics of: education, pain management, stress management, and family support. The program will create online learning modules for health care professionals about FM, ME/CFS, and Lyme Disease. There will be Mainpro-C accredited modules and the program also anticipates a strong research mandate.

- **Nova Scotia Environmental Health Centre**

The Nova Scotia Environmental Health Centre is now known as the Integrated Chronic Care Service (ICCS). It is the treatment facility in Capital Health for environmental sensitivities and complex chronic conditions.⁸⁰¹ Capital Health is Nova Scotia's largest provider of health services, including hospitals, health centres and community-based programs throughout Halifax Regional Municipality and the western part of Hants County. It provides service for the 400,000 residents of the Halifax region and specialist services to the rest of Nova Scotia, and Atlantic Canada.

The ICCS provides health services for:

- Chronic fatigue syndrome
- Chronic pain conditions
- Chemical intolerance, chemically triggered conditions, asthma, migraines, allergic conditions, building related illness
- Multiple chemical sensitivity
- Fibromyalgia
- Functional neurologic and gastrointestinal syndromes
- Multiple chronic conditions (multi-morbidities)

Their model is based on the premise that chronic disease outcomes are better managed by addressing the needs of the whole person. They integrate the physical and psychosocial needs of individuals by focusing on the person instead of the disease(s) and on improving functional health and quality of life. The care team includes: physicians, occupational therapists, a nurse practitioner, registered nurse, licensed practice nurse, a psychologist, psychotherapist and a dietitian.

Their individual treatments consist of:

- Assessment and treatment of environmental sensitivities
- Management of medication intolerance
- Occupational therapy interventions
- Elimination diet, management of food sensitivities and other dietary interventions
- Treatment for sensory processing disorders
- Psychotherapy
- Mindfulness-based interventions
- Low Dose Allergen Therapy
- Intravenous therapy

Group-based interventions include:

- Mindfulness-based interventions
- Pacing and energy management strategies
- Food sensitivities management
- Biofeedback approaches
- Health lifestyle education

Rehabilitation may also include:

- Support with return to work and workplace accommodation

- Support with family education

They have published studies measuring health outcomes of a multidisciplinary care approach in individuals with chronic environmental conditions,⁸⁰² the impact of their approaches on ES/MCS,^{803 804} among others.⁸⁰⁵

- **Environmental Health Clinic- Ontario**

In contrast, the Environmental Health Clinic at Women's College Hospital provides single physician clinical service only four days per week (0.9 FTE, four part-time doctors). In order to accommodate the demand for consultation, patients are restricted to one assessment visit (up to three-hours) and just two follow-up appointments for about one to one and a half hours each. The assessment of the most likely determinants of illness consists of: review of medical consultations accumulated by the referring physician and laboratory data (in response to suggestions by the EHC); complete review of the illness onset and progression, family history, environmental exposure history, chronological systems review and physical exam; provision of diagnosis or diagnoses; education; development of a treatment plan with the patient; and provision of a detailed report to the referring physician (average 5 pages). Besides administrative support, information in terms of websites or printed articles are provided to patients on the waiting list or patients when they visit.

In order to make the overload on patients' defence systems very understandable, and yet less frightening, a teeter totter analogy is used (see Figure 3), so that patients can see that if they reduce the load on their bodies' functions as much as they can, they will return to more balance and better overall functioning (see Figure 4). The way to get there is to plant "SEEDS of health" via a "Weed, SEEDS and Feed" method i.e. to remove stressors (weeds), plant SEEDS (an acronym meaning Sleep, Exercise, Environment, Diet and Support) and slowly but steadily grow a health garden feeding whatever works. Please see ATTACHMENT C, SEEDS of Health.

Figure 3 **Exhaustion** Marshall L.- used with permission of author

Exhaustion





Figure 4 **Adaptation**- Marshall L.- used with permission of author

Adaptation



Budget limitations currently prevent the EHC from having a multidisciplinary clinic, although in the past, staff included a nurse, community outreach coordinator, dietitian and psychologist.

An athletic therapist consults upon referral by the EHC physicians, and is deemed very helpful, but consultations with her about exercise are paid by the patients.

- The EHC nurse ensured intake forms were completed fully and would assist patients who were having difficulty. She answered questions and sent resources and tips to patients on the waiting list, completed a cumulative patient profile and some of the physical examination, and liaised with patients by telephone as they required. She compiled a newsletter 3-4 times a year with the assistance of other staff and guest writers. Every year, she taught nursing students from the University of Toronto in the EHC, and supervised their research projects where they reviewed the literature on subjects and designed informative brochures or posters. She started a nurses' discussion group in Canada and wrote an information article for the Canadian Nurse. She served on the hospital "Green Team".
- The EHC Community Outreach Coordinator also served on the hospital "Green Team", where she helped spur the progression to a "Fragrance-free" workplace with attractive signage and presentations to workers and management. She and a physician expanded the program to other willing hospitals through the Canadian Coalition for Green Health Care. She kept in contact with the patient support groups and participated in their programs. She developed power point presentations about Environment and Health and various subjects therein, and was a popular speaker at EHC education events and conferences, and with employers and schools. With the help of the Medical Director, she organized and supervised research projects for medical students as part of their Determinants of Community Health course. She served as Co-chair of the Occupational Working Group of the Toronto Cancer Prevention Coalition, which promoted toxic use reduction.
- Two part-time dietitians were referred patients by the EHC physicians who needed assistance with nutritional sufficiency of their diet, how to do elimination and reingestion challenge tests for suspected food intolerances, and, if necessary, rotate foods. They informed other dietitians of their work and the unique needs of EHC patients.
- The EHC psychologist designed a 10-week educational group "Planning for Health" program for patients that took into account their fatigue and intermittent cognitive difficulties by having freedom of movement within a safe, fragrance-free setting, regular film clips to illustrate the points she was making, and application of breathing and focused attention exercises to relieve pain and improve sleep. An EHC physician who was also trained as a GP psychotherapist attended the groups and saw patients individually as needed. The evaluations of the group and functional status reports were very positive, and patients returned one year after the group ended to review their progress.
- In addition, when she was at the EHC, Dr. Alison Bested wrote a very useful practical book for patients, now in its second edition.⁸⁰⁶ She trained in cognitive behavioural therapy for the chronically ill, and ran group programs twice a year, some of them by Ontario Telemedicine Network, which helped expand the educational range.

Accommodating patients in the EHC has challenges. A number of patients with ME/CFS or FM find the duration of the initial appointment long and difficult, due to increasing fatigue and cognitive difficulties. As well, a number of them come from a far distance, and round trip or repeated visits are also difficult. Patients with ES/MCS are not well accommodated physically. Previously, the EHC was in a separate wing of the hospital with terrazzo floors, well off-gased materials and furnishings, and operable windows. Presently, the Environmental Health Clinic (EHC) is situated in a downtown Toronto, mechanically ventilated office building, without any specific retrofitting to improve indoor air quality. Accommodation consists of one portable air filter system in each doctor's office and two large filters in the hall and examining room. The present location is considered temporary due to the reconstruction of Women's College Hospital. However, the EHC staff physicians have expressed concern because there are no specific plans for accommodation to address the environmental needs of patients with ES/MCS when the hospital reconstruction is completed.

The EHC has participated in research projects for the first 10 years with the Ontario Ministry of Health-funded Environmental Hypersensitivity Research Unit at University of Toronto and published six papers, including one validating the survey questionnaire, one determining the best case criteria for ES/MCS, and one outlining genetic susceptibility factors, and the usually normal laboratory tests. Some additional research papers have been prepared by the physicians working in collaboration with colleagues at the University of Toronto, University of Ottawa, the Ontario College of Family Physicians and Health Canada, Transport Canada and the Canadian Human Rights Commission. Dr. Bested, when she worked at the EHC, was a physician member of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and was selected by Health Canada to serve on the Expert Medical Consensus Panel that developed the Canadian Consensus Criteria and guidelines for diagnosis and treatment of ME/CFS. She also participated in writing the Primer associated with these criteria.

With regard to education and health promotion, the Women's Health Matters website contains several information resources for patients. Physicians are members of the Environmental Health Committee of the Ontario College of Family Physicians and participate in literature review and advocacy reports/brochures for cleaner environments to protect population health. Practice tools are posted on the OCFP website. Medical students and residents, as well as practising physicians have been trained on site, and, while funding allowed, we had a College of Family Physicians of Canada- and Royal College of Physicians and Surgeons of Canada- accredited rounds series, as well as an Environmental Health Fellowship Program with the Department of Family and Community Medicine at the University of Toronto. The physicians were largely responsible for developing a Mainpro-C-accredited 4-module course "Environmental Health through the Lifespan", which is being taught at OCFP and College of Family Physicians of Canada conferences, and on road trips. Two physicians have developed university credit courses, which they have combined to hopefully qualify for a University of Toronto certificate in Environmental Health. The originals were a core curriculum Environmental and Occupational Public Health course in the Master of Public Health program at Lakehead University, and an Environmental Health course for undergraduate science students at the University of Toronto. The EHC clinical staff have been long time environmental health promoters as partners in the Canadian Partnership for Children's Health and Environment and the Canadian Coalition for Green Health

Care. See ATTACHMENT B, ES/MCS Status Report, Advances in Knowledge and Current Service Gaps, Table 6 re partnerships.

- **Summary**

Systems-based medical training, including the environment as a determinant of health, is lacking in medical schools and there is lack of connection to public health. There is an absence of education about ME/CFS, FM and ES/MCS, except for annual OCFP or EHC Environmental Health Days, and presentations and Mainpro-C workshops at professional conferences for practising physicians who choose to attend. The Jurisdictional Review of Community Health Centres revealed that most physicians are not comfortable diagnosing or treating these disorders.

A feasibility study by the OCFP in 2008 concluded that an adequately funded Environmental Health Centre is long overdue. Presently, the Environmental Health Clinic at Women's College Hospital provides much less clinical service than the Nova Scotia Environmental Health Centre and the planned provision of assessment, treatment and research by the newly established Complex Chronic Diseases Program at British Columbia Women's Hospital and Health Centre.

Nevertheless, the EHC has made an important start with clinical programs, resources, education of health professionals, crucial foundational research, and partnerships for health promotion with the Ontario College of Family Physicians, the Canadian Partnership for Children's Health and Environment and the Canadian Coalition for Green Health Care. Please see APPENDIX B-ES/MCS Status Report.

They point out to patients in easy-to-understand language how overload of the body's systems can occur, and employ an innovative "Weed, SEEDS and Feed" framework for organizing complex treatments. Please see APPENDIX C- SEEDS of Health.

IV Ontario Centre of Excellence in Environmental Health- Principles

▪ Meaning of Centres of Excellence

In Canada, Centres of Excellence exist for many different professions, including industry and health, and usually have obtained the designation from federal or provincial governments.^{807 808} There are several Centres of Excellence for health in Ontario, including:

- Ontario Center of Excellence for Child and Youth Mental Health.⁸⁰⁹
- Digital Pathology Centre of Excellence.⁸¹⁰
- Kensington Eye Institute⁸¹¹ and Kensington Hospice⁸¹²
- Centre of Excellence for Integrated Senior Services⁸¹³
- Ontario Bariatric Network (4 Centres of Excellence)⁸¹⁴
 - Hamilton Bariatric Centre of Excellence
 - St. Joseph's Healthcare Hamilton
 - Hamilton Health Sciences Centre (Medical Centre)
 - University of Toronto Collaborative Bariatric Surgery Program
 - Humber River Regional Hospital
 - St. Joseph's Health Centre
 - University Health Network (Toronto Western Hospital, Toronto East General Hospital)
 - St. Michaels Hospital
 - Guelph Bariatric Centre of Excellence
 - Guelph General Hospital
 - Ottawa Bariatric Centre of Excellence
 - The Ottawa Hospital
- Mount Sinai Hospital in Toronto lists six Centres of Excellence⁸¹⁵ for:
 - Women's and Infants' Health
 - Surgical Oncology
 - Urgent and Critical Care
 - Inflammatory Bowel Disease
 - Musculoskeletal Disease
 - Biomedical Research
- West Park Healthcare Centre Long-Term Ventilation Centre of Excellence⁸¹⁶
- Toronto East General Hospital Provincial Weaning Centre of Excellence for Prolonged Ventilation⁸¹⁷
- Wabano Centre for Aboriginal Health⁸¹⁸
- Sioux Lookout's Meno Ya Win Health Centre of Excellence for Aboriginal Health Care⁸¹⁹

There does not appear to be a consistent definition or model for a Centre of Excellence. A review of multiple websites of various Centres of Excellence,^{820 821} including those above, provides some insight into the meaning. A medical centre of excellence (COE) is usually viewed or accredited by a governing agency or third party as a place of research and/or education and/or treatment, and it links with other organizations or Centres of Excellence to enable knowledge transfer and information exchange. Clinically, it should provide the highest quality health care

for specific conditions. Being designated as a COE signifies that the centre has an important and specific expertise for the service that is provided. It delivers or facilitates comprehensive, evidence-based care, that is multidisciplinary, and yields best quality outcomes and high patient satisfaction.

A multidisciplinary approach to delivering care involves a team of healthcare experts working together toward a common goal, with the patients' preferences as the focal point. These healthcare experts should provide the leadership to guide the creation of a multidisciplinary program and set the bar for excellence. This will be a challenge given the multiple systems and symptoms involved in each person's illness. In Phase I of the OCEEH, we hope to have two meetings of experienced clinicians and researchers, 1. to plan the clinical program and GRADE the evidence for various tests and treatments and 2. to set a research agenda, including evaluation strategies, and to discuss priorities.

▪ **Networks of Centres of Excellence of Canada**

The Networks of Centres of Excellence (NCE) is a Canadian government funding initiative allocated through three federal granting councils: Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council Canada (NSERC), and Social Sciences and Humanities Research Council (SSHRC).⁸²²

NCE networks are large-scale, academic-led virtual research centers that bring together multidisciplinary partners from academia, industry, government and not-for-profit organizations to accelerate the creation and application of knowledge.⁸²³ Examples include

- Allergy, Genes and Environment Network (Allergen); McMaster University
- Canadian Arthritis Network (CAN); Mount Sinai Hospital, Toronto
- Canadian Stroke Network (CSN); University of Ottawa
- Neurological Development Network (NeuroDevNet); University of British Columbia
- Stem Cell Network (SCN); University of Ottawa
- Technology Evaluation in the Elderly Network (TVN); Queen's University

As stated on their website, this network obtains funds for collaboration from companies, universities, hospitals, governments and communities to generate knowledge translation into results, such as better health care.

The Ontario Centre of Excellence in Environmental Health (OCEEH) should aspire to be part of this network, because research, while essential to develop strategies for ME/CFS, FM and ES/MCS, is at a very early stage of development. The Ministry of Health made an auspicious start by funding the Environmental Hypersensitivity Research Unit (EHRU) on the recommendation of the Ad Hoc Committee on Environmental Hypersensitivity Disorders (chaired by Judge George Thomson). The EHRU also made an auspicious start by clarifying the diagnostic criteria for ES/MCS and discovering genetic detoxification vulnerabilities. Hopefully, the MoHLTC can encourage the three federal granting councils to fund such research, as ME/CFS, FM, and ES/MCS receive very low research funding.⁸²⁴ (Please see Table 1, Chapter I-CIHR Funding for Chronic Health Conditions.)

▪ **Integration of Primary Care and Public Health in the OCEEH**

The OCEEH will utilize and integrate individual and population based approaches:

1. Primary care
2. Preventive medicine
3. Public health

Primary care focuses on providing medical services to individual patients with immediate health needs. Public health focuses on offering a broader array of services across communities and populations that collectively will help people to be healthy. Although primary care and public health share a goal of promoting the health and well-being of all people, these two disciplines historically have operated independently of one another. In 2012, the Institute of Medicine (IOM) in the US called for greater collaboration between public health and primary care because they ‘share the common goal of improving population health as well as involving the community in defining and addressing its needs’.⁸²⁵

According to the Association of Faculties of Medicine in Canada (AFMC), which represents Canada's 17 faculties of medicine, the integration of public health concepts in clinical practice is essential to providing high quality healthcare.⁸²⁶

The University of Toronto's Dalla Lana School of Public Health has recently developed a Division of Clinical Public Health to integrate primary care, preventive medicine and public health. It will foster collaborative research, training and knowledge translation programs within the University of Toronto, associated hospitals and community health centres (CHCs)⁸²⁷, as well as other primary health centres.

Examples of integrating primary care and public health already exist, funded by the Ontario MoHLTC:

- Living Healthy Champlain coordinates, promotes and facilitates self-management programs across the Champlain Local Health Integration Network (LHIN). They have adapted the Stanford Chronic Disease Self Management Model to provide a centralized program, which focuses on lifestyle change for people with chronic conditions, such as diabetes and chronic pain.⁸²⁸ As of December 2012, 150 workshop leaders have been trained and over 180 workshops have been held involving 1500 participants. Training is now offered in several languages, including English, French, Mandarin, Arabic, Punjabi and Somali, which reflect the local needs. The workshops have also been offered to Aboriginal groups across the region.⁸²⁹
- Southlake Regional Health Centre hosts a Self-Management Initiative for diabetes in the Central LHIN.
- The Central East LHIN hosts a Living a Healthy Life with Chronic Conditions six-week self-management workshop for people with chronic conditions.

Despite the significant role played by environmental exposures in the development and exacerbation of chronic disease, none of the above programs has an environmental health perspective. In the past year, the Ontario College of Family Physicians has developed a 2 day program of 4 Mainpro-C workshops for physicians to integrate environmental health practices

into primary care. These evidence-based programs were developed primarily by the physicians at the Environmental Health Clinic at Women's College Hospital. They teach how to incorporate the fundamentals of systems-based environmental medicine to diagnose and treat patients with environmentally-linked illnesses, such as ME/CFS, FM and ES/MCS. They also teach how to incorporate the use of the environmental exposure history in every day primary care to contribute to the prevention of environmentally linked chronic illnesses from preconception to old age, as well as programs for self management for those who are already chronically ill.

There is increased awareness and interest in prenatal and early exposures by the Canadian Partnership for Children's Health and Environment⁸³⁰ and a new Ontario Birth Study at Mt. Sinai Hospital, Toronto.⁸³¹

The OCEEH will participate in these and other programs to contribute to the integration of primary care, preventive medicine and public health in individual communities across the province. The primary care focus will be on providing services for those with environmentally linked illnesses, notably ME/CFS, FM and ES/MCS.

Preventive medicine will incorporate the use of systems-based environmental medicine practices into conventional primary care, including the periodic health examination, from preconception to treatment of the elderly. Most important are the environmental exposure history and education to reduce exposures.

Public health will include community based monitoring, increasing public awareness and promotion of activities to reduce pollutant exposures.

The OCEEH will provide the following services for those with environmentally linked illnesses. Provision of services is to be directed towards individuals (clinical medicine) and the community (public health). This includes:

1. Health services (assessment, diagnosis and treatment)
2. Social services and advocacy
3. Education and Health Promotion
4. Research
5. Policy development

▪ **Evidence-based Practice of Medicine**

A central role of the OCEEH is to provide evidence-based or evidence-informed assessment, diagnosis and treatment primarily focused for patients with ME/CFS, FM and ES/MCS according to the best available evidence.⁸³² In order to establish this centre of excellence, recommendations and guidance for the assessment, diagnosis and treatment of these disorders must be developed based on the model of "best" and "promising" practices, and the addition of new practices, when they emerge.

According to the US Institute of Medicine, the best evidence based practice requires the integration of the best research evidence with clinical expertise and patient values.⁸³³ When these

three elements are integrated, clinicians and patients form a diagnostic and therapeutic alliance, which optimizes clinical outcomes and improved quality of life.⁸³⁴

As stated by McMaster University's Dr. David Sackett, a Canadian pioneer in evidence-based medicine:⁸³⁵

“Evidence based medicine is the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research. By individual clinical expertise we mean the proficiency and judgment that individual clinicians acquire through clinical experience and clinical practice.”

The provision of evidence-based or evidence-informed medicine requires the use of "best" and "promising" practices and the addition of new “emerging” practices. However, there are no precise definitions which delineate them. The following definitions will be used.

- **Best practices**

Best practice is based on the application of the best available evidence to establish a diagnosis and prescribe treatment. According to the highest level of available replicated published literature, there have been positive results linked to outcome from application of specific interventions, and little or no severe side effects. Practices supported by systematic review are considered "best practices". The strength of recommendation is “strong”.

- **Promising practices**

There is no consistently applied, precise definition of a promising practice. A promising practice has been described as an approach for which there is documented evidence in at least one setting of its effectiveness in achieving intended health-related results without undue adverse effects.⁸³⁶ It is usually determined based on expert opinion.⁸³⁷ Due to accumulating data, the interventions are being used by some centres. The strength of recommendation is “strong” or “weak (conditional/ discretionary)”.

- **Emerging practices**

An emerging practice is one of interest, but does not yet have good evaluation data available to demonstrate positive outcomes and safety, when compared to other available practices. The strength of recommendation is “weak”.

- **Levels of evidence⁸³⁸:**

1. Systematic review - an organized, critical assessment and evaluation of all research studies that address a particular clinical issue. It may include pooling of data from different studies (meta-analysis)
2. Randomized trial - study participants are randomly assigned to one of two groups: the experimental group receiving the intervention that is being tested and a comparison group (controls) which receives a conventional treatment or placebo.
3. Cohort study - individuals with differing exposures to a suspected factor (chemical exposure or lifestyle event such as diet) are identified and then observed for the

occurrence of certain health effects over some period, commonly years rather than weeks or months.

4. Case series - a descriptive report of a group of cases
5. Mechanistic reasoning/expert opinion.

Unfortunately, these levels of evidence do not necessarily provide a definitive judgment about the quality of evidence because there may be variance in design or methodology of the studies reviewed.

In order to develop guidelines to recommend treatment, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for grading the strength of evidence is recommended.⁸³⁹ The GRADE system is used widely: Health Quality Ontario⁸⁴⁰, the World Health Organization, the American College of Physicians, the American Thoracic Society, UpToDate (an electronic resource widely used in North America, www.uptodate.com), and the Cochrane Collaboration are among the more than 25 organizations that have adopted GRADE. This widespread adoption of GRADE reflects GRADE's success as a methodologically rigorous, user friendly grading system.

To achieve transparency and simplicity, the GRADE system classifies the quality of evidence in one of four levels:

- **High quality** - further research is very unlikely to change our confidence in the estimate of effect
- **Moderate quality** - further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
- **Low quality** - further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
- **Very low quality** - any estimate of effect is very uncertain

Recommendations to develop guidelines are based on the level of available evidence.⁸⁴¹

- The strength of a recommendation reflects the extent to which we can be confident that desirable effects of an intervention outweigh undesirable effects. It is determined by:
 - the balance between desirable and undesirable consequences of alternative management strategies
 - quality of evidence
 - variability in values and preferences
 - resource use
- GRADE classifies recommendations as strong or weak
 - **Strong** recommendations mean that most informed patients would choose the recommended management and that clinicians can structure their interactions with patients accordingly
 - **Weak** recommendations mean that patients' choices will vary according to their values and preferences, and clinicians must ensure that patients' care is in keeping with their values and preferences

The implications of a **strong recommendation** are:

- **For patients**—most people in your situation would want the recommended course of action and only a small proportion would not; request discussion if the intervention is not offered
- **For clinicians**—most patients should receive the recommended course of action
- **For policy makers**—the recommendation can be adopted as a policy in most situations.

The implications of a **weak recommendation** are:

- **For patients**—most people in the situation would not want the recommended course of action, but many would
- **For clinicians**—should recognize that different choices will be appropriate for different patients and that each patient must be helped to arrive at a management decision consistent with her or his values and preferences
- **For policy makers**—policy making will require substantial debate and involvement of many stakeholders.

The present level of available treatment for ME/CFS, FM and ES/MCS is clearly insufficient to induce significant recovery and reduction of disability for all, especially as measured by ability to return to work. It is beyond the scope of this proposal to rate the quality of evidence available for the assessment, diagnosis and treatment of environmentally linked conditions. It is also beyond the scope of this proposal to develop guidelines for the diagnosis and treatment of these disorders. As a result, at present, the reliance is on recommendations and resources for diagnosis and therapy contained in the Mainpro-C modules, accredited by the College of Family Physicians of Canada.

Developing guidance for the assessment of environmentally linked conditions and for the treatment of these conditions separately and when comorbid will require the participation of the Hub health professionals and other experienced clinicians communicating with researchers utilizing the GRADE system. A forum (preferably 3 days) will afford such an opportunity. Such a Forum is proposed in Section VI, “Building the OCEEH”. Since research is obviously needed, a second forum is proposed to set the research agenda, including evaluation criteria, and priorities.

▪ **Hub and Spokes Model**

The care of patients in the OCEEH will be based on existing and emerging patient and person focused evidence-informed chronic care models. The proposed model for the OCEEH includes a central Hub and Spokes throughout the province. The Spokes will involve health care providers, who will receive specialized education, developed and delivered by the medical experts in the Hub. The Hub will also provide the leadership for the best and promising practices to be available for those patients and families who are assessed, treated and followed in the Spokes, and will provide the necessary continuing medical education to maintain these practices.

Ongoing research will play a key role in the OCEEH. Developing a database, with permission from patients to track long-term outcomes is essential. Collecting and analyzing data on the

patients from before they enter and after completing the clinical pathways will analyze how well the Hub and Spokes model is able to treat patients who have come through the program. Research will help to identify and assess new tools for assessment and treatments, as they are developed and become available. The Hub will also collaborate with the University of Toronto and other research centres on basic research into underlying mechanisms.

Presently, the availability of care required for patients with these disorders is inadequate. The results of the jurisdictional review of the healthcare providers in community health centres demonstrated a clear lack of comfort in the ability to diagnose and/or treat these chronic, complex, environmentally linked conditions.

The purpose of creating the OCEEH Hub and Spoke model is to fill the gap in care for these patients and to make it more accessible across Ontario. The Hub, funding permitting, is positioned to advance science in this area. Individualized care models will come from the available best and promising practices, which are defined by the weight of evidence in the medical literature. Environmental health and systems medicine approaches to care are not currently in the core curriculum of medical or nursing schools. Care will be provided to patients in the meantime, and a goal will be that these elements will be incorporated in all aspects of training in medical and nursing schools, as well as in family practice and specialty residencies.

In considering the best and promising practices, a jurisdictional review of expert centres was also conducted by the Medical Advisory Committee of the Steering Committee for this Business Case Proposal.

- **Jurisdictional Review of Expert Centres**

Reputed experts and expert centres were recommended by members of the Medical Advisory Committee and Patient Consultants and solicited to participate in a Jurisdictional review of diagnostic methodologies, assessments of function and treatment modalities. Of 14 expert centers solicited, only nine responded. One respondent only does research. 100% (8/8) of respondents see patients with ME/CFS and FM. 62.5% (5/8) see patients with ES MCS or sick building syndrome. With respect to diagnostic tests and treatments, there was wide variation in responses. Given the low number of responders, it is regarded as more productive to host a forum where a working group of experts will review and discuss best and promising practices.

- **Patient- and Person-centred Care**

- **Chronic Care Model**

The traditional model of health care has been that physicians were primarily responsible for managing chronic conditions.⁸⁴² This led to patients being passive recipients of medical advice, rather than being active participants in medical decisions.⁸⁴³ With respect to chronic care treatment, primary care encounters are usually bound by time constraints, such that multiple diagnoses, problems and patient concerns compete with each other for a place on the agenda.⁸⁴⁴ Environmental medicine has always depended on close interaction with and feedback from patients, given the lack of definitive diagnostic tests, and the patients' need for assistance in self-management, for example in pacing and avoidance of symptom triggers. However, the

physicians were often underpaid, but the healthcare system is promoting change. For example, enabling physicians to be remunerated for the time spent with patients with these chronic complex conditions (e.g., K037) is helping to encourage the transformation to provision of better healthcare.

The Chronic Care Model (CCM) is based on the concept that when proactive health care teams provide care to informed, activated patients, clinical quality and outcomes should improve.^{845 846} Patient interest and motivation to be involved in care planning and resources to participate in the interventions are central to successful outcomes. Self-management and self-management support are integral components of the CCM.⁸⁴⁷ Self-management refers to the way in which people with chronic conditions manage their lives, lifestyles and treatment.

○ **Self-management**

Because of the burden of chronic disease on individuals and families, primary care is now shifting from a predominantly medically focused diagnosis and treatment model to patient focused self-management.^{848 849 850} Self-management refers to the individual's ability to manage the symptoms, treatment, physical and psychosocial consequences and lifestyle changes inherent in living with a chronic condition. Efficacious self-management encompasses the ability to monitor one's condition and to affect the cognitive, behavioural and emotional responses necessary to maintain satisfactory quality of life. Self-management is a dynamic and continuous process of self-regulation.⁸⁵¹

Chronic disease prevention and management is founded on patients' inner strengths and their personal expertise about their health/illness experiences, in combination with information given to them by different health professionals. It focuses on supporting the modification of risk factors and encouraging self-management. It does not eliminate the need to be seen by physicians or other personnel periodically for condition-specific advice, as is provided with most other chronic illnesses. It has been shown to be effective in cardiovascular disease,⁸⁵² chronic obstructive pulmonary disease,⁸⁵³ asthma⁸⁵⁴ and diabetes,⁸⁵⁵ leading to a decrease in the use of health services, and improved functional status and quality of life.

Self-management support by the healthcare team is vital to improving care and outcomes. Providing the information and support to enable patients and families to better care for their illness is essential.⁸⁵⁶ Self management programs focus on the patient, encourage collaborative goal setting, and build self-efficacy⁸⁵⁷ to enable them to better manage their health in partnership with health-care providers.^{858 859 860} Achieving success requires an ongoing collaborative process between patients and healthcare professionals.^{861 862} Self-management support is defined as the systematic provision of education and supportive interventions by health care staff to increase patients' skills and confidence in managing their health problems, including regular assessment of progress and problems, goal setting, and problem-solving support.

○ **Patients' Needs and Preferences**

Empowering patients to self manage their symptoms using targeted education and support can lead to significant and sustained change. Most definitions of patient empowerment include some conceptualization of personal control and self-efficacy/self-mastery.^{863 864 865 866 867 868} Empowerment interventions have proven to be clinically useful, especially in the context of chronic disease.^{869 870 871 872}

Patient-centered care is not technology centered, doctor centered, hospital centered or disease centered.⁸⁷³ The hallmark of patient-centered care is to customize treatment suggestions and decision-making at visits in response to the patients' preferences and beliefs. As emphasized by the Institute of Medicine (IOM), patient-centered care with good communication and interaction is an essential component of all quality care.⁸⁷⁴ The IOM defines it as the provision of care that is respectful of and responsive to individual patient preferences, needs, and values, and ensuring that patient values guide all clinical decisions.

Patient-centered care is paying attention to patient needs and circumstances when planning care. It is associated with improved health care outcomes.⁸⁷⁵ It helps to facilitate the understanding of the impact of an illness or a treatment effect on the patient's overall quality of life, and leads to better satisfaction and improved self-management.⁸⁷⁶ When patients perceive their physician visit to be patient-centered, i.e., they feel understood and adequately involved in developing their treatment plan, they experience better recovery, better emotional health, and dramatically fewer diagnostic tests and referrals.⁸⁷⁷ A focus on patient-centred care can reduce the use of specialists and the number of visits to their primary health care provider by 20%.⁸⁷⁸

- **Ongoing Relationships with Staff**

In addition to patient-centered communication/interaction, the heart of person-centered care is the developing relationship between the client and the frontline staff and the healthcare providers.⁸⁷⁹ Person-focused care is based on the gradual, accumulated knowledge of clients. It provides the basis for better recognition of health problems and needs over time, and facilitates appropriate care for these needs in the context of other needs. It specifically focuses on the whole person.

Primary care is whole person-focused care over time, not disease-focused. To be person-focused, it must be accessible, comprehensive (dealing with all problems except those too uncommon to maintain competence), continuous over time, and coordinating when patients have to receive care elsewhere. The essence of person-focus implies a time focus rather than a visit focus. It extends beyond communication and respect for the individual because much of it relies on the knowledge of the patient that accrues over time. It is not specific to disease-oriented episodes. Relationship continuity is a key element in primary care.⁸⁸⁰

Both patient-centered and person-focused care require adequate recognition of health problems experienced by people, but they are different.⁸⁸¹ Care is better when it recognizes that the patient's problems are unique to the person's context, rather than what the diagnosis is.

The Hub is a tertiary centre, and thus the care provided by the Hub will be more patient-centered than person-focused. It will develop individualized multidiscipline treatments for each patient, using the chronic care model. It will rely on a patient-centered focus to inform and promote empowerment and self-management, recognizing as much as possible each person's context. Patients referred from the Spokes will eventually (perhaps as early as 6 months) be returned there or to their primary care provider for their longer term care, in order to make space for new referrals. Hence, a goal is to involve Family Health Teams as well as Community Health Centres

as spokes, and to eventually incorporate education about ME/CFS, FM and ES/MCS in primary care practices across the province.

The continuing care provided in the Spokes (when they are widespread across the province) will be both patient- and person-focused, emphasizing relationship continuity. This is consistent with Health Quality Ontario's bestPATH initiative, which focuses on three key elements of health care delivery:⁸⁸²

1. person-centered
2. appropriate
3. timely

▪ **Interprofessional team**

Patients with chronic, complex health conditions typically require more than one health discipline to address multiple problems. The US Institute of Medicine has suggested that healthcare professionals working in interprofessional teams can best communicate and address these complex and challenging needs.^{883 884} Members of the team have the common goal of restoring and maintaining an individual patient's health. The interprofessional team approach encourages the sharing of expertise and perspectives, and combining resources, which can improve healthcare processes and outcomes.⁸⁸⁵

There are important characteristics that determine team effectiveness, including members seeing their roles as important to the team, open communication, the existence of autonomy, and quality of resources.⁸⁸⁶

○ **Interprofessional Collaboration**

According to the Canadian Interprofessional Health Collaborative,⁸⁸⁷ collaboration is a partnership between a team of health providers and patient/client in a participatory, collaborative and coordinated approach to share decision-making around health and social issues. It is the process of developing and maintaining effective interprofessional working relationships with learners, practitioners, patients/clients/ families and communities to enable optimal health outcomes. Elements of collaboration include respect, trust, shared decision making, and partnerships.

○ **Shared Decision-making**

Shared decision-making is an interactive process in which healthcare providers and consumers collaborate to make healthcare decisions. What the patient brings to the discussion table is his or her own unique experience of illness. People with chronic illness often struggle to juggle the competing demands of their lives, including but not limited to the challenge of managing their health, dealing with the costs of illness, the personal limitations imposed by ill health, and the obstacles faced in negotiating "the system" (medical, legal, third party insurance, etc).^{888 889 890} All of this is frequently complicated further by multimorbidity.

The essential components involve healthcare providers' and consumers' participation at all stages of the treatment decision-making process, including information exchange, deliberation (discussing treatment options and consumer preferences) and arriving at an agreement on a

decision to implement.⁸⁹¹ It is a core element of patient-centered care.^{892 893} In fact, interprofessional collaboration as well as collaboration between the healthcare professionals and the patient are all vital to the concept of patient-centered care and shared decision-making.^{894 895}

- **Individualized Treatment Program**

Most patients with chronic complex conditions have multimorbidity. Therefore any treatment program must be individually designed according to that patient's needs rather than depend solely on guidelines which do not consider multimorbidity. The existence of multiple chronic conditions can result in atypical clinical presentations, poor diagnostic accuracy of laboratory tests, and conflicting treatment priorities.^{896 897 898}

The determinants of health for each individual patient also need to be considered when evaluating treatment options. These include the person's social and economic environment, individual characteristics, preferred lifestyle, and his/her own environmental exposure history.

Collaboration between multiple interprofessional team members and the patient and his/her family, with coordination, will assist the decision-making process. This model suggests an increased likelihood of success for patients attending either the Hub or Spoke, as measured by improvement of quality of life and reduction of utilization of the healthcare system.

- **Summary**

A medical centre of excellence focuses on delivering comprehensive, evidence-based or – informed care, which is multidisciplinary, aiming for best quality outcomes and high patient satisfaction. In particular, the OCEEH will utilize and integrate individual and population based approaches- primary care, preventive medicine and public health. It will provide service for complex, chronic environmentally linked illnesses, focused on ME/CFS, FM and ES/MCS, including health services, social services and advocacy, research, education and health promotion, and policy development.

The guidelines for assessment and treatment will be developed based on the level of available evidence and will be provided according to best and promising practices. The quality of evidence will be classified using the GRADE system. The strength of the recommendations will be determined by four key factors: (1) balance between desirable and undesirable effects; (2) quality of evidence; (3) patients' values and preferences and (4) costs.

The present level of available treatment is clearly insufficient to induce significant recovery and reduction of disability, especially as measured by ability to return to work. It is beyond the scope of this proposal to rate the quality of evidence available for the assessment, diagnosis and treatment of these chronic, complex, environmentally linked conditions. It is also beyond the scope of this proposal to develop guidelines for the diagnosis and treatment of these disorders. This will be a prolonged process that evolves as the centre evolves.

As a result, at present, the reliance is on recommendations and resources for diagnosis and therapy that are contained in the Mainpro-C modules, accredited by the College of Family Physicians of Canada. However, it is planned to provide a three-day workshop of experts who

will GRADE the current tests and treatments into best practices (for which there is sufficient evidence), promising practices (where there is consensus they are likely to be helpful with minimal adverse effects, plus agreement to evaluate their use), and emerging practices (which have to be tested by formal research protocol).

The proposed model for the OCEEH includes a central provincial Hub and ever-widening Spokes providing services as close to home as possible. The Spokes will involve health care providers, who will receive specialized education, developed and delivered by the experienced medical staff in the Hub and a few trained community clinicians. Ongoing research will play a key role.

The purpose of creating the OCEEH Hub and Spoke model is to fill the gap in care for these patients, to make it more accessible across Ontario, and to advance the field.

Treatment will be made available according to GRADE recommendations. Emphasis will be on the provision of education and supportive interventions by health care staff to increase patients' skills and confidence in managing their health problems, including regular assessment of progress and problems, goal setting, and problem-solving support, in a patient- and person-centered manner.

Patients will be empowered by person-centered care, developing ongoing relationships with their healthcare team.

Individual care will be delivered by an interprofessional team collaborating with the patient in shared decision-making. Treatment programs will be individualized because of the likelihood of multimorbidity and the uniqueness of each individual's determinants of health.

The OCEEH will also contribute to the integration of primary care, preventive medicine and public health in communities across Ontario.

V Function and Overview of Services in Hub and Spokes

▪ Evolution

The model of the OCEEH contains a central provincial Hub and multiple Spokes distributed throughout the province to provide health and social services as close to home as possible, and to support primary health practitioners in ongoing care for their patients.

To develop this model requires the experience of the environmental health physicians presently working in the Environmental Health Clinic (EHC) at Women's College Hospital in Toronto, as well as a few experienced community physicians, along with building health professional capacity.

Similar to the Ontario Health Technology Advisory Committee's Recommendation on Specialized Multidisciplinary Community-based Care⁸⁹⁹ for Chronic Disease,⁹⁰⁰ the most effective evaluations will be developed with the assistance of clinical experts and researchers.

The following is what is being currently envisioned, but the function, staffing, equipment and space of the OCEEH Hub and Spokes will necessarily evolve as the Centre develops. At a time of change and new linkages/integrations within the health care system, it is not possible to accurately predict now what will be most suitable in 2020. We will need to re-assess on an ongoing basis.

▪ The Hub

The Hub will be an academic, tertiary healthcare centre, providing specialized investigation and treatment to people referred primarily from primary and secondary healthcare providers, including the physicians in the Spokes. The Hub will build on the scholastic foundations of the present Environmental Health Clinic at Women's College Hospital.

It will provide tertiary level consultations for the most complex patients with ME/CFS, FM and ES/MCS referred from the Spokes and other physicians. It will also provide continuing medical education for the healthcare providers both in and outside the Spokes. It will provide leadership working collaboratively with the Spokes to develop and evolve their individual and group self-management and education programs.

The Hub will design and conduct research studies to study ME/CFS, FM and ES/MCS, in collaboration with partners, such as the Dalla Lana School of Public Health, University of Toronto, as well as other universities, international professional organizations and affiliated teaching hospitals,.

○ Association with a Teaching Hospital

The Hub must have close and direct affiliation with a teaching hospital, in order to be able to access and work with various specialists. Although the vision for the OCEEH is to be an independent, self-governed organization, this may not be possible until a later stage of development. If the Hub is part of a hospital, its funding needs to be designated according to an

accountability agreement with the MoHLTC or the LHIN. This affiliation of the Hub is mandatory for the creation of a credible, vibrant, creative and influential Centre of Excellence. Collaboration between the Hub and the hospital is necessary to support the following:

1. Multidiscipline medical and other health professional case conferences required for the most difficult and complex cases. Other health professionals include neuropsychologists, physiotherapists, respiratory technicians, etc.
2. Future research will require the use of specialized equipment available in the hospital setting (e.g. cardiopulmonary testing, tilt table, functional brain scans, pulmonary function testing, hyperbaric oxygen etc.).
3. The hospital should have a strong expertise in research. Future research will require collaboration with other medical disciplines (e.g. infectious disease, clinical pharmacology, internal medicine, toxicology, pediatrics)
4. Attracting researchers and Fellows.
5. A small number of ES/MCS patients will require hospitalization electively, primarily for other illnesses/injuries, and provision of in-hospital care in an environmentally controlled, safe room must be an available option. For example, a washed down infection control room can be environmentally controlled due to positive pressure. To create hospital policy for the proper care and management of environmentally sensitive patients within a hospital setting dictates that the Hub must be closely associated with a hospital. Collaboration between the Hub and the hospital is mandatory in order to develop and manage protocols.
6. An environmentally safe hospital setting for patients with severe chemical sensitivities should include the availability of environmental physicians to consult when their expertise and assistance in management of hospitalized patients is required, preferably on staff at that hospital. Telehealth could be used.
7. When admission to the closest hospital occurs because of urgency, advice from the Hub and hospital guidelines will serve the needs of community hospitals.
8. The knowledge gained from the developed guidelines can be transferred to community hospitals, to remove these barriers to health care for those with ES/MCS.
9. Being a centre of excellence demands credibility. It is the opinion of the patients, the environmental physicians involved in medical legal cases, the Medical Advisory Committee of this Business Case Proposal (BCP), and various other physicians consulted during the process of creating this BCP that a close and specific association with a teaching hospital must be maintained. The credibility of the Environmental Health Clinic to this point in time, assisted by its association with Women's College Hospital, has included the respect of peers and increased ability to provide support for patients experiencing medical legal issues, including obtaining disability support payments from third party insurers, accommodation in the workplace, and travel grants for medical appointments.

A partnership agreement with a teaching hospital, similar to the Canadian Forces Health Care Centre (CFHCC) and Montfort Hospital (MH) in Ottawa, is an example. These two health centres are in close proximity - CFHCC and MH share the same building. The Hub must be in close proximity to the hospital. CFHCC controls the health care services provided to Canadian Forces members, but the provision of laboratory services, diagnostic imaging services and a

number of readily accessible specialist and medical support services can be procured from Montfort when required.⁹⁰¹

It is recognized that the present financial constraints of hospitals are an obstacle to this partnership, which demands the top-down financial guarantee of designated funding from the MoHLTC and/or the Local Health Integration Network in support of the Hub.

- **Association with Academia**

Given the location of the Hub in the Greater Toronto Area (GTA), provision of education for medical students, family medicine residents and fellowship programs requires an association with the University of Toronto, in particular with the Department of Family and Community Medicine in the Faculty of Medicine, and with the Division of Clinical Public Health in the Dalla Lana School of Public Health.

- **Location**

The location of this Hub should be central and easily accessible via public transportation. Given that the Hub will be located in the GTA, consideration must be given to the air quality impact associated with being close to a major roadway, such as the 401 and the Gardiner Expressway. However, proximity to, or being physically inside, a major teaching hospital is the highest priority, in order to establish a high functioning Hub. The present recommendation for location is in the downtown Toronto area, close to teaching hospitals and the Dalla Lana School of Public Health.

- **Physical Requirements of the Hub**

An environment for the Hub with clean air quality can assist patients with sensitivities to concentrate during history taking, and aids the effective administration of treatments, while avoiding atmospheric confounders in conducting research.

A goal would be that the physical environment of this centre meets the needs of the most environmentally sensitive patients. However, it may take some time, and basic protections have served most patients since the EHC opened in 1996. Building or retrofitting this centre will require the expertise of building engineers, architects and environmental health practitioners, who have relevant expertise and experience in indoor air quality. It will require the most inert building, furnishing and maintenance materials, and ventilation at least 1–2 orders of magnitude above the present guidelines for acceptable indoor air quality. It will also require state-of-the-art filtration (HEPA) for particulate matter, and activated charcoal for volatile and semi-volatile organic compounds. Some teleconferencing or house calls may be necessary until this is achieved.

Given that the Hub will provide multidiscipline assessments for the most complex cases, including those with severe ES/MCS, provision of safe lodging in the vicinity of the Hub will be required. This Lodge will be specific to the Hub and available only for those requiring special accommodations during their visit(s).

- **Responsibilities**

The responsibilities of the Hub include provision of health services, guiding and conducting research, education, knowledge transfer and policy development.

The specific roles of the Hub are to provide:

1. Consultation for difficult, complex cases referred from the Spokes or elsewhere
2. Multidiscipline medical and other health professional case conferences, when indicated.
3. Advanced treatment programs designed for each client.
4. Individual and group programs to encourage self-management.
5. Support and perhaps assessment for patients requiring elective admission to hospital.
6. Development and promotion of hospital guidelines for patients that need emergency admission.
7. Assistance with development of undergraduate medical and nursing education in Ontario, including enhancements to the curricula.
8. Continuing medical education for both medical and other health professionals in the Hub and Spokes, as well as all primary care practitioners, including an introductory course in Environmental Health.
9. Training programs for Fellowship for graduating residents of family practice or specialists, and for practising physicians.
10. Provision of an online certificate course (a minimum of 39 hours) in “Environments, Occupations, Communities and Human Health” from Continuing Education and Professional Development at the University of Toronto (and perhaps in collaboration with different universities e.g. Northern Ontario School of Medicine) to be endorsed by the Environmental Health Committee of the Ontario College of Family Physicians.
11. Provision of four College of Family Physicians of Canada-approved Mainpro-C workshops, rotating through communities or online, that demonstrate management of chronic complex conditions and impacts of environment on health across the lifespan.
12. Generate and conduct research to improve understanding of etiology, and develop and enhance the tools for assessment, diagnosis and treatment of ME/CFS, FM and ES/MCS. This will include conducting data analysis from case series information gathered in the Spokes.
13. Maintenance of existing connections and expansion of collaboration and networking in the professional community.
14. Community health promotion and disease prevention with Public Health and community partners.
15. Policy development and support for patients federally and provincially, including such issues as ODSP and WSIB, and implementation of hospital guidelines.

- **Staff Required for Hub Clinical Services**

The numbers of physicians and other health professionals required daily in the Hub is not yet known. The present 0.9 allocation to the EHC is inadequate. It is recommended that the EHC medical staff be increased to develop the guidance, education and infrastructure required to establish and maintain the clinical components of the Hub and Spoke model.

The staff component may be reviewed after the workshops of experts to establish the grading of available evidence for treatments and to set the research agenda.

The projected future clinical staff needs for the Hub are proposed by MNP consultants (September 20, 2013), based on loose estimates from the MAC.

Hub

Physician (including a Medical Director)	4.0
Nurse Practitioner	3.0
Registered Nurse	1.4
Registered Practical Nurse	1.0
Psychologist	1.2
Other Health Staff (Social Worker and Health Promotion)	2.0
Therapeutic Staff (Dietitian, physiotherapist, occupational therapist, etc.)	5.0
Resident Fellows (PGY3)	2.0

Associated specialty medical staff, required for case conferences and research:

1. Allergy/Immunology
2. Anaesthesia
3. Clinical Pharmacology
4. Ear, Nose and Throat
5. Endocrinology
6. Gastroenterology
7. Genetics
8. Gynecology
9. Haematology
10. Infectious Diseases
11. Neurology
12. Radiology
13. Respiriology
14. Rheumatology
15. Sleep Specialist

○ Staff Required for Hub Administrative Support

Executive Director	1.0
Manager Clinical Services	1.0
Manager Policy and Education	1.0
Manager Laboratory Services	1.0
Manager Research	1.0
Information Technology Support	1.0
Medical Office Assistants	4.0

○ Staff Required for Research

In order to progress the field, the Hub will require a qualified Research Director.

- **Assessment, Treatment and Research**

The assessments and treatments in the Hub will be provided by those who are trained and have experience in the concepts of systems-based medicine, including environment as a determinant of health. Given that there is as yet no formalized special interest or specialization program in environmental medicine in Canada, these positions will be filled immediately by the experienced physicians presently working in the Environmental Health Clinic at Women's College Hospital or community clinics, who will work to increase capacity as quickly as possible.

The initial assessment for all patients requires a comprehensive, chronological history, which should include:

1. environmental exposure history
2. chronological functional inquiry

The environmental exposure history documents environmental chemical exposures chronologically. It is limited by its subjective nature and dependency on memory of the patient. Nevertheless, it is beneficial to determine an association of significant chemical exposures with onset of symptoms. It is also useful to begin the data collection to enhance the recently developed concept of the exposome.

Genetic transformation and evolution are not significantly contributing to the rapid and significant changes in health patterns that have recently emerged.⁹⁰² Only 15-20% of chronic illness is genetic.^{903 904} The exposome considers everything that is not due to the genome.⁹⁰⁵ It is defined as the measure of all the exposures of an individual in a lifetime and how those exposures relate to health.⁹⁰⁶ We do not have the ability to measure the impact of our lifetime chemical and psychosocial exposures from uterus to old age. Developing this ability is key to unravelling the major causes of chronic diseases.⁹⁰⁷ As we acquire the markers to measure and follow the exposome through life, we will add to our understanding of the complex interplay between the genome, the epigenome and the environment.⁹⁰⁸

The functional inquiry is the basis of a detailed medical history, which is taught to and practiced by every medical student. In this traditional model, the "history of the present illness" focuses on the primary complaint, which may be pain, fatigue, or heartburn. The functional inquiry acknowledges other symptoms, which are not considered to be significantly associated with the primary complaint. However, in chronic illness, and in particular environmentally linked, complex illnesses, multiple systems are always involved. It is well recognized that there are multiple pathological and environmental pathways to the development of chronic illness and subsequent multimorbidity. Establishing the chronology of all these dysfunctions aids in the understanding of the individual patient's pathology.

- **Specialized Equipment and Space**

Recommendations for equipment and space will be reviewed at the expert workshops that are considering the evidence levels for treatment and setting a research agenda. The equipment and space will be shared when available, as long as clean space is available for patients who are environmentally sensitive.

1. Cardiopulmonary exercise testing for ME/CFS patients (one large room space)
2. Tilt table (one small room)

3. Maxin MA3 device for capsaicin inhalation challenge testing (one small room)
4. Complex carbohydrate challenge breath testing to measure hydrogen and methane (Breath Tracker DP⁹⁰⁹) (one small room)
5. Hyperbaric oxygen chamber; possibly more than one (one large room; oxygen storage tank area; one small room change area)
6. Blood and urine sample collection (one small room with refrigerator)
7. Intravenous therapy (one large room; several cots or reclining chairs; IV poles)
8. Far infrared sauna (one small room and private shower/clothing change area, or multiples)

▪ **The Spokes**

○ **Responsibilities:**

- to assess, diagnose, and treat clients with ME/CFS, FM and ES/MCS
- to be able to perform functional assessments on those diagnosed with these disorders
- to accept referrals from other medical practitioners in the community to assist in the diagnosis and treatment of those clients with these disorders
- to provide accessible healthcare to those patients with ES/MCS
- until the Spokes expand to adequately reflect the needs in the province, it is expected patients referred to the Spoke will have to be referred back to their primary health practitioner (PHP) (perhaps within 6 months) to make room for new referrals. Hence the primary healthcare practitioners (PHPs) will need to be educated too, and coached/advised as necessary.
- to refer the more complex or difficult cases to the Hub
- to use the same comprehensive chronological history, including the same environmental exposure and chronological functional inquiry questionnaires as the Hub to collect clinical data as well as for research and analysis
- to provide information so that individual patients may reduce chemical pollutant exposures
- to provide educational programs to the community to promote lifestyle changes and reduce environmental chemical exposures
- to provide individual and group chronic care management programs, the training for which is available from the Mainpro-C programs provided by the OCFP and the physicians in the Hub
- to initiate and oversee chronic disease self-management programs (some programs, such as the Stanford model, will require further specific training)
- to use the environmental exposure history whenever appropriate in the family practice setting (e.g. change in illness, such as exacerbation of asthma, moving, change in job)
- to practice preventive medicine by using the environmental exposure history whenever appropriate in the family practice setting (e.g. preconception and prenatal counseling, annual wellness visits, etc.)
- to educate other Ontario primary health providers, so that all will be using the exposure history when applicable in everyday practice
- to obtain and use electronic record keeping for the comprehensive clinical history, environmental exposure history and chronological functional inquiry, to be developed in

the Hub, and, with patients' permission, to store and share data for future research reference

- **Staff Required for Spokes Clinical Support**

The projected clinical staff needs for the Spokes were proposed by MNP consultants (September 20, 2013), on the basis of loose estimates by the MAC.

1. Staff Physician trained in systems-based environmental medicine	1.0
2. 1 Nurse/Nurse Practitioner or Physician Assistant	1.0
3. Physiotherapist	1.0
4. Psychologist/Counselor	1.0
5. Social Worker	1.0
6. Dietician	1.0
7. Community Outreach Coordinator	1.0
8. Compounding Pharmacist in the community	0.25

- **Staff Required for Spokes Administrative Support**

It is proposed that administrative support persons will be required by somewhat lesser numbers for the Spokes. However, there will be requirement for an Administrative director, a Manager Clinical and Laboratory Services, Manager Policy and Education, Manager Research and Information Technology, and medical office assistants.

- **Education of Staff**

Clinicians and other healthcare professionals will be educated in the basic concepts of systems-based medicine, incorporating environment as a determinant of health, and will maintain that level of competency via continuing medical education. The initial education will be based upon the Mainpro-C programs already available from the OCFP, provided by the staff physicians in the Hub and the OCFP Environmental Health Committee.

Health professionals in the Spokes will use the same comprehensive clinical history, environmental exposure history and chronological functional inquiry as that used in the Hub, which will be made available online for all health care practitioners involved in OCEEH patients' care. Healthcare practitioners in the Spokes will be capable of making the diagnoses and initiating recommended treatments for ME/CFS, FM and ES/MCS. Routine lab screening will be obtained to minimize costs for assessment, as recommended by the guidelines to be developed by the Hub.

Spokes clinicians will also be taught to conduct functional assessments, i.e., measure the impact of pain and/or fatigue on quality of life in patients with ME/CFS, FM and ES/MCS. These assessments will be used to follow the outcome of treatments including self-management. These validated measurements will allow the healthcare practitioners to advocate for their clients for disability claims with third party insurance carriers and accommodation at the workplace, when indicated.

The Spokes will provide the following:

1. initiation of fragrance-free and safe cleaning products policies
2. provision of a "safe room" for patients, to be used as required
3. organize and manage patient support groups
 - a. gather and provide community-centered information, such as access to resources, e.g., a reference list of local relevant specialty stores, organic farms and farmers markets, specialty restaurants, and lists of products catering to gluten free, dairy free, and other elimination diets
 - b. menu planning and cooking classes can be provided
4. develop education tools to reduce chemical exposures for all individuals in the community

○ **Physical Requirements**

The physical environment of Spoke centres should evolve according to future research designs or results, with aspirations to meet the needs of most environmentally sensitive patients. Given the difficulty in guaranteeing that every patient/client/visitor to the Spoke will be scent and chemical free, there needs to be a safe, designated area available when required. Building or renovating this designated area will require the expertise of building engineers, architects and environmental health practitioners, who have an expertise and experience in indoor air quality. It will usually require the most inert building and furnishing materials, and appropriate ventilation and filtration for particulate matter, and volatile and semi-volatile organic compounds. Where it is not possible to provide a safe room, home or Ontario Telemedicine Network visits may be necessary. A portion of ME/CFS and FM patients do not have environmental sensitivities, and so the Spokes would be able to meet their needs in a usual fragrance-free patient environment.

▪ **Integration of Responsibilities of Hub and Spokes**

There are four areas of service provided by the Hub and Spokes:

- health services
- social services and policy enhancement
- education and health promotion
- research

○ **Health Services**

The healthcare providers of the Hub will consult on the difficult cases referred from Spokes and other secondary sources. Being available in the hospital setting will allow for providing expert opinion on patients admitted electively. Hub clinical practitioners will consult with other specialties as required in case conferences, which may be required for the most difficult cases.

The primary healthcare providers in the Spokes will provide assessment, diagnosis, treatment and support for patients with a focus on ME/CFS, FM and ES/MCS and other environmentally linked conditions. These providers receive specialized education, developed and delivered by the those with clinical experience in the Hub. They will integrate the concepts of systems-based environmental medicine, public health and preventive medicine into clinical practice. Because they will have the training and expertise, the healthcare providers in the ever-expanding Spokes

will also provide consultation (by telephone or telehealth) on request from other local primary care providers.

They will promote individual self-management, which is patient- and person- centered. They will also be able to provide group education and self-management support. They will link with other self-management support groups which are locally available.

- **Social Services and Policy Advancement**

Social service support is frequently necessary for chronic illness, especially for those in lower socioeconomic groups. For example, financial support can be provided to obtain HEPA and/or activated charcoal filtration systems for those with ES/MCS, or those requiring specific elimination diets. Public health can and should be involved in promoting equity.⁹¹⁰

The healthcare providers can also advocate for workplace accommodation or, if necessary, a request for disability third party insurance coverage.

They can advocate for safe healthcare facilities and housing for those diagnosed with ES/MCS. Furthermore, they can advocate for reduction of pollution exposures in their community, such as promoting the initiation of fragrance free policies in public buildings and local workplace environments.

- **Education**

Education to train fellows, primary caregivers in the Spokes, residents, medical students and nurses will initially be provided in the Hub setting by presentations in person, or by telehealth. Individual education will be maintained by regularly scheduled case presentations and/or journal clubs. Knowledge transfer will also occur via networking with other centres of excellence and should help to inform government policy development.

The education of patients is mandatory for chronic patient-centered care. These programs need to be further developed. The Spokes must also contribute to educating the community at large with respect to lifestyle change and reduction of pollutant exposures.

- **Research**

Research is required to develop etiological understanding, diagnostic markers and treatments. Research design and use of specialized medical technology and equipment (e.g. 2-day cardiopulmonary exercise tests, tilt table, capsaicin challenge tests, functional scans, etc.) will be provided by the Hub. Sharing of space and equipment will take place when available, provided safety for patients with special needs is maintained.

The Spokes will participate with data collection, including demographics, symptoms and function. Treatments can be evaluated with continuing case studies or under research protocols, depending on the level of available evidence.

- **Assessments**

- **Introduction**

The driving force behind this Business Case Proposal is the patients' need, for more effective treatment and increased capability to self-manage these disorders with better support, and the need for research into etiology, assessment and treatment. Presently, there is an absence of identified biological markers and most tests performed clinically are used to rule out other known biological entities that could explain the symptoms of ME/CFS, FM and ES/MCS. There are tests available in the United States, which aid in understanding the pathophysiology of these conditions. However, there is a clear need for better, evidence-based tools for the assessment and treatment of chronic, complex environmentally linked conditions, including ME/CFS, FM and ES/MCS.

The following section provides a list of tools used for assessment and treatment for ME/CFS, FM and ES/MCS. They were obtained from the medical literature and the jurisdictional review of expert centres.

- **Laboratory Assessments**

Presently, the following tests are obtained routinely by the Environmental Health Clinic at Women's College Hospital, prior to attendance, to screen for readily treatable problems that may be contributing to symptoms:

- Complete blood count with differential (CBC)
- Erythrocyte sedimentation rate (ESR)
- Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase
- Total Protein, Albumin, Globulin
- Calcium, ionized, Phosphorus
- Glucose
- Electrolytes
- Creatinine
- Thyroid stimulating hormone (TSH)
- Antinuclear antibody (ANA)
- Cholesterol/lipid screen
- Immunoelectrophoresis
- Vitamin B 12
- Ferritin
- Urinalysis

Most of these tests are recommendations for screening patients with potential ME/CFS; to rule out other causes for chronic fatigue.⁹¹¹ According to the 2012 Guidelines for Fibromyalgia, testing to screen patients should be limited to simple blood testing including a CBC, ESR and TSH as above, plus C-reactive protein (CRP) and creatine kinase (CK).⁹¹² The diagnosis is established as a clinical construct.

○ **Additional Laboratory Tests**

Additional laboratory tests have been suggested particularly for ME/CFS, to rule out other conditions known to cause fatigue:⁹¹³

- Infectious Screen: Hep B&C, Lyme, Epstein-Barr virus (EBV), Venereal Disease Research Laboratory tests for syphilis (VDRL), Human Immunodeficiency virus (HIV), tuberculosis (TB)
- Urine/blood for mycoplasma/ureaplasma
- Protein/Immuno-electrophoresis, complement (C3, C4)
- Rheumatoid factor, anti-ds-DNA, anti-thyroid antibodies
- Celiac profile
- RBC Magnesium, Folic Acid, Vitamin D,
- Free T3, free T4
- AM/PM Cortisol, ACTH
- Heavy metals (arsenic, cadmium, mercury, lead): blood and 24-hour urine collection
- Flow cytometry T suppressor lymphocyte subsets and function (CD4, CD8, natural killer cells (NK), B-cell)

○ **Experts' Opinions**

In the small jurisdictional review by 8 experts, along with the tests reviewed above, the following were also mentioned as possible tests for assessment:

- Sex hormones, estradiol, FSH, prolactin, testosterone
- Stool for Ova & Parasites
- Specific tests for celiac: gliadin and endomysial antibodies (IgG, IgA; serum, stool)
- Lipid screen should include oxidized LDL
- Glomerular filtration rate (GFR)
- ACTH challenge
- Insulin (to measure resistance)
- Infectious screen should include human herpes virus (HHV-6, HHV-7), cytomegalovirus (CMV)
- Western Blot (Lyme) for *Borrelia burgdorferi* (and other *Borrelia*-(*afzelii*, *garinii*, *sensu stricto*), and other related tests
- Candida antibodies; intradermal testing
- Urine mycotoxins
- NK cytotoxic activity
- Other lymphocytes CD56, CD16⁺
- Cytokines
- Xenobiotic and heavy metal testing (blood, urine, sweat)
 - Heavy metal screening should include:
 - RBC levels
 - Hair analysis
- Test Phase 1 and Phase 2 detoxification
- Oxidative stress markers
- Mitochondrial function testing

Numerous tests have been proposed for the determination of oxidative stress in clinical situations, but there are problems with establishing reference values.^{914 915 916 917 918} Case-control studies are needed. Oxidative stress can be measured in numerous ways,^{919 920 921} including the following in Table 4- Oxidative Stress Biomarkers.

Development of clinically available markers of oxidative stress that are sensitive, specific, reliable, and accurate in reflecting underlying oxidative stress states is essential. It will enable clinicians to be able to assess therapy and predict risks in chronic illness, including increased morbidity and risk from environmental exposures. Patients who meet the criteria for environmentally linked illnesses, can be assessed for oxidative stress and compared to control groups, which would likely be those healthy individuals identified from the environmental exposure history as also having lower pollutant exposures.

Methods to probe mitochondrial function *in vivo* are being developed, using near infrared and magnetic resonance spectroscopies.^{922 923 924}

Table 4

Oxidative Stress Biomarkers DNA/RNA Oxidation: • 8-hydroxyguanosine (8-OHG) • 8-hydroxydeoxyguanosine (8-OHdG) Protein Oxidation: • Protein carbonyls Lipid Peroxidation: • 8-iso-Prostaglandin F2alpha (8-isoprostane) • Malondialdehyde (MDA) • Thiobarbituric acid reactive substances (TBARS) • Oxidized low density lipoprotein Non-enzymatic Antioxidants • Lipid soluble ○ α-tocopherol (vitamin E) ○ Carotenoids ▪ α-carotene ▪ β-carotene ○ lycopene ○ Retinol (vitamin A) • Water soluble ○ Ascorbic acid (Vitamin C) ○ Glutathione ○ Total antioxidant status Enzymatic Antioxidants • Catalase activity • Glutathione peroxidase • Superoxide dismutase
--

It is beyond the scope of this review to do an appropriate literature review to categorize which tests for assessment are best, promising, emerging or not indicated. It is recommended that, for now, the tests obtained routinely by the Environmental Health Clinic at Women's College Hospital, prior to attendance (see above), is an appropriate screen for readily treatable problems that may be contributing to symptoms. However, further discussion is recommended in an experts' forum to assign the above and other proposed tests to the aforementioned designations of best, promising and emerging practices that will allow for more specific analysis, i.e., case series or more rigorous research protocols.

- **Assessments of Function**

There are no global, generally available, or cheap biomarkers of fatigue,⁹²⁵ which is difficult to define but even more difficult to measure. Fatigue perception is most frequently measured by application of self-report scales, many of which have demonstrated reliability, validity, ability to detect change, and clinical and research usability.⁹²⁶

Like fatigue, the assessment of the widespread pain of fibromyalgia is challenging because there are no biomarkers. The Fibromyalgia Impact Questionnaire (FIQ) was developed to meet the need for comprehensive fibromyalgia patient evaluation. It is a validated questionnaire,⁹²⁷ which has been used to assess people in the community who have chronic pain,⁹²⁸ to determine the impact of fibromyalgia on everyday life⁹²⁹ and to measure disability⁹³⁰ as well as outcomes in drug studies, exercise treatment, multidisciplinary approaches and treatment program evaluation. It is an instrument designed to quantify the overall impact of fibromyalgia over many dimensions using visual analog scales (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.).

The FIQ and Fibromyalgia Impact Questionnaire Revised (FIQR) are useful assessment tools in fibromyalgia because they evaluate the total spectrum of problems related to fibromyalgia, including functional impairment, overall impact, and fibromyalgia-related symptoms. The FIQ total score has proved to be a useful outcome measure in key clinical trials of fibromyalgia.⁹³¹ Currently, the FIQ is considered among the best measures of self-reported function and work disability in fibromyalgia.⁹³²

The FIQR⁹³³ has the same 3 domains as the FIQ: function, overall impact and symptoms. It differs from the FIQ in having modified function questions and the inclusion of questions on memory, tenderness, balance and environmental sensitivity. It has sound psychometric properties, discriminates between fibromyalgia patients and patients with rheumatoid arthritis, lupus, and major depression disorder, takes just over one minute to complete, is easy to score, and can be used in online surveys. The FIQR has a good correlation with the original FIQ.

The FIQ and FIQR should be used to initially assess and follow all the patients with chronic fibromyalgia.

The Short Form (RAND)-36 Health Status Inventory (SF-36), comprising 36 questions, is a validated questionnaire which has been used in countless health outcome studies, health care financing studies, and clinical practice evaluations. It is a multidimensional, general health status patient-reported outcome measure containing subscales for 8 domains. It assesses functional

status on 8 descriptively named subscales: physical functioning, role limitations due to physical health problems, bodily pain, general health perceptions, energy and fatigue, social functioning, role limitations due to personal or emotional health problems, and emotional well-being.⁹³⁴ Each has been shown to have high reliability and validity. The SF-36 has been used in general population surveys of Canadians,^{935 936} in a range of patient populations, including those with ME/CFS,^{937 938 939} fibromyalgia,^{940 941 942} or ES/MCS,⁹⁴³ as well as in a comparative study of all 3 groups.⁹⁴⁴

The SF-36 is an evaluation tool employed at every patient encounter in the Environmental Health Clinic at Women's College Hospital. It should continue to be utilized to assess and follow all patients with environmentally linked conditions.

Other tests which are suggested for consideration to be used to assess function include:

- Multidimensional Fatigue Inventory
- Multidimensional Assessment of Fatigue
- Activity Log
- Functional Capacity Scale⁹⁴⁵
- Karnofsky Energy Rating Scale⁹⁴⁶
- Central Sensitization Inventory Scale
- Pain Catastrophising Scale
- Quick Environmental Exposure and Sensitivity Inventory (QEESI)
- Chronic Pain Coping Questionnaire
- Beck Depression Inventory
- General Anxiety Disorder Scale
- Neuropsychological testing:

-Neuropsychological testing

Objective measures of neuropsychological performance have not consistently yielded evidence of neuropsychological dysfunction. However, most studies support the observations that patients with ME/CFS have decrements in cognitive performance. Impairments have been measured in verbal fluency, memory, motor speed, sustained attention, speed of cognitive processing, and deficits in verbal and nonverbal memory tasks.^{947 948 949}

Similarly, a review of the literature reveals that patients who have fibromyalgia seem especially sensitive to distraction, and the cognitive mechanisms most affected in fibromyalgia are working memory, episodic memory, and semantic memory.⁹⁵⁰

In validating the case criteria for the diagnosis of ES/MCS, the Environmental Hypersensitivity Research Unit at the University of Toronto found that the symptoms of difficulty concentrating, feeling dull or groggy, and feeling spacey also distinguish patients with ES/MCS from controls.⁹⁵¹

More research is required to determine which battery of neuropsychological tests best discriminate environmentally linked conditions from controls and, in particular, whether this testing can discriminate between ME/CFS, FM and ES/MCS.

- **Other Medical Tests**

Other tests mentioned in the jurisdictional review include:

- Skin prick testing for allergies
- Intradermal serial dilution endpoint titration testing for natural inhalant and food allergies and sensitivities
- IgG food testing (ELISA, RAST)
- Pedometer
- Functional brain scan
 - fMRI
 - SPECT
- Heart rate variability testing
- Tilt table
- Overnight polysomnogram
- Venous pO₂
- Complex carbohydrate challenge breath testing
- Patch testing for chemicals

- **Potential diagnostic tests**

- Capsaicin inhalation challenge for ES/MCS
- Repeat cardiopulmonary exercise tests (24 hours) for ME/CFS

- **Treatment**

- **Present Guidelines and Treatment**

Guidelines for ME/CFS remain controversial. The recommendation of exercise in some of these guidelines⁹⁵² must be tempered by the fact that the most prominent characteristic of ME/CFS is that minimal exertion exacerbates the fatigue, recovery is prolonged, and it significantly increases oxidative stress.

Given the fact that many patients with fibromyalgia also have comorbid ME/CFS, there is conflict regarding recommendations for exercise, emphasizing the need to develop the appropriate guidelines for comorbidity.

According to the 2012 Fibromyalgia Guidelines, ideal management includes both non-pharmacologic and pharmacologic treatments in a multimodal approach, with active patient participation fostered by a strong patient-centered locus of control. The essence of the evidence is that there is no “gold standard” of treatment; with responses mostly modest at best. These 2012 Guidelines note that, in a meta-analysis of 49 outcome studies published 14 years ago, non-pharmacologic treatments appeared more effective than pharmacological interventions.⁹⁵³ They state that non-pharmacologic treatments have a positive effect with improvements in self-reported outcome measures including physical status, fibromyalgia symptoms, psychological status and daily functioning, but also state that many of the studies have been poorly executed.

Pharmacological treatments are those used for chronic pain disorders and include antiseizure and antidepressant medications. Antiseizure medications consist of those that dampen incoming ascending pain signals and those that augment descending pain inhibitory mechanisms.⁹⁵⁴ The

descending pathways may be affected by antidepressant drugs that increase the level of the transmitters serotonin and norepinephrine at the synapse.⁹⁵⁵ Medications in the opioid and cannabinoid classes act at many levels in the nervous system, affecting both the sensory and emotional components of pain.

With respect to antidepressants, amitriptyline has been a first-line treatment for neuropathic pain for many years. However, a Cochrane systematic review reveals that there is no supportive, unbiased evidence for a beneficial effect. The authors' recommendation was to balance this against decades of observed improvement in many patients with neuropathic pain or fibromyalgia. There is no good evidence of a lack of effect either; but concern for overestimation of treatment effect.⁹⁵⁶

However, in a British review of the evidence of efficacy for antidepressants prescribed for nonpsychiatric conditions in primary care,⁹⁵⁷ it was opined that tricyclic antidepressants (TCA) did show some evidence for effectiveness, and two selective norepinephrine reuptake inhibitors (SNRIs) were recommended for fibromyalgia: milnacipran, which is not available in Canada, and duloxetine. It was opined that venlafaxine could be prescribed but selective serotonin reuptake inhibitors (SSRIs) were not recommended.

A European systematic review and meta-analysis determined that the TCA amitriptyline and the SNRIs duloxetine and milnacipran, along with pregabalin (antiseizure medication), are first-line options for the treatment of fibromyalgia patients.⁹⁵⁸ However, only a small number of patients experience substantial symptom relief with no or minor adverse effects and overall, the incremental benefit over placebo is small. Most studies that show benefit report only a greater than 30% reduction of pain, and the studies are short term (6 months).⁹⁵⁹ A remarkable number of patients drop out of therapy because of intolerable adverse effects or because they experience only a small relief of symptoms. Medications provide only modest relief at best, with doses often lower than suggested, and drug combinations being used according to clinical judgment.⁹⁶⁰

Systematic reviews have also demonstrated the efficacy of aerobic exercise, balneotherapy and multicomponent therapy for fibromyalgia.^{961 962 963} Inhaled glutathione is also purported to be of help.⁹⁶⁴

The best known treatment for ES/MCS is consistent with the case criteria and what clinicians observe; environmental control and reduction of exposures to known triggers. In a review of self-reported perceived treatment efficacy by 917 persons with self-reported ES/MCS,⁹⁶⁵ creating a chemical-free living space and chemical avoidance were rated by 95% of respondents as helpful. This review identified more than 100 treatments tried by ES/MCS patients, including environmental medicine techniques, holistic therapies, individual nutritional supplements, detoxification techniques, body therapies, Eastern-origin techniques, prescription items, thyroid supplements, herbs and others. Results observed by these patients for most therapies, apart from exposure avoidance itself and prayer (focused attention/meditation), were mixed.

○ **Future Guidance**

Presently, treatment is directed towards the specific clinical defining characteristics of ME/CFS, FM and ES/MCS. Given the fact that 70% of these patients have multimorbidity, treatment must

take a multidiscipline, systems medicine approach and consider the underlying common denominators, frequently found in patients with these disorders:^{966 967}

- Organ dysfunction
 - Central nervous system
 - central sensitization
 - limbic system dysfunction
 - Gastrointestinal system (IBS/GERD)
 - imbalance of microbiota
 - small intestine bacterial overgrowth (SIBO)
 - Immune system
 - allergies
 - food intolerance
 - systemic inflammation
 - Endocrine system
 - hormonal deficits
 - elevated BMI
- Cell dysfunction
 - TRPV1 sensitization
 - NMDA activation
 - mitochondrial dysfunction
 - oxidative stress

These therapies deserve literature review and discussion by experts, and recommendations will necessarily evolve as the OCEEH evolves.

- **Organ Dysfunction**
 - **Central Nervous System**

The systems medicine approach to treating the CNS component of these disorders is to reduce the total load, i.e. to reduce the impact of all factors which could be influencing the hypervigilance of the limbic system. This includes reducing the sensory impact of pain, sleep disturbance and chemical exposures, and the influence of the other organ systems, including the gastrointestinal, immune and endocrine systems. It should also include the treatment of psychosocial issues, when indicated.

Stabilization of the limbic system can also be enhanced by the practice of various stress management techniques including:

- meditation
- mindfulness
- relaxation therapies
- Tai chi
- Qigong
- biofeedback, including neural biofeedback

- Biofeedback

Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies. It is a patient-guided treatment, which uses a monitoring device to measure physiological

information, of which the patient is normally unaware. The name biofeedback refers to the biological signals that are fed back, or returned, to the patient in order for the patient to develop the techniques to manipulate them.

Using this information, an individual can be taught through relaxation, visualization, and other techniques to actively influence muscle tension, pain, body temperature, brain waves, and other bodily functions and processes. For example, one commonly used type of machine, picks up electrical signals in the muscles. It translates these signals into a form that patients can detect, such that every time muscles grow more tense, the signals trigger a flashing light or activate a beeper. If patients want to relax tense muscles, they try to slow down the flashing or beeping.

Biofeedback is primarily used to treat high blood pressure, tension and migraine headache, and chronic pain. Voluntary control of brain systems is possible. Early studies demonstrated that human subjects can exert voluntary control over certain EEG characteristics.^{968 969}

- Neural Biofeedback

Functional magnetic resonance imaging (fMRI) has revolutionized the study of the human brain over the last 20 years, since it allows high-resolution non-invasive recordings of the blood oxygen level dependent (BOLD) response as an indirect measure of neuroelectric activity.⁹⁷⁰ In most fMRI studies results become available to the researcher after a delay of hours or days. But, with additional software,⁹⁷¹ real-time fMRI (rtfMRI) processes images as fast as they are acquired.⁹⁷²

Using rtfMRI allows a person to watch and regulate the functional fMRI signal from his or her own brain.⁹⁷³ Biofeedback using rtfMRI has a unique advantage in that it can precisely localize neurophysiological activity. In particular, it can be used to control neurophysiological activity in various parts of the limbic system.^{974 975 976 977 978 979 980}

Numerous studies indicate rtfMRI feedback assisted control over specific brain areas can be applied to pain management.^{981 982} Given the evidence for central sensitization and limbic system dysfunction, rtfMRI biofeedback appears to be a promising therapy for ES/MCS as well as fibromyalgia.

○ **Gastrointestinal System**

The brain-gut axis is a bidirectional communication system, comprised of neural pathways, including the limbic system,^{983 984 985} and humoral pathways, which include cytokines, hormones, and neuropeptides as signaling molecules.⁹⁸⁶ The intestinal microbiota, which are often abnormal in IBS, can activate neural pathways in the CNS signaling systems.^{987 988} Treatments which might be beneficial include:

- Elimination (and rechallenge) diet, based on tests for food sensitivities (including gluten) and evidence for flora imbalance

- Hydrochloric acid
- Pancreatic enzyme therapy
- Probiotics
- Antibiotic therapy for small intestine bacterial overgrowth (SIBO)

○ Immune system

The CNS is the organ system most often involved in patients with ME/CFS, FM, and ES/MCS, but it does not act alone. Psychoneuroimmunology is the study of the well established, bidirectional communication between the brain and the immune system, in which the limbic system plays an important role.^{989 990 991 992} Numerous studies of ME/CFS and fibromyalgia have demonstrated involvement of the immune system, although these findings are inconsistent.^{993 994}

Multiple studies of ME/CFS have sought evidence for ongoing, active infection with or reactivation of a variety of viral infections, most notably herpes virus, Epstein-Barr virus and cytomegalovirus.^{995 996 997 998} However, the question still remains whether virus reactivation triggers ME/CFS in a subset of patients or viral infection reactivation is yet another outcome of a ME/CFS episode triggered by other agents.⁹⁹⁹ Patients with ME/CFS appear to have a variety of immunological abnormalities, which suggest they may have an infection, and that the immune system is chronically activated in response.¹⁰⁰⁰

Similarly, patients with fibromyalgia also demonstrate involvement of the immune system.¹⁰⁰¹ Different types of autoantibodies, such as antinuclear antibodies (ANA) and anti-thyroid antibodies, are more likely to be found in fibromyalgia patients.^{1002 1003} Moreover, there is a relationship with fibromyalgia and autoimmune disease.^{1004 1005 1006 1007}

Many of these patients also have allergies and food sensitivities, suggesting that therapy can have a positive influence on the outcome of these disorders.¹⁰⁰⁸ Assessments include:

- Skin prick testing (inhalants and foods, when indicated)
- Intradermal serial dilution titration (inhalants and foods, when indicated)
- Patch testing
- Assessment of cytokines

Treatments include:

- Environmental control and avoidance of identified triggers (e.g. mould, dust mites etc. and non-tolerated foods)
- Desensitization
 - subcutaneous standard or optimal dose
 - low dose antigen therapy
 - sublingual

One of the postulates in the 1990s to explain ES/MCS was neurogenic inflammation. This is a well-defined physiological mechanism by which mediators are directly released from sensory nerves to produce-vasodilatation, edema, and other manifestations of inflammation.¹⁰⁰⁹ Particulate matter can induce neurogenic inflammation via TRPV1 receptors, which lends some support that it occurs in ES/MCS.¹⁰¹⁰ However, little is known about the role of airway

neurogenic inflammation in human diseases, although it has been studied in detail in laboratory animal models.¹⁰¹¹

In one study of patients with contact allergy, there did not appear to be a relationship with their skin and respiratory symptoms and positive skin prick tests for proteins.¹⁰¹² On the other hand, there was an association of respiratory reactions to chemicals, such as perfumes, with cutaneous reactions based on positive patch tests in patients reporting chemical sensitivity. The mechanism responsible for positive patch tests to chemicals appears to involve the innate inflammatory immune response, involving reactive T helper 1 and CD8 T cells,¹⁰¹³ and it appears to be induced by oxidative stress.¹⁰¹⁴ Consideration must be given to patch testing patients with ES/MCS as a potential aid in identifying specific chemical sensitivities.

- **Endocrine system**

- Hormonal Deficits

Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been linked to the pathophysiology of ME/CFS and fibromyalgia.¹⁰¹⁵ Several studies have reported the results of unstimulated plasma and salivary cortisol levels in patients with ME/CFS. Some, but not all, reported significantly lower blood cortisol levels compared with healthy controls. However, meta-analysis of the data published from the mid-1960s to 2010 reveals that patients with ME/CFS have significant hypocortisolism, but the reduction is more modest when not stimulated.¹⁰¹⁶ Women have more marked reductions. There can also be a flattening of the diurnal rhythm.^{1017 1018}

When challenge tests are used to assess the hormone reserve capacity of the HPA axis, the majority of published tests on ME/CFS patients demonstrate a blunted response to challenge.¹⁰¹⁹ Similarly, these challenge tests demonstrate hypocortisolism in women with fibromyalgia.^{1020 1021}

Cortisol exerts negative feedback control on corticotrophin-releasing hormone and adrenocorticotrophic hormone (ACTH) secretion via the glucocorticoid and mineralocorticoid receptors in the hippocampus, the hypothalamus and the pituitary gland. Since the levels of cortisol are low in patients with ME/CFS, one of the suggested mechanisms underlying the chronic hypocortisolism is hyper-responsiveness of these corticosteroid receptors, leading to an enhanced negative feedback mechanism. In fact, this has been demonstrated by several suppression tests.^{1022 1023 1024} ME/CFS patients with comorbid depression have more suppression.¹⁰²⁵

Unfortunately, the evidence of benefit in patients with ME/CFS from low dose steroid use is weak.¹⁰²⁶ Changes in the HPA axis in patients with ME/CFS is likely an epiphenomenon of the illness rather than of particular etiological significance.¹⁰²⁷ Nevertheless, it has been observed that those patients with low cortisol levels or flattened diurnal variation respond more poorly to treatment.^{1028 1029 1030} These tests might help to determine prognosis.

- Body Mass Index

There is an association with ME/CFS, and high waist circumference and metabolic syndrome.¹⁰³¹ The number of metabolic syndrome factors is also significantly correlated with worse fatigue. People who are overweight are more likely to have fibromyalgia.¹⁰³² Overweight and obese individuals with ME/CFS demonstrate poorer functioning.¹⁰³³ In fibromyalgia, the symptoms are more severe if the BMI is higher,^{1034 1035 1036} and there is a positive correlation with the number of tender points.¹⁰³⁷

An abnormal BMI is seen in two studies of children with ME/CFS. However, the results are conflicting; either low¹⁰³⁸ or high.¹⁰³⁹

Patients with ME/CFS and/or fibromyalgia with an elevated BMI should be encouraged to lose weight. Given the evidence for oxidative stress, they should be informed about a calorie sparse, nutrient (antioxidants) dense diet. Options include vegan^{1040 1041 1042} paleolithic^{1043 1044} and Mediterranean diets.¹⁰⁴⁵

○ **Treatment on a cellular level**

As already reviewed, environmentally linked conditions, including ME/CFS, FM, and ES/MCS, are associated with pollution exposure, poor detoxification, oxidative stress with cell dysfunction, including changes in mitochondrial function and upregulation of receptors. This primarily affects different organ systems according to genetic susceptibility or other, as yet unclear factors. There should be stabilization at least by lowering the total load on body defence mechanisms i.e. avoidance of toxins/symptom triggers.

Presently, pollution exposure can only be reduced via education and lifestyle changes to enhance avoidance. The body burden of exposures also can be reduced by detoxification, presently limited to exercise followed by heat depuration. Heat therapy reduces oxidative stress.^{1046 1047}
^{1048 1049} Levels of heavy metals can be reduced by chelation,¹⁰⁵⁰ especially with antioxidant support.¹⁰⁵¹ Whether the cell dysfunction due to the damage from oxidative stress can be at all reversed is not clear. Evidence to date suggests that diet, detoxification and antioxidant supplementation may be beneficial, but thus far, the evidence is low.

Treatment requires providing patient education, and multidiscipline, multiple treatments, individually developed for each patient, using the patient focused model of chronic care. Guidance needs to be developed by the medical leaders in the Hub in collaboration with experts from other centres, which will expand as research expands. When considering ME/CFS, FM or ES/MCS individually, the following assessments and treatments should be considered.

○ **Specifics for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome**

Measurements of the fatigue can be performed using the Multidimensional Fatigue Inventory scale, the Multidimensional Assessment of Fatigue and a pedometer.

The most important parameter for treatment appears to be pacing, consistent with the characteristic of the fatigue. There is conflicting evidence for graduated exercise, which may in part be dependent upon the severity of the illness.

The goal is self-management of usable energy, which can be guided with the use of an activity log. Mild graduated exercise may be prescribed, when appropriate. Patients need to be taught to monitor their exertion, which can be guided by appropriate pulse measurement, calculated by 60% Vmax or by 24 hour repeat cardiopulmonary stress testing.

One potential future treatment specific for ME/CFS is anti-B cell therapy using Rituximab. B cell immunophenotyping in these patients demonstrates abnormal proportions, with a greater number of naïve and transitional B cell subsets.¹⁰⁵² Treatment with anti-B cell therapy using Rituximab has shown benefit in one randomized controlled trial of 30 patients.¹⁰⁵³ None of the participants in the Jurisdictional review had any experience with this treatment option.

○ **Specifics for Fibromyalgia**

The diagnosis is made by the description of unexplained, widespread pain. Some objective evidence to support the diagnosis can be found in the physical examination (11/18 fibromyalgia tender points) and occasionally from an overnight polysomnogram demonstrating sleep abnormality. There is evidence for prolonged sleep latencies, low sleep efficiency and an increased amount of stage I non-rapid eye movement (non-REM) sleep, reduction in slow wave sleep and in REM sleep percentages, and increased number of arousals and restless leg movements. In particular, there are a number of reports describing the presence of alpha electroencephalographic (EEG) activity during non-REM sleep (phasic alpha activity, or "alpha wave intrusion").¹⁰⁵⁴

Ruling out other disorders:

Fibromyalgia physical assessment screen for primary care¹⁰⁵⁵

1. Tender point assessment (bilateral)
2. Joint evaluation (bilateral swollen or boggy joints on palpation)
3. Muscle strength evaluation for proximal muscle weakness
 - Deltoid
 - Biceps
 - Triceps
 - Hip flexors
4. Connective tissue signs
 - Alopecia
 - Rash (malar, photosensitive, or discoid)
 - Oral or nasal ulcers
 - Digital pits or ulcers
5. Multiple sclerosis (MS) signs or symptoms
 - Visual changes (unilateral partial or complete loss, double vision)
 - Ascending numbness in a leg or band-like truncal numbness
 - Slurred speech (dysarthria)
6. Screen laboratory tests
 - For all patients: comprehensive metabolic panel, complete blood count (CBC), thyroid-stimulating hormone (TSH), erythrocyte sedimentation rate (ESR)
 - Consider:
 - If any bilateral swollen joints: check rheumatoid factor (RF)

- If any connective tissue signs: check antinuclear antibody (ANA)
- If any proximal muscle weakness: check creatine phosphokinase (CPK)
- If any risk factor for hepatitis: check hepatitis C antibody
- If any sign or symptom of MS: consider further MS workup

Treatment

Quantification of the severity of pain plus its impact on function should be performed prior to treatment, in order to assess efficacy. This is best performed using the FIQ or FIQR.

Present recommendations for treatment of chronic pain:

- Exercise (aerobic, strength training, pool, Pilates and multi-component)
- Stretching/yoga
- Medication
 - Antiseizure medication
 - Antidepressant medication
 - SSRI/SNRI
 - Cannabinoids
 - Analgesics
- Treatment of sleep disturbance
 - medication
 - sleep hygiene

Presently, there is some evidence for the effectiveness of:

- Waon sauna therapy¹⁰⁵⁶
- Hydrotherapy, which includes spa- and balneotherapy^{1057 1058 1059 1060}
- IV therapy, thus far consists of one study using Myer's cocktail¹⁰⁶¹ (which consists of vitamins B and C, magnesium and calcium¹⁰⁶²). There is significant clinical observational evidence.
- Hyperbaric oxygen therapy^{1063 1064 1065}
- Repetitive transcranial magnetic stimulation (rTMS)^{1066 1067}
- Brain biofeedback, including transcranial magnetic stimulation (TMS), electroencephalography (EEG) neurofeedback and real-time functional MRI feedback¹⁰⁶⁸
- Acupuncture evidence of effectiveness is mixed.^{1069 1070 1071}
- Meditative movement therapies (qi gong, tai chi, yoga) are strongly recommended by the German S3 guidelines on fibromyalgia syndrome.¹⁰⁷²
- Mind-body therapies (mindfulness)^{1073 1074}
- Low Dose Naltrexone Therapy¹⁰⁷⁵

○ **Specifics for Environmental Sensitivities/Multiple Chemical Sensitivity**

The diagnosis is established by the history. One promising objective measure as a biomarker for the disorder is the capsaicin inhalation challenge, although caution with dosage will be required. Treatment consists of:

- Providing advice and education to create a chemical-free living space
- Environmental control - avoidance of inhalant irritants and food intolerances

- Support accommodation in the workplace
- Activated charcoal filter masks (e.g., N95-OV with activated charcoal)

Clinical observational evidence exists for the use of:

- oral supplements
- IV nutritional therapy
- daily oxygen therapy
- oxygen to treat reactions
- alkali salts

○ Lowering the Xenobiotic Load

Various methods exist which may lower the xenobiotic load in humans. The question remains as to whether this could significantly improve detoxification, reduce oxidative stress, enhance cell function including the promotion of mitochondrial biogenesis, create measurable change in function in patients with environmentally linked conditions such as ME/CFS, FM, or ES/MCS, or have a positive impact on chronic diseases linked to the environment, including prevention of the development of multimorbidity.

However, there are many purported detoxification remedies with varying, including low or no scientific validation, 18 of which are reviewed by Stephen Genuis.¹⁰⁷⁶ On the other hand, supportive animal and case studies include interference with the enterohepatic circulation of organochlorine compounds and their metabolites^{1077 1078 1079} using bile acid sequestrants (e.g., cholestyramine)^{1080 1081 1082} or a non-absorbable dietary fat substitute (olestra).^{1083 1084 1085 1086} Fibre also interferes with enterohepatic circulation.¹⁰⁸⁷

There are two old observational studies using sweat (heat depuration) to detoxify mercury¹⁰⁸⁸ and lead¹⁰⁸⁹ (available only in Russian) using sauna. The idea is based on finding drugs in sweat^{1090 1091 1092 1093} and enhancing their elimination via sweat induction (sauna).¹⁰⁹⁴ Physical exercise mobilizes lipids,^{1095 1096} which will also mobilize persistent organic pollutants,¹⁰⁹⁷ and uncontrolled and controlled small trials and observational studies demonstrate that subsequent sweating after exercise can reduce the xenobiotic load and/or reduce symptoms associated with known exposures.^{1098 1099 1100 1101 1102 1103} Several protocols have been described¹¹⁰⁴ but not compared.

▪ Summary

The model of the OCEEH contains a central Hub and multiple Spokes, expanding across the province to provide access to care as close to home as possible.

The Hub will be an academic, tertiary healthcare center, providing specialized investigation and treatment to people referred primarily from primary and secondary healthcare providers, including the physicians in the Spokes. It will be responsible for the provision of health services through a range of tests and treatments, guiding and conducting research on etiological mechanisms, diagnostic tests and treatments, and effective health promotion techniques. It will be involved in developing education of health care professionals, patients and the public, as well as knowledge transfer resources and policy development. The Hub must have close and direct affiliation with a teaching hospital. It must be associated with academia. Multiple specialized

medical and other clinical staff as well as specialized equipment and space (which cannot be shared) will be required.

Physical requirements include being accessible to those patients with ES/MCS, knowing that special arrangements will need to be made for those who are severely sensitive.

Health professionals in the Spokes will utilize the environmental exposure history and chronological functional inquiry and will be capable of making the diagnoses and initiating recommended treatments for ME/CFS, FM and ES/MCS. The Spokes will provide generally safe facilities (having a fragrance-free policy and utilizing non-toxic cleaning and laundry products) and aim to provide a "safe room" for severely environmentally sensitive patients or contingencies. They will make use of the environmental exposure history in everyday practice to identify patients at risk for developing chronic conditions linked to the environment. They will work with the Hub to engage in innovative research, including evaluating assessment and treatment tools, to provide education programs and service in collaboration with Department of Clinical Public Health at the Dalla Lana School of Public Health, University of Toronto, and other universities.

The Hub and Spokes will integrate the responsibilities of individual and public health services, social services and policy enhancement, research, education and health promotion.

VI Building the OCEEH

▪ Introduction and Steps Required

The Hub must be built before the spokes, although collaboration with interested spokes should begin as soon as possible. The Hub must increase trained health professional capacity, update the tools presently being used, such as the clinical intake history and the environmental exposure history, and make them available online. It must further develop the present guidance for treatment in collaboration with experts from other centres. It must refine the teaching program for the Spokes, including all that is required for both medical and support staff. Once these are established, knowledge transfer to the Spokes can begin.

The allocation of responsibilities between the Hub and Spokes will be an ongoing and evolving process. There is a significant need for treatments to be made available in the Spokes model in various communities around the province. Therefore, best practices should be made available as soon as possible in the Spokes. Thus, the Hub should begin to develop this guidance for dissemination.

If the Hub hosts a forum of clinicians and researchers experienced in the assessment and treatment of people with ME/CFS, FM and ES/MCS, they may agree that promising practices could be made available in the Hub and Spokes and evaluated as case series with close attention to benefit, adverse effects, and help:harm ratio. Emerging practices can be evaluated in the Hub and Spokes under research protocols with external funding.

However, some emerging practices will require specific expertise and/or equipment and will therefore be restricted to the Hub location. For example, 24 hour repeat cardiopulmonary exercise testing must be studied further to determine if it is reliable and necessary to design individual exercise and pacing programs for patients with ME/CFS. If so, the recommended protocol can be transferred to community hospitals with suitably trained personnel, and made accessible to local Spokes, by referral.

If other treatments are found to be efficacious, such as specific intravenous (IV) therapies, transferring this knowledge directly to the Spokes and other practising physicians will make these treatments more available to patients in each local community. This knowledge transfer can occur via medical conference, grand rounds, Ontario Telemedicine Network, and publications. Thus, guidelines for the assessment, diagnosis and treatment for ME/CFS, FM and ES/MCS will continue to be updated by the Hub.

The OCEEH must provide the highest quality of healthcare for ME/CFS, FM and ES/MCS. The designation of centre of excellence mandates that the expertise and care it provides is comprehensive and evidence-based or -informed. It must yield the best quality outcomes and high patient satisfaction. It will involve teams of healthcare professionals with the primary goal of meeting patients' needs and preferences. The approach to delivering care will be multidisciplinary; medical, other clinical and social. The OCEEH will pursue policy discussions to make services more accessible e.g. home care, ODSP etc.

The experts will set the bar for excellence and provide the leadership to guide the creation of the OCEEH, as follows. It is estimated that it will take up to two years to create and expand the foundation, and then initiation of programming, maintenance and expansion could be rolled out over the next three years and thereafter.

- **Create the Foundation**

- **Increase EHC Clinical Staff**

Immediately increase the EHC medical staff from 0.9 FTE to 4 FTEs physicians, including a Medical director, and restore other clinical staff. Presently, the wait list for consultation at the EHC is 13 months. Moreover, there is an immediate and significant demand for more physician time required to develop the foundation and programs for the OCEEH, which is extra challenging considering the early stages of this field.

- **Begin training of Fellows**

Three quarters of the present staff at the EHC are over 65 years old. There is an urgent need to begin training of new physicians to build physician capacity. If funding can be guaranteed before December 2013, advertising for applications for Fellowship training can begin immediately. If so, training can begin in July 2014, at the onset of the new academic training year.

- **Organize research projects for Fellows and Clinical Staff**

Organize literature review projects for the Fellows and clinical staff, followed by development and organization of online and paper resources for patients and primary care physicians.

- **Organize workshop of experts to develop GRADE recommendations**

As reviewed above, provision of new tools for assessment and treatment can be made available as "best" and "promising" practices. Determination of these designations must be made by invited experts in systems-based medicine from national and international centres and organizations, and relevant experts in related fields, using GRADE as a guide for recommendations. This workshop requires expert facilitation, and will likely require at least three full days. It may also consider financial implications and suggest priorities. This would also assist the MoHLTC in projecting possible longer range costs.

- **Upgrade and refine methods for data gathering**

Prior to the initial assessment at the Environmental Health Clinic at Women's College Hospital (EHC), patients are required to fill out an environmental exposure and comprehensive medical history form. Presently, the EHC uses the environmental exposure history developed more than 10 years ago by Dr. Lynn Marshall¹¹⁰⁵, one of the EHC staff physicians. It was recently updated in 2013, but needs to be made electronic so that it can be completed online, and electronic data gathered with the patient's permission.

The present comprehensive medical history form, which was developed for research and not clinical purposes, is inadequate. While symptoms in the functional enquiry are listed, it is

missing chronology, severity, impact on function, and links to the environment. It needs to be updated, and should be the first priority for the development of the Hub and Spoke model.

Once this form is updated, it needs to be uploaded online. This will allow patients to fill it out online, piecemeal if necessary, or to download it, and fill out various sections when expedient. Given the expected length of the questionnaire, this should ease the burden on patients, especially those with chronic fatigue. Furthermore, having this information returned online in an electronic form will simplify the data collection required for ongoing research, with the patient's consent. A data base registry will be created, using electronic medical records (EMR).

Putting the form online may also be helpful to primary care providers, CHCs, FHTs and public health.

- **Develop specific Hub agreements**

The importance of collaborations/associations to create a credible health provision model worthy of the designation of Center of Excellence have been reviewed above. Specific agreements must be obtained with one or more teaching hospital(s), the University of Toronto, and the Dalla Lana School of Public Health. Most significant is the agreement with a teaching hospital. Because of the costs involved, the importance of guaranteed designated funding from the MoHLTC or LHIN cannot be over emphasized.

- **Prepare education program for Spokes**

Provision of care by health practitioners in the Spokes cannot begin without additional training. Collaboration with Spokes and primary care providers is important to develop the most effective education program, aiming for a consistent quality approach to most aspects of care in both Hub and Spokes.

There are 5 Mainpro-C education modules for health care professionals available from the Ontario College of Family Physicians (OCFP).

One is called "Climate Change and Health: Should we care? Can we make a difference?" This presentation describes the health effects of climate change, including increased heat and smog, waterborne disease and Lyme disease and provides tools for family physicians to deal with clinical cases, as well as reducing the carbon footprints of our medical activities. These tools should be taught to all primary care physicians. Those practicing in the Spokes can take the lead in the dissemination of this knowledge in their medical regions.

The other four Mainpro-C modules were developed by the staff physicians at the EHC and the Environmental Health Committee of the OCFP. They are more specific with respect to the impact of environmental chemical exposures on health and are divided according to the stages in life. They include the following:

- 1) Pregnancy & Early Childhood Environmental Exposures: Impacts, Prevention, Diagnosis and Management
- 2) Risks of Environmental Exposures to Child and Adolescent Health and Remedies in Clinical Practice

- 3) Chronic Pain, Fatigue and Chemical Intolerance Linked to Environment Exposures: Office Assessment and Management
- 4) Common Chronic Illnesses and the Environment

These four modules were initially developed by different authors to be provided separately. Feedback from attendees at the Continuing Medical Education Mainpro-C program (Environment-linked Illnesses: Prevention, Diagnosis and Management from Preconception to Old Age) in March 2013, which included all 4 modules, indicated that there was overlap in content, which required streamlining. Furthermore, provision of more detail for practical application (e.g. self education and management groups) will also likely be necessary before offering training. It is important to note that these modules begin to address the clinical aspects of multimorbidity.

- **Accreditation in Environmental Health**

Education courses already designed and taught online and in the classroom by physicians in the EHC for Environmental, Occupational and Public Health should be integrated into the required training program for a certificate in Environmental Health granted by the University of Toronto, and possibly by the Northern Ontario School of Medicine (NOSM). Application for special interest designation of Environmental Health in the CFPC should then be sought. Combination of these courses with an MPH program may be possible.

- **Develop updated hospital guidelines**

Patients with ME/CFS, FM or ES/MCS do not often have admissions for their conditions, but they are prone, like everyone else, to need emergency care or admission for injuries or illnesses, or to have elective surgery. Hospital guidelines are required to overcome barriers to safe access for patients with ES/MCS during admission to emergency, day surgery, outpatient clinics, inpatient hospital wards, and intensive care facilities. Several guidelines are available,^{1106 1107 1108 1109} but are considered to need updating by the Medical Advisory Committee. They need to be updated by environmental physicians working with hospital administration, pharmacy, anaesthesia, emergency, housekeeping, laundry, engineering and maintenance. They need to be implemented and studied for effectiveness.

Some information is available for ME/CFS patients undergoing surgery.¹¹¹⁰

Once these guidelines have been established, they can be provided to patients and their physicians planning for elective admissions. Not only will this be good for patient care, but also it will save the hospital staff time and effort. Knowledge transfer to the Ontario Hospital Association will assist in implementing these guidelines in hospitals across Ontario.

These guidelines will be valuable to Community Care Access Centres regarding home care.

- **Expand the Foundation**

- **Begin education of Spoke health care providers**

Training programs provided by the EHC physicians will be initiated for all the healthcare providers involved in the Spokes. Most important, consideration must also be given to

provide shadowing by healthcare practitioners at the EHC and designated community clinics before assessment and treatment programs can be administered in the Spokes.

- **Develop education modules for medical students and residents, and graduate physicians**

Case-based learning and problem-based tutorial programs need to be developed. A start has been made at NOSM, which can be built upon. The ultimate goal would be to include Environmental Health in many aspects of the medical curriculum. All graduating medical students should have developed the skills to take an environmental exposure history, and know when it should be applied clinically.

- **Develop education modules for nursing and other health professionals**

The above-mentioned Mainpro-C modules can be adapted for training other health professionals, including nurses, physiotherapists, occupational therapists, respiratory technicians, dietitians and particularly social workers, who must be able to address housing, diet needs and accommodation issues. A specific education program might be developed to train health coaches re lifestyle.

- **Organize workshop of experts to set research agenda, evaluate criteria and initiate research collaborations**

While the OCEEH must proceed with implementing the very best evidence-based and GRADE-supported approaches to the management of these patients, the base of such evidence is sparse. It is marked by a paucity of well-conducted research on potential fundamental mechanisms of the diseases and trials of therapeutic approaches that are developed based on the understanding of such mechanisms. Thus, research (the development of research faculty, hypotheses, and externally-funded projects) will be critical to coming up with improved strategies for the clinical management of these patients.¹¹¹ The OCEEH, by creating a community of patients and clinicians with a strong relationship with scientists in a leading Division of Clinical Public Health in a top Faculty of Public Health, will be in a strong position to pursue such research.

Initiating this program will involve a workshop (preferably 3 days) of clinician and research experts from Canada and international centres/professional organizations to set the research agenda, including evaluation strategies, and begin collaborations that will lead to submission of research proposals to the three major research funding sources in Canada.

Linkage with one or more academic hospitals interested in research would be helpful as they would have the infrastructure for research and would attract skilled researchers.

- **Develop programs for University Sciences**

Many programs already exist in colleges and universities, which educate students in a variety of areas regarding changes in the environment (e.g. humanities, natural and social science, environmental policy and urban planning). However, none of them teach about the significance of environmental factors on human health, from preconception to old age. Useful small research projects should be incorporated into these programs.

- **Develop education modules for patients**

Environmentally-linked illnesses and conditions are chronic and thus require self-management. Patient education is a major component. Education modules need to be developed and can include oral individual or group sessions, as well as written information supplied by CD, DVD or downloading from the OCEEH future website.

Successful group education programs have been developed already by staff physicians at the EHC. It would be helpful if they were re-established e.g. the group education program models developed by Dr. Alison Bested and by Drs. Annette Lorenz and Lynn Marshall.

- **Develop modules for self-management**

The fourth Mainpro-C module, title Common Chronic Illnesses and the Environment provides information for physicians to help their patients achieve self-management of chronic complex conditions including ME/CFS, FM, and ES/MCS.

Study of the Stanford training program¹¹¹² by Hub clinical staff would be helpful, including training a Hub physician and possibly a social worker to become a Stanford Master Trainer who would become a T-Trainer, who trains master Trainers in Spokes. Training of physicians and other clinical staff in the Spokes will enable the establishment and supervision of sustainable self-management support programs.¹¹¹³

- **Develop safe rooms in Spokes**

Access to primary health care must be available for those with ES/MCS. Exact specifications required are unknown at present. Barriers to care due to exposures to normal indoor air contaminants routinely occur in waiting rooms, at reception, in examining rooms, and public areas containing patient groups (self-management and community outreach). Given the dynamics of indoor air, the quality of "safe rooms" to be provided for patients with severe ES/MCS will be partially dependent on the quality of the indoor environment of the clinic in which they reside.

Enforcing a scent free policy and use of non-toxic, generally well-tolerated cleaning products will be mandatory. Guidelines for lighting, ventilation, air filtration, cleaning and maintenance need to be established. It is strongly recommended that they are developed by a multidiscipline team, including building engineers, architects and health practitioners all of whom should have experience dealing with indoor air quality and people with ES/MCS. Collaboration with the engineering experts at the Material Emissions Testing Facilities of the National Research Council¹¹¹⁴ should also be considered.

- **Create temporary lodging for patients attending the Hub**

Some patients referred to the hub for consultation will likely require extended stays in order to have multiple discipline assessments and case conference(s). Some may be partaking in specific treatment programs. They must be provided with safe lodging during their stay. This is not only necessary for provision of access to care. It is also mandatory in order to eliminate any interference from outside (environmental) sources which may impact on the measured results of assessments to be performed, whether they are functional or physiological.

However, there are no criteria established to ensure a healthy environment.¹¹¹⁵ We do not have guidelines for ventilation to control pollutants at this level. The information to date is experiential and anecdotal. The threshold for sensitivity to chemical pollutants varies individually from day to day and from person to person. Guidelines to accommodate are based on trial and error. The goal is to maximize ventilation, to filter the incoming air, and reduce indoor contamination by choosing materials with low emissions.

A review of the peer-reviewed literature published from 1995 to 2010 found 77 studies that measured chemical pollutants in residences in the United States and in countries with similar lifestyles.¹¹¹⁶ The review considered all chemical contaminants measured in the residential indoor air. There were 267 different pollutants found.

In 1995, the Canada Mortgage and Housing Corporation (CMHC) constructed a prototype research house for environmentally sensitive patients.¹¹¹⁷ They provided low off-gasing building materials and furnishings, ventilation and filtration. However, no studies were published with respect to measurements of indoor air quality. Eventually, this building was sold to the Department of Respiriology at the Ottawa Hospital, General Campus, and used as an education library for patients with asthma.

The Environmental Health Center in Dallas, Texas provides lodging for patients.¹¹¹⁸ According to their website, this housing includes:

- a clean and updated HVAC system with environmentally correct components utilizing the most effective filtration media (not described)
- filtered kitchen and shower water
- two Austin or AllerMed air purifiers
- ceramic tile, non-toxic grout floors and non-toxic paint
- organic cotton sheets, towels, mattresses and shower curtains; linens are changed twice a week and rooms are cleaned with non-toxic products twice a week with daily inspections
- all furniture is made from hardwood or metal

It is recommended that an expert group be formed to determine the requirements for the provision of safe rooms and housing for those with ES/MCS. The group should be comprised of building engineers, architects and environmental health practitioners with an expertise and experience in indoor air quality needs for the environmentally sensitive population.

▪ **Initiate Programming**

○ **Begin provision of care in Spokes**

It is a prominent goal for the OCEEH to provide province-wide state-of-the-art, systems-based healthcare, including environment as a determinant of health, in order to meet the needs of those with ME/CFS, FM and ES/MCS and their families. It is also a key goal to incorporate education/health promotion and social/policy support. The long term success of this model is dependent on first building a solid foundation. It necessitates good bilateral communication between the Spokes and their referral sources, and the Spokes and the Hub.

- **Develop teleconference and e-consultation services for provision of consultations in remote areas**

Waiting for specialist care remains the most important barrier to health care access in Canada,¹¹¹⁹ especially in underserved areas. Telemedicine can improve access to medical expertise and increase care delivery. It can also increase access to professional education, in this case involving the Hub¹¹²⁰ and spokes across the province. However, it requires specialized and expensive equipment, which makes it inaccessible to most primary care providers.

An electronic consultation (e-consultation) system was recently successfully piloted in the Champlain Local Health Integration Network (LHIN), encompassing Ottawa and its surrounding communities.¹¹²¹ It allowed primary care providers to submit patient-specific clinical questions to a specialist, who provided answers or requested additional information before providing advice, within one week. This same service could be provided regionally by the Spokes, with further consultation being passed upwards to the Hub when necessary.

- **Further develop research agenda and research associates**

There are many gaps in knowledge about environmental health and chronic complex conditions. The pathology of ME/CFS, FM and ES/MCS is not well understood. While a strong similarity exists between the three conditions (ME/CFS, FM and ES/MCS) and other chronic diseases, in terms of overlapping symptoms and patient profiles, the upstream etiology and "branches" of mechanistic pathways that ultimately result in the common symptoms remain unclear but is a critical area of research.

The hub will develop associations with other medical disciplines and associated research units and international professional associations, as well as other centres of excellence with links to the environment, and other groups and institutions mandated to seek and transfer knowledge to improve the environment and reduce its impact on health.

The Dean of the Dalla Lana School of Public Health has expressed interest in being a partner in this effort, particularly in relation to creating and executing a research agenda, recognizing that any research requiring significant resources will need to be supported by additional grant applications.¹¹²²

- **Apply for research funding**

Once the research agenda and foundation is in place, applications can begin for funding defined research projects by three federal granting councils: Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), and the Social Sciences and Humanities Research Council (SSHRC). Hopefully, the MoHLTC will encourage these funding councils and other agencies to fund worthy OCEEH grant applications.

- **Initiate research programs**

With the agreement of experts in the field, clinical case series can be initiated in the Hub and Spokes for "promising" practices, and the Hub plans to submit formal research protocols for "emerging" practices. Collaboration of the OCEEH with the Division of Clinical Public

Health in the Dalla Lana School of Public Health and the Department of Family and Community Medicine in the Faculty of Medicine at the University of Toronto will enhance this initiative. Being closely linked with an academic health sciences centre could be helpful in attracting researchers in other areas, such as genetics, and would assist in providing research infrastructure. Other resources and collaborations will be sought.

This is an important field that has been neglected with almost no funds (please see Table 1, Chapter I), and research in this area may have important impacts on understanding etiology, management of ME/CFS, FM and ES/MCS and other chronic complex conditions, perhaps preventing multimorbidity. Preventing multimorbidity would help manage these conditions, sustain the health care system and enhance the patient experience.

The Networks of Centres of Excellence is a Canadian government funding initiative allocated through the three federal granting councils. As stated on their website, this network obtains funds for collaboration between companies, universities, hospitals, governments and communities to generate knowledge translation into results, such as better health care. The Ontario Centre of Excellence in Environmental Health (OCEEH) should explore being a part of this network, which could also increase the likelihood of obtaining research funds.

- **Create an OCEEH website**

An attractive website needs to be built to promote the OCEEH, provide resources for patients, researchers, and the public, as well as linking to other associated sites.

- **Maintenance and expansion**

The following list speaks to the future of the OCEEH and its commitment to excellence.

1. Gather research data
2. Refine assessments and treatment protocols
3. Disseminate knowledge
4. Network
5. Continue research in Hub and Spokes with academic collaborators
6. Expand Spoke availability in Ontario

There is an obvious need and great potential to create a first-class Centre of Excellence in Environmental Health in the Province of Ontario. It is important to carefully build it and maximize patients' access, equity, choice, value and quality in health and social services.¹¹²³

- **Summary**

In order to provide the highest quality of health care for people with ME/CFS, FM and ES/MCS, the Hub must be built before the Spokes, although collaboration with interested spokes should take place as soon as possible. The Spokes may be in Community Health Centres or Family Health Teams and will eventually spread to other primary health care practitioners around the province.

The Hub must update the tools presently being used, develop guidance for treatment, and refine and provide the teaching program for the Spokes. Building the OCEEH requires the first steps

outlined in Table 5 to create and expand the foundation, and the next steps outlined in Table 6 to initiate, maintain and expand the program.

Table 5 First Steps to Building the OCEEH

Create the Foundation	Expand the Foundation
Immediate increase of EHC medical staff to 4 FTEs, including a Medical Director	Begin education of Spoke health care providers, starting with an introductory course
Begin training of Fellows to expand medical staff	Develop education modules and case-based training for medical students, residents, Spoke providers and primary care providers
Organize research projects for Fellows and clinical staff	Develop education modules for nursing and other health professionals
Organize workshop (preferably 3 days) of clinical and research experts to develop GRADE recommendations, and advise re “promising” practices	Organize workshop (preferably 3 days) of clinical and research experts to set research agenda, including evaluation strategies, and initiate research collaborations
Upgrade and refine methods for data gathering	Develop programs for University Sciences (humanities, natural and social science, environmental policy and urban planning)
Develop specific Hub agreements with the university(ies) and teaching hospital(s)	Develop education modules for patients
Prepare education program for Spokes	Develop modules for self-management
Develop university certificate in Environmental Health, and apply for CFPC special practice designation	Develop safe rooms in Spokes
Develop updated hospital guidelines	Create temporary lodging for patients attending the Hub

Table 6 Next Steps in Building the OCEEH

Initiate Programming	Maintenance and Expansion
Begin provision of care in Spokes, and provide support consultations	Gather research data
Develop teleconference and e-consultation service for provision of consultations in remote areas by Hub and Spokes	Refine assessments and treatment protocols
Further develop Research Agenda and Research Associates	Disseminate knowledge
Initiate research programs; case studies and research protocols	Network
Apply for Research Funding	Continue research in Hub and Spokes
Create a website	Expand Spoke availability in Ontario

References

Note: To save space, only the primary author is named. Most of these citations are readily available in Medline.

- ¹ Lucchini RG. Neurological impacts from inhalation of pollutants and the nose-brain connection. *Neurotoxicology*. 2012; 33(4):838-41.
- ² Migliore L. Environmental-induced oxidative stress in neurodegenerative disorders and aging. *Mutat Res*. 2009; 674(1-2):73-84.
- ³ Brook RD, Rajagopalan S, Pope CA 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC Jr, Whitsel L, Kaufman JD; American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and Metabolism. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. *Circulation*. 2010 Jun 1;121(21):2331-78.
- ⁴ Shah AS. Global association of air pollution and heart failure: a systematic review and meta-analysis. *Lancet*. 2013 Jul 9. pii: S0140-6736(13)60898-3.
- ⁵ Sava F. Respiratory health effects of ambient air pollution: an update. *Clin Chest Med*. 2012; 33(4):759-69.
- ⁶ Wright RJ. Programming of respiratory health in childhood: influence of outdoor air pollution. *Curr Opin Pediatr*. 2013; 25(2):232-9.
- ⁷ Auerbach A. The effect of environmental oxidative stress on airway inflammation. *Curr Opin Allergy Clin Immunol*. 2012; 12(2):133-9.
- ⁸ Miyata R. The innate and adaptive immune response induced by alveolar macrophages exposed to ambient particulate matter. *Toxicol Appl Pharmacol*. 2011; 257(2):209-26.
- ⁹ United Nations Environment Programme and World Health Organization State of the science of endocrine disrupting chemicals 2012 / edited by Ake Bergman, Jerrold J. Heindel, Susan Jobling, Karen A. Kidd and R. Thomas Zoeller. http://unep.org/pdf/9789241505031_eng.pdf (Accessed September 7, 2013).
- ¹⁰ De Coster S. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. *J Environ Public Health*. 2012; 2012:713696.
- ¹¹ <http://www.womenscollegehospital.ca/programs-and-services/environmental-health-clinic469/>
- ¹² Bell IR. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. *Am J Med*. 1998; 105(3A):74S-82S.
- ¹³ Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948. <http://www.who.int/about/definition/en/print.html> (accessed April 6, 2013).
- ¹⁴ Health and Environment Primer, Health and Environment Alliance, Brussels (Belgium), December, 2007, latest update June, 2011: http://www.euro.who.int/_data/assets/pdf_file/0011/116012/WA3095.pdf WHO Regional Publications, European Series, No. 35 (accessed September 2, 2013).
- ¹⁵ Public Health Ontario. <http://www.publichealthontario.ca/en/BrowseByTopic/EnvironmentalandOccupationalHealth/Pages/Environmental-and-Occupational-Health.aspx> (accessed July 3, 2013).
- ¹⁶ Women's College Hospital. Environmental Health Clinic. <http://www.womenscollegehospital.ca/programs-and-services/environmental-health-clinic469/> (accessed July 3, 2013).
- ¹⁷ Warshaw G. Introduction: advances and challenges in care of older people with chronic illness. *Generation*. 2006; 30(3):5-10.
- ¹⁸ World Health Organization. Global status report on noncommunicable diseases, 2010; ISBN 978 92 4 068645 8 (PDF). http://www.who.int/nmh/publications/ncd_report_full_en.pdf (accessed September 19 2012).
- ¹⁹ Cooper K. Early exposures to hazardous chemicals/pollution and associations with chronic disease: a scoping review. A report from the Canadian Environmental Law Association, the Ontario College of Family Physicians and the Environmental Health Institute of Canada. 2011. <http://www.cela.ca/sites/cela.ca/files/EarlyExpandCDScopingReview-lowres.pdf> (accessed July 18 2012).

-
- ²⁰ Sears ME. Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification. *J Environ Public Health*. 2012;2012:356798.
- ²¹ The Collaborative on Health and the Environment. CHE Toxicant and Disease Database. <http://www.healthandenvironment.org/tddb> (accessed September 19, 2012).
- ²² National Institutes of Environmental Health Science (NIEHS). US Department of Health and Human Services. Health & Education. Conditions & Diseases. <http://www.niehs.nih.gov/health/topics/conditions/index.cfm> (accessed September 19, 2012)
- ²³ Canadian Community Health Survey (CCHS) - Cycle 1.1. Statistics Canada, 2003.
- ²⁴ Valderas JM. Defining comorbidity: Implications for understanding health and human services. *Ann Fam Med*. 2009; 7(4):357-363.
- ²⁵ Sevrick MA. Patients with Complex Chronic Diseases: perspectives on supporting self-management. *J Gen Intern Med*. 2007; 22(Suppl 3):438-44.
- ²⁶ Bayliss EA. Supporting self-management for patients with complex medical needs: recommendations of a working group. *Chronic Illness*. 2007; 3:167-175.
- ²⁷ Nasmith L. Transforming care for Canadians with chronic health conditions: Put people first, expect the best, manage for results. Canadian Academy of Health Sciences. Ottawa, ON, Canada. 2010. <http://www.cahs-acss.ca/wp-content/uploads/2011/09/cdm-final-English.pdf> (accessed September 16, 2013).
- ²⁸ Glynn LG. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. *J Fam Pract*. 2011; 28:516-523.
- ²⁹ Public Health Agency of Canada. Economic Burden of Illness in Canada (1998 data). Statistics Canada, 2002. <http://www.phac-aspc.gc.ca/ebic-femc/ebic-femc98/index-eng.php> (accessed September 19, 2012)
- ³⁰ Hunger M. Multimorbidity and health-related quality of life in the older population: results from the German KORA-Age study. *Health Quality Life Outcomes*. 2011; 9:53.
- ³¹ Fortin M. Multimorbidity's many challenges. *BMJ*. 2007; 334:1016-7.
- ³² Smith SM. Chronic diseases: what happens when they come in multiples? *Br J Gen Pract*. 2007; 57:268-70.
- ³³ Vogeli C. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. *J Gen Intern Med*. 2007; 22(suppl 3):391-5.
- ³⁴ Fortin M. Multimorbidity and quality of life in primary care: a systematic review. *Health Qual Life Outcomes*. 2004; 2:51.
- ³⁵ Health Council of Canada. Why health care renewal matters: Learning from Canadians with chronic health conditions. Toronto: Health Council. www.healthcouncilcanada.ca (accessed May 9, 2013).
- ³⁶ Taylor A. Multimorbidity – not just an older person's issue. Results from an Australian biomedical study. *BMC Public Health*. 2010; 10:718.
- ³⁷ Sevrick MA. Patients with complex chronic diseases: perspectives on supporting self-management. *J Gen Intern Med*. 2007; 22:438-444.
- ³⁸ Noel P. The challenges of multimorbidity from the patient perspective. *J Gen Intern Med*. 2007; 22:419-424.
- ³⁹ Fortin M. Relationship between multimorbidity and health-related quality of life of patients in primary care. *Qual Life Res*. 2006; 15:83-91.
- ⁴⁰ Bayliss EA. Descriptions of barriers to self-care by persons with comorbid chronic diseases. *Ann Fam Med*. 2003; 1:15-21.
- ⁴¹ Grumbach K. Chronic illness, comorbidities, and the need for medical generalism. *Ann Fam Med*. 2003; 1(1):4-7.
- ⁴² Starfield B. Comorbidity: implications for the importance of primary care in "case" management. *Ann Fam Med*. 2003;1:8-14.
- ⁴³ Luijckx HD. GPs' considerations in multimorbidity management: a qualitative study. *Br J Gen Pract*. 2012; 62(600):503-10.
- ⁴⁴ Boyd CM. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA*. 2005; 294(6):716-724.
- ⁴⁵ American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. http://www.americangeriatrics.org/annual_meeting/2012_meeting_handouts/amhandouts050512/guiding_principles_050512. (accessed August 20, 2013)
- ⁴⁶ Fried TR. Primary care clinicians' experiences with treatment decision making for older persons with multiple conditions. *Arch Intern Med*. 2011; 171(1):75-80

- ⁴⁷ Tinetti ME. Designing health care for the most common chronic condition - multimorbidity. *JAMA*. 2012; 307(23):2493-4
- ⁴⁸ Upshur REG. Chronicity and complexity: Is what's good for the diseases always good for the patients? *Can Fam Physician*. 2008; 54(12):1655-8.
- ⁴⁹ World Health Organization. Health Impact Assessment. The Determinants of Health. Use of Evidence. <http://www.who.int/hia/evidence/doh/en/> (accessed September 22, 2012).
- ⁵⁰ Halliday JL. Genetics and public health - evolution, or revolution? *J Epidemiol Community Health*. 2004; 58:894-899.
- ⁵¹ Rappaport S. Environment and disease risks. *Science*. 22 October 2010; 330(6003):460-461
- ⁵² http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml
- ⁵³ <http://www.who.int/genomics/public/geneticdiseases/en/index3.html>
- ⁵⁴ Anway MD. Epigenetic transgenerational actions of endocrine disruptors, *Endocrinology*. 2006; 147(6):s43-s49.
- ⁵⁵ Crews D. Epigenetics, evolution, endocrine disruption, health and disease, *Endocrinology*. 2006; 147(6):s43-s49.
- ⁵⁶ Korkina L. The chemical defensive system in the pathobiology of idiopathic environment-associated diseases, *Current Drug Metabolism*. 2008; 10:914-31.
- ⁵⁷ Genuis SJ. Medical practice and community health care in the 21st century: A time of change. *Public Health*. 2008; 122:671-80.
- ⁵⁸ Berger SL. An operational definition of epigenetics. *Genes Dev*. 2009; 23:781-783.
- ⁵⁹ Bayarsaihan D. Epigenetic mechanisms in inflammation. *J Dent Res*. 2011; 90(1):9-17.
- ⁶⁰ Luco RF. Epigenetics in alternative pre-mRNA splicing. *Cell*. 2011; 144(1):16-26.
- ⁶¹ Jardim MJ. microRNAs: implications for air pollution research. *Mutat Res*. 2011; 717:38-45.
- ⁶² Baccarelli A. Epigenetics and environmental chemicals. *Curr Opin Pediatr*. 2009; 21:243-251.
- ⁶³ Bollati V. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. 2007; *Cancer Res*. 67:876-880
- ⁶⁴ Madrigano J. Prolonged exposure to particulate pollution, genes associated with glutathione pathways, and DNA methylation in a cohort of older men. *Environ Health Perspect*. 2011; 119:977-982.
- ⁶⁵ Ziech D. Reactive oxygen species (ROS)--induced genetic and epigenetic alterations in human carcinogenesis. *Mutat Res*. 2011; 711(1-2):167-73.
- ⁶⁶ Flora SJ. Arsenic-induced oxidative stress and its reversibility. *Free Radic Biol Med*. 2011; 51(2):257-81.
- ⁶⁷ Franco R. Oxidative stress, DNA methylation and carcinogenesis. *Cancer Lett*. 2008; 266(1):6-11.
- ⁶⁸ Lim SO. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. *Gastroenterology*. 2008; 135(6):2128-2140.
- ⁶⁹ Wachsman JT. DNA methylation and the association between genetic and epigenetic. *Mutat Res*. 1997;375(1):1-8.
- ⁷⁰ Donkena KV. Oxidative stress and DNA methylation in prostate cancer. *Obstet Gynecol Int*. 2010; 302051.
- ⁷¹ Ziech D. The role of epigenetics in environmental and occupational carcinogenesis. *Chem Biol Interact*. 2010; 188(2):340-349.
- ⁷² Sundar IK. Oxidative stress, thiol redox signaling methods in epigenetics. *Methods Enzymol*. 2010; 474:213-244.
- ⁷³ Valinluck V. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res*. 2004; 32:4100-4108
- ⁷⁴ Jirtle RL. Environmental epigenomics and disease susceptibility. *Nat Rev Genet*. 2007; 8(4):253-62.
- ⁷⁵ Weinhold B. Epigenetics: the science of change. *Environ Health Perspect*. 2006; 114(3):A160-A167.
- ⁷⁶ Cortessis VK. Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. *Hum Genet*. 2012; 131(10):1565-89.
- ⁷⁷ Miller RL. Environmental epigenetics and asthma: current concepts and call for studies. *Am J Respir Crit Care Med*. 2008; 177:567-73.
- ⁷⁸ Baccarelli A. Rapid DNA methylation changes after exposure to traffic particles. *Am J Respir Crit Care Med*. 2009; 179:572-8.
- ⁷⁹ Truyen E. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. *Thorax*. 2006; 61:202-8.

- ⁸⁰ Nadeau K. Ambient air pollution impairs regulatory T-cell function in asthma. *J Allergy Clin Immunol.* 2010; 126:845–852
- ⁸¹ Herbstman JB. Prenatal exposure to polycyclic aromatic hydrocarbons, benzo[a]pyrene-DNA adducts and genomic DNA methylation in cord blood. *Environ Health Perspect.* 2012; 120(5):733-8.
- ⁸² Perera F. Relation of DNA methylation of 50-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. *PLoS One*, 2009; 4:E4488
- ⁸³ Au WW. Life style factors and acquired susceptibility to environmental disease. *Int J Hyg Environ Health.* 2001; 204(1):17-22.
- ⁸⁴ Cooper K. Early exposures to hazardous chemicals/pollution and associations with chronic disease: a scoping review. A report from the Canadian Environmental Law Association, the Ontario College of Family Physicians and the Environmental Health Institute of Canada. 2011. <http://www.cela.ca/sites/cela.ca/files/EarlyExpandCDScopingReview-lowres.pdf> (accessed July 18 2012).
- ⁸⁵ World Health Organization. World Health Report. "Reducing Risk, Promoting Healthy Life." Geneva. 2002; http://www.who.int/whr/2002/en/whr02_en.pdf (accessed September 22, 2012)
- ⁸⁶ Rudders SA. Trends in pediatric emergency department visits for food-induced anaphylaxis. *J Allergy Clin Immunol.* 2010; 126:385-8.
- ⁸⁷ Clark S. Frequency of US emergency department visits for food-related acute allergic reactions. *J Allergy Clin Immunol.* 2011; 127(3):682-3.
- ⁸⁸ Ring J. Why are allergies increasing? *Curr Opinion Immunol.* 2001; 13(6):701–708.
- ⁸⁹ Branum AM. Food allergy among U.S. children: Trends in prevalence and hospitalizations. NCHS data brief, no 10. Hyattsville, MD: National Center for Health Statistics. 2008.
- ⁹⁰ Sicherer SH. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. *J Allergy Clin Immunol* 2003; 112:1203-7.
- ⁹¹ Lieberman P. Epidemiology of anaphylaxis. *Curr Opin Allergy Clin Immunol.* 2008; 8(4):316-20.
- ⁹² Koplin JJ. An update on epidemiology of anaphylaxis in children and adults. *Curr Opin Allergy Clin Immunol.* 2011; 11(5):492-6.
- ⁹³ Ring J. Environmental pollution and allergy. *Ann Allergy Asthma Immunol.* 2001; 87(6 Suppl 3):2-6.
- ⁹⁴ Diaz-Sanchez D. Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity. *J Allergy Clin Immunol.* 2000; 106(6):1140-6.
- ⁹⁵ Schmidt CW. Questions persist: Environmental factors in autoimmune disease. *Environ Health Perspect.* 2011; 119(6).
- ⁹⁶ Gourley M. Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease. *Nat Clin Practice Rheumatol.* 2007; 3(3):172–180.
- ⁹⁷ Farhat SC. Air pollution in autoimmune rheumatic diseases: a review. *Autoimmun Rev.* 2011; 11(1):14-21.
- ⁹⁸ To T. The burden of illness experienced by young children associated with asthma: a population-based cohort study. *J Asthma.* 2008; 45(1):45-9.
- ⁹⁹ ISAAC Steering Committee. Worldwide variation in prevalence symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. *Lancet.* 1998; 351:1225e32.
- ¹⁰⁰ Braman SS. The global burden of asthma. *Chest.* 2006; 130(1 Suppl):4S-12S.
- ¹⁰¹ Takenoue Y. The influence of outdoor NO(2) exposure on asthma in childhood: a meta-analysis. *Pediatr Int.* 2012; 54(6):762-9.
- ¹⁰² Jung KH. Childhood exposure to fine particulate matter and black carbon and the development of new wheeze between ages 5 and 7 in an urban prospective cohort. *Environ Int.* 2012; 45:44-50.
- ¹⁰³ Xu X. Long-term exposure to ambient fine particulate pollution induces insulin resistance and mitochondrial alteration in adipose tissue. *Toxicol Sci.* 2011; 124(1):88-98.
- ¹⁰⁴ Chen H. Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada. *Env Health Perspect.* 2013; 121(7):804-10.
- ¹⁰⁵ Pearson JF. Association between fine particulate matter and diabetes prevalence in the U.S. *Diabetes Care.* 2010; 33(10):2196-201.
- ¹⁰⁶ Coogan PF. Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. *Circulation.* 2012; 125(6):767-72.

- ¹⁰⁷ Andersen ZJ. Diabetes incidence and long-term exposure to air pollution: a cohort study. *Diabetes Care*. 2012; 35(1):92-8.
- ¹⁰⁸ Chiusolo M. Short term effects of nitrogen dioxide on mortality and susceptibility factors in ten Italian cities: the EpiAir study. *Environ Health Perspect*. 2011 119(9):1233-1238.
- ¹⁰⁹ Howard SG. What is the role of human contamination by environmental chemicals in the development of type 1 diabetes? *J Epidemiol Community Health*. 2012; 66(6):479-81.
- ¹¹⁰ Howard SG. Environmental pollutants and beta cell function: relevance for type 1 and gestational diabetes. *Diabetologia*. 2011; 54(12):3168-9.
- ¹¹¹ Hathout EH. Air pollution and type 1 diabetes in children. *Pediatr Diabetes*. 2006;7:81e7.
- ¹¹² Carpenter DO. Environmental contaminants as risk factors for developing diabetes. *Rev Environ Health*. 2008; 23:59e74.
- ¹¹³ Longnecker MP. Polychlorinated biphenyl serum levels in pregnant subjects with diabetes. *Diabetes Care*. 2001; 24:1099e101.
- ¹¹⁴ Xu X. Effect of early particulate air pollution exposure on obesity in mice: role of p47phox. *Atheroscler Thromb Vasc Biol*. 2010; 30:2518-2527.
- ¹¹⁵ Goldberg MS. Associations between ambient air pollution and daily mortality among persons with diabetes and cardiovascular disease. *Environ Res*. 2006; 100:255-267.
- ¹¹⁶ O'Neill MS. Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function. *Circulation*. 2005; 111:2913-2920.
- ¹¹⁷ Dales RE. Air pollution and hospitalization for acute complications of diabetes in Chile. *Environ Int*. 2012; 46C:1-5.
- ¹¹⁸ Canadian Institute for Health Information. Inpatient hospitalizations and average length of stay trends in Canada, 2003-04 and 2004-05. November 30, 2005. <http://www.ihe.ca/documents/IHIYP.pdf> (accessed August 31 2012).
- ¹¹⁹ Brook RD. Expert Panel on Population and Prevention Science of the American Heart Association. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. *Circulation*. 2004;109:2655-2671.
- ¹²⁰ Brook RD. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association *Circulation*. 2010; 121(21):2331-78.
- ¹²¹ Sun Q. Cardiovascular effects of ambient particulate air pollution exposure. *Circulation*. 2010; 121(25):2755-65.
- ¹²² Lewtas J. Air pollution combustion emissions: characterization of causative agents and mechanisms associated with cancer, reproductive, and cardiovascular effects. *Mutat Res*. 2007; 636(1-3):95-133.
- ¹²³ Franchini M. Air pollution and cardiovascular disease. 2012; 129(3):230-4.
- ¹²⁴ Tonne C. A case-control analysis of exposure to traffic and acute myocardial infarction. *Environ Health Perspect*. 2007; 115(1):53-57.
- ¹²⁵ Hoek G. Association between mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study. *Lancet*. 2002; 360(9341):1203-9.
- ¹²⁶ Chen LH. The association between fatal coronary heart disease and ambient particulate air pollution: Are females at greater risk? *Environ Health Perspect*. 2005; 113(12):1723-1729.
- ¹²⁷ Dockery DW. An association between air pollution and mortality in six U.S. cities. *N Engl J Med*. 1993; 329(24):1753-9.
- ¹²⁸ Maheswaran R. Impact of outdoor air pollution on survival after stroke. *Stroke*. 2010; 41:869-877.
- ¹²⁹ Sun Q. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. *JAMA* 2005; 21:3003-3010.
- ¹³⁰ Brook RD. An update to the scientific statement from the American Heart Association. *Circulation*. 2010; 121:2331-2378.
- ¹³¹ Lund AK. Vehicular emissions induce vascular MMP-9 expression and activity associated with endothelin-1 mediated pathways. *Arterioscler Thromb Vasc Biol*. 2009; 29:511-517.
- ¹³² Hoffmann B. Residential exposure to traffic is associated with coronary atherosclerosis. *Circulation*. 2007; 116:489-496.
- ¹³³ Grahame TJ. Cardiovascular health and particulate vehicular emissions: a critical evaluation of the evidence. *Air Qual Atmos Health*. 2010; 3:3-27.

- ¹³⁴ Lund AK. The oxidized low-density lipoprotein receptor mediates vascular effects of inhaled vehicle emissions. *Am J Respir Crit Care Med*. 2011; 184:82–91.
- ¹³⁵ Fuks K. Long-term urban particulate air pollution, traffic noise and arterial blood pressure. *Env Health Perspect*. 2011; 119(12):1706–1711.
- ¹³⁶ Park SK. HFE genotype, particulate air pollution, and heart rate variability: a gene-environment interaction. *Circulation*. 2006; 114: 2798–2805.
- ¹³⁷ Baccarelli A. Cardiac autonomic dysfunction: effects from particulate air pollution and protection by dietary methyl nutrients and metabolic polymorphisms. *Circulation*. 2008; 117:1802–1809.
- ¹³⁸ Chahine T. Particulate air pollution, oxidative stress genes, and heart rate variability in an elderly cohort. *Environ Health Perspect*. 2007; 115(11):1617-1622
- ¹³⁹ Le Tertre A. Empirical Bayes and adjusted estimates approach to estimating the relation of mortality to exposure of PM(10). *Risk Anal*. 2005; 25(3):711-718.
- ¹⁴⁰ Baja ES. Traffic-related air pollution and QT interval: modification by diabetes, obesity, and oxidative stress gene polymorphisms in the Normative Aging Study. *Environ Health Perspect*. 2010; 118:840-846.
- ¹⁴¹ Madrigano J. Air pollution, obesity, genes, and cellular adhesion molecules. *Occup Environ Med*. 2010; 67:312-317
- ¹⁴² Ren C. Air pollution and homocysteine: modification by oxidative stress related genes. *Epidemiology*. 2010; 21(2):198-206
- ¹⁴³ Islam T. Glutathione-S-transferase (GST) P1, GSTM1, exercise, ozone and asthma incidence in school children. *Thorax*. 2009; 64(3):197-202.
- ¹⁴⁴ Romieu I. GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone. *Eur Respir J*. 2006 Nov;28(5):953-9.
- ¹⁴⁵ McCunney RJ. Asthma, genes, and air pollution. *J Occup Environ Med*. 2005; 47(12):1285-91
- ¹⁴⁶ Schroer KT. Associations between multiple environmental exposures and glutathione S-transferase P1 on persistent wheezing in a birth cohort. *J Pediatr*. 2009; 154(3):401-408.
- ¹⁴⁷ Santiago-Lopez D. Oxidative stress, progressive damage in the substantia nigra and plasma dopamine oxidation, in rats chronically exposed to ozone. *Toxicol Lett*. 2010; 197:193-200.
- ¹⁴⁸ Guxens M. A review of epidemiological studies on neuropsychological effects of air pollution. *Swiss Med Wkly*. 2012; 141:w13322.
- ¹⁴⁹ Levesque S. The role of MAC1 in diesel exhaust particle-induced microglial activation and loss of dopaminergic neuron function. *J Neurochem*. 2013; 125(5):756-65.
- ¹⁵⁰ Guxens M. Prenatal exposure to residential air pollution and infant mental development: modulation by antioxidants and detoxification factors. *Environ Health Perspect*. 2012; 120:144–149.
- ¹⁵¹ Vrijheid M. Indoor air pollution from gas cooking and infant neurodevelopment. *Epidemiology*. 2012; 23:23–32.
- ¹⁵² Perera FP. Effects of transplacental exposure to environmental pollutants on birth outcomes in a multiethnic population. *Environ Health Perspect*. 2003; 111(2):201-205.
- ¹⁵³ Perera FP. Molecular evidence of an interaction between prenatal environmental exposures and birth outcomes in a multiethnic population. *Environ Health Perspect*. 2004; 112(5):626-630.
- ¹⁵⁴ Perera FP. Effect of prenatal exposure to airborne polycyclic aromatic hydrocarbons on neurodevelopment in the first 3 years of life among inner-city children. *Environ Health Perspect*. 2006; 114(8):1287-1292.
- ¹⁵⁵ Wang S. Association of traffic-related air pollution with children's neurobehavioral functions in Quanzhou, China. *Environ Health Perspect*. 2009; 117:1612–1618.
- ¹⁵⁶ Volk HE. Residential proximity to freeways and autism in the CHARGE study. *Environ Health Perspect*. 2011; 119(6):873-7.
- ¹⁵⁷ Volk HE. Traffic-related air pollution, particulate matter, and autism. *JAMA Psychiatry*. 2013; 70(1):71-7.
- ¹⁵⁸ Becerra TA. Ambient air pollution and autism in Los Angeles county, California. *Environ Health Perspect*. 2013; 121(3):380-6
- ¹⁵⁹ Calderon-Garciduenas L. Air pollution, cognitive deficits and brain abnormalities: a pilot study with children and dogs. *Brain Cogn*. 2008; 68:117–127.
- ¹⁶⁰ Suglia SF. Association of black carbon with cognition among children in a prospective birth cohort study. *Am J Epidemiol*. 2008; 167:280–286.

-
- ¹⁶¹ Chen JC. Neurobehavioral effects of ambient air pollution on cognitive performance in US adults. *Neurotoxicology*. 2009; 30:231–239.
- ¹⁶² Ranft U. Long-term exposure to traffic-related particulate matter impairs cognitive function in the elderly. *Environ Res*. 2009; 109:1004–1011.
- ¹⁶³ Power MC. Traffic-related air pollution and cognitive function in a cohort of older men. *Environ Health Perspect*. 2011; 119:682–687.
- ¹⁶⁴ Weuve J. Exposure to particulate air pollution and cognitive decline in older women. *Arch Intern Med*. 2012; 172:219–227.
- ¹⁶⁵ Block ML. Air pollution: mechanisms of neuroinflammation and CNS disease. *Trends Neurosci*. 2009; 32:506–516.
- ¹⁶⁶ Calderon-Garciduenas L. Urban air pollution: influences on olfactory function and pathology in exposed children and young adults. *Exp Toxicol Pathol*. 2010; 62:91–102.
- ¹⁶⁷ Calderon-Garciduenas L. Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution. *Toxicol Pathol*. 2004; 32:650–658.
- ¹⁶⁸ Calderon-Garciduenas L. Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. *J Alzheimers Dis*. 2012; 28:93–107.
- ¹⁶⁹ Morales E. Association of early-life exposure to household gas appliances and indoor nitrogen dioxide with cognition and attention behavior in preschoolers. *Am J Epidemiol*. 2009; 169:1327–1336.
- ¹⁷⁰ Hong GS. Gene variations in GSTM3 are a risk factor for Alzheimer's disease. *Neurobiol Aging*. 2009; 30(5):691-6.
- ¹⁷¹ Pinhel MA. Glutathione S-transferase variants increase susceptibility for late-onset Alzheimer's disease: association study and relationship with apolipoprotein E epsilon4 allele. *Clin Chem Lab Med*. 2008; 46(4):439-45.
- ¹⁷² Singh M. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease. *Dis Markers*. 2010; 28(2):87-93.
- ¹⁷³ Singh M. Polymorphism in environment responsive genes and association with Parkinson disease. *Mol Cell Biochem*. 2008; 312(1-2):131-8
- ¹⁷⁴ Wilk JB. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. *Neurology*. 2006; 67(12):2206-10.
- ¹⁷⁵ Gash DM. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. *Ann Neurol*. 2008; 63(2):184-92.
- ¹⁷⁶ Liu M. Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. *J Neurochem*. 2010; 112(3):773-83.
- ¹⁷⁷ Gash DM. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. *Ann Neurol*. 2008; 63(2):184-92.
- ¹⁷⁸ Wang A. Parkinson's disease risk from ambient exposure to pesticides. *Eur J Epidemiol*. 2011; 26(7):547-55.
- ¹⁷⁹ Tanner CM. Rotenone, Paraquat and Parkinson's disease. *Environ Health Perspect*. 2011; 119:866–872.
- ¹⁸⁰ Dutheil F. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. *Arch Neurol*. 2010; 67(6):739-745.
- ¹⁸¹ Costello S. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. *Am J Epidemiol*. 2009; 169(8):919-26.
- ¹⁸² Tanner CM. Occupation and risk of parkinsonism: a multicenter case-control study. *Arch Neurol* 2009; 66(9):1106-1113.
- ¹⁸³ Hancock DB. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. *BMC Neurology*. 2008; 8(6):1471-2377.
- ¹⁸⁴ Dich FD. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. *Occup Environ Med*. 2007; 64:666-672.
- ¹⁸⁵ Kamel F. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. *Am J Epidemiol*. 2007; 165(4):364–374.
- ¹⁸⁶ Ascherio A. Pesticide exposure and risk for Parkinson's disease. *Ann Neurol*. 2006; 60(2):197-203.

- ¹⁸⁷ Calderon-Garciduenas L. Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. *Toxicol Pathol.* 2008; 36:289–310.
- ¹⁸⁸ Zanchi AC. Hippocampus lipid peroxidation induced by residual oil fly ash intranasal instillation versus habituation to the open field. *Inhal Toxicol.* 2010; 22:84–88
- ¹⁸⁹ Calderon-Garciduenas L. DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. *Toxicol Pathol.* 2003; 31:524–538.
- ¹⁹⁰ Bos I. Changed gene expression in brains of mice exposed to traffic in a highway tunnel. *Inhal Toxicol.* 2012; 24:676–686.
- ¹⁹¹ Cassee FR. The biological effects of subacute inhalation of diesel exhaust following addition of cerium oxide nanoparticles in atherosclerosis-prone mice. *Environ Res.* 2012; 115:1–10.
- ¹⁹² Gerlofs-Nijland ME. Effect of prolonged exposure to diesel engine exhaust on proinflammatory markers in different regions of the rat brain. *Par Fibre Toxicol.* 2010; 7:12.
- ¹⁹³ Levesque S. Diesel exhaust activates and primes microglia: air pollution, neuroinflammation, and regulation of dopaminergic neurotoxicity. *Environ Health Perspect.* 2011; 119:1149–1155.
- ¹⁹⁴ Levesque S. Air pollution & the brain: subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease. *J Neuroinflammation.* 2011; 8:105.
- ¹⁹⁵ Bolton JL. Prenatal air pollution exposure induces neuroinflammation and predisposes offspring to weight gain in adulthood in a sex-specific manner. *FASEB J.* 2012; 26:4743–4754.
- ¹⁹⁶ Morgan TE. Glutamatergic neurons in rodent models respond to nanoscale particulate urban air pollutants in vivo and in vitro. *Environ. Health Perspect.* 2011; 119:1003–1009.
- ¹⁹⁷ Stavropoulou C. The C609T inborn polymorphism in NAD(P)H:quinone oxidoreductase 1 is associated with susceptibility to multiple sclerosis and affects the risk of development of the primary progressive form of the disease. *Free Radic Biol Med.* 2011; 51(3):713-8.
- ¹⁹⁸ Shastry BS. Genetic diversity and new therapeutic concepts. *J Hum Genet.* 2005; 50(7):321-8.
- ¹⁹⁹ Polimanti R. Genetic variability of glutathione S-transferase enzymes in human populations: functional inter-ethnic differences in detoxification systems. *Gene.* 2013; 512(1):102-7.
- ²⁰⁰ CDC: Center for Disease Control and Prevention. Fourth National Report on Human Exposure to Environmental Chemicals. 2009 Atlanta: Centers for Disease Control and Prevention.
- ²⁰¹ Rappaport SM. Implications of the exposome for exposure science. *Expo Sci Environ Epidemiol.* 2011; 21(1):5-9
- ²⁰² Rappaport SM. Environment and disease risks. *Science.* 2010; 330:460–461
- ²⁰³ Marshall L., Environmental Health Clinic, Women's College Hospital. Environmental sensitivities-multiple chemical sensitivities Status Report 2010, Advances in knowledge, and current service gaps. updated June 2, 2011.
- ²⁰⁴ Grant DM. Detoxification pathways in the liver. *J Inher Metab Dis.* 1991; 14:421-430.
- ²⁰⁵ Iyanagi T. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. *Int Rev Cytol.* 2007; 260:35-112.
- ²⁰⁶ Liska DJ. The detoxification enzyme systems. *Altern Med Rev.* 1998; 3(3):187-198
- ²⁰⁷ Johnson CH. Xenobiotic metabolomics: major impact on the metabolome. *Annu Rev Pharmacol Toxicol.* 2012; 52:37–56.
- ²⁰⁸ Butow RA, On the mechanism of respiratory control. *J Gen Physiol.* 1965; 49(1):Suppl:149-62.
- ²⁰⁹ Duchon MR. Roles of mitochondria in health and disease. *Diabetes* 2004; 53(suppl 1):S96-S102.
- ²¹⁰ Ferrari CK. Effects of xenobiotics on total antioxidant capacity. *Interdiscip Toxicol.* 2012; 5(3):117-22.
- ²¹¹ Raha S. Mitochondria, oxygen free radicals, disease and ageing. *Trends Biochem Sci.* 2002; 25:502–508.
- ²¹² Stadtman ER. Protein oxidation in aging and age-related diseases. *Ann NY Acad Sci.* 2001; 928:22–38.
- ²¹³ Hensley K. Reactive oxygen species and protein oxidation in aging: A look back, a look ahead. *Arch Biochem Biophys.* 2002; 397:377–383.
- ²¹⁴ Go YM. Redox control systems in the nucleus: mechanisms and functions. *Antioxid Redox Sign.* 2010; 13(4):489-509.
- ²¹⁵ Richter C. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. *Proc Natl Acad Sci USA.* 1988; 85:6465–6467.

- ²¹⁶ Yakes FM. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. *PNAS*. 1997; 94(2):514-519.
- ²¹⁷ Halliwell B. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. *Antioxid Redox Signal*. 2010; 13(2):145-56.
- ²¹⁸ Shacter E. Quantification and significance of protein oxidation in biological samples. *Drug Metab Rev*. 2000; 32(3-4):307-26.
- ²¹⁹ Grune T. Markers of oxidative stress in ICU clinical settings: present and future. *Curr Opin Clin Nutr Metab Care*. 2007; 10:712-717.
- ²²⁰ Comparison of different methods of measuring 8-oxoguanine as a marker of oxidative DNA damage. ESCODD (European Standards Committee on Oxidative DNA Damage). *Free Radic Res* 2000; 32:333-341.
- ²²¹ Breusing N. Biomarkers of protein oxidation from a chemical, biological and medical point of view. *Exp Gerontol*. 2010; 45(10):733-7.
- ²²² Lee R. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. *Curr Med Chem*. 2012; 19(16):2504-20.
- ²²³ Stephens JW. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. *Atherosclerosis*. 2009; 202(2):321-9.
- ²²⁴ Marshall NJ. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. *Growth Regul*. 1995; 5(2):69-84.
- ²²⁵ Brand MD. Assessing mitochondrial dysfunction in cells. *Biochem J*. 2011; 435(Pt 2):297-312.
- ²²⁶ Heslop CL. Combined polymorphisms in oxidative stress genes predict coronary artery disease and oxidative stress in coronary angiography patients. *Ann Hum Genet*. 2012; 76(6):435-47.
- ²²⁷ García-Bermúdez M. Association of the methionine sulfoxide reductase A rs10903323 gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2012; 41(5):350-3.
- ²²⁸ Pietras T. The sequence polymorphism of MnSOD gene in subjects with respiratory insufficiency in COPD. *Med Sci Monit*. 2010; 16(9):CR427-32.
- ²²⁹ Allen M. Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. *Mol Neurodegener*. 2012; 7:13.
- ²³⁰ Kiyohara C. APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population. *J Neural Transm*. 2011; 118(9):1335-44.
- ²³¹ Anderson JO. Clearing the air: a review of the effects of particulate matter air pollution on human health. *J Med Toxicol*. 2012; 8(2):166-75.
- ²³² Williams N. Philosophy of science: biologists cut reductionist approach down to size. *Science*. 1997; 277(5325):476-477.
- ²³³ Ahn AC. The limits of reductionism in medicine: could systems biology offer an alternative? *PLoS Med*. 2006; 3(6):e208.
- ²³⁴ Strange K. The end of "naïve reductionism": rise of systems biology or renaissance of physiology? *Am J Physiol Cell Physiol*. 2005; 288:C968-C974.
- ²³⁵ Bloom FE. What does it all mean to you? *J Neurosci*. 2001; 21: 8304-8305.
- ²³⁶ Sauer U. Getting Closer to the Whole Picture. *Science*. 2007; 316(5824):550-551.
- ²³⁷ Ahn AC. The clinical application of a systems approach. *PLoS Med*. 2006; 3(7):e209.
- ²³⁸ Canadian Institutes of Health Research (CIHR). Environments, Genes and Chronic Disease National Workshop Report. February 7-8, 2012. <http://www.cihr-irsc.gc.ca/e/46037.html#a9> (accessed August 5 2013)
- ²³⁹ Kirschner MW. The meaning of systems biology. *Cell*. 2005; 121(4):503-4.
- ²⁴⁰ Kohl P. Systems biology and the virtual physiological human. *Molecular Systems Biology* 2009; 5:292
- ²⁴¹ http://en.wikipedia.org/wiki/List_of_systems_biology_research_groups (accessed July 18 2012).
- ²⁴² European Commission, Directorate of Health, Directorate General for Research. From Systems Biology to Systems Medicine Workshop. Brussels, June 14-15 2010. Edited by Kyriakopoulou C. and Mulligan B. ftp://ftp.cordis.europa.eu/pub/fp7/health/docs/final-report-systems-medicine-workshop_en.pdf (accessed October 20, 2013).
- ²⁴³ Federoff HJ. Evolving from reductionism to holism: is there a future for systems medicine? *JAMA*. 2009; 302(9):994-6.

- ²⁴⁴ Lavergne MR. Functional impairment in chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivity. *Can Fam Physician* 2010;56(2):e57-65
- ²⁴⁵ Holmes GP. Defining the chronic fatigue syndrome. *Rev Infect Dis*. 1991; 13(Suppl 1):S53-5.
- ²⁴⁶ Sharpe MC. A report – chronic fatigue syndrome: guidelines for research. *J R Soc Med*. 1991; 84:118–21.
- ²⁴⁷ Fukuda K. Chronic Fatigue Syndrome: a comprehensive approach to its definition and study. *Ann Intern Med*. 1994; 121:953–9.
- ²⁴⁸ Carruthers BM. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *J. Chronic Fatigue Syndr*. 2003; 11(1):7–116.
- ²⁴⁹ Reeves WC. Chronic fatigue syndrome – a clinically empirical approach to its definition and study. *BMC Med* 2005; 3:19.
- ²⁵⁰ Jason LA. Evaluating the Centers for Disease Control’s empirical chronic fatigue syndrome case definition. *J Disabil Pol Studies*. 2009; 20:91–100.
- ²⁵¹ Carruthers BM. Myalgic encephalomyelitis: International consensus criteria. *J Intern Med*. 2011; 270(4): 327-338.
- ²⁵² Wyller VB. The chronic fatigue syndrome - an update. *Acta Neurol Scand Suppl*. 2007; 187:7-14.
- ²⁵³ Clauw DJ. Perspectives on fatigue from the study of chronic fatigue syndrome and related conditions. *PMR*. 2010; 2(5):414-30.
- ²⁵⁴ Devanur LD. Chronic fatigue syndrome. *J Clin Virol*. 2006; 37:139–50.
- ²⁵⁵ Jason LA. Chronic fatigue syndrome: Sociodemographic subtypes in a community based sample. *Evaluation Health Professions*. 2000; 23:243-63.
- ²⁵⁶ Torres-Harding SR. Fatigue severity, attributions, medical utilization, and symptoms in persons with chronic fatigue. *J Behav Med*. 2002; 25:99-113.
- ²⁵⁷ Jones JF. Chronic fatigue syndrome and other fatiguing illnesses in adolescents: A population-based study. *J Adolesc Health*. 2004; 35:34–40.
- ²⁵⁸ Katz BZ. Chronic fatigue syndrome following infections in adolescents. *Curr Opin Pediatr*. 2013; 25(1):95-102.
- ²⁵⁹ Garralda ME. Impairment and coping in children and adolescents with chronic fatigue syndrome: a comparative study with other paediatric disorders. *J Child Psychol Psychiatry*. 2004; 45(3):543-52.
- ²⁶⁰ Gordon B. Promising outcomes of an adolescent chronic fatigue syndrome inpatient programme. *J Paediatr Child Health*. 2009; 45(5):286-90.
- ²⁶¹ Fisher H. Why do young people with CFS/ME feel anxious? A qualitative study. *Clin Child Psychol Psychiatry*. 2012 Oct 23. (ahead of print).
- ²⁶² Chalder T. Epidemiology of chronic fatigue syndrome and self reported myalgic encephalomyelitis in 5-15 year olds: cross sectional study. *BMJ*. 2003; 327:654-655.
- ²⁶³ Rimes KA. Incidence, prognosis, and risk factors for fatigue and chronic fatigue syndrome in adolescents: a prospective community study. *Pediatrics*. 2007; 119:e603-e609.
- ²⁶⁴ Farmer A. Prevalence of chronic disabling fatigue in children and adolescents. *Br J Psychiatry*. 2004; 184:477-481.
- ²⁶⁵ Rangel L. The course of severe chronic fatigue syndrome in childhood. *J R Soc Med*. 2000; 93:129-134.
- ²⁶⁶ Webb CM. What stops children with a chronic illness accessing health care: a mixed methods study in children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. (CFS/ME). *BMC Health Serv Res*. 2011; 11:308.
- ²⁶⁷ Craig T. Chronic fatigue syndrome: evaluation and treatment. *Am Fam Physician*. 2002; 65(6):1083-90.
- ²⁶⁸ National Institute of Health and Clinical Excellence. Nice Clinical Guideline 53. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy). Diagnosis and management of CFS/ME in adults and children. August 2007; <http://www.nice.org.uk/nicemedia/pdf/CG53QuickRefGuide.pdf> (accessed March 22, 2013)
- ²⁶⁹ Carruthers BM. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Clinical Case Definition and Guidelines for Medical Practitioners. An Overview of the Canadian Consensus Document. ISBN: 097393350X
- ²⁷⁰ CDC (Centers for Disease Control and Prevention) Last updated May 16, 2012. <http://www.cdc.gov/cfs/> (accessed March 21 2013)
- ²⁷¹ South Australian Department of Human Services. Primary Health Care Branch. Myalgic encephalopathy (ME) and chronic fatigue syndrome (CFS): management guidelines for general practitioners. ISBN 0 7308 9334 0 http://www.cfids-cab.org/MESA/AU_CFS.pdf (accessed March 21 2013)
- ²⁷² IACFS. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. ME/CFS: A Primer for Clinical Practitioners. 2012; <http://www.iacfsme.org/Home/Primer/tabid/509/Default.aspx> (accessed April 4 2013)

- ²⁷³ Ortega-Hernandez OD. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? *Ann NY Acad Sci.* 2009; 1173:600-9.
- ²⁷⁴ Lorusso L. Immunological aspects of chronic fatigue syndrome. *Autoimmun Rev.* 2009; 8(4):287-91.
- ²⁷⁵ Mihavlova I. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. *Neuro endocrinol Lett.* 2007; 28(4):477-83
- ²⁷⁶ Sharpe MC. A report – chronic fatigue syndrome: guidelines for research. *J R Soc Med* 1991;84:118–21.
- ²⁷⁷ Fukuda K. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med.* 1994; 121(12):953-9.
- ²⁷⁸ Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols. *J Chron Fatigue Syn.* 2003; 11(1):7-116.
- ²⁷⁹ Carruthers BM. ME/CFS: Clinical Working Case Definition, Diagnostic and Treatment Protocols, *J CFS.* 2003; 11(1):7-115.
- ²⁸⁰ An open letter to the Honorable Kathleen Sebelius, U.S. Secretary of Health and Human Services. September 23, 2013. <https://dl.dropboxusercontent.com/u/89158245/Case%20Definition%20Letter%20Sept%2023%202013.pdf> (accessed October 20, 2013).
- ²⁸¹ Komaroff AL. Role of infection and neurologic dysfunction in chronic fatigue syndrome. *Semin Neurol.* 2011; 31(3):325–37.
- ²⁸² Katon W. Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness. *Gen Hosp Psychiatry.* 1999; 21(1):21–9.
- ²⁸³ Hickie I. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. *BMJ.* 2006; 333(7568):575.
- ²⁸⁴ Naess H. Chronic fatigue syndrome after *Giardia* enteritis: clinical characteristics, disability and long-term sickness absence. *BMC Gastroenterol.* 2012; 12:13.
- ²⁸⁵ Lerner AM. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. *In Vivo.* 2004; 18(2):101-6.
- ²⁸⁶ Lerner AM. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome. *In Vivo.* 2004; 18(4):417–24.
- ²⁸⁷ Fremont M. Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. *In Vivo.* 2009;23(2):209–13.
- ²⁸⁸ Silverman MN. Neuroendocrine and immune contributors to fatigue. *PM R.* 2010; 2(5):338–46.
- ²⁸⁹ Juillard F. Epstein-Barr virus protein EB2 stimulates cytoplasmic mRNA accumulation by counteracting the deleterious effects of SRp20 on viral mRNAs. *Nucleic Acids Res.* 2012; 40(14):6834–49.
- ²⁹⁰ Proal AD. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. *Immunol Res.* 2013; 56(2-3):398-412.
- ²⁹¹ Endresen GK. Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. *Rheumatol Int.* 2003; 23(5):211-5.
- ²⁹² Nijls J. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. *FEMS Immunol Med Microbiol.* 2002; 34(3):209–14.
- ²⁹³ Donta ST. Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2004; 141(2):85-94.
- ²⁹⁴ The Marshall Protocol Knowledge Base. http://mpkb.org/home/protocol/mp_antibiotics/dosing (accessed August 30, 2013).
- ²⁹⁵ FDA Patient-focused Drug Development Initiative. Voice of the patient report, September, 2013. <http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM368806.pdf>
- ²⁹⁶ Nijls J. Tired of being inactive: a systematic literature review of physical activity, physiological exercise capacity and muscle strength in patients with chronic fatigue syndrome. *Disabil Rehabil.* 2011; 33(17-18):1493-500.
- ²⁹⁷ Nijls J. Can pacing self-management alter physical behavior and symptom severity in chronic fatigue syndrome? A case series. *J Rehabil Res Dev.* 2009; 46(7):985-96.
- ²⁹⁸ Sisto SA. Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome. *Am J Med.* 1996; 100(6):634-40.
- ²⁹⁹ Make B. Impairment of patients with chronic fatigue syndrome. *J Chron Fatigue Syn.* 1997; 3(4):43-55.

- ³⁰⁰ Nagelkirk PR. Aerobic capacity of Gulf War veterans with chronic fatigue syndrome. *Mil Med.* 2003; 168(9):750-5.
- ³⁰¹ Inbar O. Physiological responses to incremental exercise in patients with chronic fatigue syndrome. *Med Sci Sports Exerc.* 2001; 33(9):1463-70.
- ³⁰² Vanness JM. Subclassifying chronic fatigue syndrome through exercise testing. *Med Sci Sports Exerc.* 2003; 35(6):908-13.
- ³⁰³ De Becker P. Exercise capacity in chronic fatigue syndrome. *Arch Intern Med* 2000; 160:3270–3277.
- ³⁰⁴ Javierre C. Physiological responses to arm and leg exercise in women patients with chronic fatigue syndrome. *JCFS* 2007; 14:43–53.
- ³⁰⁵ Van Ness JM. Diminished cardiopulmonary capacity during post-exertional malaise. *J Chron Fatigue Syn.* 2007; 14(2):77-85.
- ³⁰⁶ Van Ness JM. Diminished cardiopulmonary capacity during post-exertional malaise. *J Chron Fatigue Syn.* 2007; 14(2):77-85.
- ³⁰⁷ Van Ness JM. Postexertional malaise in women with chronic fatigue syndrome. *J Womens Health.* 2010; 19(2):239-44.
- ³⁰⁸ Whistler T. Gene expression correlates of unexplained fatigue. *Pharmacogenomics.* 2006; 7:395–405.
- ³⁰⁹ Fulle S. Specific oxidative alterations in vastus lateralis muscle of individuals with the diagnosis of chronic fatigue syndrome. *Free Radic Biol Med.* 2000; 29:1252–1259.
- ³¹⁰ Wong R. Skeletal muscle metabolism in the chronic fatigue syndrome: in vivo assessment by ³¹P nuclear magnetic resonance spectroscopy. *Chest.* 1992; 102:1716–1722.
- ³¹¹ Myhill S, et al. Chronic fatigue syndrome and mitochondrial dysfunction. *Int J Clin Exp Med* 2009; 2(1):1–16.
- ³¹² Vermeulen RC. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. *J Transl Med.* 2010; 8:93.
- ³¹³ Jones DE. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. *Eur J Clin Invest.* 2012; 42(2):186-94.
- ³¹⁴ VanNess JM. Subclassifying chronic fatigue syndrome through exercise testing. *Med Sci Sports Exerc.* 2003; 35:908–913.
- ³¹⁵ De Becker P. Exercise capacity in chronic fatigue syndrome. *Arch Intern Med.* 2000; 160:3270–3277.
- ³¹⁶ Twisk FNM. A review on cognitive behavioral therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients. *Neuro Endocr Lett.* 2009; 30:284–99.
- ³¹⁷ Nijs J. In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. *Eur J Clin Invest.* 2012; 42(2):203-212.
- ³¹⁸ Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. *Curr Opin Psychiatry.* 2009; 22:75-83.
- ³¹⁹ Richards RS. Erythrocyte oxidative damage in chronic fatigue syndrome. *Arch Med Res.* 2007; 38(1):94-8.
- ³²⁰ Maes M. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopeptides formed by oxidative or nitrosative damage to lipids and proteins. *Neuro Endocrinol Lett.* 2006; 27:615-621.
- ³²¹ Kennedy G. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. *Free Rad Biol Med.* 2005; 39(5):584-9.
- ³²² Fulle S. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. *Free Radic Biol Med.* 2000; 29(12):1252-9.
- ³²³ Richards RS. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. *Redox Rep.* 2000; 5(1):35-41.
- ³²⁴ Maes M. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuro Endocrinol Lett.* 2009; 30:470-476.
- ³²⁵ Fulle S. Modification of the functional capacity of sarcoplasmic reticulum membranes in patients suffering from chronic fatigue syndrome. *Neuromuscul Disord.* 2003; 13: 479–84.
- ³²⁶ Samii A. Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome or depression. *Neurology.* 1996; 47:1410–4.
- ³²⁷ Paul L. Demonstration of delayed recovery from fatiguing exercise in chronic fatigue syndrome. *Eur J Neurol.* 1999; 6: 63–9.

- ³²⁸ Jammes Y. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. *J Intern Med*. 2005; 257(3):299-310.
- ³²⁹ Robinson M. Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome. *Scand J Med Sci Sports*. 2010; 20(2):282-90.
- ³³⁰ Suárez A. Nitric oxide metabolite production during exercise in chronic fatigue syndrome: a case-control study. *J Womens Health*. 2010; 19(6):1073-7.
- ³³¹ Myhill S. Chronic fatigue syndrome and mitochondrial dysfunction. *Inter J Clin Exp Med*. 2009; 2:1-16.
- ³³² Lane RJ. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. *Neuromuscul Disord*. 1998; 8(3-4):204-9.
- ³³³ Wong R. Skeletal muscle metabolism in the chronic fatigue syndrome: in vivo assessment by ³¹P nuclear magnetic resonance spectroscopy. *Chest*. 1992; 102:1716-1722.
- ³³⁴ White PD. Protocol for the PACE trial: a randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. *BMC Neurol*. 2007;7:6.
- ³³⁵ Light AR. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. *J Pain*. 2009; 10(10):1099-112.
- ³³⁶ Maes M. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor- α , PMN-elastase, lysozyme and neopterin. *J Affect Disord*. 2012; 136(3):933-9.
- ³³⁷ Patarca R. Cytokines and chronic fatigue syndrome. *Ann N Y Acad Sci*. 2001; 933:185-200.
- ³³⁸ Cannon JG. Acute phase response and cytokines secretion in chronic fatigue syndrome. *J Clin Immunol*. 1999; 10:414-421.
- ³³⁹ Kerr JR. Seven genomic subtypes of CFS/ME: a detailed analysis of gene networks and clinical phenotypes. *J Clin Pathol*. 2008; 61:730-739
- ³⁴⁰ Aaron LA. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. *Arch Intern Med*. 2000; 160(2):221-7.
- ³⁴¹ Ravindran MK. Migraine headaches in chronic fatigue syndrome (CFS): comparison of two prospective cross-sectional studies. *BMC Neurol*. 2011; 11:30.
- ³⁴² Maloney EM. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. *Metabolism*. 2010; 59(9):1351-7.
- ³⁴³ Dansie EJ. Conditions comorbid with chronic fatigue in a population-based sample. *Psychosomatics*. 2012 Jan-Feb;53(1):44-50.
- ³⁴⁴ Dansie EJ. The comorbidity of self-reported chronic fatigue syndrome, post-traumatic stress disorder, and traumatic symptoms. *Psychosomatics*. 2012; 53(3):250-7.
- ³⁴⁵ Ciccone DS. Comorbid illness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis. *Psychosom Med*. 2003; 65(2):268-75.
- ³⁴⁶ Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? *J Am Diet Assoc*. 2007; 107(1):92-9.
- ³⁴⁷ Cooper Z. A new cognitive behavioral approach to the treatment of obesity. *Behav Res Ther*. 2001; 39:499-511.
- ³⁴⁸ Price JR. Cognitive behaviour therapy for chronic fatigue syndrome in adults. *Cochrane Database Syst Rev*. 2008; (3):CD001027.
- ³⁴⁹ White PD. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. *Lancet*. 2011 Mar 5;377(9768):823-36.
- ³⁵⁰ Phoenix Rising. A hitch in its step: PACE Trial indicates CBT/GET no cure for CFS, 60% of patients show no significant effects. <http://phoenixrising.me/archives/2433> (accessed May 12, 2013).
- ³⁵¹ Grøndahl JR. Hypnosis as a treatment of chronic widespread pain in general practice: a randomized controlled pilot trial. *BMC Musculoskelet Disord*. 2008; 9:124.
- ³⁵² Jensen MP. Long-term outcome of hypnotic-analgesia treatment for chronic pain in persons with disabilities. *Int J Clin Exp Hypn*. 2008; 56(2):156-69.
- ³⁵³ Elkins G, Johnson A, Fisher W. Cognitive hypnotherapy for pain management. *Am J Clin Hypn* 2012; 54:294-310
- ³⁵⁴ Astin JA. Mind-body therapies for the management of pain. *Clin J Pain* 2004; 20:27-32
- ³⁵⁵ Hassed C. Mind-body therapies--use in chronic pain management. *Aust Fam Physician*. 2013; 42(3):112-7.

- ³⁵⁶ Heapy AA. Tailoring cognitive-behavioral therapy for chronic pain: a case example. *J Clin Psychol.* 2006; 62(11):1345-54.
- ³⁵⁷ Jensen MP. Toward the development of a motivational model of pain self-management. *J Pain.* 2005; 4:477-492.
- ³⁵⁸ Habib S. Preparing for pain management: A pilot study to enhance engagement. *J Pain.* 2005; 6:48-54.
- ³⁵⁹ Burns JW. Stages of change in readiness to adopt a self-management approach to chronic pain: the moderating role of early-treatment stage progression in predicting outcome. *Pain.* 2005; 115(3):322-31.
- ³⁶⁰ Murphy BM. Reduction in 2-Year Recurrent Risk Score and Improved Behavioral Outcomes After Participation in the "Beating Heart Problems" Self-management Program: Results of a Randomized Controlled Trial. *J Cardiopulm Rehabil Prev.* 2013; 33(4):220-8.
- ³⁶¹ Mendes E. An application of the transtheoretical model to becoming vegan. *Soc Work Public Health.* 2013; 28(2):142-9.
- ³⁶² Di Noia J. Application of the transtheoretical model to fruit and vegetable consumption among economically disadvantaged African-American adolescents: preliminary findings. *Am J Health Promot.* 2006; 20(5):342-8.
- ³⁶³ Marshall SJ. The transtheoretical model of behavior change: a meta-analysis of applications to physical activity and exercise. *Ann Behav Med.* 2001; 23(4):229-46.
- ³⁶⁴ Ni Mhurchu C. Applying the stages-of-change model to dietary change. *Nutr Rev.* 1997; 55(1 Pt 1):10-6.
- ³⁶⁵ Keefe FJ. Understanding the adoption of arthritis self-management: stages of change profiles among arthritis patients. *Pain.* 2000; 87(3):303-13.
- ³⁶⁶ Greene GW. Stages of change for reducing dietary fat to 30% of energy or less. *J Am Diet Assoc.* 1994; 94(10):1105-10.
- ³⁶⁷ Cairns R. A systematic review describing the prognosis of chronic fatigue syndrome. *Occup Med (Lond).* 2005; 55(1):20-31.
- ³⁶⁸ Taylor RR. Prognosis of chronic fatigue in a community-based sample. *Psychosomat Med.* 2002; 64:319-327.
- ³⁶⁹ Hamilton WT. The prognosis of different fatigue diagnostic labels: a longitudinal survey. *Fam Pract.* 2005; 22(4):383-8.
- ³⁷⁰ Hill NF. Natural history of severe chronic fatigue syndrome. *Arch Phys Med Rehabil.* 1999; 80(9):1090-4.
- ³⁷¹ White PD. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. *Lancet.* 2011; 377(9768):823-36.
- ³⁷² Shinohara M. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011; 377(9780):1833-4.
- ³⁷³ Kindlon T. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011; 377(9780):1833.
- ³⁷⁴ Vlaeyen JW. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011 May 28;377(9780):1834.
- ³⁷⁵ Stouten B. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011; 377(9780):1832-3.
- ³⁷⁶ Feehan SM. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011; 377(9780):1831-2.
- ³⁷⁷ Mitchell JT Jr. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011; 377(9780):1831.
- ³⁷⁸ Giakoumakis J. The PACE trial in chronic fatigue syndrome. *Lancet.* 2011; 377(9780):1831.
- ³⁷⁹ Kindlon T. Harms of cognitive behaviour therapy designed to increase activity levels in chronic fatigue syndrome: questions remain. *Psychother Psychosom.* 2011; 80:110-11.
- ³⁸⁰ Twisk FN. A review on cognitive behavioral therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. *Neuro Endocrinol Lett.* 2009; 30:284-99.
- ³⁸¹ Ciccone DS. Illness trajectories in the chronic fatigue syndrome: a longitudinal study of improvers versus non-improvers. *J Nerv Ment Dis.* 2010; 198(7):486-93.
- ³⁸² Fitzcharles MA. National Fibromyalgia Guideline Advisory Panel. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: Executive summary. *Pain Res Manag.* 2013; 18(3):119-26.
- ³⁸³ Fitzcharles MA. Canadian Pain Society and Canadian Rheumatology Association Recommendations for Rational Care of Persons with Fibromyalgia. A Summary Report. *J Rheumatol.* 2013; 40(8):1388-1393.
- ³⁸⁴ Shaver JL. Fibromyalgia syndrome in women. *Nurs Clin North Am.* 2004; 39(1):195-204, viii.
- ³⁸⁵ McNally JD. The epidemiology of self-reported fibromyalgia in Canada. *Chronic Dis Can.* 2006;27(1):9-16
- ³⁸⁶ McNally JD. The epidemiology of self-reported fibromyalgia in Canada. *Chronic Dis Can.* 2006;27(1):9-16
- ³⁸⁷ Ibid
- ³⁸⁸ Siegel DM. Fibromyalgia syndrome in children and adolescents: clinical features at presentation and status at follow-up. *Pediatrics.* 1998; 101(3 Pt 1):377-82.
- ³⁸⁹ Anthony KK. Juvenile primary fibromyalgia syndrome. *Curr Rheumatol Rep.* 2001; 3(2):165-71.

- ³⁹⁰ Buskila D. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. *J Rheumatol.* 1993; 20(2):368-70.
- ³⁹¹ Kashikar-Zuck S. A review of biobehavioral research in juvenile primary fibromyalgia syndrome. *Arthritis Care Res.* 2000; 13(6):388-97.
- ³⁹² Kashikar-Zuck S. Social functioning and peer relationships of adolescents with juvenile fibromyalgia syndrome. *Arthritis Rheum.* 2007; 57:474-80.
- ³⁹³ Kashikar-Zuck S. Family factors, emotional functioning, and functional impairment in juvenile fibromyalgia syndrome. *Arthritis Rheum.* 2008; 59:1392-8.
- ³⁹⁴ Reid GJ. Primary juvenile fibromyalgia: psychological adjustment, family functioning, coping, and functional disability. *Arthritis Rheum.* 1997; 40:752-60.
- ³⁹⁵ Kashikar-Zuck S. Controlled follow-up study of physical and psychosocial functioning of adolescents with juvenile primary fibromyalgia syndrome. *Rheumatology.* 2010; 49:2204-9.
- ³⁹⁶ Glombiewski JA. Psychological treatments for fibromyalgia: a metaanalysis. *Pain.* 2010; 151:280-95.
- ³⁹⁷ Bernardy K. Efficacy of cognitive behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials. *J Rheumatol.* 2010; 37:1991-2005.
- ³⁹⁸ Farrar JT. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain.* 2001; 94:149-58.
- ³⁹⁹ Kashikar-Zuck S. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial. *Arthritis Rheum.* 2012; 64(1):297-305.
- ⁴⁰⁰ Wolfe F. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* 1990; 33(2):160-72.
- ⁴⁰¹ McBeth J. Fibromyalgia: mechanisms and potential impact of the ACR, 2010 classification criteria. *Nature Rev Rheumatol.* 2012; 8:108-116.
- ⁴⁰² Harden RN. A critical analysis of the tender points in fibromyalgia. *Pain Med.* 2007; 8(2):147-56.
- ⁴⁰³ Fitzcharles MA. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. *Rheumatol.* 2003; 42(2):263-267.
- ⁴⁰⁴ Gracely RH. Evoked pain measures in fibromyalgia. *Best Pract Res Clin Rheumatol.* 2003; 17(4):593-609.
- ⁴⁰⁵ Bidari A. Reliability of ACR criteria over time to differentiate classic fibromyalgia from nonspecific widespread pain syndrome: a 6-month prospective cohort study. *Mod Rheumatol.* 2009; 19(6):663-9.
- ⁴⁰⁶ Tastekin N. Which of the three different tender points assessment methods is more useful for predicting the severity of fibromyalgia syndrome? *Rheumatol Int.* 2007; 27(5):447-51.
- ⁴⁰⁷ Petzke F. What do tender points measure? Influence of distress on 4 measures of tenderness. *J Rheumatol.* 2003; 30(3):567-74.
- ⁴⁰⁸ Croft P. Population study of tender point counts and pain as evidence of fibromyalgia. *BMJ.* 1994; 309:696-699.
- ⁴⁰⁹ Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. *Ann Rheum Dis.* 1997; 56:268-271.
- ⁴¹⁰ Harth M. The fibromyalgia tender points: use them or lose them? A brief review of the controversy. *J Rheumatol.* 2007; 34:914-922.
- ⁴¹¹ Mease PJ. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. *Arthritis Rheum.* 2008; 59:952-960.
- ⁴¹² Choy EH. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. *J Rheumatol.* 2009; 36(10):2330-2334.
- ⁴¹³ Mease PJ. Fibromyalgia syndrome. *J Rheumatol.* 2007; 34(6):1415-1425.
- ⁴¹⁴ Jain AK, et al. Fibromyalgia Syndrome: Canadian Clinical Working Case Definition, Diagnostic and treatment protocols- A consensus document. *J of Musculoskeletal Pain* 11(4): 3-107, 2003; co-published simultaneously with Russell IJ, Ed. *The Fibromyalgia Syndrome: A clinical case definition for practitioners*, Haworth Medical Press, :3-197, 2004.
- ⁴¹⁵ A Canadian Clinical Working Case Definition of Fibromyalgia. <http://ocfp.on.ca/docs/environmental-health-committee/a-canadian-clinical-working-case-definition-of-fibromyalgia.pdf?sfvrsn=0> (accessed October 20, 2013).
- ⁴¹⁶ Wolfe F. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res.* 2010; 62(5):600-10.
- ⁴¹⁷ Wolfe F. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res.* 2010; 62(5):600-10.
- ⁴¹⁸ Wolfe F. Fibromyalgia diagnosis and diagnostic criteria. *Ann Med.* 2011; 43(7):495-502.

- ⁴¹⁹ Fitzcharles MA. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome. http://www.canadianpainsociety.ca/pdf/Fibromyalgia_Guidelines_2012.pdf (accessed August 21, 2013).
- ⁴²⁰ National Fibromyalgia Association. National Fibromyalgia Association responds to new ACR criteria for fibromyalgia. <http://www.fmaware.org/News2101f.html?page=NewsArticle&id=9685&AddInterest=1002> (accessed October 20, 2013).
- ⁴²¹ Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. *Rheum Dis Clin North Am.* 2009; 35(2):215-32.
- ⁴²² Epstein SA. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. *Psychosomatics.* 1999; 40(1):57-63.
- ⁴²³ Aaron LA. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. *Arthritis Rheum.* 1996; 39:436-445.
- ⁴²⁴ Cleveland CH Jr. Chronic rhinitis: An under recognized association with fibromyalgia. *Allergy Proc.* 1992; 13:263-267.
- ⁴²⁵ Frieri M. Is there a relationship between fibromyalgia and rhinitis? *Allergy Asthma Proc.* 2012; 33(6):443-9
- ⁴²⁶ Torresani C. Chronic urticaria is usually associated with fibromyalgia syndrome. *Acta Derm Venereol.* 2009; 89(4):389-92.
- ⁴²⁷ Goodwin RD. Impact of allergy treatment on the association between allergies and mood and anxiety in a population sample. *Clin Exp Allergy.* 2012; 42(12):1765-71.
- ⁴²⁸ Loerbroks A. The association of asthma and wheezing with major depressive episodes: an analysis of 245 727 women and men from 57 countries. *Int J Epidemiol.* 2012; 41(5):1436-44.
- ⁴²⁹ Labor S. The prevalence and pulmonary consequences of anxiety and depressive disorders in patients with asthma. *Coll Antropol.* 2012; 36(2):473-81.
- ⁴³⁰ Elderon L. Depression and cardiovascular disease. *Prog Cardiovasc Dis.* 2013; 55(6):511-23
- ⁴³¹ Rotella F. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. *J Clin Psychiatry.* 2013; 74(1):31-7.
- ⁴³² Slotkoff AT. The relationship between fibromyalgia and the multiple chemical sensitivity syndrome. *Scand J Rheumatol.* 1997; 26(5):364-7.
- ⁴³³ Buchwald D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. *Arch. Intern. Med.* 1994; 154:2049-2053.
- ⁴³⁴ Donnay A. Prevalence and overlap of chronic fatigue syndrome and fibromyalgia syndrome with multiple chemical sensitivity syndrome. *J Chronic Fatigue Syndr.* 1999; 5:1-80.
- ⁴³⁵ Janson LA. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms. *Psychosom Med.* 2000; 62:655-663.
- ⁴³⁶ Aaron LA. A review of the evidence for overlap among unexplained clinical conditions. *Ann Intern Med.* 2001; 134:868-881.
- ⁴³⁷ Aaron LA. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. *Best Pract Res Clin Rheumatol.* 2003; 17:563-574.
- ⁴³⁸ Ciccone DS. Comorbid illness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis. *Psychosom Med.* 2003; 65:268-275.
- ⁴³⁹ Parlor M. National ME/FM Action Network. *Quest*, 2012; 92:1-12.
- ⁴⁴⁰ Nielsen LA. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition. *Best Pract. Res Clin. Rheumatol.* 2007; 21:465-480.
- ⁴⁴¹ Phillips K. Central pain mechanisms in chronic pain states--maybe it is all in their head. *Best Pract Res Clin Rheumatol.* 2011; 25(2):141-54.
- ⁴⁴² Clauw DJ. The science of fibromyalgia. *Mayo Clin Proc.* 2011; 86(9):907-11.
- ⁴⁴³ Petersen DL. Central amplification and fibromyalgia: disorder of pain processing. *J Neurosci Res.* 2011; 89(1):29-34.
- ⁴⁴⁴ Bolay H. Mechanisms of pain modulation in chronic syndromes. *Neurology.* 2002; 59(5 Suppl 2):S2-7.
- ⁴⁴⁵ Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. *Semin Arthritis Rheum.* 2008; 37:339-352.
- ⁴⁴⁶ Bleakman D. Glutamate receptors and pain. *Semin Cell Dev Biol.* 2006 Oct 28;
- ⁴⁴⁷ Ikeda R. NMDA receptor-independent synaptic plasticity in the central amygdala in the rat model of neuropathic pain. *Pain.* 2007 Jan;127(1-2):161-72.
- ⁴⁴⁸ Salter MW. Cellular neuroplasticity mechanisms mediating pain persistence. *J Orofac Pain.* 2004 Fall;18(4):318-24.

- ⁴⁴⁹ Koltzenburg M. The role of TRP channels in sensory neurons. *Novartis Found Symp.* 2004;260:206-13; discussion 213-20, 277-9.
- ⁴⁵⁰ Staud R. Peripheral and central sensitization in fibromyalgia: pathogenetic role. *Curr Pain Headache Rep* 2002 Aug;6(4):259-66
- ⁴⁵¹ Soman S. Oxidative stress induced NMDA receptor alteration leads to spatial memory deficits in temporal lobe epilepsy: ameliorative effects of Withania somnifera and Withanolide A. *Neurochem Res.* 2012; 37(9):1915-27.
- ⁴⁵² Miller BA. TRP channels as mediators of oxidative stress. *Adv Exp Med Biol.* 2011; 704:531-44.
- ⁴⁵³ Cordero MD. Clinical symptoms in fibromyalgia are better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma. *PLoS One.* 2011;6(10):e26915.
- ⁴⁵⁴ Gerhold KA. Molecular and cellular mechanisms of trigeminal chemosensation. *Ann N Y Acad Sci.* 2009; 1170:184-9
- ⁴⁵⁵ Brooks SM. Occupational, environmental, and irritant-induced cough. *Otolaryngol Clin North Am.* 2010; 3(1):85-96, ix.
- ⁴⁵⁶ Cordero MD. Oxidative stress and mitochondrial dysfunction in fibromyalgia. *Neuro Endocrinol Lett.* 2010; 31(2):169-73
- ⁴⁵⁷ Salemi S. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. *J Rheumatol.* 2003; 30(1):146-150.
- ⁴⁵⁸ Uçeyler N. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. *BMC Musculoskelet Disord.* 2011; 12:245.
- ⁴⁵⁹ Gursoy S, Erdal E, Herken H, et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. *Rheumatol Int.* 2003;b23:104-7.
- ⁴⁶⁰ Weir PT. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. *J Clin Rheumatol.* 2006; 12(3):124-8.
- ⁴⁶¹ Abbi B. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. *QJM.* 2013; 106(1):3-9.
- ⁴⁶² Leavitt F. Distraction as a key determinant of impaired memory in patients with fibromyalgia. *J Rheumatol.* 2006; 33(1):127-32.
- ⁴⁶³ Landis CA. Decreased sleep spindles and spindle activity in midlife women with fibromyalgia and pain. *Sleep.* 2004 Jun 15;27(4):741-50
- ⁴⁶⁴ Roizenblatt S. Alpha sleep characteristics in fibromyalgia. *Arthritis Rheum.* 2001; 44(1):222-30.
- ⁴⁶⁵ Rizzi M. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? *J Rheumatol.* 2004 Jun;31(6):1193-9.
- ⁴⁶⁶ Weir PT. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. *J Clin Rheumatol.* 2006; 12(3):124-8
- ⁴⁶⁷ Aaron LA. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. *Best Pract Res Clin Rheumatol.* 2003; 17(4):563-74.
- ⁴⁶⁸ Arnold LD. Vulvodynia: Characteristics and Associations With Comorbidities and Quality of Life. *Obstet Gynecol* 2006; 107(3):617-624.
- ⁴⁶⁹ Cole JA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. *BMC Gastroenterol.* 2006; 6:26.
- ⁴⁷⁰ Arnold LD. Vulvodynia: Characteristics and Associations With Comorbidities and Quality of Life. *Obstet Gynecol* 2006; 107(3):617-624.
- ⁴⁷¹ Cakit BD. Comorbidity of fibromyalgia and cervical myofascial pain syndrome. *Clin Rheumatol.* 2010; 29(4):405-11.
- ⁴⁷² Küçükşen S. The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine. *Clin Rheumatol.* 2013; 32(7):983-90.
- ⁴⁷³ Arranz L. Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. *Rheumatol Int.* 2012; 32(11):3605-11.
- ⁴⁷⁴ Okifuji A. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. *J Pain.* 2010; 11(12):1329-37.
- ⁴⁷⁵ Gold AR. Inspiratory airflow dynamics during sleep in women with fibromyalgia. *Sleep.* 2004; 27(3):459-66.
- ⁴⁷⁶ Shah MA. Sleep-disordered breathing among women with fibromyalgia syndrome. *J Clin Rheumatol.* 2006; 12(6):277-81.
- ⁴⁷⁷ Frieri M. Is there a relationship between fibromyalgia and rhinitis? *Allergy Asthma Proc.* 2012; 33(6):443-9.

- ⁴⁷⁸ Torresani C. Chronic urticaria is usually associated with fibromyalgia syndrome. *Acta Derm Venereol.* 2009; 89(4):389-92.
- ⁴⁷⁹ Thune PO. The prevalence of fibromyalgia among patients with psoriasis. *Acta Derm Venereol.* 2005; 85(1):33-7.
- ⁴⁸⁰ Sinaii N. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. *Hum Reprod.* 2002; 17(10):2715-24.
- ⁴⁸¹ Weir PT. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. *J Clin Rheumatol.* 2006; 12(3):124-8
- ⁴⁸² Arnold LM. A framework for fibromyalgia management for primary care providers. *Mayo Clin Proc.* 2012; 87(5): 488-496.
- ⁴⁸³ Fitzcharles MA. Canadian Pain Society and Canadian Rheumatology Association Recommendations for Rational Care of Persons with Fibromyalgia. A Summary Report. *J Rheumatol.* 2013; 40(8):1388-1393.
- ⁴⁸⁴ Bellato E. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. *Pain Res Treat.* 2012; 2012:426130.
- ⁴⁸⁵ Häuser W. Guidelines on the management of fibromyalgia syndrome—a systematic review. *Eur J Pain.* 2010; 14(1):5–10
- ⁴⁸⁶ Chandran A. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. *J Manag Care Pharm.* 2012; 18(6):415-26.
- ⁴⁸⁷ Rivera J. Resource utilization and health care costs in patients diagnosed with Fibromyalgia in Spain. *Clin Exp Rheumatol.* 2009; 27(sup. 56):S39–S45.
- ⁴⁸⁸ Penrod JR. Health services costs and their determinants in women with fibromyalgia. *J Rheumatol.* 2004; 31:1391–1398.
- ⁴⁸⁹ Sicras-Mainar A. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. *Arthritis Res Ther.* 2009; 11(2):R54.
- ⁴⁹⁰ Kivimäki M. Increased absence due to sickness among employees with Fibromyalgia. *Ann Rheum Dis.* 2007; 66:65–693
- ⁴⁹¹ White LA. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. *J Occup Environ Med.* 2008; 50:13–24.
- ⁴⁹² Kleinman N. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. *J Occup Environ Med.* 2009; 51(12):1384-93.
- ⁴⁹³ Henriksson C. Women with fibromyalgia: Work and rehabilitation. *Disab Rehabil.* 2005; 27:685–695
- ⁴⁹⁴ Mannerkorpi K. Hinders for continued work among persons with fibromyalgia. *BMC Musculoskelet Disord.* 2012; 13:96.
- ⁴⁹⁵ Burckhardt CS. The fibromyalgia impact questionnaire: development and validation. *J Rheumatol* 1994;21:714-20.
- ⁴⁹⁶ White KP. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. 2002 *Arthritis Rheum* 47: 260-265.
- ⁴⁹⁷ Henriksson C. Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. *Disabil Rehabil.* 1996; 18:241-248.
- ⁴⁹⁸ White KP. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the Long Fibromyalgia Epidemiology. *Arthritis Rheum* 1999 42:76-83.
- ⁴⁹⁹ White KP. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. *Arthritis & Rheumatism* Vol. 42, No. 1, January 1999, pp 76–83
- ⁵⁰⁰ Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. *Arthritis Res Ther.* 2009; 11(3):117
- ⁵⁰¹ Ghazan-Shahi S. Should rheumatologists retain ownership of fibromyalgia? A survey of Ontario rheumatologists. *Clin Rheumatol.* 2012; 31(8):1177-81.
- ⁵⁰² Thomson GM. Report of the ad hoc committee on environmental hypersensitivity disorders. Government of Ontario: Ministry of Health, August 1985.
- ⁵⁰³ McKeown-Eyssen G. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. *Int J Epidemiol.* 2004; 33:1-8.
- ⁵⁰⁴ Groves PM. Habituation: a dual-process theory. *Psychol Rev.* 1970; 77:419-450.

- ⁵⁰⁵ Gibson PR. Sickness-related dysfunction in persons with self-reported multiple chemical sensitivity at four levels of severity. *J Clin Nurs*. 2009; 18(1):72-81.
- ⁵⁰⁶ Ashford NA, Miller CS. *Chemical Exposures. Low Levels and High Stakes*. New York:Van Nostrand-Reinhold, 1991
- ⁵⁰⁷ BioInitiative Working Group. *Bioinitiative Report 2012. A rationale for biologically-based exposure standards for low-intensity electromagnetic radiation*. <http://www.bioinitiative.org/report/wp-content/uploads/pdfs/BioInitiativeReport2012.pdf>. (accessed April 28, 2013)
- ⁵⁰⁸ Bergqvist U. A possible health implications of the subjective symptoms and electromagnetic fields. A report prepared by a European group of experts for the European commission, DG V. Solna, Sweden: European Commission DG V, National Institute for Working Life. 1997.
- ⁵⁰⁹ Levallois, P. (2002). Study of self-reported hypersensitivity to electromagnetic fields in California. *Environ Health Perspect*. 2002; 110(Suppl. 4):619–623.
- ⁵¹⁰ Schreier N. The prevalence of symptoms attributed to electromagnetic field exposure: a cross-sectional representative survey in Switzerland. *Soz Praventivmed*. 2006; 51(4):202-9.
- ⁵¹¹ Schreier N. The prevalence of symptoms attributed to electromagnetic field exposure: a cross-sectional representative survey in Switzerland. *Soz Praventivmed*. 2006; 51(4):202-9.
- ⁵¹² Rubin GJ. Electromagnetic hypersensitivity: A systematic review of provocation studies. *Psychosom Med*. 2005; 67(2):224–232.
- ⁵¹³ Rubin J. Idiopathic environmental intolerance attributed to electromagnetic fields. *Bioelectromagnetics*. 2010; 31(1):1-11
- ⁵¹⁴ Carrubba S. Evidence of a nonlinear human magnetic sense. *Neuroscience*. 2007; 144:356–367.
- ⁵¹⁵ Marino AA. Simulated MR magnetic field induces steady-state changes in brain dynamics: Implications for interpretation of functional MR studies. *Magnetic Resonance Med*. 2010; 64:349–357.
- ⁵¹⁶ Bioinitiative Report 2012. <http://www.bioinitiative.org/table-of-contents/> (accessed March 28, 2013)
- ⁵¹⁷ Divan HA. Cell phone use and behavioural problems in young children. *J Epidemiol Community Health*. 2012; 66(6):524-9
- ⁵¹⁸ WHO. World Health Organization. Electromagnetic fields and public health. Exposure to extremely low frequency fields. Fact Sheet no. 322, 2007. <http://pbadupws.nrc.gov/docs/ML1004/ML100481077.pdf> (accessed March 28, 2013).
- ⁵¹⁹ Huss A. Project: “Electromagnetic Hypersensitivity”: Definition, Tool and Assessment in the Netherlands. <http://www.zonmw.nl/nl/projecten/projectdetail/electromagnetic-hypersensitivity-definition-tool-andassessment-in-the-netherlands/samenvatting/>. (Accessed March 27, 2013).
- ⁵²⁰ Tuengler A. Hypothesis on how to measure electromagnetic hypersensitivity. *Electromagn Biol Med*. 2013; 32(3):281-90.
- ⁵²¹ Caress SM. A national population study of the prevalence of multiple chemical sensitivity. *Arch Environ Health*. 2004; 59(6):300-5.
- ⁵²² Joffres MR. Environmental sensitivities: prevalence of major symptoms in a referral center: the Nova Scotia Environmental Sensitivities Research Center Study. *Environ Health Perspect*. 2001; 109(2):161-5.
- ⁵²³ Adinoff B. Gender differences in limbic responsiveness, by SPECT, following a pharmacologic challenge in healthy subjects. *Neuro Image*. 2003; 18:697–706.
- ⁵²⁴ Greenspan JD. Studying sex and gender differences in pain and analgesia: a consensus report. *Pain* 2007; 132:S26-S45.
- ⁵²⁵ Fillingim RB. Sex, gender, and pain: a review of recent clinical and experimental findings. *J Pain*. 2009;10:447-85.
- ⁵²⁶ Berkley KJ. Sex and gender differences in pain and inflammation: a rapidly maturing field. *Am J Physiol Regul Integr Comp Physiol*. 2006; 291:R241-R244.
- ⁵²⁷ Straub RH. The complex role of estrogens in inflammation. *Endocr Rev*. 2007; 28:521-74.
- ⁵²⁸ McHugh MK. Prevalence of asthma among adult females and males in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2001-2004. *J Asthma*. 2009; 46(8):759-66.
- ⁵²⁹ Ha MH. Association between serum concentrations of persistent organic pollutants and prevalence of newly diagnosed hypertension: results from the National Health and Nutrition Examination Survey 1999-2002. *J Hum Hypertens*. 2009 23(4):274-86.
- ⁵³⁰ Uhl SA. Association of Osteoarthritis with Perfluorooctanoate and Perfluorooctane Sulfonate in NHANES 2003-2008. *Environ Health Perspect*. 2013; 121(4):447-52.
- ⁵³¹ Harris RZ. Gender effects in pharmacokinetics and pharmacodynamics. *Drugs*. 1995; 50:222-39.

- ⁵³² Wrighton SA. The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol.* 1992; 22:1-21.
- ⁵³³ Schwartz JB. The influence of sex on pharmacokinetics. *Clin Pharmacokinet.* 2003; 42(2):107-21.
- ⁵³⁴ Gross JL. Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. *Braz J Med Biol Res.* 1992; 25(2):129-34.
- ⁵³⁵ Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? *Pharmacogenetics, pharmacokinetics, and pharmacodynamics.* *J Womens Health.* 2005; 14(1):19-29.
- ⁵³⁶ Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. *Clin Pharmacol Ther.* 2007;82(1):87-96.
- ⁵³⁷ Whitley HP. Sex-based differences in drug activity. *Am Fam Physician.* 2009; 80(11):1254-1258.
- ⁵³⁸ Kohn MC. Species differences in the production and clearance of 1,3-butadiene metabolites: a mechanistic model indicates predominantly physiological, not biochemical, control. *Carcinogenesis.* 1993; 14(4):619-628.
- ⁵³⁹ Lin YS. Human physiologic factors in respiratory uptake of 1,3-butadiene. *Environ Health Perspect.* 2001; 109(9):921-926.
- ⁵⁴⁰ Vahl N. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. *J Clin Endocrinol Metab.* 1998; 82:3612-8.
- ⁵⁴¹ Gandhi M. Sex differences in pharmacokinetics and pharmacodynamics. *Annu Rev Pharmacol Toxicol.* 2004; 44:499-523.
- ⁵⁴² Kristjansson F. Disposition of alprazolam in human volunteers: differences between genders. *Acta Pharm Nord.* 1991; 3:249-50.
- ⁵⁴³ Lin YS. Relationships between levels of volatile organic compounds in air and blood from the general population. *J Expo Sci Environ Epidemiol.* 2008; 18(4):421-429.
- ⁵⁴⁴ Moya J. Children's behavior and physiology and how it affects exposure to environmental contaminants. *Pediatrics.* 2004; 113(4 Suppl):996-1006.
- ⁵⁴⁵ Miller MD. Differences between children and adults: implications for risk assessment at California EPA. *Int J Toxicol.* 2002; 21:403-18.
- ⁵⁴⁶ Ginsberg G. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. *Toxicol Sci.* 2002; 66(2):185-200.
- ⁵⁴⁷ Boyle CA. Trends in the prevalence of developmental disabilities in US children, 1997-2008. *Pediatrics.* 2011; 127(6):1034-42.
- ⁵⁴⁸ Environmental Working Group 2005. Body Burden -The Pollution in Newborns. <http://www.ewg.org/reports/bodyburden2/execsumm.php>. (accessed July 18, 2012).
- ⁵⁴⁹ Environmental Working Group. Pollution in people. Cord blood contaminants in minority newborns. 2009 <http://www.ewg.org/files/2009-Minority-Cord-Blood-Report.pdf>. (accessed July 18, 2012).
- ⁵⁵⁰ Cooper K. Early exposures to hazardous chemicals/pollution and associations with chronic disease: a scoping review. A report from the Canadian Environmental Law Association, the Ontario College of Family Physicians and the Environmental Health Institute of Canada. 2011. <http://www.cela.ca/sites/cela.ca/files/EarlyExpandCDScopingReview-lowres.pdf> (accessed July 18 2012).
- ⁵⁵¹ Riikjarv MA. Similar prevalence of respiratory symptoms and atopy in Estonian schoolchildren with changing lifestyle over 4 yrs. *Eur Respir J* 2000; 16:86- 90.
- ⁵⁵² Viera L. The impact of air pollutants as an adjuvant for allergic sensitization and asthma. *Curr Allergy Asthma Rep.* 2009; 9(4):327-33.
- ⁵⁵³ Garty BZ. Emergency room visits of asthmatic children, relation to air pollution, weather and airborne allergens. *Ann Allergy Asthma Immunol.* 1998;81:563-70.
- ⁵⁵⁴ Epton MJ. The effect of ambient air pollution on respiratory health of school children: a panel study. *Environ Health.* 2008; 14:7-16.
- ⁵⁵⁵ Jedrychowski W. The adverse effect of low levels of ambient air pollutants on lung function growth in preadolescent children. *Environ Health Perspect.* 1999; 107: 669-74.
- ⁵⁵⁶ Horak FJ. Particulate matter and lung function growth in children: a 3-yr follow-up study in Austrian schoolchildren. *Eur Respir J.* 2002; 19: 838-45.
- ⁵⁵⁷ Miller MD. Impact of environmental chemicals on lung development. *Environ Health Perspect* 2010; 118:1155-1164.
- ⁵⁵⁸ Gauderman WJ. Association between air pollution and lung function growth in Southern California children. Results from a second cohort. *Am J Respir Crit Care Med.* 2002; 166(1):76-84.

- ⁵⁵⁹ Gauderman WJ. Effect of exposure to traffic on lung development from 10 to 18 years of age: a cohort study. *Lancet*. 2007; 369(9561):571-577.
- ⁵⁶⁰ Kabesch M. Gene by environment interactions and the development of asthma and allergy. *Toxicol Lett*. 2006; 162(1):43-8.
- ⁵⁶¹ Breton CV. Genetic variation in the glutathione synthesis pathway, air pollution, and children's lung function growth. *Am J Respir Crit Care Med*. 2011; 183(2):243-8.
- ⁵⁶² Volk HE. Residential proximity to freeways and autism in the CHARGE study. *Environ Health Perspect*. 2011; 119(6):873-7.
- ⁵⁶³ Volk HE. Traffic-related air pollution, particulate matter, and autism. *JAMA Psychiatry*. 2013; 70(1):71-7.
- ⁵⁶⁴ Becerra TA. Ambient air pollution and autism in Los Angeles county, California. *Environ Health Perspect*. 2013; 121(3):380-6.
- ⁵⁶⁵ Windham GC. Autism spectrum disorders in relation to distribution of hazardous air pollutants in the San Francisco Bay area. *Environ Health Perspect*. 2006; 114(9):1438-1444.
- ⁵⁶⁶ Geier DA. Biomarkers of environmental toxicity and susceptibility in autism. *J Neurol Sci*. 2009; 15;280(1-2):101-8.
- ⁵⁶⁷ James SJ. A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. *Am J Med Genet B Neuropsychiatr Genet*. 2010; 153B(6):1209-20.
- ⁵⁶⁸ Nethercott JR. Multiple chemical sensitivities syndrome: toward a working case definition. *Arch Environ Health*. 1993; 48:19-26.
- ⁵⁶⁹ Bartha L. Multiple Chemical Sensitivity: a 1999 consensus. *Arch Environ Health*. 1999; 54(3):147-9.
- ⁵⁷⁰ Thomson GM. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders. Ontario Ministry of Health, 1985:17-18.
- ⁵⁷¹ McKeown-Eyssen GE. Reproducibility of the University of Toronto self-administered questionnaire used to assess Environmental Sensitivity, *Am J Epidemiol*. 2000; 151(12):1216-22.
- ⁵⁷² OCFP. Environmental Health Committee. College of Family Physicians (Ontario). <http://www.ocfp.on.ca/docs/environmental-health-committee/multiple-chemical-sensitivity-1999-consensus-definition-criteria-and-validation.pdf?sfvrsn=0> (accessed March 31, 2013).
- ⁵⁷³ McKeown-Eyssen GE. Multiple chemical sensitivity: discriminant validity of case definitions. *Arch Environ Health*. 2001; 56(5):406-412.
- ⁵⁷⁴ Lacour M. Multiple chemical sensitivity syndrome (ES/MCS) - suggestions for an extension of the U.S. ES/MCS-case definition. *Int J Hyg Environ Health*. 2005; 208(3):141-151.
- ⁵⁷⁵ Thomson GM, Chair. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders to the Ontario Ministry of Health, 1985.
- ⁵⁷⁶ Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. *Nature*. 1967; 214:1020-1021.
- ⁵⁷⁷ Goddard GV. Does the engram of kindling model the engram of normal long term memory? *Can J Neurol Sci*. 1975; 2(4):385-94.
- ⁵⁷⁸ Grover LM. Activation of NMDA receptors in hippocampal area CA1 by low and high frequency orthodromic stimulation and their contribution to induction of long-term potentiation. *Synapse*. 1994; 16(1):66-75.
- ⁵⁷⁹ Lin J. Repeated exposure to trimethylolpropane phosphate induces central nervous system sensitization and facilitates electrical kindling. *Physiol Behav*. 1998; 65(1):51-8.
- ⁵⁸⁰ Rössler AS. Long-lasting potentiation effects induced in rats by kindling with an inverse agonist of the benzodiazepine receptor. *Exp Brain Res*. 2002; 146(1):77-85.
- ⁵⁸¹ Nutt DJ. Repeated administration of subconvulsant doses of GABA antagonist drugs. I. Effect on seizure threshold (kindling). *Psychopharmacology*. 1982; 76(1):84-7.
- ⁵⁸² Joy RM. The effects of neurotoxicants on kindling and kindled seizures. *Fundam Appl Toxicol*. 1985; 5(1):41-65.
- ⁵⁸³ Bell IR. An olfactory-limbic model of multiple chemical sensitivity syndrome: possible relationships to kindling and affective spectrum disorders. *Biol Psychiatry*. 1992; 32(3):218-42.
- ⁵⁸⁴ Gilbert ME. Does the kindling model of epilepsy contribute to our understanding of multiple chemical sensitivity? *Ann N Y Acad Sci* 2001; 933:68-91.
- ⁵⁸⁵ Rossi J 3rd. Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. *Toxicology*. 1996; 111(1-3):87-100.
- ⁵⁸⁶ Bowen SE. Tolerance and sensitization to inhaled 1,1,1-trichloroethane in mice: results from open-field behavior and a functional observational battery. *Psychopharmacology*. 2006; 185(4):405-15.

- ⁵⁸⁷ Berenguer P. Behavioral and neurochemical effects induced by subchronic exposure to 40 ppm toluene in rats. *Pharmacol Biochem Behav.* 2003; 74(4):997-1003.
- ⁵⁸⁸ Rofers WR. A rat model of neurobehavioral sensitization to toluene. *Toxicol Ind Health.* 1999; 15(3-4):356-69.
- ⁵⁸⁹ Sorg BA. Repeated formaldehyde effects in an animal model for multiple chemical sensitivity. *Ann N Y Acad Sci.* 2001; 933:57-67.
- ⁵⁹⁰ Reeves R. Behavioral sensitization and long-term neurochemical alterations associated with the fungicide triadimefon. *Pharmacol Biochem Behav.* 2003; 76(2):315-26.
- ⁵⁹¹ Duffard R. Environmental chemical compounds could induce sensitization to drugs of abuse. *Ann N Y Acad Sci.* 2002; 965:305-13.
- ⁵⁹² Gilbert ME. Repeated exposure to lindane leads to behavioral sensitization and facilitates electrical kindling. *Neurotoxicol Teratol.* 1995 Mar-Apr; 17(2):131-41.
- ⁵⁹³ Gilbert ME. A characterization of chemical kindling with the pesticide endosulfan. *Neurotoxicol Teratol.* 1992; 14:151-158.
- ⁵⁹⁴ Gilbert ME. An examination of the proconvulsant actions of pyrethroid insecticides using pentylentetrazol and amygdala kindling seizure models. *Neurotoxicology.* 1990; 11(1):73-86.
- ⁵⁹⁵ Wiley JL. Evaluation of toluene dependence and cross-sensitization to diazepam. *Life Sci.* 2003; 72(26):3023-33.
- ⁵⁹⁶ Wiley JL. Evaluation of 1,1,1-trichloroethane and flurothyl locomotor effects following diazepam treatment in mice. *Pharmacol Biochem Behav.* 2002; 71(1-2):163-9.
- ⁵⁹⁷ Beyer CE. Repeated exposure to inhaled toluene induces behavioral and neurochemical cross-sensitization to cocaine in rats. *Psychopharmacology.* 2001; 154(2):198-204.
- ⁵⁹⁸ Sorg BA. Repeated low-level formaldehyde exposure produces cross-sensitization to cocaine: possible relevance to chemical sensitivity in humans. *Neuropsychopharmacology.* 1998; 18(5):385-94.
- ⁵⁹⁹ Overstreet DH. A genetic rat model of cholinergic hypersensitivity: Implications for chemical intolerance, chronic fatigue, and asthma. *Ann N Y Acad Sci.* 2001; 933:92-102.
- ⁶⁰⁰ Mejia-Toiber J. D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo. *Neurochem Res.* 2006; 31(12):1399-408.
- ⁶⁰¹ Cain DP. Evidence for different neurochemical contributions to long-term potentiation and to kindling and kindling-induced potentiation: role of NMDA and urethane-sensitive mechanisms. *Exp Neurol.* 1992; 116(3):330-8.
- ⁶⁰² Giorgi O. MK-801 prevents chemical kindling induced by pentylentetrazol in rats. *European J Pharmacol* 1991; 193(3):363-365.
- ⁶⁰³ Caterina MJ. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature.* 1997; 389 (6653): 816-24.
- ⁶⁰⁴ Tóth A. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. *Brain Res Mol Brain Res.* 2005; 135(1-2):162-8.
- ⁶⁰⁵ Lilja J. Surfactant-induced TRPV1 activity - A novel mechanism for eye irritation? *Toxicolog Sci.* 2007; 99(1):174-180.
- ⁶⁰⁶ Avelino A. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. *Naunyn Schmiedebergs Arch Pharmacol.* 2006; 373:287-99.
- ⁶⁰⁷ Birder LA. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. *Proc Natl Acad Sci USA.* 2001; 98:13396-401.
- ⁶⁰⁸ Stander S. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. *M Exp Dermatol.* 2004; 13:129-39.
- ⁶⁰⁹ Kato S. Gastroprotective effect of the mixture of α - and β -amyrin from protium heptaphyllum: Role of capsaicin-sensitive primary afferent neurons. *Biochem Pharmacol.* 2003; 66:1115-21.
- ⁶¹⁰ Kechagias S. Expression of vanilloid receptor-1 in epithelial cells of human antral gastric mucosa. *Scand J Gastroenterol.* 2005; 40:775-82.
- ⁶¹¹ Akbar A. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. *Gut.* 2008; 57(7):923.
- ⁶¹² Holzer P. TRPV1: a new target for treatment of visceral pain in IBS? *Gut.* 2008; 57(7):882-84.
- ⁶¹³ Hamamoto T. Localization of transient receptor potential vanilloid (TRPV) in the human larynx. *Acta Otolaryngol.* 2009; 129(5):560-8.
- ⁶¹⁴ Takemura M. Is TRPV1 a useful target in respiratory diseases? *Pulm Pharmacol Ther.* 2008; 21(6):833-9.
- ⁶¹⁵ Dicipinigitis PV. Clinical cough III: measuring the cough response in the laboratory. *Handb Exp Pharmacol.* 2009; (187):297-310.
- ⁶¹⁶ Fuller R. Bronchoconstrictor response to inhaled capsaicin in humans. *J Appl Physiol.* 1985; 58:1080-4.

- ⁶¹⁷ Karlsson J-A. Afferent neural pathways in cough and reflex bronchoconstriction. *J Appl Physiol*. 1988; 65:1007-23.
- ⁶¹⁸ Midgren B. Capsaicin-induced cough in humans. *Am Rev Respir Dis*. 1992; 146:347-51.
- ⁶¹⁹ Morice AH. Cough 5: the type 1 vanilloid receptor: a sensory receptor for cough. *Thorax*. 2004; 59:257-8.
- ⁶²⁰ Ternesten-Hasseus E. Capsaicin provocation using two different inhalation devices. *Resp Med*. 2008; 102:1784-1790.
- ⁶²¹ Dicpinigaitis PV. Short- and long-term reproducibility of capsaicin cough challenge testing. *Pulm Pharmacol Ther*. 2003; 16(1):61-5.
- ⁶²² Dicpinigaitis PV. Safety of capsaicin cough challenge testing. *Chest*. 2005; 128(1):196-202.
- ⁶²³ Ternesten-Hasseus E. Increased capsaicin cough sensitivity in patients with multiple chemical sensitivity. *J Occup Environ Med*. 2002; 44(11):1012-7.
- ⁶²⁴ Millqvist E. Cough provocation with capsaicin is an objective way to test sensory hyperreactivity in patients with asthma-like symptoms. *Allergy*. 2000; 55(6):546-50.
- ⁶²⁵ Elberling J. The capsaicin cough reflex in eczema patients with respiratory symptoms elicited by perfume. *Contact Dermatitis*. 2006; 54(3):158-64.
- ⁶²⁶ Millqvist E. Relationship of airway symptoms from chemicals to capsaicin cough sensitivity in atopic subjects. *Clin Exp Allergy*. 2004; 34(4):619-23.
- ⁶²⁷ Holst H. The capsaicin cough reflex in patients with symptoms elicited by odorous chemicals. *Int J Hyg Environ Health*. 2010; 213(1): 66-71.
- ⁶²⁸ Andersson L. Prevalence and risk factors for chemical sensitivity and sensory hyperreactivity in teenagers. *Int J Hyg Environ Health*. 2008; 211(5-6):690-7.
- ⁶²⁹ Ternesten-Hasséus E. Capsaicin sensitivity in patients with chronic cough- results from a cross-sectional study. *Cough*. 2013; 9(1):5.
- ⁶³⁰ Millqvist E. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals. *Environ Health Perspect*. 2005; 113:849-852.
- ⁶³¹ Pingle SC. Capsaicin receptor: TRPV1 a promiscuous TRP channel. *Handb Exp Pharmacol*. 2007; 179:155-71.
- ⁶³² Calixto JB. Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions. *Pharmacol Ther*. 2005; 106(2):179-208.
- ⁶³³ Cristino L. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. *Neuroscience* 2006; 139:1405-15.
- ⁶³⁴ Liapi A. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. *Eur J Neurosci*. 2005; 22:825-34.
- ⁶³⁵ Toth A. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. *Brain Res Mol Brain Res*. 2005; 135:162-8.
- ⁶³⁶ Cavanaugh DJ. Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. *J Neurosci*. 2011; 31(13):5067-77.
- ⁶³⁷ Li HB. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. *Biol Psychiatry*. 2008; 64(4):286-92.
- ⁶³⁸ Fu M. TRPV1: a potential target for antiepileptogenesis. *Med Hypotheses*. 2009; 73(1):100-2.
- ⁶³⁹ Matta JA. TRPV1 and synaptic transmission. *Curr Pharm Biotechnol*. 2011; 12(1):95-101.
- ⁶⁴⁰ McKeown-Eyssen G. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. *Int J Epidemiol*. 2004; 33(5):971-8.
- ⁶⁴¹ Schnakenberg E. A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. *Environ Health*. 2007; 6:6.
- ⁶⁴² Korkina L. The chemical defensive system in the pathobiology of idiopathic environment-associated diseases. *Curr Drug Metab*. 2009; 10(8):914-31.
- ⁶⁴³ De Luca C. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. *Toxicol Appl Pharmacol*. 2010; 248(3):285-92.
- ⁶⁴⁴ Chuang HH. Oxidative challenges sensitize the capsaicin receptor by covalent cysteine modification. *Proc Natl Acad Sci USA*. 2009; 106(47):20097-102.
- ⁶⁴⁵ Yoshida T. Nitric oxide activates TRP channels by cysteine S-nitrosylation. *Nat Chem Biol* 2006; 2:596-607.
- ⁶⁴⁶ Susankova K. Reducing and oxidizing agents sensitize heat-activated vanilloid receptor (TRPV1) current. *Mol Pharmacol*. 2006; 70(1):383-94.
- ⁶⁴⁷ Miller BA. TRP channels as mediators of oxidative stress. *Adv Exp Med Biol*. 2011; 704:531-44.

- ⁶⁴⁸ Pall ML. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. *FASEB J.* 2002; 16:1407–17.
- ⁶⁴⁹ Pall ML. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. *Environ Health Perspect* 2003; 111:1461–4.
- ⁶⁵⁰ De Luca C. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. *Toxicol Appl Pharmacol.* 2010; 248(3):285-92.
- ⁶⁵¹ Hill AB: The environment and disease: Association or causation? *Proc R Soc Med.* 1965; 58:295-300.
- ⁶⁵² Hill AB: The environment and disease: Association or causation? *Proc R Soc Med.* 1965; 58:295-300.
- ⁶⁵³ Staudenmayer H. Idiopathic environmental intolerance: Part 2: A causation analysis applying Bradford Hill's criteria to the psychogenic theory. *Toxicol Rev.* 2003; 22(4):247-61.
- ⁶⁵⁴ Staudenmayer H. Idiopathic environmental intolerance: Part 1: A causation analysis applying Bradford Hill's criteria to the toxicogenic theory. *Toxicol Rev.* 2003; 22(4):235-46.
- ⁶⁵⁵ La Du BN. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. *Drug Metab Dispos.* 2001; 29:566-9.
- ⁶⁵⁶ McKeown-Eyssen G. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR, *Int J Epidemiol.* 2004; 33(5): 971-978 [funded by the Ontario Ministry of Health].
- ⁶⁵⁷ Furlong CE. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants, *Neurotoxicology.* 2005; 26:651-9.
- ⁶⁵⁸ Schnakenberg EA cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug metabolizing enzymes. *Environ Health.* 2007; 6:6.
- ⁶⁵⁹ Muller KE, Schnakenberg E. Die Bedeutung der Glukuronidierung bei umweltmedizinischen Erkrankungen am Beispiel der UDP-Glukuronosyltransferase 1A1. *Umwelt Medizin Gesellschaft,* 2008; 21(4): 295-300. (abstract available in English).
- ⁶⁶⁰ De Luca C. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. *Toxicol Appl Pharmacol.* 2010; 248(3):285-92.
- ⁶⁶¹ Boyd CM. Future of multimorbidity research: How should understanding of multimorbidity inform health system design? *Public Health Reviews.* 2011; 32 (2):451–474.
- ⁶⁶² Bayliss EA. Barriers to self-management and quality-of-life outcomes in seniors with multimorbidities. *Ann Fam Med.* 2007; 5(5): it's 395–402.
- ⁶⁶³ Tinetti ME. The end of the disease era. *Am J Med.* 2004; 116:179–185.
- ⁶⁶⁴ Gross CP. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? *Ann Intern Med.* 2002; 137:10–16.
- ⁶⁶⁵ Van Spall HG. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. *JAMA.* 2007; 297(11):1233–40.
- ⁶⁶⁶ Jadad AR. Consideration of multiple chronic diseases in randomized controlled trials. *JAMA.* 2011; 306(24):2670–2.
- ⁶⁶⁷ Buchwald D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. *Arch Intern Med* 1994;154(18):2049-53.
- ⁶⁶⁸ Pollet C. Medical evaluation of Persian Gulf veterans with fatigue and/or chemical sensitivity. *J Med.* 1998; 29:101–13.
- ⁶⁶⁹ Jason LA. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms. *Psychosom Med.* 2000; 62(5):655-63.
- ⁶⁷⁰ Ziem G. Profile of patients with chemical injury and sensitivity. *Environ Health Perspect.* 1997 Mar;105 Suppl 2:417-36.
- ⁶⁷¹ Rainville P. Representation of acute and persistent pain in the human CNS: potential implications for chemical intolerance. *Ann N Y Acad Sci.* 2001; 933:130-41..
- ⁶⁷² Black DW. The Iowa follow-up of chemically sensitive persons. *Ann N Y Acad Sci.* 2001; 933:48-56.
- ⁶⁷³ Gray GC. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. *Am J Epidemiol.* 2002; 155(11):1033-44.
- ⁶⁷⁴ Bell IR. Quantitative EEG patterns during nose versus mouth inhalation of filtered room air in young adults with and without self-reported chemical odor intolerances. *Int J Psychophysiol.* 1998; 28(1):23-35.
- ⁶⁷⁵ Bell IR. Differential resting quantitative electroencephalographic alpha patterns in women with environmental chemical intolerance, depressives, and normals. *Biol Psychiatry.* 1998 1;43(5):376-88.
- ⁶⁷⁶ Bell IR. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. *Am J Med.* 1998; 105(3A):74S-82S.

- ⁶⁷⁷ Gibson PR. Sickness-related dysfunction in persons with self-reported multiple chemical sensitivity at four levels of severity. *J Clin Nurs*. 2008; 18:72–81.
- ⁶⁷⁸ Gibson PR. Sickness-related dysfunction in persons with self-reported multiple chemical sensitivity at four levels of severity. *J Clin Nurs*. 2009; 18(1):72–81.
- ⁶⁷⁹ Söderholm A. The experience of living with sensory hyperreactivity-accessibility, financial security, and social relationships. *Health Care Women Int*. 2011; 32(8):686–707.
- ⁶⁸⁰ Gibson PR. Of the world but not in it: barriers to community access and education for persons with environmental sensitivities. *Health Care Women Int*. 2010; 31(1):3–16.
- ⁶⁸¹ Larsson C. Experiences of problems in individuals with hypersensitivity to odours and chemicals. *J Clin Nursing*. 2009; 18, 737–744.
- ⁶⁸² Gibson PR. Work accommodation for people with multiple chemical sensitivity. Disability Society. 2007; 22:717–732.
- ⁶⁸³ Skovbjerg S. Impact of self-reported multiple chemical sensitivity on everyday life: A qualitative study. *Scand J Pub Health*. 2009; 37:621–626.
- ⁶⁸⁴ Caress SM. Symptomatology and etiology of multiple chemical sensitivities in the southeastern United States. *Arch Environ Health*. 2002; 57(5):429–436.
- ⁶⁸⁵ Miller CS. A controlled comparison of symptoms and chemical intolerances reported by Gulf War veterans, implant recipients and persons with multiple chemical sensitivity. *Toxicol Ind Health*. 1999; 15(3–4):386–397.
- ⁶⁸⁶ Lax MB. Patients with multiple chemical sensitivities in an occupational health clinic: presentation and follow-up. *Arch Environ Health*. 1995; 50(6):425–431.
- ⁶⁸⁷ Gibson PR. Isolation and lack of access in multiple chemical sensitivity: A qualitative study. *Nurs Health Sci*. 2011; 13(3):232–7.
- ⁶⁸⁸ Lipson, JG. Environmental issues and work: Women with multiple chemical sensitivities. *Health Care Women Intern*. 2006; 27:571–584.
- ⁶⁸⁹ Lipson JG. We are the canaries: Self care in multiple chemical sensitivity sufferers. *Qualitative Health Research*, 2001; 11:103–116.
- ⁶⁹⁰ Gibson PR. Chemical sensitivity/chemical injury and life disruption. *Women Therapy*. 1996; 19:63–79.
- ⁶⁹¹ Genuis SJ. Chemical sensitivity: Pathophysiology or psychopathology? *Clin Ther*. 2013; 35(5):572–7.
- ⁶⁹² Koch L. A qualitative investigation of the psychosocial impact of chemical sensitivity. *J Appl Rehab Counseling*. 2006; 37(3):33–40.
- ⁶⁹³ Canadian Coalition for Green Health Care Toolkit: <http://www.greenhealthcare.ca/images/projects/FragranceFreeImplementationKit.pdf>
- ⁶⁹⁴ Brown MM. Functioning in individuals with chronic fatigue syndrome: increased impairment with co-occurring multiple chemical sensitivity and fibromyalgia. *Dyn Med*. 2007; 6:6.
- ⁶⁹⁵ Lavergne MR. Functional impairment in chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity. *Can Fam Physician*. 2010; 56: e60–1.
- ⁶⁹⁶ Ware JE Jr, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473–83.
- ⁶⁹⁷ SF-36® Health Survey Update. SF-36.org (accessed June 4 2013).
- ⁶⁹⁸ Hopman WM. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. *CMAJ* 2000;163(3):265–71.
- ⁶⁹⁹ Hopman WM. Stability of normative data for the SF-36: results of a three-year prospective study in middle-aged Canadians. *Can J Public Health* 2004;95(5):387–9.
- ⁷⁰⁰ Komaroff AL. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. *Am J Med* 1996;101(3):281–90.
- ⁷⁰¹ Hardt J. Health-related quality of life in patients with chronic fatigue syndrome: an international study. *J Psychosom Res* 2001;51(2):431–4.
- ⁷⁰² Herrell R. Chronic fatigue and chronic fatigue syndrome: a co-twin control study of functional status. *Qual Life Res* 2002;11(5):463–71.
- ⁷⁰³ Alanoglu E. Auditory event-related brain potentials in fibromyalgia syndrome. *Rheumatol Int* 2005;25(5):345–9. Epub 2004 Feb 21.
- ⁷⁰⁴ Neumann L. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). *Semin Arthritis Rheum* 2000;29(6):400–8.

- ⁷⁰⁵ Bergman S. Psychosocial aspects of chronic widespread pain and fibromyalgia. *Disabil Rehabil* 2005;27(12):675-83.
- ⁷⁰⁶ Black DW. Quality of life and health-services utilization in a population-based sample of military personnel reporting multiple chemical sensitivities. *J Occup Environ Med* 1999;41(10):928-33.
- ⁷⁰⁷ Jason LA. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms. *Psychosom Med* 2000;62(5):655-63.
- ⁷⁰⁸ Gibson PR. Disability induced identity changes in persons with multiple chemical sensitivity. *Qual Health Res*. 2005; 15:502–524.
- ⁷⁰⁹ Chircop A. Women living with environmental illness. *Health Care Women Int*. 2003; 24:371–383.
- ⁷¹⁰ Lipson JG. Multiple chemical sensitivities: Stigma and social experiences. *Med Anthropol*. 2004; 18:200–213.
- ⁷¹¹ Åsbring P. Women's experiences of stigma in relation to chronic fatigue syndrome and fibromyalgia. *Qual Health Res*. 2002; 12:148–160.
- ⁷¹² Shah R. Chapter 29: Unproved and controversial methods and theories in allergy-immunology. *Allergy Asthma Proc*. 2012; 33 Suppl 1:S100-2.
- ⁷¹³ Terr AI. Clinical ecology in the workplace. *J Occup Med*. 1989; 31:257–261.
- ⁷¹⁴ Wessely S. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. *Am J Psychiatry*. 1996; 153:1050–1059.
- ⁷¹⁵ Katon WJ. Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis. *J Gen Intern Med*. 1991; 6:277–285.
- ⁷¹⁶ Wood GC. A comparative assessment of patients with chronic fatigue syndrome and muscle disease. *Psychol Med*. 1991; 21:618–628.
- ⁷¹⁷ Wessely S. Fatigue syndromes: a comparison of chronic “postviral” fatigue with neuromuscular and affective disorders. *J Neurol Neurosurg Psychiatry*. 1989; 52:940–948.
- ⁷¹⁸ Manu P. Depression among patients with a chief complaint of chronic fatigue. *J Affect Disord*. 1989; 17:165–172.
- ⁷¹⁹ 122. Stewart DE. Emotional disorders misdiagnosed as physical illness: environmental hypersensitivity, candidiasis hypersensitivity, and chronic fatigue syndrome. *Int J Ment Health*. 1990; 19:56–68.
- ⁷²⁰ Manu P. Hypochondriasis influences quality-of-life outcomes in patients with chronic fatigue syndrome. *Psychother Psychosom*. 1996; 65:76–81.
- ⁷²¹ Greenberg DB. Neurasthenia in the 1980s: chronic mononucleosis, chronic fatigue syndrome, and anxiety and depressive disorders. *Psychosomatics*. 1990; 31:129–137.
- ⁷²² Manu P. The mental health of patients with a chief complaint of chronic fatigue: a prospective evaluation and follow-up. *Arch Intern Med* 1988; 148:2213–2217.
- ⁷²³ Abbey SE. Chronic fatigue syndrome and depression: cause, effect, or covariate. *Rev Infect Dis* 1991; 18(suppl 1):S73–S83.
- ⁷²⁴ Brodsky CM. Psychological factors contributing to somatoform disorders attributed to the workplace. The case of intoxication. *J Occup Med*. 1983; 25:459-64.
- ⁷²⁵ Selner JC. Neuropsychophysiologic observations in patients presenting with environmental illness. *Toxicol Indust Health*. 1992; 8:145–155.
- ⁷²⁶ Davidoff AL. Psychogenic origins of multiple chemical sensitivities syndrome: a critical review of the research literature. *Arch Environ Health*. 1994; 49(5):316-25.
- ⁷²⁷ Terr AL. Environmental illness: a clinical review of 50 cases. *Arch Intern Med*. 1986; 146:145-49.
- ⁷²⁸ Binkley KE. Panic response to sodium lactate infusion in patients with multiple chemical sensitivity syndrome. *J Allergy Clin Immunol*. 1997; 99(4):570-574.
- ⁷²⁹ Binkley K. Idiopathic environmental intolerance: increased prevalence of panic disorder-associated cholecystokinin B receptor allele 7. *J Allergy Clin Immunol*. 2001; 107(5):887-890.
- ⁷³⁰ Black DW. A nine-year follow-up of people diagnosed with multiple chemical sensitivities. *Psychosomatics*. 2000; 41(3):253-261
- ⁷³¹ Lax MB. Patients with multiple chemical sensitivities in an occupational health clinic: presentation and follow-up. *Arch Environ Health*. 1995; 50(6):425-43.
- ⁷³² Black DW, Okiishi C, Schlosser S. The Iowa follow-up of chemically sensitive persons. *Ann N Y Acad Sci*. 2001; 933:48-56.

- ⁷³³ Goodwin RD. Impact of allergy treatment on the association between allergies and mood and anxiety in a population sample. *Clin Exp Allergy*. 2012; 42(12):1765-71.
- ⁷³⁴ Loerbroks A. The association of asthma and wheezing with major depressive episodes: an analysis of 245 727 women and men from 57 countries. *Int J Epidemiol*. 2012; 41(5):1436-44.
- ⁷³⁵ Rotella F. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. *J Clin Psychiatry*. 2013; 74(1):31-7.
- ⁷³⁶ Elderon L. Depression and cardiovascular disease. *Prog Cardiovasc Dis*. 2013; 55(6):511-23
- ⁷³⁷ Hausteiner C. Dysfunctional cognitions in idiopathic environmental intolerances (IEI)--an integrative psychiatric perspective. *Toxicol Lett*. 2007; 171(1-2):1-9.
- ⁷³⁸ Lehrer PM. Psychophysiological hypotheses regarding multiple chemical sensitivity syndrome. *Environ Health Perspect*. 1997; 105 Suppl 2:479-83.
- ⁷³⁹ Binkley K. Idiopathic environmental intolerance: Increased prevalence of panic disorder--associated cholecystokinin B receptor allele 7. *J Allergy Clin Immunol*. 2001 May;107(5):887-90.
- ⁷⁴⁰ Tarlo SM. Responses to panic induction procedures in subjects with multiple chemical sensitivity/idiopathic environmental intolerance: understanding the relationship with panic disorder. *Environ Health Perspect*. 2002 Aug;110 Suppl 4:669-71.
- ⁷⁴¹ Poonai NP. Psychological features of subjects with idiopathic environmental intolerance. *J Psychosom Res*. 2001; 51(3):537-41.
- ⁷⁴² Giardino ND. Behavioral conditioning and idiopathic environmental intolerance. *Occup Med*. 2000; 15(3):519-28.
- ⁷⁴³ Staudenmayer H. Idiopathic Environmental Intolerance, *Toxicol Rev* 2003; 22(4):247-61
- ⁷⁴⁴ Staudenmayer H. Clinical consequences of the EI/MCS "diagnosis": two paths. *Regul Toxicol Pharmacol*. 1996; 24(1 Pt 2):S96-110.
- ⁷⁴⁵ Boyd I. Taking refuge from modernity: 21st century hermits. *J R Soc Med*. 2012; 105(12):523-9.
- ⁷⁴⁶ Graneheim UH. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. *Nurse Education Today*. 2004; 24:105-112.
- ⁷⁴⁷ Larsson C. Experiences of problems in individuals with hypersensitivity to odours and chemicals. *J Clin Nurs*. 2009; 18(5):737-44.
- ⁷⁴⁸ Das-Munshi J. Multiple Chemical Sensitivities: a systematic review of provocation studies. *J Allerg Clin Immunol* 2006; 118:1257-1264.
- ⁷⁴⁹ Staudenmayer H. Psychological treatment of psychogenic idiopathic environmental intolerance. *Occup Med*. 2000; 15(3):627-46.
- ⁷⁵⁰ Guglielmi RS. Behavioral treatment of phobic avoidance in multiple chemical sensitivity. *J Behav Ther Exp Psychiatry*. 1994; 25(3):197-209.
- ⁷⁵¹ Andiné P. Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities. *Acta Psychiatr Scand*. 1997; 96(1):82-3
- ⁷⁵² Stenn P. Successful outcome in a patient with chemical sensitivity. Treatment with psychological desensitization and selective serotonin reuptake inhibitor. *Psychosomatics*. 1998; 39(6):547-50.
- ⁷⁵³ Spyker DA. Multiple chemical sensitivities--syndrome and solution. *J Toxicol Clin Toxicol*. 1995; 33(2):95-9.
- ⁷⁵⁴ Blazek-O'Neill B. Complementary and alternative medicine in allergy, otitis media, and asthma. *Curr Allergy Asthma Rep*. 2005; 5(4):313-8.
- ⁷⁵⁵ Yorke J. Psychological interventions for adults with asthma: a systematic review. *Respir Med*. 2007; 101(1):1-14.
- ⁷⁵⁶ Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. *Continuum (Minneapolis)*. 2012; 18(4):796-806.
- ⁷⁵⁷ Ross A. The health benefits of yoga and exercise; a review of comparison studies. *J Altern Complement Med*. 2010;16(1):3-12.
- ⁷⁵⁸ Innes K. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: A systematic review. *J Am Board Fam Pract*. 2005; 18(6):491-519.
- ⁷⁵⁹ Khatri D. Effects of yoga and meditation on clinical and biochemical parameters of metabolic syndrome. *Diabetes Res Clin Pract*. 2007; 78(3):e9-10.

- ⁷⁶⁰ Hagins M. Effectiveness of yoga for hypertension: systematic review and meta-analysis. *Evid Based Complement Alternat Med.* 2013; 2013:649836.
- ⁷⁶¹ Brook RD. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. *Hypertension.* 2013; 61(6):1360-83.
- ⁷⁶² Katerndahl DA. Chemical intolerance in primary care settings: prevalence, comorbidity, and outcomes. *Ann Fam Med.* 2012; 10(4):357-65
- ⁷⁶³ Treatment - Integrated Chronic Care Services. Nova Scotia Environmental Health Center. <http://www.cdha.nshealth.ca/integrated-chronic-care-service-iccs/treatment> (access August 27, 2013).
- ⁷⁶⁴ Davenport TE. Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis. *Phys Ther.* 2010; 90(4):602-14.
- ⁷⁶⁵ Gibson PR. Sickness-related dysfunction in persons with self-reported multiple chemical sensitivity at four levels of severity. *J Clin Nurs.* 2008; 18:72–81.
- ⁷⁶⁶ Nöller V. Prospective epidemiological observations on the course of the disease in fibromyalgia patients. *J Negat Results Biomed.* 2003; 2:4–9.
- ⁷⁶⁷ Wolfe F. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. *Arthritis Rheum.* 1997; 40:1571–1579.
- ⁷⁶⁸ Sharpe M. Why do doctors find some patients difficult to help? *Q J Med.* 1994; 87:187–193.
- ⁷⁶⁹ Lauche R. Patient-related predictors of treatment satisfaction of patients with fibromyalgia syndrome: results of a cross-sectional survey. *Clin Exp Rheumatol.* 2013 May 27; (ahead of print)
- ⁷⁷⁰ Leone SS. Long-term predictors of outcome in fatigued employees on sick leave: a 4-year follow-up study. *Psychol Med.* 2006; 36(9):1293-300.
- ⁷⁷¹ Henriksson CM. Women with fibromyalgia: work and rehabilitation. *Disabil Rehabil.* 2005; 27(12):685-94.
- ⁷⁷² Skouen JS. Return to work after comparing outpatient multidisciplinary treatment programs versus treatment in general practice for patients with chronic widespread pain. *Eur J Pain.* 2006; 10(2):145-52
- ⁷⁷³ Huibers MJ. Chronic fatigue syndrome-like caseness as a predictor of work status in fatigued employees on sick leave: four year follow up study. *Occup Environ Med.* 2006; 63(8):570-2.
- ⁷⁷⁴ Altomonte L. Fibromyalgia syndrome: preventive, social and economic aspects. *Reumatismo.* 2008; 60 Suppl 1:70-8.
- ⁷⁷⁵ Institute of Medicine. Environmental medicine and the medical school curriculum. Washington, DC; National Academy Press. 1993.
- ⁷⁷⁶ Institute of Medicine. Role of the primary care physician in occupational and environmental medicine. Washington, DC; National Academy Press. 1988; 5-9.
- ⁷⁷⁷ Schenk M. Environmental medicine content in medical school curricula. *Acad Med.* 1996 May;71(5):499-501.
- ⁷⁷⁸ Graber DR. Environmental health in medical school curricula: views of academic deans. *J Occup Environ Med.* 1995 Jul;37(7):807-11.
- ⁷⁷⁹ Sokas RS. Environmental medicine: its introduction into a medical school primary requirement. *Med Educ.* 1993; 27:410-415.
- ⁷⁸⁰ Martin GJ. The content of internal medicine residency training and its relevance to the practice of medicine. *J Gen Intern Med.* 1989; 4:304-308.
- ⁷⁸¹ Le Moal J. Do we need a specialization in Environmental Medicine? *J Neurol Sci.* 2011; 302(1-2):106-7.
- ⁷⁸² Tyler IV. Canadian medical students' perceptions of public health education in the undergraduate medical curriculum. *Acad Med.* 2009; 84(9):1307-12.
- ⁷⁸³ Rosenberg S. A survey of physicians who studied public health during medical school. *Am J Prev Med.* 1998;14:184 –188.
- ⁷⁸⁴ Bellas P. What students bring to medical school: Attitudes toward health promotion and prevention. *Am J Prev Med.* 2000; 18:242–248.
- ⁷⁸⁵ Gibson PR. Physicians' perceptions and practices regarding patient reports of multiple chemical sensitivity. *ISRN Nurs.* 2011; 2011:838930.
- ⁷⁸⁶ Katerndahl DA. Chemical intolerance in primary care settings: prevalence, comorbidity, and outcomes. *Ann Fam Med.* 2012; 10:357–365.
- ⁷⁸⁷ Cooper C. Multiple chemical sensitivity in the clinical setting. *Am J Nurs.* 2007; 107:40–47.
- ⁷⁸⁸ Ghazan-Shahi S. Should rheumatologists retain ownership of fibromyalgia? A survey of Ontario rheumatologists. *Clin Rheumatol.* 2012; 31(8):1177-81.

- ⁷⁸⁹ Chew-Graham C. Making the diagnosis of CFS/ME in primary care: a qualitative study. *BMC Fam Pract.* 2010; 11:16.
- ⁷⁹⁰ Bowen J. Chronic Fatigue Syndrome: a survey of GPs' attitudes and knowledge. *Fam Pract.* 2005; 22(4):389-93.
- ⁷⁹¹ Hartz AJ. Unexplained symptoms in primary care: perspectives of doctors and patients. *Gen Hosp Psychiatry.* 2000; 22:144–152.
- ⁷⁹² Reid S. Medically unexplained symptoms - GPs' attitudes towards their cause and management. *Fam Pract.* 2001; 18:519–523.
- ⁷⁹³ National Institute for Clinical Excellence. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): Diagnosis and management of CFS/ME in adults and children. NHS National Institute for Health and Clinical Excellence. 2007; 7 NICE clinical guideline 53.
- ⁷⁹⁴ Henriksson C. Factors of importance for work disability in women with fibromyalgia. *J Rheumatol.* 2000; 27(5):1271-6.
- ⁷⁹⁵ Richards KL. Health Guide. Survey Shows Early Diagnosis Improves Fibromyalgia Outcomes. <http://www.healthcentral.com/chronic-pain/c/5949/125542/fibromyalgia> (accessed August 5, 2013).
- ⁷⁹⁶ Drachler ML. The expressed needs of people with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A systematic review. *BMC Publ Health.* 2009; 9:458
- ⁷⁹⁷ Dickenson A. Stigma and the delegitimation experience: An interpretative phenomenological analysis of people living with chronic fatigue syndrome. *Health Psychol.* 2007;22(Suppl 7):851–867.
- ⁷⁹⁸ Kasperski MJ. Results of the Research Project to Determine the Feasibility of Establishing “A Centre for Environmental Health in the Great Lakes Basin”. May 26, 2008.
- ⁷⁹⁹ Pediatric Environmental Health Specialty Units. <http://aoec.org/pehsu/serviceareas.html#canada> (accessed September 16, 2013).
- ⁸⁰⁰ Complex Chronic Diseases Program. Services. BC Women's Hospital & Health Centre. <http://www.bcwomens.ca/Services/HealthServices/complex-chronic-disease-program/for-professionals/default.htm> (accessed August 28, 2013).
- ⁸⁰¹ Capital Health. Integrated Chronic Care Service (ICCS). <http://www.cdha.nshealth.ca/integrated-chronic-care-service-iccs> (accessed August 28, 2013)
- ⁸⁰² Fox R. Measuring health outcomes of a multidisciplinary care approach in individuals with chronic environmental conditions using an abbreviated symptoms questionnaire. *J Multidiscip Healthc.* 2008; 1:97-104.
- ⁸⁰³ Fox RA. The impact of a multidisciplinary, holistic approach to management of patients diagnosed with Multiple Chemical Sensitivity on healthcare utilization costs: An observational study. *J Altern Complement Med.* 13(2):223-229.
- ⁸⁰⁴ Sampalli T. A controlled study of the effect of a mindfulness-based stress reduction technique in women with multiple chemical sensitivity, chronic fatigue syndrome and fibromyalgia. *J Multidiscip Healthc.* 2009; 2:53-9.
- ⁸⁰⁵ Publications-Integrated Chronic Care Service (ICCS). Capital Health. <http://www.cdha.nshealth.ca/integrated-chronic-care-service-iccs/publications> (accessed August 28, 2013).
- ⁸⁰⁶ Bested A. et al. Hope and Help for Chronic Fatigue Syndrome and Fibromyalgia, Cumberland House, 2006 and 2008
- ⁸⁰⁷ Networks of Centres of Excellence of Canada. http://www.nce-rce.gc.ca/Index_eng.asp (accessed May 11, 2013).
- ⁸⁰⁸ Ontario Centres of Excellence. <http://www.oce-ontario.org/> (accessed May 11, 2013).
- ⁸⁰⁹ Ontario Centre Excellence for Child and Youth Mental Health. <http://www.excellenceforchildand youth.ca/> (accessed May 11, 2013).
- ⁸¹⁰ GE Healthcare IT Canada. <http://www.gehealthcare.com/canada/it/index.html> (accessed May 11, 2013)
- ⁸¹¹ Kensington Health. Kensington Eye Institute. <http://www.kensingtonhealth.org/index.php?page=eye> (accessed September 8, 2013).
- ⁸¹² Kensington Health. Kensington Hospice. <http://www.kensingtonhealth.org/index.php?page=hospice> accessed September 8, 2013).
- ⁸¹³ Centre of Excellence for Integrated Senior Services <http://www.montgomerysisam.com/projects/centre-excellence-integrated-seniors-services> (accessed September 8, 2013).
- ⁸¹⁴ Ontario Bariatric Network. <http://www.ontariobariatricnetwork.ca/our-centres.aspx> (accessed September 8, 2013).
- ⁸¹⁵ Mount Sinai Hospital. http://www.mountsinai.on.ca/about_us/who-we-are/centres (accessed May 11, 2013).
- ⁸¹⁶ West Park Healthcare Centre. <http://www.ltvcoe.com/> (accessed September 8, 2013).

- ⁸¹⁷ Toronto East General Hospital Provincial Weaning Centre of Excellence for Prolonged Ventilation. http://www.tegh.on.ca/bins/content_page.asp?cid=3-2850 (accessed September 15, 2013).
- ⁸¹⁸ Wabano Centre for Aboriginal Health. National Centre of Excellence. <http://www.wabano.com/national-centre-of-excellence/> (accessed September 18, 2013).
- ⁸¹⁹ Sioux Lookout's Meno Ya Win Health Centre of Excellence for Aboriginal Health Care. <http://www.slmhc.on.ca/> (accessed September 16, 2013).
- ⁸²⁰ Memorial University Medical Center. Centers of Excellence: Seeking to Perfect the Patient's Experience. <http://memorialhealth.com/story-detail.aspx?id=3806> (accessed May 11, 2013).
- ⁸²¹ British Columbia Centre of Excellence for Women's Health. <http://www.bccewh.bc.ca/about-us/default.htm> (accessed May 11, 2013).
- ⁸²² The Networks of Centres of Excellence of Canada. http://www.nce-rce.gc.ca/index_eng.asp (accessed September 15, 2013).
- ⁸²³ Government of Canada. Networks Centres of Excellence. http://www.nce-rce.gc.ca/Index_eng.asp (accessed May 5, 2013).
- ⁸²⁴ National ME/FM Action Network. http://www.mefmaction.com/index.php?option=com_content&view=article&id=448:network-inquiry-to-cihr&catid=69:networknews&Itemid=287 (accessed September 16, 2013).
- ⁸²⁵ Institute of Medicine. Primary Care and Public Health: Exploring Integration to Improve Population Health. http://www.nationalahec.org/pdfs/PrimaryCareandPublicHealth_ReportBrief.pdf (accessed June 5 2013).
- ⁸²⁶ Association of Faculties of Medicine in Canada. <http://www.afmc.ca/social-public-health-e.php> (accessed June 6 2013).
- ⁸²⁷ University of Toronto. Dalla Lana School of Public Health. Divisions. Clinical Public Health. <http://www.dlsph.utoronto.ca/discipline/clinical-public-health> (accessed June 6 2013).
- ⁸²⁸ Liddy C. The Community Connection Model: implementation of best evidence into practice for self-management of chronic diseases. *Public Health*. 2013; 127(6):538-45.
- ⁸²⁹ Living Healthy Champlain. <http://www.livinghealthychamplain.ca/main.aspx?lang=en&nongraphical=false> (accessed June 6 2013).
- ⁸³⁰ Cooper K. Early exposures to hazardous chemicals/pollution and associations with chronic disease: a scoping review. A report from the Canadian Environmental Law Association, the Ontario College of Family Physicians and the Environmental Health Institute of Canada. 2011. <http://www.cela.ca/sites/cela.ca/files/EarlyExpandCDScopingReview-lowres.pdf> (accessed July 18 2012).
- ⁸³¹ Mt. Sinai Hospital. The best medicine matters, Summer 2013:15.
- ⁸³² Guyatt G. Users' Guides to the Medical Literature: A manual for evidence-based clinical practice, 2nd Edition, 2008, McGraw Hill.
- ⁸³³ Institute of Medicine (IOM) Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001. <http://www.nap.edu/openbook.php?isbn=0309072808>. (accessed March 19, 2013)
- ⁸³⁴ Centre for Evidence Based Medicine Toronto. <http://ktclearinghouse.ca/cebm/intro/whatisebm> (accessed March 8 2013)
- ⁸³⁵ Sackett DL. Evidence based medicine: what it is and what it isn't. *BMJ*. 1996; 312(7023): 71-72.
- ⁸³⁶ Ackerman Gulaid L. Lessons learnt from promising practices in community engagement for the elimination of new HIV infections in children by 2015 and keeping their mothers alive: summary of a desk review. *J Int AIDS Soc*. 2012; 15 Suppl 2:17390.
- ⁸³⁷ LaFrance AB. Creating an online "promising practices" clearinghouse for pandemic influenza. *Public Health Rep*. 2010; 125(5):634-41.
- ⁸³⁸ Howick J. The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document). Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/index.aspx?o=5653> (accessed June 7 2013).
- ⁸³⁹ Guyatt GH. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008; 336(7650):924-6
- ⁸⁴⁰ Health Quality Ontario. Evaluating the Quality of Evidence. <http://www.hqontario.ca/evidence/evidence-process/evidence-review-process/evaluating-the-quality-of-evidence> (accessed September 16, 2013).
- ⁸⁴¹ Guyatt GH. Going from evidence to recommendations. *BMJ*. 2008; 336:1049-1051.

- ⁸⁴² Battersby M. Twelve evidence-based principles for implementing self-management support in primary care. *Jt Comm J Qual Patient Saf.* 2010; 36(12):561-70.
- ⁸⁴³ Bodenheimer T. Helping patients improve their health-related behaviors: what system changes do we need? *Dis Manag.* 2005; 8:319–330.
- ⁸⁴⁴ Parchman ML. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. *Ann Fam Med.* 2007; 5:196–201.
- ⁸⁴⁵ Bonomi AE. Assessment of chronic illness care (ACIC): a practical tool to measure quality improvement. *Health Serv Res.* 2002; 37:791–820
- ⁸⁴⁶ Parchman ML. Glucose control, self-care behaviors, and the presence of the chronic care model in primary care clinics. *Diabetes Care.* 2007; 30:2849–54.
- ⁸⁴⁷ Swerissen H. A randomised trial of a self-management program for people with a chronic illness from Vietnamese, Chinese, Italian Greek backgrounds. *Patient Educ Couns.* 2006; 64: 360–68.
- ⁸⁴⁸ Johnston S. The patient's voice: an exploratory study of the impact of a group self-management support program. *BMC Fam Pract.* 2012; 13:65.
- ⁸⁴⁹ Epping-Jordan J. Improving the quality of health care for chronic conditions. *Qual Saf Health Care.* 2004; 13(4):299–305.
- ⁸⁵⁰ Wagner E. Improving chronic illness care: translating evidence into action. *Health Aff.* 2001; 20(6):64–78.
- ⁸⁵¹ Barlow J. Self-management approaches for people with chronic conditions: a review. *Patient Educ Couns.* 2002; 48(2):177-87
- ⁸⁵² Clark AM. Meta-analysis: secondary prevention programs for patients with coronary artery disease. *Ann Intern Med.* 2005; 143:659–672.
- ⁸⁵³ Peytremann-Bridevaux I. Effectiveness of chronic obstructive pulmonary disease-management programs: systematic review and meta-analysis. *Am J Med.* 2008; 121:433–443.
- ⁸⁵⁴ Gibson PG. Self-management education and regular practitioner review for adults with asthma. *Cochrane Database Syst Rev.* 2003;(2):CD001117.
- ⁸⁵⁵ Gary TL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. *Diabetes Educ.* 2003; 29:488–501.
- ⁸⁵⁶ Bodenheimer T. Patient self-management of chronic disease in primary care. *JAMA.* 2002; 288:2469–75.
- ⁸⁵⁷ McGowan P. The Chronic Disease Self-Management Program in British Columbia. J Dorland, McColl MA, Queen's University, Kingston, Ontario; 2007. pp. 79–90.
- ⁸⁵⁸ Jovicic A. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. *BMC Cardiovasc Disord.* 2006; 6:43.
- ⁸⁵⁹ Bourbeau J. Economic benefits of self-management education in COPD. *Chest.* 2006; 130:1704–11.
- ⁸⁶⁰ Lorig K. Self-management education: History, definition, outcomes and mechanisms. *Ann Behav Med.* 2003; 26(1):1–7.
- ⁸⁶¹ Glasgow RE. Self-management aspects of the improving chronic illness care breakthrough series: implementation with diabetes and heart failure teams. *Ann Behav Med.* 2002; 27:80–7.
- ⁸⁶² Norris SL. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. *Diabetes Care.* 2002; 25:1159–71.
- ⁸⁶³ Guadagnoli E. Patient participation in decision-making. *Soc Sci Med.* 1998; 47:329–39.
- ⁸⁶⁴ Anderson RM. Patient empowerment: reflections on the challenge of fostering the adoption of a new paradigm. *Pat Ed Counsel.* 2005; 57:153–7.
- ⁸⁶⁵ Aujoulat I. Patient empowerment in theory and practice: Polysemy or cacophony? *Pat Ed Counsel.* 2007; 66:13–20.
- ⁸⁶⁶ Aujoulat I. Reconsidering patient empowerment in chronic illness: A critique of models of self-efficacy and bodily control. *Soc Sci Med.* 2008; 66:1228–39.
- ⁸⁶⁷ Lorig K. Community-based peer-led diabetes self-management: a randomized trial. *Diabetes Educ.* 2009; 35:641–51.
- ⁸⁶⁸ Funnell MM. Patient Empowerment: A look back, a look head. *Diabetes Educ.* 2003; 29:454–64.
- ⁸⁶⁹ Friedman B. Patient satisfaction, empowerment, and health and disability status effects of a disease management-health promotion nurse intervention among Medicare beneficiaries with disabilities. *Gerontologist.* 2009; 49:778-792.

- ⁸⁷⁰ Anderson RM. Evaluating the efficacy of an empowerment-based self-management consultant intervention: Results of a two-year randomized controlled trial. *Ther Patient Educ*. 2009; 1:3-11.
- ⁸⁷¹ Viklund G. Assessment of an empowerment education programme. A randomized study in teenagers with diabetes. *Diabet Med*. 2007; 24:550-556.
- ⁸⁷² Cooper H. A trial of empowerment-based education in type 2 diabetes—global rather than glycaemic benefits. *Diabetes Res Clin Pract*. 2008; 82:165-171.
- ⁸⁷³ Stewart M. Towards a global definition of patient centred care. *BMJ*. 2001; 322(7284):444-5.
- ⁸⁷⁴ Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. 2001; National Academy Press. http://www.nap.edu/html/quality_chasm/reportbrief.pdf (accessed April 23, 2013).
- ⁸⁷⁵ Weiner SJ. Patient-centered decision making and health care outcomes: an observational study. *Ann Intern Med*. 2013; 158(8):573-9.
- ⁸⁷⁶ Rathert C. Patient-centered care and outcomes: A systematic review of the literature. *Med Care Res Rev*. 2013; 70(4):351-79.
- ⁸⁷⁷ Stewart M. The impact of patient-centered care on patient outcomes. *J Fam Pract*. 2000; 49:796-804.
- ⁸⁷⁸ Lewis S. Patient-Centred Care: An Introduction to What It Is and How to Achieve It: A discussion Paper for the Saskatchewan Ministry of Health. July 29, 2009.
- ⁸⁷⁹ Jones CS. Person-centered care. The heart of culture change. *J Gerontol Nurs*. 2011; 37(6):18-23.
- ⁸⁸⁰ Kon AA. The shared decision-making continuum. *JAMA*. 2010; 304(8):903-4.
- ⁸⁸¹ Starfield B. Is patient-centered care the same as person-focused care? *Perm J*. 2011; 15(2):63-9.
- ⁸⁸² Health Quality Ontario. bestPath. <http://www.hqontario.ca/bestpath> (accessed August 5, 2013).
- ⁸⁸³ Institute of Medicine Committee on Quality of Health Care in America, editor. Crossing the Quality Chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001.
- ⁸⁸⁴ Lumague M. Interprofessional education: the student perspective. *J Interprof Care*. 2008; 20:246-53.
- ⁸⁸⁵ Zwarenstein M. Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes. *Cochrane Database Syst Rev*. 2009 Jul 8;(3):CD000072.
- ⁸⁸⁶ Morrison S. Working together: why bother with collaboration? *Work Bas Learn Prim Care*. 2007; 5:65-70.
- ⁸⁸⁷ Canadian Interprofessional Health Collaborative. A national interprofessional competency framework. February 2010. Available from: http://www.cihc.ca/files/CIHC_IPCompetencies_Feb1210.pdf (accessed April 23, 2013).
- ⁸⁸⁸ Jeon YH.. Economic hardship associated with managing chronic illness: a qualitative enquiry. *BMC BMC Health Serv Res*. 2009; 9:182.
- ⁸⁸⁹ Jowsey T. Challenges for co-morbid chronic illness care and policy in Australia: a qualitative study. *Aust New Zealand Health Policy*. 2009; 8;6:22.
- ⁸⁹⁰ Jeon YH. Achieving a balanced life in the face of chronic illness. *Aust J Prim Health*. 2010; 16(1):66-74.
- ⁸⁹¹ Charles C. Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango). *Soc Sci Med*. 1997; 44(5):681-692.
- ⁸⁹² Weston WW. Informed and shared decision-making: The crux of patient-centered care. *CMAJ*. 2001; 165(4):438-439.
- ⁸⁹³ Adams JR. Shared decision-making and evidence-based practice. *Community Ment Health J*. 2006; 42(1):87-105.
- ⁸⁹⁴ Lown BA. Continuing professional development for interprofessional teams supporting patients in healthcare decision making. *J Interprof Care*. 2011 Nov;25(6):401-8.
- ⁸⁹⁵ Légaré F. Advancing theories, models and measurement for an interprofessional approach to shared decision making in primary care: a study protocol. *BMC Health Serv Res*. 2008; 8:2.
- ⁸⁹⁶ Bowling CB. Managing older adults with CKD: individualized versus disease-based approaches. *Am J Kidney Dis*. 2012; 59(2):293-302.
- ⁸⁹⁷ Piette JD. The impact of comorbid chronic conditions on diabetes care. *Diabetes Care*. 2006; 29(3):725-731.
- ⁸⁹⁸ Ritchie C. Health care quality and multimorbidity: the jury is still out. *Med Care*. 2007; 45(6):477-479.
- ⁸⁹⁹ MoHLTC. Ontario Health Technology Advisory Committee Recommendation, Specialized multidisciplinary community-based care, October 2009.
- ⁹⁰⁰ MoHLTC. Ontario Health Technology Advisory Committee Recommendation, Specialized multidisciplinary community-based care for chronic disease, November 2012.

- ⁹⁰¹ Treasury Board of Canada Secretariat. Department of National Defence. Archived-RPP 2007-2008. DND/Montfort Hospital Collaborative Arrangement <http://www.tbs-sct.gc.ca/rpp/2007-2008/nd-dn/nd-dn06-eng.asp> (accessed August 21, 2013).
- ⁹⁰² Halliday JL. Genetics and public health - evolution, or revolution? *J Epidemiol Community Health*. 2004; 58:894-899.
- ⁹⁰³ Hemminki K. The balance between heritable and environmental aetiology of human disease. *Nat Rev Genet*. 2006; 7(12):958-65.
- ⁹⁰⁴ Lichtenstein P. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med*. 2000; 343:78-85.
- ⁹⁰⁵ Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. *Cancer Epidemiol Biomarkers Prev*. 2005; 14:1847e50.
- ⁹⁰⁶ Centers for Disease Control and Prevention. Workplace Safety & Health Topics. Exposome and Exposomics. <http://www.cdc.gov/niosh/topics/exposome/> (accessed August 31, 2013).
- ⁹⁰⁷ Rappaport SM. Epidemiology. Environment and disease risk. *Science*. 2010; 33: 460–61.
- ⁹⁰⁸ Paoloni-Giacobino A. Post genomic decade--the epigenome and exposome challenges. *Swiss Med Wkly*. 2011; 141.
- ⁹⁰⁹ Quintrion http://www.quintrion-eu.com/QT02444_Catalog.pdf
- ⁹¹⁰ Joint OPHA /alPHA Health Equity Working Group. Activities to Address the Social Determinants of Health in Ontario Local Public Health Units: Summary Report. Toronto, ON, December 2010 http://c.ymcdn.com/sites/www.alphaweb.org/resource/collection/822EC60D-0D03-413E-B590-AFE1AA8620A9/OPHA-alPHA_report_ActivitiestoAddresstheSocialDeterminants__16-12-3210.pdf (accessed September 16 2013).
- ⁹¹¹ Fukuda K. Chronic Fatigue Syndrome: a comprehensive approach to its definition and study. *Ann Intern Med*. 1994; 121:953–9.
- ⁹¹² Fitzcharles MA. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome. http://www.canadianpainsociety.ca/pdf/Fibromyalgia_Guidelines_2012.pdf (accessed August 21, 2013).
- ⁹¹³ Carruthers BM. Myalgic encephalomyelitis/chronic fatigue syndrome. Clinical working case definition, diagnostic and treatment protocols. *J Chronic Fatigue Syndrome*. 2003; 11 (1):7-115.
- ⁹¹⁴ Grune T. Markers of oxidative stress in ICU clinical settings: present and future. *Curr Opin Clin Nutr Metab Care*. 2007; 10:712–717.
- ⁹¹⁵ Comparison of different methods of measuring 8-oxoguanine as a marker of oxidative DNA damage. ESCODD (European Standards Committee on Oxidative DNA Damage). *Free Radic Res* 2000; 32:333–341.
- ⁹¹⁶ Breusing N. Biomarkers of protein oxidation from a chemical, biological and medical point of view. *Exp Gerontol*. 2010; 45(10):733-7.
- ⁹¹⁷ Lee R. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. *Curr Med Chem*. 2012; 19(16):2504-20.
- ⁹¹⁸ Stephens JW. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. *Atherosclerosis*. 2009; 202(2):321-9.
- ⁹¹⁹ Moller P, and Loft S. Oxidative damage to DNA and lipids as biomarkers of exposure to air pollution. *Environ Health Perspect*. 2010; 118:1126-1136.
- ⁹²⁰ Jacob KD. Markers of oxidant stress that are clinically relevant in aging and age-related disease. *Mech Ageing Dev*. 2013; 134(3-4):139-57.
- ⁹²¹ Tucker PS. Clinical and research markers of oxidative stress in chronic kidney disease. *Biomarkers*. 2013; 18(2):103-15.
- ⁹²² Lanza IR. Mitochondrial metabolic function assessed in vivo and in vitro. *Curr Opin Clin Nutr Metab Care*. 2010; 13(5):511-7.
- ⁹²³ Marshall NJ. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. *Growth Regul*. 1995; 5(2):69-84.
- ⁹²⁴ Brand MD. Assessing mitochondrial dysfunction in cells. *Biochem J*. 2011; 435(Pt 2):297–312.
- ⁹²⁵ Finsterer J. Fatigue in Healthy and Diseased Individuals. *Am J Hosp Palliat Care*. 2013 Jul 26. (ahead of print).
- ⁹²⁶ Hewlett S. Measures of fatigue. Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAFMQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAFNRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-

Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). *Arthritis Care Res.* 2011 Nov;63 Suppl 11:S263-86.

⁹²⁷ Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. *Clin Exp Rheumatol.* 2005 Sep-Oct;23(5 Suppl 39):S154-62.

⁹²⁸ White KP. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. 2002 *Arthritis Rheum* 47: 260-265.

⁹²⁹ Henriksson C. Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. *Disabil Rehabil* 1996 18:241-248

⁹³⁰ White KP. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the Long Fibromyalgia Epidemiology. *Arthritis Rheum* 1999 42:76-83

⁹³¹ Williams DA. Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). *Arthritis Care Res.* 2011 Nov;63 Suppl 11:S86-97.

⁹³² van Wilgen CP. Not throwing out the baby with the bathwater: lessons from the Fibromyalgia Impact Questionnaire. *Clin Rheumatol.* 2013; 32(3):333-9.

⁹³³ Bennett RM. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. *Arthritis Res Ther.* 2009; 11(4):R120.

⁹³⁴ Ware JE Jr, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.

⁹³⁵ Hopman WM. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. *CMAJ* 2000;163(3):265-71.

⁹³⁶ Hopman WM. Stability of normative data for the SF-36: results of a three-year prospective study in middle-aged Canadians. *Can J Public Health* 2004;95(5):387-9

⁹³⁷ Komaroff AL. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. *Am J Med* 1996;101(3):281-90.

⁹³⁸ Hardt J. Health-related quality of life in patients with chronic fatigue syndrome: an international study. *J Psychosom Res* 2001;51(2):431-4.

⁹³⁹ Herrell R. Chronic fatigue and chronic fatigue syndrome: a co-twin control study of functional status. *Qual Life Res* 2002;11(5):463-71.

⁹⁴⁰ Alanoglu E. Auditory event-related brain potentials in fibromyalgia syndrome. *Rheumatol Int* 2005;25(5):345-9. Epub 2004 Feb 21.

⁹⁴¹ Neumann L. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). *Semin Arthritis Rheum* 2000;29(6):400-8.

⁹⁴² Bergman S. Psychosocial aspects of chronic widespread pain and fibromyalgia. *Disabil Rehabil* 2005;27(12):675-83

⁹⁴³ Black DW. Quality of life and health-services utilization in a population-based sample of military personnel reporting multiple chemical sensitivities. *J Occup Environ Med* 1999;41(10):928-33.

⁹⁴⁴ Jason LA. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms. *Psychosom Med* 2000;62(5):655-63.

⁹⁴⁵ IACFS. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. ME/CFS: A Primer for Clinical Practitioners. 2012; pg 37. <http://www.iacfsme.org/Home/Primer/tabid/509/Default.aspx> (accessed April 4 2013)

⁹⁴⁶ Karnofsky Energy Rating Scale adapted for use in ME/CFS. From Bell DS. (1995) *The Doctor's Guide to Chronic Fatigue Syndrome*, Boston, MA. Adapted further by Dr. Ellie Stein.

⁹⁴⁷ Thomas M. An investigation into the cognitive deficits associated with chronic fatigue syndrome. *Open Neurol J.* 2009; 3:13-23.

⁹⁴⁸ Busichio K. Neuropsychological deficits in patients with chronic fatigue syndrome. *J Int Neuropsychol Soc.* 2004; 10(2):278-85.

⁹⁴⁹ Majer M. Neuropsychological performance in persons with chronic fatigue syndrome: results from a population-based study. *Psychosom Med.* 2008; 70(7):829-36.

⁹⁵⁰ Glass JM. Review of cognitive dysfunction in fibromyalgia: a convergence on working memory and attentional control and impairments. *Rheum Dis Clin N Am.* 2009; 35:299-311.

- ⁹⁵¹ McKeown-Eyssen GE. Multiple chemical sensitivity: discriminant validity of case definitions. *Arch Environ Health*. 2001; 56(5):406-412.
- ⁹⁵² White PD. Protocol for the PACE trial: a randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. *BMC Neurol*. 2007;7:6.
- ⁹⁵³ Rossy LA. A meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med*. 1999; 21(2): 180-91.
- ⁹⁵⁴ Dickenson A. Pain and its control. *Curr Med Res Opin*. 2011; 27:2075-8.
- ⁹⁵⁵ Perrot S. Fibromyalgia: harmonizing science with clinical practice considerations. *Pain Pract*. 2008; 8:177-89.
- ⁹⁵⁶ Moore RA. Amitriptyline for neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev*. 2012; 12:CD008242.
- ⁹⁵⁷ Mercier A. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: an analysis of guidelines and systematic reviews. *BMC Fam Pract*. 2013; 14:55.
- ⁹⁵⁸ Häuser W. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. *CNS Drugs*. 2012; 26(4):297-307.
- ⁹⁵⁹ Häuser W. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. *J Pain*. 2010; 11(6):505-21.
- ⁹⁶⁰ Fitzcharles MA. Canadian Pain Society and Canadian Rheumatology Association Recommendations for Rational Care of Persons with Fibromyalgia. A Summary Report. *J Rheumatol*. 2013; 40(8):1388-1393.
- ⁹⁶¹ Häuser W. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. *Arthritis Res Ther*. 2010;12:R79.
- ⁹⁶² Langhorst J. Efficacy of hydrotherapy in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. *Rheumatol (Oxford)*. 2009; 48:1155-9.
- ⁹⁶³ Häuser W. Efficacy of multicomponent treatment of fibromyalgia syndrome: a meta-analysis of randomised controlled trials. *Arthritis Rheum*. 2009; 61:216-24.
- ⁹⁶⁴ Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite; Med Hypotheses. 2001; 57(2):139-145.
- ⁹⁶⁵ Gibson PR. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity. *Environ Health Perspect*. 2003; 111:1498-1504.
- ⁹⁶⁶ Upshur RE. Chronicity and complexity: is what's good for the diseases always good for the patients? *Can Fam Physician*. 2008; 54(12):1655-8.
- ⁹⁶⁷ Upshur Ross E.G. Can family physicians practise good medicine without following clinical practice guidelines? YES. *Can Fam Physician*. 2010; 56(6):518-520.
- ⁹⁶⁸ Sterman MB. Basic concepts and clinical findings in the treatment of seizure disorders with EEG operant conditioning. *Clin Electroencephalogr*. 2000; 31(1):45-55.
- ⁹⁶⁹ Nowlis DP. The control of electroencephalographic alpha rhythms through auditory feedback and the associated mental activity. *Psychophysiology*. 1970; 6(4):476-484.
- ⁹⁷⁰ Logothetis NK. Neurophysiological investigation of the basis of the fMRI signal. *Nature*. 2001; 412:150-157.
- ⁹⁷¹ Caria A. Real-time fMRI: a tool for local brain regulation. *Neuroscientist*. 2012; 18(5):487-501.
- ⁹⁷² Cox RW. Real-time functional magnetic resonance imaging. *Magn. Reson. Med*. 1995; 33:230-236.
- ⁹⁷³ deCharms RC. Applications of real-time fMRI. *Nat Rev Neurosci*. 2008; 9(9):720-729.
- ⁹⁷⁴ Weiskopf N. Selfregulation of local brain activity using real-time functional magnetic resonance imaging (fMRI). *J Physiol Paris*. 2004; 98(4-6):357-373.
- ⁹⁷⁵ Yoo SS. Braincomputer interface using fMRI: spatial navigation by thoughts. *Neuroreport*. 2004; 15(10):1591-1595.
- ⁹⁷⁶ deCharms RC. Control over brain activation and pain learned by using real-time functional MRI. *Proc Natl Acad Sci USA*. 2005; 102(51):18626-18631.
- ⁹⁷⁷ Weiskopf N. Physiological self-regulation of regional brain activity using real-time functional magnetic resonance imaging (fMRI): methodology and exemplary data. *Neuroimage*. 2003; 19(3):577-586.
- ⁹⁷⁸ Zotev V. Self-regulation of amygdala activation using real-time FMRI neurofeedback. *PLoS One*. 2011; 6(9):e24522.
- ⁹⁷⁹ Levesque J. Effect of neurofeedback training on the neural substrates of selective attention in children with attention-deficit/hyperactivity disorder: a functional magnetic resonance imaging study. *Neurosci Lett*. 2006; 394:216-224.

- ⁹⁸⁰ Johnston SJ. Neurofeedback: A promising tool for the self-regulation of emotion networks. *Neuroimage*. 2010; 49(1):1066-72.
- ⁹⁸¹ Chapin H. Real-time fMRI applied to pain management. *Neurosci Lett*. 2012; 520(2):174-81
- ⁹⁸² Weiskopf N. Real-time fMRI and its application to neurofeedback. *Neuroimage*. 2012; 62(2):682-92.
- ⁹⁸³ Derbyshire SW. A systematic review of neuroimaging data during visceral stimulation. *Am J Gastroenterol*. 2003; 98:12–20.
- ⁹⁸⁴ Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. *Gastroenterol Clin North Am*. 2011; 40(1):21-43.
- ⁹⁸⁵ Hall GB.(2010).Heightened central affective response to visceral sensations of pain and discomfort in IBS. *Neurogastroenterol Motil*. 2010; 22:276-e80.
- ⁹⁸⁶ Cryan JF. The microbiome-gut-brain axis: from bowel to behavior. *Neurogastroenterol Motil* 2011; 23 187–192.
- ⁹⁸⁷ Foster JA. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci*. 2013; 6(5):305-12.
- ⁹⁸⁸ Forsythe P. On communication between gut microbes and the brain. *Curr Opin Gastroenterol*. 2012; 28(6):557-62.
- ⁹⁸⁹ Maier SF. Psychoneuroimmunology. The interface between behavior, brain, and immunity. *Am Psychol*. 1994; 49(12):1004-17.
- ⁹⁹⁰ Ziemssen T. Psychoneuroimmunology--cross-talk between the immune and nervous systems. *J Neurol*. 2007; 254 Suppl 2:I18-11.
- ⁹⁹¹ Irwin MR. Human psychoneuroimmunology: 20 years of discovery. *Brain Behav Immun*. 2008; 22(2):129-39.
- ⁹⁹² Haas HS. Neuroimmunomodulation via limbic structures--the neuroanatomy of psychoimmunology. *Prog Neurobiol*. 1997; 51(2):195-222.
- ⁹⁹³ Menzies V. Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. *Biol Res Nurs*. 2010; 11:387–394.
- ⁹⁹⁴ Üceyler N. Systemic review with meta-analysis: cytokines in fibromyalgia syndrome. *BMC Musculoskeletal Disorders*. 2011; 12:245.
- ⁹⁹⁵ Chapenko S. Activation of human herpesviruses 6 and 7 in patients with chronic fatigue syndrome. *J Clin Virol*. 2006; 37 Suppl 1:S47-51.
- ⁹⁹⁶ Bjorn G. Is chronic fatigue syndrome caused by a rare brain infection of a common, normally benign virus? *Med Hypotheses*. 2008; 71:270–4.
- ⁹⁹⁷ Hickie I. Prospective cohort study precipitated by viral and nonviral pathogens: post-infective and chronic fatigue syndromes. *BMJ*. 2006; 333:575.
- ⁹⁹⁸ Maher KJ. Chronic fatigue syndrome is associated with diminished intracellular perforin. *J Clin Exp Immunol*. 2005; 142:505–11.
- ⁹⁹⁹ Cameron B. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome. *J Med Virol*. 2010 Oct;82(10):1684-8.
- ¹⁰⁰⁰ Lorusso L. Immunological aspects of chronic fatigue syndrome. *Autoimmun Rev*. 2009; 8(4):287-91.
- ¹⁰⁰¹ Di Franco M. Neuroendocrine immunology of fibromyalgia. *Ann N Y Acad Sci*. 2010; 1193:84–90.
- ¹⁰⁰² Kotter I. Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. *Rheumatol Int*. 2007; 27:1031–1039.
- ¹⁰⁰³ Pamuk ON. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. *Clin. Rheumatol*. 2007; 26: 55–59.
- ¹⁰⁰⁴ Middleton GD. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. *Arthritis Rheum*. 1994; 37:1181–1188.
- ¹⁰⁰⁵ . Morand EF. Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. *Lupus*.1994; 3: 187–191.
- ¹⁰⁰⁶ Morand EF. Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. *Lupus*.1994; 3: 187–191.
- ¹⁰⁰⁷ Wolfe F. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. *J. Rheumatol*. 2004; 1:695–700.
- ¹⁰⁰⁸ Costa-Pinto FA. Neural correlates of IgE-mediated allergy. *Ann N Y Acad Sci*. 2006; 1088:116-31.
- ¹⁰⁰⁹ Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. *Environ Health Perspect*. 1993; 101:234-238.


- ¹⁰¹⁰ Verones B. Neurogenic inflammation and particulate matter (PM) air pollutants. *Neurotoxicology*. 2001; 22(6):795-810.
- ¹⁰¹¹ Groneberg DA. Neurogenic mechanisms in bronchial inflammatory diseases. *Allergy*. 2004; 59(11):1139-52.
- ¹⁰¹² Elberling J. Airborne chemicals cause respiratory symptoms in individuals with contact allergy. *Contact Dermatitis*. 2005; 52(2):65-72.
- ¹⁰¹³ Martin SF. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. *Allergy*. 2011; 66:1152–1163.
- ¹⁰¹⁴ Corsini, E. Role of oxidative stress in chemical allergens induced skin cells activation. *Food Chem. Toxicol*. 2013; Feb 27 (ahead of print).
- ¹⁰¹⁵ Crofford LJ. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. *Brain Behav Immun*. 2004; 18:314–325.
- ¹⁰¹⁶ Tak LM. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. *Biol. Psychol*. 2011; 87:183–194.
- ¹⁰¹⁷ Di Giorgio A. 24-hour pituitary and adrenal hormone profiles in chronic fatigue syndrome. *Psychosom Med*. 2005; 67:433–440.
- ¹⁰¹⁸ Jerjes WK. Diurnal patterns of salivary cortisol and cortisone output in chronic fatigue syndrome. *J Affect Disord*. 2005; 87:299–304.
- ¹⁰¹⁹ Papadopoulos AS. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. *Nat Rev Endocrinol*. 2011; 8(1):22-32.
- ¹⁰²⁰ Riva R. Fibromyalgia syndrome is associated with hypocortisolism. *Int J Behav Med*. 2010; 17(3):223-33.
- ¹⁰²¹ Riva R. Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. *Psychoneuroendocrinology*. 2012; 37(2):299-306.
- ¹⁰²² Gaab J. Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. *Psychosom. Med*. 2002; 64, 311–318.
- ¹⁰²³ Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. *Endocr Rev*. 2003; 24:236–252.
- ¹⁰²⁴ Jerjes WK. Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. *Psychoneuroendocrinology* 2007; 32:192–198.
- ¹⁰²⁵ Van Den Eede F. Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. *Psychol Med*. 2008; 38:963–973.
- ¹⁰²⁶ Reid SF. Chronic fatigue syndrome. *Clin Evid*. (Online) pii, 1101 (2011).
- ¹⁰²⁷ Van Houdenhove B. Does hypothalamic-pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect a ‘crash’ in the stress system? *Med Hypotheses*. 2009; 72:701–705.
- ¹⁰²⁸ Roberts AD. Salivary cortisol output before and after cognitive behavioural therapy for chronic fatigue syndrome. *J Affect Disord*. 2009; 115:280–286.
- ¹⁰²⁹ Jason L. Baseline cortisol levels predict treatment outcomes in chronic fatigue syndrome non-pharmacologic clinical trial. *J Chronic Fatigue Syndr*. 2007; 14:39–59.
- ¹⁰³⁰ Roberts AD. Does hypocortisolism predict a poor response to cognitive behavioural therapy in chronic fatigue syndrome? *Psychol Med*. 2010; 40:515–522.
- ¹⁰³¹ Maloney EM. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. *Metabolism*. 2010; 59(9):1351-7.
- ¹⁰³² Arranz L. Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. *Rheumatol Int*. 2012; 32(11):3605-11.
- ¹⁰³³ Flores S. Examining the impact of obesity on individuals with chronic fatigue syndrome. *Workplace Health Saf*. 2013; 61(7):299-307.
- ¹⁰³⁴ Kim CH. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. *Arthritis Care Res*. 2012; 64(2):222-8.
- ¹⁰³⁵ Arranz L. Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. *Rheumatol Int*. 2012; 32(11):3605-11.
- ¹⁰³⁶ Okifuji A. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. *J Pain*. 2010; 11(12):1329-37.
- ¹⁰³⁷ Cordero MD. Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. *Rheumatol Int*. 2013 Jan 3; (ahead of print).
- ¹⁰³⁸ Elgen I. CFS in Children and Adolescent: Ten Years of Retrospective Clinical Evaluation. *Int J Pediatr*. 2013; 2013:270373.

- ¹⁰³⁹ D Petrov. Factors affecting duration of chronic fatigue syndrome in pediatric patients,”. *Ind J Pediatr*, 2012; 79(1):52–55.
- ¹⁰⁴⁰ Rauma A. Antioxidant status in long-term adherents to a strict uncooked vegan diet. *Am Soc Clin Nutr*. 1995; 62:1221–1227.
- ¹⁰⁴¹ Szeto YT. Effects of a long-term vegetarian diet on biomarkers of antioxidant status and cardiovascular disease risk. *Nutrition*. 2004; 20:863–866.
- ¹⁰⁴² Dewell A. A very-low-fat vegan diet increases intake of protective dietary factors and decreases intake of pathogenic dietary factors. *J Am Diet Assoc*. 2008; 108(2):347-56.
- ¹⁰⁴³ Benzie IFF. Vegetarian diets and public health: biomarker and redox connections. *Antioxid Redox Signal*. 2010; 13(10): 1575-1591.
- ¹⁰⁴⁴ Benzie IFF. Evolution of dietary antioxidants. *Comp Biochem Physiol A Mol Integr Physiol* 136: 113–126, 2003.
- ¹⁰⁴⁵ Bonaccio M. Adherence to a Mediterranean diet is associated with a better health-related quality of life: a possible role of high dietary antioxidant content. *BMJ Open*. 2013; 3(8).
- ¹⁰⁴⁶ Fujita S. Effect of Waon therapy on oxidative stress in chronic heart failure. *Circ J*. 2011; 75(2):348-56.
- ¹⁰⁴⁷ Kawaura A. The effect of leg hyperthermia using far infrared rays in bedridden subjects with type 2 diabetes mellitus. *Acta Med Okayama*. 2010; 64(2):143-7.
- ¹⁰⁴⁸ Masuda A. Repeated sauna therapy reduced urinary 8-epi-prostaglandin-F2a. *Jpn Heart J*. 2004; 45:297-303.
- ¹⁰⁴⁹ Ikeda Y. Repeated thermal therapy upregulates arterial endothelial nitric oxide synthase expression in Syrian golden hamsters. *Jpn Circ J*. 2001; 65:434-8.
- ¹⁰⁵⁰ Sears ME. Chelation: harnessing and enhancing heavy metal detoxification--a review. *ScientificWorldJournal*. 2013; 2013:219840.
- ¹⁰⁵¹ Flora SJ. Heavy metal induced oxidative stress & its possible reversal by chelation therapy. *Indian J Med Res*. 2008; 128(4):501-23.
- ¹⁰⁵² Bradley AS. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. *Clin Exp Immunol*. 2013; 172(1):73-80.
- ¹⁰⁵³ Fluge Ø. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. *PLoS One*. 2011;6(10):e26358.
- ¹⁰⁵⁴ Roizenblatt S. Alpha sleep characteristics in fibromyalgia. *Arthritis Rheum*. 2001; 44(1):222–230.
- ¹⁰⁵⁵ Development and testing of the Fibromyalgia Diagnostic Screen for primary care. Arnold LM. *J Women's Health*. 2012; 21(2):231-239.
- ¹⁰⁵⁶ Matsushita K. Efficacy of Waon therapy for fibromyalgia. *Intern Med*. 2008; 47(16):1473-6.
- ¹⁰⁵⁷ Langhorst J. Efficacy of hydrotherapy in fibromyalgia syndrome--a meta-analysis of randomized controlled clinical trials. *Rheumatology*. 2009; 48(9):1155-9.
- ¹⁰⁵⁸ Fraioli A. Clinical researches on the efficacy of spa therapy in fibromyalgia. A systematic review. *Ann Ist Super Sanita*. 2013; 49(2):219-29.
- ¹⁰⁵⁹ Guidelli GM. Fibromyalgia syndrome and spa therapy: myth or reality? *Clin Med Insights Arthritis Musculoskelet Disord*. 2012; 5:19-26.
- ¹⁰⁶⁰ Ozkurt S. Balneotherapy in fibromyalgia: a single blind randomized controlled clinical study. *Rheumatol Int*. 2012; 32(7):1949-54.
- ¹⁰⁶¹ Ali A. Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study. *J Altern Complement Med*. 2009; 15(3):247-57.
- ¹⁰⁶² Gaby AR. Intravenous nutrient therapy: the "Myers' cocktail". *Altern Med Rev*. 2002; 7(5):389-403.
- ¹⁰⁶³ Yildiz S. Hyperbaric oxygen therapy in chronic pain management. *Curr Pain Headache Rep*. 2006; 10(2):95-100.
- ¹⁰⁶⁴ Kiralp MZ. A novel treatment modality for myofascial pain syndrome: hyperbaric oxygen therapy. *J Natl Med Assoc*. 2009; 101(1):77-80.
- ¹⁰⁶⁵ Yildiz S. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. *J Int Med Res*. 2004; 32(3):263-7.
- ¹⁰⁶⁶ Li CT. Efficacy and practical issues of repetitive transcranial magnetic stimulation on chronic medically unexplained symptoms of pain. *Acta Anaesthesiol Taiwan*. 2013; 51(2):81-7.
- ¹⁰⁶⁷ Marlow NM. Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. *Pain Pract*. 2013; 13(2):131-45.
- ¹⁰⁶⁸ Chapin H. Real-time fMRI applied to pain management. *Neurosci Lett*. 2012; 520(2):174-81.

- ¹⁰⁶⁹ Mayhew E. Acupuncture for fibromyalgia--a systematic review of randomized clinical trials. *Rheumatology*. 2007; 46(5):801-4.
- ¹⁰⁷⁰ Bastos JL. Effect of acupuncture at tender points for the management of fibromyalgia syndrome: a case series. *J Acupunct Meridian Stud*. 2013; 6(3):163-8.
- ¹⁰⁷¹ Deare JC. Acupuncture for treating fibromyalgia. *Cochrane Database Syst Rev*. 2013 May 31; 5:CD007070.
- ¹⁰⁷² Langhorst J. [Complementary and alternative therapies for fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. [Article in German]. *Schmerz*. 2012; 26(3):311-7. Abstract only
- ¹⁰⁷³ Terhorst L. Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. *J Manipulative Physiol Ther*. 2011; 34(7):483-96.
- ¹⁰⁷⁴ Schmidt S. Treating fibromyalgia with mindfulness-based stress reduction: results from a 3-armed randomized controlled trial. *Pain*. 2011; 152(2):361-9.
- ¹⁰⁷⁵ Younger J. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. *Arthritis Rheum*. 2013; 65(2):529-38.
- ¹⁰⁷⁶ Genuis SJ. Elimination of persistent toxicants from the human body. *Hum Exp Toxicol*. 2011; 30(1):3-18
- ¹⁰⁷⁷ Jandacek RJ. Enterohepatic circulation of organochlorine compounds: a site for nutritional intervention. *J Nutr Biochem* 2007; 18:163–167.
- ¹⁰⁷⁸ Makino K. Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma – case report. *Neurol Med Chir (Tokyo)* 2005; 45:650–652.
- ¹⁰⁷⁹ Cohn WJ. Treatment of chlordecone (Kepone) toxicity with cholestyramine. Results of a controlled clinical trial. *N Engl J Med* 1978; 298:243–248.
- ¹⁰⁸⁰ . Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium perfluorooctanoate or potassium perfluorooctanesulfonate. *Fundam Appl Toxicol* 1984; 4:972–6.
- ¹⁰⁸¹ Cohn WJ. Treatment of chlordecone (Kepone) toxicity with cholestyramine. Results of a controlled clinical trial. *N Engl J Med* 1978; 298:243–248
- ¹⁰⁸² Genuis SJ. Human detoxification of perfluorinated compounds. *Public Health*. 2010; 124(7):367-75
- ¹⁰⁸³ Arguin H. Impact of adopting a vegan diet or an olestra supplementation on plasma organochlorine concentrations: results from two pilot studies. *Br J Nutr*. 2010; 103(10):1433-41
- ¹⁰⁸⁴ Jandacek RJ. Enterohepatic circulation of organochlorine compounds: a site for nutritional intervention. *J Nutr Biochem* 2007; 18:163–167
- ¹⁰⁸⁵ Geusau A. Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzop-dioxin. *Lancet* 2009; 354:1266–1267.
- ¹⁰⁸⁶ Redgrave TG. Treatment with a dietary fat substitute decreased Arochlor 1254 contamination in an obese diabetic male. *J Nutr Biochem* 2005; 16:383–384.
- ¹⁰⁸⁷ Eastwood MA. Fibre and enterohepatic circulation. *Nutr Rev*. 1977; 35(3):42-4.
- ¹⁰⁸⁸ Lovejoy HB. Mercury exposure evaluations and their correlation with urine mercury excretions. 4. Elimination of mercury by sweating. *J Occup Med*. 1973; 15(7):590-1.
- ¹⁰⁸⁹ Pärpalei IA. The use of the sauna for disease prevention in the workers of enterprises with chemical and physical occupational hazards. *Vrach Delo*. 1991; (5):93-5.
- ¹⁰⁹⁰ Fucci N. Sweat testing in addicts under methadone treatment: an Italian experience. *Forensic Sci Int* 2008; 174:107–110
- ¹⁰⁹¹ Huestis MA. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. *J Anal Toxicol*. 2000; 24(7):509-21.
- ¹⁰⁹² Huestis MA. Sweat testing for cocaine, codeine and metabolites by gas chromatography-mass spectrometry. *J Chromatogr B Biomed Sci Appl*. 1999; 733(1-2):247-64.
- ¹⁰⁹³ Schwilke EW. Opioid disposition in human sweat after controlled oral codeine administration. *Clin Chem*. 2006; 52(8):1539-45
- ¹⁰⁹⁴ Barnes AJ. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. *Clin Chem* 2008; 54:172–180.
- ¹⁰⁹⁵ Thompson D. Physical activity and exercise in the regulation of human adipose tissue physiology. *Physiol Rev*. 2012 ; 92(1):157-91.
- ¹⁰⁹⁶ Ranallo RF. Lipid metabolism during exercise. *Sports Med*. 1998; 26(1):29-42.
- ¹⁰⁹⁷ Findlay GM. DDT movement from adipocyte to muscle cell during lipid utilization. *Nature* 1971; 229:63.
- ¹⁰⁹⁸ Schnare DW. Reduction of the human body burdens of hexachlorobenzene and polychlorinated biphenyls. *IARC Sci Publ*. 1986;(77):597-603

- ¹⁰⁹⁹ Dahlgren J. Persistent organic pollutants in 9/11 world trade center rescue workers: reduction following detoxification. *Chemosphere*. 2007; 69(8):1320-5
- ¹¹⁰⁰ Schnare DW. Body burden reduction of PCBs, PBBs and chlorinated pesticides in human subjects. *Ambio* 1984; 13:378–380
- ¹¹⁰¹ Ross GH. Methamphetamine exposure and chronic illness in police officers: significant improvement with sauna-based detoxification therapy. *Toxicol Ind Health*. 2012 Jan 24 (ahead of print)
- ¹¹⁰² Rea WJ. Reduction of chemical sensitivity by means of heat depuration, physical therapy and nutritional supplementation. *J Nutr Env Med* 1996; 6:141–148.
- ¹¹⁰³ Tretjak Z. PCB reduction and clinical improvement by detoxification: an unexploited approach? *Hum Exp Toxicol* 1990; 9(4):235–244.
- ¹¹⁰⁴ Crinnion W. Components of practical clinical detox programs—sauna as a therapeutic tool. *Altern Ther Health Med* 2007; 13(2):S154–S156
- ¹¹⁰⁵ Marshall L. Identifying and managing adverse environmental health effects: 1. Taking an exposure history. *CMAJ*. 2002; 166(8):1049-55
- ¹¹⁰⁶ Canberra Hospital and Health Services. Standard Operating Procedure. Multiple Chemical Sensitivities (MCS) - Care of Patients. <http://www.health.act.gov.au/c/health?a=dlpubpoldoc&document=2787> (accessed September 2, 2013).
- ¹¹⁰⁷ Government of South Australia. Guidelines for South Australian hospitals. Multiple Chemical Sensitivity (MCS). 2010;
- ¹¹⁰⁸ Marshall LM. Environmental Health in Hospital. Canadian Society for Environmental Medicine . A Practical Guide for Hospital Staff. Part I: Pollution Prevention. Copies available from the Environmental health Clinic. Women's College Hospital.
- ¹¹⁰⁹ Marshall LM. Environmental Health in Hospital. Canadian Society for Environmental Medicine . A Practical Guide for Hospital Staff. Part II: Environment-sensitive Care. Copies available from the Environmental health Clinic. Women's College Hospital.
- ¹¹¹⁰ International Association of Chronic Fatigue Syndrome- Myalgic Encephalomyelitis. CFS-ME Primer for Clinical Practitioners, 2012: 40-41.
- ¹¹¹¹ Howard Hu. Personal communication. September 19, 2013.
- ¹¹¹² Stanford Chronic Disease Self-Management Trainings <http://patienteducation.stanford.edu/training/> (accessed June 6 2013)
- Leaders Teach / Facilitate community workshops for people with chronic diseases;
 - Master Trainers In addition to what Leaders do, Master Trainers train Leaders
 - T-Trainers In addition to what Master Trainers do, T-Trainers train Master Trainers
- ¹¹¹³ Liddy C. The Community Connection Model: implementation of best evidence into practice for self-management of chronic diseases. *Public Health*. 2013; 127(6):538-45.
- ¹¹¹⁴ National Research Council. http://www.nrc-cnrc.gc.ca/eng/solutions/facilities/material_emissions.html (accessed September 2, 2013)
- ¹¹¹⁵ Franchi M. Working towards healthy air in dwellings in Europe. *Allergy*. 2006; 61(7):864-8.
- ¹¹¹⁶ Logue JM. Hazard assessment of chemical air contaminants measured in residences. *Indoor Air* 2011; 21:92-109.
- ¹¹¹⁷ Rafuse J. Practical application of air-quality research incorporated in CMHC's research house. *CMAJ*. 1995; 152(8):1310-1.
- ¹¹¹⁸ Environmental Health Center-Dallas. <http://www.ehcd.com/ehc-d-patient-less-toxic-housing-services/> (accessed September 8 2013).
- ¹¹¹⁹ Berthelot JM. Access to health care services in Canada, January to December 2005. Ottawa (ON): Statistics Canada; 2006. Report No.: 82-575-XIE.
- ¹¹²⁰ Hjelm NM. Benefits and drawbacks of telemedicine. *J Telemed Telecare*. 2005; 11(2):60–70.
- ¹¹²¹ Liddy C. Building access to specialist care through e-consultation. *Open Med*. 2013 Jan 8;7(1):e1-8.
- ¹¹²² Howard Hu. Personal Communication. September 19, 2013.
- ¹¹²³ Government of Ontario. Excellent Care for All Act, 2010; S.O. 2010, e-laws Ontario.

APPENDIX A



***Overlapping diagnoses
For 23 Chronic Condition Cohorts
Source: Canadian Community Health Survey 2005***

The Canadian Community Health Survey (CCHS) is an important source of information about health issues in Canada. Statistics Canada released survey results for 2005 in database format on a "Public Use Micro-data File". Data have been extracted from this file .

The target population of CCHS 2005 was Canadians age 12 and up, with several exclusions:

- persons living on Indian Reserves
- residents of institutions
- full time members of Canadian Armed Forces
- residents of certain remote regions.

Overall, there were 27,126,165 Canadians in the target population. This is about 98% of Canadians age 12 and up.

Statistics Canada interviewed 132,221 Canadians (about 1 in every 200 members of the target population). Respondents were asked a series of health related questions. Their responses were weighted to arrive at estimates for the target population.

Respondents were asked about chronic health conditions as follows:

"Now I'd like to ask you about certain chronic health conditions which you may have. We are interested in long term conditions, which are expected to last or have already lasted 6 months or more and that have been diagnosed by a health professional. Do you have".

Respondents were read a list of chronic health conditions and asked to respond to each one. Possible answers include yes, no, don't know, refuse, and not stated. The chronic condition cohorts in this fact-sheet include only those people who responded "yes" to that condition. The same individual may be included in several chronic condition cohorts.

It is very important to remember that CCHS data is based on self-reporting of diagnosis. The data may or may not reflect how many people actually have the chronic condition. Note also that the statistics are based on sampling and therefore are only estimates.

CCHS was not conducted in 2006. It was conducted in 2007, 2008 and 2009 but the questions on Chronic Fatigue Syndrome, Fibromyalgia and Multiple Chemical Sensitivities were omitted.

The National ME/FM Action Network represents Canadians with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia. Ms Parlor worked as a professional data analyst for many years.

National ME/FM Action Network

	% of people with MCS having this additional diagnosis	% of people with CFS having this additional diagnosis	% of people with FM having this additional diagnosis	% of target population having this diagnosis
Food Allergies	27.3	16.2	19.4	7.2
Other allergies (not food)	61.1	42.8	51.0	26.6
Asthma	25.7	21.3	21.2	8.3
Fibromyalgia	10.0	28.5	n/a	1.4
Arthritis/rheumatism	38.5	47.1	58.8	16.4
Other back problem (not arthritis or FM)	39.7	51.9	50.4	18.8
High blood pressure	24.5	28.3	30.6	14.9
Migraine headache	26.3	32.7	28.0	10.5
Chronic Bronchitis	11.4	11.5	9.3	2.5
Diabetes	6.9	11.6	11.0	4.9
Epilepsy	1.3	2.1	1.4	0.6
Heart disease	9.8	14.9	10.5	4.7
Cancer	2.3	4.4	3.5	1.4
Stomach/Intestinal ulcers	8.9	14.6	12.3	3.1
Effects of stroke	2.5	5.4	3.6	1.1
Bowel disorder	13.1	19.7	23.7	3.9
Cataracts	9.1	10.5	10.3	4.2
Glaucoma	3.9	3.5	3.1	1.5
Thyroid condition	13.8	20.0	17.0	5.6
Chronic Fatigue Syndrome	9.9	n/a	24.4	1.2
Multiple Chemical Sensitivities	n/a	17.7	15.4	2.2
Mood disorder	15.9	34.4	22.3	5.6
Anxiety Disorder	14.5	24.5	15.5	4.4

National ME/FM Action Network

	People with MCS are roughly x-times more likely than the target population to have this diagnosis	People with CFS are roughly x-times more likely than the target population to have this diagnosis	People with FM are roughly x-times more likely than the target population to have this diagnosis
Food Allergies	4	2	3
Other allergies (not food)	2	2	2
Asthma	3	3	3
Fibromyalgia	7	20	n/a
Arthritis/rheumatism	2	3	4
Other back problem (not arthritis)	2	3	3
High blood pressure	2	2	2
Migraine headache	3	3	3
Chronic Bronchitis	5	5	4
Diabetes	1	2	2
Epilepsy	2	4	2
Heart disease	2	3	2
Cancer	2	3	3
Stomach/Intestinal ulcers	3	5	4
Effects of stroke	2	5	3
Bowel disorder	3	5	6
Cataracts	2	3	2
Glaucoma	3	2	2
Thyroid condition	2	4	3
Chronic Fatigue Syndrome	8	n/a	20
Multiple Chemical Sensitivities	n/a	8	7
Mood disorder	3	6	4
Anxiety Disorder	3	6	4

APPENDIX B

Environmental Sensitivities-Multiple Chemical Sensitivities Status Report

Advances in Knowledge, and Current Service Gaps

Environmental Health Clinic Women's College Hospital, Toronto

Lynn Marshall MD, FAAEM, FRSM, MCFP

Alison Bested MD, FRCPC

John Molot, MD, FCFP

Kathleen Kerr MD, Dip Env Health

Riina I. Bray BAsc, MSc, MD, FCFP, MHSc

Contact Person: Dr. Lynn Marshall, 905-845-3462, lynn.marshall@utoronto.ca

October 31, 2010

Updated February 17, June 2, August 10, 2011

Environmental Sensitivities-Multiple Chemical Sensitivities (ES-MCS) Status Report Advances in Knowledge, and Current Service Gaps

CONTENTS

Contents	2
Executive Summary	3
Background	4
Overview of Efforts with regard to ES-MCS	4
<i>Case Criteria Development</i>	
<i>Initial Steps toward Addressing Patients' Needs</i>	
<i>Cost Implications and Recognition of the Need to Accommodate</i>	
Etiology	10
<i>Increased Chemical Exposure</i>	
<i>Overwhelmed Body Defence Mechanisms</i>	
<i>Genetic Susceptibility Factors</i>	
<i>Metabolic Vicious Cycle</i>	
<i>Sensory Hypersensitivity</i>	
<i>Evolving Toxicology</i>	
<i>Central Nervous System Hypoperfusion</i>	
<i>'Physical' vs 'Psychological' and Consequences, or Multiple Determinants</i>	
Prevalence	19
<i>Diagnosis by a Health Professional</i>	
<i>Self-reported MCS</i>	
<i>Poverty Influence</i>	
<i>Prevalence in Childhood and Incidence</i>	
<i>Co-morbid Conditions</i>	
Diagnosis	24
<i>Ruling Out Other Conditions</i>	
<i>Exposure Assessment</i>	
<i>Ruling In MCS</i>	
<i>Functional Status</i>	
<i>Chemical Provocation Tests</i>	
<i>Allergy Tests</i>	
<i>SPECT Scans</i>	
<i>Etiological Understanding and Diagnosis</i>	
Treatment	28
<i>Duty to Provide Care</i>	
<i>Patient-centred Trend in Health Care</i>	
<i>Empirical Evidence-informed Approaches</i>	
<i>Reduction of Exposure to Triggers and Toxins</i>	
<i>Enhancing Internal Processing and Elimination of Chemicals</i>	
<i>Decreasing Body Burden</i>	
<i>Symptomatic Treatment and Desensitization</i>	
<i>Oxygen</i>	
<i>Randomized Controlled Trials of Therapies</i>	
<i>Self- management Strategies</i>	
Primary Prevention	39
<i>Health Promotion and Partnerships</i>	

Environmental Sensitivities-Multiple Chemical Sensitivities (ES-MCS) Status Report Advances in Knowledge, and Current Service Gaps

Executive Summary:

There have been many advances in understanding of ES-MCS since the mid-1990's, including validation of consensus case criteria and refinement thereof, funded by the Ontario Ministry of Health; proposal and evolution of testing of etiological hypotheses; prevalence, co-morbidity and disability data from the U.S. and Canada; and development of diagnostic, therapeutic, education and health promotion strategies. Academically-affiliated, Ministry of Health-funded referral clinics have been established in Ontario and Nova Scotia, and a Paediatric Environmental Health Specialty Unit integrated into academically-affiliated paediatric services in Alberta. MCS has been recognized as a disability requiring accommodation by the Ontario (2000) and Canadian (2007) Human Rights Commissions.

While the causes and underlying mechanisms of MCS are still not fully understood, there has been increased recognition of the large number of ubiquitous chemicals to which we are all exposed in varying amounts and combinations. Their potential impacts on body defence mechanisms and the contributions of genetic and epigenetic susceptibility factors and metabolic consequences have been hypothesized and are slowly being tested. The science of toxicology has evolved substantially and there is a move away from "physical" versus "psychological" models of disease/illness to the multiple determinants of health model utilized by the World Health Organization (WHO). There is also increasing understanding of unique responses to low doses.

Prevalence surveys have now been conducted in several of the United States for both physician-diagnosed and self-reported MCS. The Canadian Community Health Survey has reported health professional-diagnosed MCS in those over the age of twelve in Canada (2.4% in adults, 3.4% in women and in those with the lowest household income), and has shed light on demographics, functional impacts, and the influence of poverty as well as of co-morbid conditions. In spite of high prevalence and morbidity, there are significant gaps in health, social and housing services.

Diagnosis of MCS in both the provincial Environmental Health Clinic in Ontario and the Nova Scotia Environmental Health Centre is accomplished by ruling out or carefully treating other conditions that could account for or contribute to the presenting symptoms, by assessing each individual's exposures, and by determining whether or not the person's pattern of symptoms fits validated consensus criteria. A few objective tests are helpful in assessing body burden of various chemicals, functional status, co-morbid allergies, and diminished blood flow to the brain.

There being a duty to provide care and not abandon patients with newly reported complex clinical conditions to their own devices, treatment for ES-MCS has evolved based upon approximately 50 years of international clinical case reports and case series, supported by treatment surveys. It is empirically evidence-informed best practice; individualized, holistic and person-centred. It focuses on assisting patients at the earliest possible opportunity to reduce their exposures to their unique symptom triggers and known hazardous chemicals, optimizing their internal processing and elimination of such chemicals through nutrition and dietary fibre, and reducing body burdens when necessary and possible. If co-morbid allergies are not relieved by environmental controls, ventilation or filtration at home or in the workplace, they may be helped by individualized desensitization or medications to relieve symptoms. Dysbiosis (imbalanced microflora in the gastrointestinal tract) may be helped by probiotics and stabilization of pH. Patients are encouraged and supported to take control and self-manage, instituting and nurturing elements of good health. While early diagnosis and prompt treatment can significantly improve individual functioning/quality of life and reduce healthcare utilization, primary prevention through partnering and health promotion is the ultimate goal.

Background:

In response to the Environmental Health Association of Ontario's request for more information on the available scientific evidence underpinning current assessment and management of ES-MCS, this Status Report was developed by the provincial Environmental Health Clinic (EHC) physicians as an explanatory review of the evolution of knowledge of ES-MCS. Although EHC physicians have previously participated in systematic literature reviews on environmental health topics, the financial resources were not available to conduct such a review on ES-MCS at this time. None of the contributors to this report received any remuneration.

Ongoing input on issues included in this report has been provided by members of the Environmental Health Association of Ontario, Myalgic Encephalomyelitis Association of Ontario, and the National ME-FM Action Network, as well as our partners in the Canadian Coalition for Green Health Care, Canadian Partnership for Children's Health and the Environment, and Toronto Cancer Prevention Coalition. Consumer advisors to the EHC, Eleanor Johnston, Varda Burstyn and Lin Grist, as well as EHC Manager Lynn Carter and researcher Dr. Margaret Sears, were consulted and their suggestions to improve structure and clarity of language were gratefully received.

Overview of Efforts with regard to ES-MCS:

With emerging conditions such as ES-MCS, there are many research questions to be answered, including about description, definition, etiological contributors/mechanisms, assessment, diagnosis, prevalence, functional status, and health care utilization, while providing increasingly targeted treatments as evidence evolves. There have been advances in validation of consensus ES-MCS case criteria and in assembling pieces of the etiological puzzle in Ontario Ministry of Health-funded research, in compilation of prevalence data by Statistics Canada via Canadian Community Health Surveys, and in determining functional status and healthcare utilization while providing clinical care in government-funded clinics in Ontario and Nova Scotia. ES-MCS has now been recognized as a disability requiring accommodation through avoidance of symptom-triggering exposures and toxin reduction by the Canadian and Ontario Human Rights Commissions, but there remain many gaps in primary care and specialty health services, income/other social supports, and safe, affordable housing.

In order for multi-centre research to provide the most useful ever-developing picture of a condition, it is important that there be agreement on the definition/case criteria for what is being studied, as outlined below. Patients' needs cannot ethically be ignored while answers to the many research questions slowly accrue, with some uncertainty almost always remaining. Health, social, and housing services need to continually improve, not only to meet immediate patient needs, but also to protect all citizens from health impacts of known or suspected environmental hazards. An ounce of protection can truly prevent a pound of costs- to individuals, the health/social service systems, and the economy.

Case Criteria Development

- In the 1980s and 90s various criteria had been proposed for defining a case of MCS, also called environmental sensitivities, hypersensitivities, illness, intolerances, or toxicant-induced loss of tolerance, names which were inclusive of a broader range of environmental agents. Based on the previous work of Nethercott et al ([Nethercott JR, Davidoff LL, Curbow B, et al. Multiple chemical sensitivities syndrome: toward a working case definition. Arch Environ Health 1993;48:19-26](#)), a list of criteria that reflected an internationally *consistently observed pattern* of symptom presentation was agreed upon by 34 North American clinicians and researchers who collectively had experience with thousands of MCS patients ([Bartha et al. Multiple Chemical Sensitivity: a 1999 consensus. Archives of Environmental Health, May/June 1999; 54\(3\): 147-9](#)).

- Part of the definitional challenge was, and is, related to the fact that symptoms and signs triggered by low level exposures to environmental agents vary among affected individuals and within individuals depending on inciting agents as well as the doses, timing, and combinations of exposures. Also, while there can be abnormal physical and laboratory findings, the same findings are not *consistently* abnormal in all patients or in individual patients all the time (Thomson GM, Day JH, Evers S, et al. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders. Ontario Ministry of Health, 1985:17-18).
- The 1999 consensus criteria were subsequently validated using a reproducible questionnaire (McKeown-Eyssen Gail E., Sokoloff Ellen R., Jazmaji Vartouhi, Marshall Lynn M., Baines Cornelia J. Reproducibility of the University of Toronto self-administered questionnaire used to assess Environmental Sensitivity, American J. of Epidemiology, 2000; 151 (12): 1216-22). In addition, four *specific* neurological symptoms were found to discriminate between most patients and controls in a study by the Ministry of Health-funded Environmental Hypersensitivity Research Unit at the University of Toronto (McKeown-Eyssen GE, Baines CJ, Marshall LM, et al. Multiple Chemical Sensitivity: Discriminant validity of case definitions; Arch Environ Health, 2001; 56(5):406–12) (Table 1). A checklist of the criteria is posted on the Ontario College of Family Physicians website for use by practising clinicians (<http://www.ocfp.on.ca>, → Environmental Health Committee).

Table 1:

Multiple Chemical Sensitivity Case Criteria

Multiple Chemical Sensitivity: A 1999 Consensus	
Bartha et al. Archives of Environmental Health, May/June 1999; 54(3): 147-9; Based on: Nethercott JR, Davidoff LL, Curbow B, et al. Multiple chemical sensitivities syndrome: toward a working case definition. Arch Environ Health 1993;48:19-26	
▪ The symptoms are reproducible with [repeated chemical] exposure. ▪ The condition is chronic. ▪ Low levels of exposure [lower than previously or commonly tolerated] result in manifestations of the syndrome. ▪ The symptoms improve or resolve when the incitants are removed. ▪ Responses occur to multiple chemically unrelated substances. ▪ [Added in 1999]: Symptoms involve multiple organ systems.	
Multiple Chemical Sensitivity: Discriminant Validity of Case Definitions	
McKeown-Eyssen GE, Baines CJ, Marshall LM, et al. Arch Environ Health, 2001; 56(5):406–12	
▪ Having a stronger sense of smell than most people ▪ Feeling spacey ▪ Feeling dull or groggy ▪ Having difficulty concentrating	

- Lacour et al suggested adding non-discriminating non-specific complaints of the central nervous system and functional disturbances in other organ systems to the case definition, but this would decrease discriminative ability. (Lacour M, Zunder T, Schmidtke K, Vaith P, Scheidt C. Multiple chemical sensitivity syndrome (MCS)- suggestions for an extension of the US MCS-case definition, Int J. Hyg. Environ. Health, 2005; 203:141-51).

- Since the validated combined MCS case criteria do not distinguish mild, moderate and severe MCS, functional status measures have been employed clinically as well. Further clarity in research on MCS of varying degrees of severity may be possible using six evaluated domains of questionnaire-based criteria for MCS ([Kutsogiannis DJ, Davidoff AL. A multiple center study of multiple chemical sensitivity syndrome, Arch Environ Health, May/June 2001; 56\(3\):196-207- funded by Ontario Ministry of Health](#)).
- The validated combined 1999 MCS consensus criteria and four specific neurological symptoms were used to select cases in subsequent case control studies funded by the MOH/MOHLTC at the University of Toronto ([McKeown-Eyssen G, Baines C, Cole DEC, Riley N, Tyndale RF, Marshall L, Jazmaji V. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR, Int. J. Epidemiol. July 15, 2004; 33: 1-8; Baines CJ, McKeown-Eyssen GE, Riley N, Cole DE, Marshall L, Loeschner B, Jazmaji V. Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins, and serum volatile organic compound measures, September 2004; 54 \(6\):408-18; Baines CJ, McKeown-Eyssen GE, Riley N, Marshall L, Jazmaji V. University of Toronto case-control study of multiple chemical sensitivity-3: intra-erythrocytic mineral levels, Occupational Medicine, published online October 17, 2006](#)).

Initial Steps toward Addressing Patients' Needs

- Those with ES-MCS have long complained about lack of availability of knowledgeable healthcare professionals and effective health services for their condition, borne out by Gibson et al's finding in a U.S. cross-sectional survey of 917 members of MCS support groups that participants had consulted a mean of twelve health care providers, but only found a mean of three helpful ([Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environmental Health Perspectives, September 2003; 111\(12\):1499](#)).
- In Ontario, after carefully reviewing the available evidence on ES-MCS in 1984, both published and revealed in interviews and focus groups, the Ad Hoc Committee on Environmental Hypersensitivity Disorders, appointed by the then Ontario Minister of Health, Keith Norton, and chaired by Judge George M. Thomson (http://www.lsuc.on.ca/media/june1209_georgebio.pdf), concluded that there was sufficient evidence that environmental hypersensitivity was a health problem that needed to be addressed, and recommended funding of a collaborating university research program and academically-affiliated provincial clinic to fill the scientific and service gaps ([Thomson GM, Chair. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders to the Ontario Ministry of Health, 1985](#)). Health Minister Elinor Caplan appointed a liaison committee, arranged for interested researchers and clinicians to meet to discuss priorities, and funded several research initiatives.
- In the early 1990's, when Ontario Health Minister Frances Lankin learned that there had been other reports ([Ashford NA, Miller CS. Chemical sensitivity: A report to the New Jersey State Department of Health, December, 1989; Health Canada. Environmental Sensitivities Workshop, Chronic Diseases in Canada, Supplement, January, 1991](#)) that had very similar findings and had made similar recommendations as the Thomson Committee, she ordered funding, and the subsequent Health Minister Ruth Grier instituted the Environmental Hypersensitivity Research Unit (EHRU) at the University of Toronto (for a total of \$1,500, 000) ([McKeown-Eyssen G, Marshall L, Baines C, Rodin G](#)).

Research Initiatives at the University of Toronto Environmental Hypersensitivity Research Unit, Regulatory Toxicology and Pharmacology, 1996; 24: S126-S128). A collaborating Environmental Health Clinic was also established for the province at Women's College Hospital, Toronto. Decisions regarding priorities for clinical services and research studies were effectively guided by a Clinical and Research Advisory Board (CRAB) appointed by the Ontario Ministry of Health in the 1990's.

- Pioneering research was done in the EHRU that validated published MCS case criteria and refined them (McKeown-Eyssen GE, Baines CJ, Marshall LM, et al. Multiple Chemical Sensitivity: Discriminant validity of case definitions; Arch Environ Health, 2001; 56(5):406–12), and that pointed to potential genetic susceptibility factors (McKeown-Eyssen G, Baines C, Cole DEC, Riley N, Tyndale RF, Marshall L, Jazmaji V. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR, Int. J. Epidemiol. July 15, 2004; 33: 1-8), as well as investigating other potential etiological factors and diagnostic test possibilities. However, the EHRU funding ended before further studies on etiology, diagnosis and treatment could be mounted.
- The enduring provincial Environmental Health Clinic (EHC) at Women's College Hospital, with a total annual budget of \$408,000, essentially static since 1998, employs 0.9 of a full time equivalent (FTE) physician, shared among 5 physicians, supplemented somewhat for clinical work by the Ontario Health Insurance Plan and recently for teaching by a hospital family practice group alternate funding plan. It also employs one full time Nurse Educator, 0.8 FTE Community Outreach Coordinator, 0.8 FTE receptionist/dictatypist, and approximately 0.3 FTE shared manager. The clinic provides comprehensive assessments and treatment advice to ongoing care physicians, and self management advice to physician-referred patients from a provincial population base of over 13 million (http://www.ontario.ca/en/about_ontario/EC001035 - accessed August 13, 2010-website last modified May 5, 2010). The EHC has a virtually perpetual six to eight month waiting list, is unable to offer urgent or ongoing treatment, and generally cannot provide consultations for children or out-of-province residents.
- Canada has one paediatric environmental health consulting clinic integrated into a regular multi-function paediatric clinic in Edmonton, Alberta, affiliated with the University of Alberta and a group of Paediatric Environmental Health Specialty Units in the U.S.
- The Nova Scotia Environmental Health Centre (NSEHC) is located in Fall River just outside Halifax, Nova Scotia. The NSEHC is funded by the Capital District Health Authority and is affiliated with Dalhousie University. The NSEHC has been able to offer assessments and ongoing multi-faceted, individualized treatment and psychosocial support to both adults and children in Nova Scotia, with a provincial population of 938,183 (<http://www.gov.ns.ca/finance/statistics/agency/default.asp>, July 1, 2009), as well as to some out-of-province residents. The NSEHC has an annual budget of \$1,410,000 and employs two physicians, two nurses, one licensed practical nurse, one dietician, one psychologist, one psychotherapist, one occupational therapist, one rehabilitation counsellor, one manager/researcher, and five administrative staff (Merritt C, NSEHC. Personal communication with Drs. A. Bested, R. Bray and L. Marshall by telephone and e-mail, October 2010). The average waiting time for referred patients in Nova Scotia is approximately four months, but eight months if from out of province.

- It has been extremely challenging to assist EHC patients in Ontario to obtain adequate ongoing care in their communities when primary care physicians, specialists, and other local healthcare/homecare professionals have had little training in environmental health. The provincial EHC in Ontario has leveraged its resources by collaborating with multiple partners (**Table 6**) for education/training, research, community support, and health promotion with regard to ES-MCS and other environment-associated conditions.
- There is currently no Ontario Health Insurance Plan diagnostic code for ES-MCS, and no time-based complex case code to pay physicians for the extra time required for them to assess and treat those with ES-MCS. Hence, although Ontarians' needs are great, it is difficult to attract new physicians, given this reality.

Cost Implications and Recognition of the Need to Accommodate

- Health care utilization costs for patients referred to the Nova Scotia Environmental Health Centre between 1998 and 2000, who were diagnosed with MCS by NSEHC physicians, were almost twice the provincial average. However, a NSEHC cohort study combining chart review and medical insurance records revealed reduced healthcare utilization by NSEHC patients subsequent to treatment, resulting in significant health care system savings. The largest reduction in health system utilization occurred in those who were initially most severely ill (Fox RA, Joffres MR, Sampalli T, Casey J. The impact of a multidisciplinary, holistic approach to management of patients diagnosed with multiple chemical sensitivity on health care utilization costs: An observational study, *The Journal of Alternative and Complementary Medicine*, 2007; 13(2):223-9).
- A chart review study in the provincial Environmental Health Clinic in Ontario of 128 consecutive patients diagnosed with one or more of MCS, chronic fatigue syndrome, or fibromyalgia revealed that the mean number of visits to a family physician in the twelve months before completion of the intake questionnaire was 10.7 (SD 8.7; n=123), and to other physicians was 13.7 (SD 18.2; n=123). This was far higher than for the general population in Canada where the mean numbers of visits were 2.9 (SD 4.3) and 0.79 (SD 2.0) respectively. Furthermore, most (68.8%) had stopped work, on average about three years after symptom onset, and had "markedly lower functional scores than population average values" (Lavergne MR, Cole DC, Kerr K, Marshall LM. Functional impairment in chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity, *Canadian Family Physician*, February 2010; 56: e60-1).
- Although some of the basic steps to fill scientific and service gaps have been taken as suggested by Thomson et al (Thomson GM, Chair. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders to the Ontario Ministry of Health, 1985), there is unfortunately still a disturbing lack of recognition of the many challenges for those with ES-MCS in accessing knowledgeable health care (both urgent and ongoing) in safe facilities, adequate nutrition, supportive dietetic and community services, workplace accommodation, and safe healthy housing (Canada Mortgage and Housing Corporation. Research House for the environmentally sensitive, 1994, reprinted 1995, 1998, 2002, Cat. No. NH15-90/1994E; <http://journals.lww.com/jphmp/toc/2010/09001#-1750774083>; Building materials for the environmentally hypersensitive 61089, 1995, revised 2005, www.cmhc-schl.gc.ca/; <http://journals.lww.com/jphmp/toc/2010/09001#-1750774083> *J of Public Health Management and Practice*, September/October 2010 16 (E-Supplement 5): S1-S93).

- In 2006, having received many complaints from Canadians with ES-MCS about the lack of health and financial support services and dismissal or trivialization of their health problems, the Canadian Human Rights Commission (CHRC) ordered a scientific literature review on environmental sensitivities ([Sears M. The Medical Perspective on Environmental Sensitivities. Canadian Human Rights Commission, 2007,
http://www.chrc-ccdp.ca/pdf/envsensivity_en.pdf](#)). The CHRC subsequently declared the condition to be a disability requiring accommodation under the *Canadian Human Rights Act* (the policy is posted at: [http://www.chrc-ccdp.ca/legislation_policies/policy_environ_politique-en.asp](#)) .
- The Department for Transport Energy and Infrastructure in South Australia has also specified a detailed disability accommodation policy for those with MCS in government buildings: [http://www.sacfs.asn.au/download/SA%20Gov%20Access%20Assement%20%20guide%20version%20SBF%20final%20DTEI%202007_30_11.pdf](#)
- Environmental sensitivities were included as “non-evident disabilities” in the Ontario Human Rights Commission’s *Policy and Guidelines on the Duty to Accommodate* in 2000, and are also specifically mentioned when defining disabilities that must be accommodated under the Ontario *Human Rights Code* [http://www.ohrc.on.ca/en/issues/disability](#).
- The Ontario Accessible Built Environment Standards Development Committee under the *Accessibility for Ontarians with Disabilities Act, 2005* has appointed the Environmental Health Clinic’s Community Outreach Coordinator to represent those with environmental sensitivities.
- The Public Service Alliance of Canada (PSAC) has a policy statement on scent-free environments (Chemical Sensitivities - Environmental Disabilities) on their website that includes the PSAC Awareness Kit on Scent-Free Environments, January 2006 [http://psac.com/documents/what/scent-free-kit-feb2006-e.pdf](#) .
- The Canadian Centre for Occupational Health and Safety has information on its website on how to establish a “Scent-Free Policy for the Workplace” ([www.ccohs.ca/oshanswers/hsprograms/scent_free.html](#)) , as does National Defence and the Canadian Forces. (*Environmental sensitivities, Safety Digest, Edition 6/2010, reproduced from the Safety, Emergency and Security Management Division of Treasury Board; retrieved August 27, 2010.
http://www.vcds-vcemd.forces.gc.ca/dsafeg-dsg/pi/sd-dsg/6-10/article-07-eng.asp*.)
- The Ontario provincial Environmental Health Clinic team, other Women’s College Hospital staff and consumer support groups have collaborated with the Canadian Society for Environmental Medicine on information for hospital staff to enable accommodation of those with allergies or sensitivities ([Marshall LM, MacLennan JG. Environmental health in hospital: A practical guide for hospital staff. Part I Pollution prevention, Part II Environment-sensitive care, Canadian Society for Environmental Medicine, 1993, revised editions 2001,
www.mcscanadian.org/hospital.html](#))

- Through participation in the Canadian Coalition for Green Health Care (www.greenhealthcare.ca), the provincial Environmental Health Clinic in Ontario has been a leader in promoting fragrance/scent-free programs and policies in health care facilities across the country, with the assistance of an Ontario Trillium Foundation grant.

Etiology:

While the causes and underlying mechanisms of ES-MCS are still not fully understood, progress has been made over the past 15 or so years. There has been increased recognition of the large number of ubiquitous chemicals to which we are all exposed in varying amounts and combinations. Their potential impacts on body defence mechanisms and the contributions of genetic and epigenetic susceptibility factors and metabolic consequences have been hypothesized and are slowly being tested. The science of toxicology has evolved substantially and there is a move away from “physical” versus “psychological” dualistic models of disease/illness to the multiple determinants of health model utilized by the World Health Organization (WHO).

Increased Chemical Exposure

- More than 80,000 potentially toxic chemicals have been introduced into commerce in North America mostly since World War II ([Grossman E. What the EPA’s “Chemicals of Concern” plans really mean, Scientific American, January 11, 2010](#)), and 23,000 in Canada ([Health Canada. Assessing Chemicals in Canada for Risk: Protecting the Health of Canadians and their Environment. Health Canada. Dec. 15, 2006. March 27, 2009 <http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/brochure/index-eng.php>](#)), to which Canadians are virtually all regularly exposed ([Genuis SJ. Nowhere to hide: chemical toxicants and the unborn child, Reprod Toxicology, 2009; 28:115-6](#)).
- Some patients began reporting a variety of symptoms linked with intermittent exposure to synthetic chemicals in the 1950’s and 60’s, and their physicians reported the phenomenon to colleagues (e.g. [Randolph T.G. Human ecology and susceptibility to the chemical environment. Springfield, IL: Charles C Thomas, 1962](#)), but little notice seemed to be taken initially- perhaps not surprising since the effects of chemical sensitivities are usually not visible to others, and it can be hard to believe that chemicals at levels not bothering most people could be adversely affecting some.
- In the 1970’s, in the wake of an oil embargo in the Middle East, buildings were “tightened” to prevent heat loss, trapping chemicals indoors, at the same time as regulated ventilation rates were lowered to save energy. Reports of symptoms in multiple body systems occurring “with increased frequency in buildings with indoor climate problems” were recognized by the World Health Organization as a clinical phenomenon called “Sick Building Syndrome” ([WHO, Indoor Air Quality Research. Euro-Reports and Studies. Copenhagen, No. 103. 1984](#)).
- ES-MCS was reported more in the 1980’s and 90’s - a similar phenomenon to Sick Building Syndrome occurring in a broader range of locations and circumstances. Symptoms were triggered by ‘everyday’ exposures, often after a recognizable initiating event, usually of a pronounced chemical exposure, such as a chemical spill at work, pesticide application or building renovation, or by a combination of chemical exposures in the stressful context of war ([Cullen, MR. The worker with multiple chemical sensitivities: an overview. Occup. Med. 1987; 2:655-661](#); [Ashford NA, Miller CS. Chemical sensitivity: a report to the New Jersey State Department of Health, December, 1989](#); [Ashford NA, Miller CS. Chemical exposures, low levels and high stakes, Van](#)

Nostrand Reinhold, New York, 1991, and 2nd Edition, John Wiley & Sons Inc., 1998; Ross GH. History and clinical presentation of the chemically sensitive patient. *Toxicol. Ind. Health.* 1992; 8, 21-28; Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. *Arch. Environ. Health*, 1995; 50, 119-129; Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans, *Toxicol Appl Pharmacol* 1999;157:227-233; Gulf War and Health, Vol. 8: Health Effects of Serving in the Gulf War Update 2009 , National Academies Press, 2010, <http://www.nap.edu>).

- Early on, the most common symptom-triggering agents, reported by occupants of sick buildings and those with ES-MCS, were usually not recognized as containing potentially harmful ingredients (e.g. the unlabeled volatile organic compounds (VOC's) being emitted from many common building and furnishing materials, cleaning, laundry, and personal care products), or exposures were considered to be at levels too low to be harmful. While reports of chronic conditions in children, such as asthma and neurocognitive difficulties, were increasing, they were not necessarily seen as related (McKeown D. Toronto Public Health. *Environmental threats to children: Understanding the risks, enabling prevention*, September 2005; Grandjean P, Landrigan JP. Developmental neurotoxicity of industrial chemicals, doi:10.1016/S0140-6736(06)69665-7, 2006).
- In the first decade of the 21st century, as uses of electrical appliances/equipment and radiofrequency telecommunications have expanded, there have been reports of a condition with a pattern like MCS of multisystem symptoms occurring in relation to exposures to everyday levels of electromagnetic radiation (Huss A, Roosli M. *Consultations in primary care for symptoms attributed to electromagnetic fields- a survey among general practitioners*, BMC Public Health, Oct. 30 2006;6:267). An international committee of scientists have examined and reported on the evidence to date (The Bioinitiative Working Group. *Bioinitiative report: A rationale for a biologically-based public exposure standard for electromagnetic fields*, 2006, last updated 24 May 2010; www.bioinitiative.org). Although there is still much uncertainty, in response to public enquiries, Toronto Public Health has developed fact sheets (Toronto Public Health. *Electromagnetic fields-Fact sheet*, <http://www.toronto.ca/health/emfs.htm>, last updated February 2011; Toronto Public Health, *Cell Phone Use and Human Health*, last updated January, 2011, http://www.toronto.ca/health/hphe/pdf/factsheet_cellphone.pdf. In addition, Health Canada outlines risk reduction measures on its webpage on the Safety of Cell Phones and Cell Phone Towers- <http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/prod/cell-eng.php>, last updated May 2009.
- It may be that people in many industrialized nations reporting the pattern of ES-MCS from the 1950s on are the ‘canaries’ for the general population with respect to responses to the multitude of chemicals introduced into our air, food, water, soil, and consumer products since World War II, as well as to increasing exposure to electromagnetic radiation.

Overwhelmed Body Defence Mechanisms

- Fortunately, the body may normally utilize many mechanisms and combinations thereof to defend against foreign biological, chemical or physical agents, or rapidly dividing cancer cells. However, defence mechanisms can become overwhelmed and individuals may become more sensitive to a variety of chemicals at everyday dosages, for example patients with cirrhosis of the liver, or undergoing chemotherapy for cancer.

- Primary body defence mechanisms include the following (simplified):
 - Surface barriers: Inhaled particles and chemicals may be breathed out or trapped in mucus in the nose and sneezed out, or in the bronchi and lungs and coughed out. The gastrointestinal tract wall and mucus can block absorption of ingested hazardous substances. Substances may be brushed or washed off the skin before they are absorbed.
 - Cellular Immune Responses: immune cells, including neutrophils, monocytes and lymphocytes e.g. B cells, T cells and Natural Killer cells, are found in the blood and throughout the body in organs such as the lungs, liver, spleen and brain. When viruses, bacteria or other foreign proteins enter the body, the immune cells become activated to release chemical mediators to ‘chew’ them up (Klaasen CD. Casarett and Doull’s Toxicology, the basic science of poisons, 7th Edition, 2008, McGraw-Hill Inc.; Guyton AC, Hall JE. Textbook of Medical Physiology, 11th Edition, Saunders, July 2005).

Immune responses are powerful mechanisms in the body, with potential to cause harm (e.g. anaphylaxis or autoimmune disease). Danish researchers have demonstrated dose response-related increased histamine release from the basophils of patients with asthma and perfume contact allergy, in comparison with controls, on exposure to perfume (Elberling J, Skov PS, Mosbech H, Holst H, Dirksen A, Johansen JD. Increased release of histamine in patients with respiratory symptoms related to perfume, Clin and Experim Allergy, 2007; 37:1676-1680).

- Humoral Non-Cellular Immunity: there are many different humoral immune pathways where the body produces or reacts with large complicated proteins such as immunoglobulins (antibodies), complex proteins and enzymes for the coagulation or clotting system and the complement system, or reactive proteins such as cytokines or other chemicals that are produced in response to what the body identifies as foreign: bacteria, viruses, fungi, cancer cells, radiation and chemicals. The proteins and chemicals travel through Phase I and Phase II biotransformation pathways that occur mainly in the liver (Klaasen CD. Casarett and Doull’s Toxicology, the basic science of poisons, 7th Edition, 2008, McGraw-Hill Inc.; Guyton AC, Hall JE. Textbook of Medical Physiology, 11th Edition, Saunders, July 2005, 1152 pgs).
- Phase I and Phase II Biotransformation, followed by Phase III Excretion: the Phase I (Cytochrome P-450) enzyme system prepares (bioactivates) the parent substance via various mechanisms, so that it can connect (conjugate) with another substance in a Phase II pathway to make the compound water soluble in order that it may be excreted more easily in Phase III. The rate at which Phase I produces activated intermediates must be balanced by the rate at which Phase II conjugates and Phase III excretes toxins in the urine via the kidneys, in the bile and stool via the bowel, and to some degree in sweat. Otherwise, there can be a build up of the parent substance and its active intermediate metabolites, which, in some cases can be more toxic than the parent.

Many drugs are P-450 enzyme inhibitors which may result in accumulation of medications and foreign chemicals (xenobiotics) with increased side effects and toxicity. Examples are cimetidine, ciprofloxacin, diltiazem, erythromycin,

ketoconazole, verapamil, and a number of selective serotonin reuptake inhibitors (SSRIs).

There are essentially six Phase II conjugation pathways:

- Glutathione conjugation
- Amino acid conjugation
- Methylation
- Sulfation
- Acetylation
- Glucuronidation

There must be adequate nutrients available for efficient operation of Phase I and II biotransformation pathways, in particular, high intake of highly-coloured vegetables, ascorbate, anti-oxidants, glutathione precursors provided by adequate protein, niacin and cobalamin, as well as balanced essential fatty acid intake and phosphatidyl choline, along with high fibre to enhance GI transit function in Phase III and sufficient fluid to assist excretion via kidneys. (Burford-Mason A. What foods need to deliver, Nutrition for Docs, Dalla Lana School of Public Health, University of Toronto, Syllabus, April 17-18, 2010).

Genetic Susceptibility Factors

- From 1990-2003, the human genome was categorized (http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml). Genetic polymorphisms have been found in those with ES-MCS in comparison with controls that seem to indicate that people with ES-MCS may have more difficulty than the majority of the population metabolizing and excreting commonly encountered environmental chemicals and medications (La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos. 2001;29:566-9; McKeown-Eyssen G, Baines C, Cole DEC, Riley N, Tyndale RF, Marshall L, Jazmaji V. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR, International Journal of Epidemiology 2004; 33:1–8 [funded by the Ontario Ministry of Health]; Furlong CE, Cole TB, Jarvik GP et al. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants, Neurotoxicology 2005;26:651-9; Schnakenberg E, Fabig KR, Stanulla M et al. A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug metabolizing enzymes. Environ Health. 2007; 6:6 ; Muller KE, Schnakenberg E. Die Bedeutung der Glukuronidierung bei umweltmedizinischen Erkrankungen am Beispiel der UDP-Glukuronosyltransferase 1A1. Umwelt Medizin Gesellschaft, 2008; 21(4): 295-300).
- The science of epigenetics and how environmental stimuli influence genes to turn on and off their expression of metabolic enzymes is in its infancy and is evolving rapidly (Anway MD, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors, Endocrinology 2006, Vol. 147, No. 6 s43-s49; Crews D, McLachlan JA. Epigenetics, evolution, endocrine disruption, health and disease, Endocrinology, 2006, Vol. 147, No. 6 s43-s49; Korkina L, Scordo MG, Deeva T, Cesareo E, De Luca C. The chemical defensive system in the pathobiology of idiopathic environment-associated diseases, Current Drug Metabolism, 2008; 10:914-31). Genuis noted “Just as a loaded gun needs to be triggered to unload destruction, epigenetic research confirms that disease is often

the result of vulnerable genes being triggered by specific determinants. Mounting evidence suggests that without activation, some disease processes will not develop, and removal of the initiating trigger may allow developing illness to abate or subside.” (Genuis SJ. *Medical practice and community health care in the 21st century: A time of change*, Public Health, 2008; 122:671-80).

- In a recent Italian study comparing diagnosed or suspected MCS patients with healthy controls, even though some measured genes were not noted to be different in the combined ‘case’ population, it was found that several key metabolizing enzymes were. The authors concluded, “Altered redox and cytokine patterns suggest inhibition of expression/activity of metabolizing and antioxidant enzymes in MCS. Metabolic parameters indicating accelerated lipid oxidation, increased nitric oxide production, and glutathione depletion in combination with increased plasma inflammatory cytokines should be considered in biological definition and diagnosis of MCS” (De Luca C, Scordo MG, Cesareo E, Pastore S, et al. *Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes*, Toxicology and Applied Pharmacology, 2010, doi:10.1016/j.taap.2010.04.017).

Metabolic Vicious Cycle

- Human metabolic systems, identical in all cells, are responsible for conversion of matter into the energy of adenosine triphosphate (ATP) to perform life- and health-necessary functions. Humans are equipped with alternate pathways to maintain or restore normal levels of bio-energetic potential, even with genetic and environmental insult (Strohma R. *Manoeuvring in the complex path from genotype to phenotype*, Science, 26 April 2002;296(5568):701-3). A comprehensive catalogue of human metabolic pathways is now readily accessible (<http://www.genome.jp/kegg/pathway.html>).
- Plausible biochemical vicious cycle mechanisms (the nitric oxide-peroxynitrite or NO-ONOO cycle) in MCS and other commonly overlapping complex chronic conditions such as myalgic encephalomyelitis/chronic fatigue syndrome have been proposed and partially tested (Pall ML, Satterlee J. *Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and post traumatic stress disorder*, Ann NY Acad Sci 2001; 933:323-9; Pall ML. *Elevated Nitric Oxide/Peroxynitrite theory of Multiple Chemical Sensitivity: Central role of N-Methyl-D-Aspartate Receptors in the Sensitivity Mechanism*, EHP, September 2003; 111(12):1461-4; Pall ML, Anderson JH. *The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity*, Arch Environ Health, July 2004; 59(7):363-75; Pall ML. *Multiple Chemical Sensitivity: Toxicological Questions and Mechanisms*, Part 8, Environmental and Ecotoxicology, 92, in General and Applied Toxicology, 6 volume set, 3rd Edition. Editors: Ballantyne B, Marrs T, and Syversen T. November 2009, John Wiley & Sons Inc., 3940 pages).
- Pall proposed that cases of Multiple Chemical Sensitivity may be initiated by seven classes of chemicals, each acting along a specific pathway in the body, stimulating the N-Methyl-D-Aspartate (NMDA) cell membrane receptors. The chemical stimulation produces increased NMDA cell membrane receptor activity in mammals that can be measured, and toxic effects, which are diminished by giving NMDA antagonists. The NMDA receptors are found on the surface of cell membranes throughout the body including in the brain, the peripheral nervous system, the bronchi and the gut. Hence, the

NMDA cell membrane receptors can become sensitized by chemical contaminants, become over-active and trigger sensitivity responses in MCS patients. Further support for these metabolic mechanisms has come recently from an Italian study (De Luca C, Scordo MG, Cesareo E, Pastore S, et al. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes, *Toxicology and Applied Pharmacology*, 2010, doi:10.1016/j.taap.2010.04.017).

- Pall has been able to relate the NO-ONOO vicious cycle to previously published MCS etiological hypotheses (Bell I, Miller C, Schwartz G. An olfactory limbic model of multiple chemical sensitivity syndrome: possible relationships to kindling and affective spectrum disorders, *Biol Psychiatry*, 1992;32:218-42; Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals, *Environ Health Perspect*, 1993; 101:234-38; Meggs WJ. Neurogenic switching: A hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity, *Environ Health Perspect*, 1995; 103(1):54-56; Miller CS. Toxicant-induced loss of tolerance- an emerging theory of disease? *Environ Health Perspect* March 1997; 105S:445-53).

Sensory Hypersensitivity

- Capsaicin is the heat producing ingredient in hot peppers and is a well known cough inducer when inhaled, by stimulating vanilloid-sensitive receptors in the bronchial tubes. There are several double-blind capsaicin inhalation challenge studies which demonstrate hypersensitivity in those with MCS when compared to controls, even when asthma has been ruled out (Terneston-Hasseus E. Increased capsaicin cough sensitivity in patients with multiple chemical sensitivity. *J Occup Environ Med*. 2002 Nov; 44(11):1012-7; Nogami H. Capsaicin provocation test as a diagnostic method for determining multiple chemical sensitivity. *Allergology Int* 2004 53(2):153-157(155).
- Challenge studies in those with atopy, and upper and lower airway symptoms have produced the same results, demonstrating neural receptor hypersensitivity to chemicals (Millqvist E. Cough provocation with capsaicin is an objective way to test sensory hyperreactivity in patients with asthma-like symptoms, *Allergy*, June 2000; 55(6):546-50; Millqvist E. Relationship of airway symptoms from chemicals to capsaicin cough sensitivity in atopic subjects, *Clin Exp Allergy*, April 2004; 34(4):619-23; Millqvist E. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals, *Environ Health Perspective*, July 2005; 113(7):849-52).
- Patients with capsaicin sensitivity have faster CNS processing of other chemosomatosensory substances as well (Andersson L. On the relation between capsaicin sensitivity and responsiveness to CO2: detection sensitivity and event-related brain potentials. *Arch Environ Health*, February 2009; 82(3):285-90).
- Given that vanilloid receptors are involved in pain perception, it is perhaps not surprising that MCS patients are also more likely to have fibromyalgia (Ziem G. Profile of patients with chemical injury and sensitivity, *Environ Health Perspect*, March 1997; 105 Suppl 2:417-36; Rainville P. Representation of acute and persistent pain in the human CNS: potential implications for chemical intolerance, *Ann NY Acad Sci*, March 2001; 933:130-41; Black DW. The Iowa follow-up of chemically sensitive persons. *Ann NY Acad Sci*, March 2001; 933:48-56).

Evolving Toxicology

- The science of toxicology has only recently evolved to understand concepts such as quasi-persistence and chronic toxicity of substances to which there is frequent or continuous exposure, even at low levels ([Genuis SJ. Elimination of persistent toxicants from the human body, Hum Exp Toxicol Online First, April 16, 2010; doi:10.1177/0960327110368417](#)) (particularly relevant for those with MCS who may not be able to metabolize and excrete xenobiotics as readily as most adults and for vulnerable fetuses and children whose metabolic capacities are still under development ([Furlong CE, Cole TB, Jarvik GP et al. Role of paraoxonase \(PON1\) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology. 2005; 26:651-659; McKeown D. Environmental threats to children: Understanding the risks, enabling prevention, Toronto Public Health, September, 2005](#)).
- It was also not until recently considered that dose response curves could be non-monotonic, and that some substances encountered at exceedingly low levels could adversely affect the endocrine and immune systems ([American Chemical Society. \[http://portal.acs.org/portal/PublicWebSite/policy/publicpolicies/promote/endocrinedisruptors/CNBP_023441\]\(http://portal.acs.org/portal/PublicWebSite/policy/publicpolicies/promote/endocrinedisruptors/CNBP_023441\); Martin OV, Lester JN, Voulvoulis N, Boobis AR. Human health and endocrine disruption: A simple multicriteria framework for the qualitative assessment of end point-specific risks in a context of scientific uncertainty, Toxicological Sciences, 2007; 98\(2\):332-48; \[www.ourstolenfuture.org\]\(http://www.ourstolenfuture.org\) --> Does the dose make the poison?; Vogel SA. The politics of plastics: The making and unmaking of Bisphenol A “safety”, Amer J Pub Health, 2009 99\(S3\):S559-66; American Chemical Society. Testing for Endocrine Disruption. Public Policy Statement 2009-2010. \[http://portal.acs.org/portal/PublicWebSite/policy/publicpolicies/promote/endocrinedisruptors/CNBP_023441\]\(http://portal.acs.org/portal/PublicWebSite/policy/publicpolicies/promote/endocrinedisruptors/CNBP_023441\)\).](#)
- It has recently been realized that there might be no safe threshold of exposure below which there would be no adverse health effects for some substances, such as lead ([American Academy of Pediatrics, Committee on Environmental Health. Lead exposure, including: prevention, detection and management, Pediatrics, Oct. 2005, 116\(4\):1036-46; Abelsohn AR, Sanborn M. Lead and children, clinical management for family physicians, Canadian Family Physician, June 2010:531-5](#)). High dose laboratory animal experimental “no observable adverse effect levels” (NOAELs) are typically relied upon to estimate regulatory exposure limits, with somewhat arbitrary ‘safety’ factors applied to protect those more vulnerable.

Central Nervous System Hypoperfusion

- Baseline and post-chemical challenge brain perfusion decreases have been noted in MCS patients compared with controls on single photon emission computed tomography (SPECT) brain scans. Decreased perfusion correlated with psychometric test results of decreased quality of life and neurocognitive function in cases at baseline, and neurocognitive worsening after chemical exposure “at non-toxic concentrations” ([Orriols R, Costa R, Cuberas G, Jacas C, Castell J, Sunyer J. Brain dysfunction in multiple chemical sensitivity, Journal of the Neurological Sciences, 2009; 287:72-8](#)).

‘Physical’ vs ‘Psychological’ and Consequences, or Multiple Determinants

- Since the time of French philosopher Rene Descartes (1596-1650), the mechanistic concept of separation of mind and body has persisted in medicine ([Gold J. Cartesian dualism and](#)

the current crisis in medicine- a plea for a philosophical approach: discussion paper, J of the Royal Soc of Med, August 1985; 78: 663-6), in spite of ongoing evidence of mutual influence of each on the other (e.g. Choi J, Fauce SR, Effros RB. Reduced telomerase activity in human T lymphocytes exposed to cortisol, Brain, Behavior and Immunity, May, 2008; 22(4): 600-605). There has correspondingly been a tendency to categorize ES-MCS etiological factors as *either* physical *or* psychological. This reductionist dichotomous view and ensuing discordant medial debate about ‘physical’ versus ‘psychological’ origins for ES-MCS has lead to public confusion and misunderstandings, since society looks to the medical community for information and guidance. The Thomson Committee commented “We believe that confidence in the health care system is eroded when productive dialogue between different medical specialties disappears or is replaced by acrimonious debate before a confused public” (Thomson GM, Day JH, Evers S, et al. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders. Ontario Ministry of Health, 1985:266-70).

- Since consistently abnormal objective physical findings and laboratory test results are presently not established to ‘prove’ a physical origin for ES-MCS, the dichotomous view can lead to an assumption of psychogenic etiology, with a tendency for this assumption to be favoured by industry, insurers and government agencies, as discussed by Ziem and Spencer and Schur (Ziem G. Multiple chemical sensitivity: Treatment and follow up with avoidance and control of chemical exposures, Toxicol Ind Health July 1, 1992; 8(4):73-86; Spencer TR, Schur PM. The challenge of multiple chemical sensitivity. J Environ Health 2008, 70(10):24-7).
- Although there is no objective evidence of psychogenesis, some people disbelieve patients reporting ES-MCS, diminish the significance of symptoms and experiences, and dismiss even the possibility of the condition. Also, Genuis has noted the tendency of some authors to have “disregard for recent laboratory and animal evidence” and to categorize sensitivity-related illness as a “psychogenic confabulation” (Genuis SJ. Sensitivity-related illness: The escalating pandemic of allergy, food intolerance and chemical sensitivity, Science of the Total Environment, 2010; 408: 6047-61; 6057). For instance, Staudenmayer et al concluded that “idiopathic environmental intolerance” “is a belief characterised by an over-valued idea of toxic attribution of symptoms and disability, fulfilling criteria for a somatoform disorder and a functional somatic syndrome” (Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic Environmental Intolerance, Toxicol Rev 2003;22(4):247-61). Even psychiatrists can tend to hold patients responsible for “psychological” illnesses (Miresco MJ, Kirmayer LJ. The persistence of mind-brain dualism in psychiatric reasoning about clinical scenarios, Am J Psychiatry, May, 2006, 163:913-18).
- Studies supporting MCS psychogenesis, when critically reviewed, had various methodological problems and were often subject to selection biases (Davidoff AL, Fogarty L. Psychogenic origins of multiple chemical sensitivities syndrome: a critical review of the research literature, Archives of Environmental Health, 1994; 49(5):316-25).
- In contrast, in a 2001 multi-center cross-sectional survey of 1,166 patients who visited outpatient occupational, otolaryngology, allergy and clinical ecological/environmental clinics, the authors found that the majority (60-79%) of those who met the criteria for MCS did not report treatment for anxiety, depression, or distress/adjustment problems,


and 73% reported “good” or “excellent” health during their first 30 years of life which they thought was “not supportive of the idea that MCS syndrome is primarily a psychiatric or psychosomatic condition”. However, they reported that MCS patients were 5-6 times more likely than controls to seek treatment for psychological concerns secondary to chemical sensitivity “congruent with the hypothesis that much of the psychopathology seen in MCS syndrome is secondary to feeling ill” ([Kutsogiannis DJ, Davidoff AL. A multiple center study of multiple chemical sensitivity syndrome, Arch Environ Health, May/June 2001, 56\(3\):196-207.](#)

- Also, a 2003 population-based survey (N=1582) revealed that few of 199 individuals reporting MCS (1.4%) had a history of prior emotional problems, whereas a substantial number (37.7%) developed such problems after the onset of physical symptoms associated with chemical exposures ([Caress SM, Steinemann AC A review of a two-phase study of multiple chemical sensitivities, Environ. Health Perspect. 2003, 111\(12\), 1490.](#)
- Furthermore, Gibson et al found that the 917 persons with self-reported MCS who participated in their treatment survey reported a higher help-harm ratio for “psychotherapy to cope with MCS” and “support group” than for “psychotherapy to cure MCS”. Psychotropic medications were consistently rated more likely to harm than to help ([Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environmental Health Perspectives, September 2003; 111\(12\):1501-2.](#)
- Disbelief, diminishment and/or dismissal lead to stigmatization and a lack of appropriate emergency or ongoing medical care for sufferers, as well as barriers to obtaining workplace and housing accommodation and income support. Being marginalized and impoverished can in turn lead to increased illness and disability ([Lipson JG. Multiple chemical sensitivities: Stigma and social experiences, Medical Anthropology Quarterly, 2004;18\(2\):200–213.](#) Das-Munshi et al noted that those with MCS were frequently refused Workers’ Compensation “on the grounds it is psychological” ([Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivity: Review, Current Opinion in Otolaryngology Head Neck Surgery, 2007; 15:274-80.](#)
- Delegitimizing those with ES-MCS, who may be warning us all of the need for toxics reduction, also tends to impede development of practical, precautionary, potentially preventive and cost-saving public health strategies.
- Trivialization and disparagement of ES-MCS as a legitimate medical condition, and of ES-MCS patients, has also extended to their physicians, prompting the Thomson Committee’s Recommendation 8: “We recommend that the fee schedule permit an enlargement of the fee to be charged if added time is required to obtain good histories, to counsel a patient on avoidance procedures and to monitor the patient’s performance” ([Thomson GM, Day JH, Evers S, et al. Report of the Ad Hoc Committee on Environmental Hypersensitivity Disorders. Ontario Ministry of Health, 1985:280.](#) Recommendation 33 of a May 24, 1990 Health and Welfare Canada Workshop on environmental sensitivities stated: “Physicians who show interest in the field should not be stigmatized and should be adequately compensated for the time they spend with patients with complicated illnesses” ([Health and Welfare Canada. Environmental sensitivities workshop, Chronic Diseases in Canada, Supplement, January 1991, ISSN-0228-8699.](#) Unfortunately, the

situations leading to these recommendations have not changed, and so few physicians are attracted to the field of environmental health, and research progress is hampered.

- The World Health Organization (WHO) describes multiple determinants of health (**Figure 1**), which may be addressed for each ill individual, allowing many more treatment options. A “multifactorial model” for MCS was suggested by Das-Munshi et al, although psychological-behavioural treatment approaches were, perhaps not surprisingly, favoured by the psychiatrist and psychologist authors (Das–Munshi J, Rubin GJ, Wessely S. *Multiple chemical sensitivities: review*, *Curr Opin Otolaryngol Head Neck Surg* 2007, 15(4): 274-80).

Figure 1: World Health Organization’s Multiple Determinants of Health
(Child Health and the Environment- A Primer, Canadian Partnership for Children’s Health and the Environment, August 2005, www.healthyenvironmentforkids.ca)



Prevalence:

Prevalence surveys have now been conducted in several of the United States for both physician-diagnosed and self-reported MCS. The Canadian Community Health Survey has reported health professional-diagnosed MCS in those over the age of twelve in Canada, and has shed light on demographics, functional impacts, influence of poverty and co-morbid conditions. There is no available incidence data nor are there prevalence statistics for children under twelve.

Diagnosis by a Health Professional

- In a study funded by the Ontario Ministry of Health, Kutsogiannis and Davidoff noted that several statewide surveys in the U.S. found that 3.1-6.3 percent of the American population reported diagnosis of MCS by a physician (Kutsogiannis DJ, Davidoff AL. *A multiple center study of multiple chemical sensitivity syndrome*, *Arch Environ Health*, May/June 2001, 56(3):196-207). Also, the 2002 and 2003 Canadian Community Health Surveys (CCHS) revealed that 2-3 % of Canadians reported being diagnosed with MCS

by a health professional ([Park J, Knudson s. Medically unexplained physical symptoms, Health Reports, Statistics Canada Catalogue 82-003, February 2007, 18\(1\):43-7](#)).

- We believe it is important to recognize the significant reporting of MCS compared with a few other well known “long term conditions” in the Canadian Community Health Survey (2000-2003) that are “expected to last or have already lasted 6 months or more and that have been diagnosed by a health professional” (**Table 2**).

Table 2:

Prevalence of Multiple Chemical Sensitivity and Other Long Term Conditions

(From online Statistics Canada-based prevalence reports, 13/08/2010, compiled by L. Marshall)

Long Term Health Condition	Prevalence over age 12 or 15 (CCHS, 2000-2003)
Multiple Sclerosis	0.24%
AIDS	0.4%
Breast Cancer	1%
All cancers	2.6%
Multiple Chemical Sensitivity	2.4% (1.4% men, 3.4 % women)
Type 2 Diabetes	3-4%
Heart Disease	5.4% men, 4.6% women
Arthritis/Rheumatism	16% (2/3 women)

- In the 2005 Canadian Community Health Survey, 2.5% of adult Ontarians had been diagnosed by a health professional with MCS, with prevalence increasing with age, peaking at 5.8% in women between the ages of 60 and 64 years (**Table 3**).
- The provincial Environmental Health Clinic in Ontario recently reported considerably decreased functional status of our MCS patients relative to the Canadian population on the eight functional status scales of the well-validated Short Form-36 ([Ware JE, Sherbourne CD. The MOS 36-item short-form health survey \(SF-36\). 1. Conceptual framework and item selection, Med Care 1992, 30\(6\):473-83](#)), and markedly increased health care utilization rates ([Lavergne MR, Cole DC, Kerr K, Marshall LM. Functional impairment in chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity, Canadian Family Physician, February 2010; 56: e57-65](#)).

Table 3:

Prevalence of Multiple Chemical Sensitivity (MCS) by Age and Gender in a Target Population*

(From the 2005 Public Use Microdata File of the Canadian Community Health Survey, Statistics Canada, 10-10-2007, compiled by Margaret Parlor, BA, LLB, Statistical Analyst)

	% of population* with MCS	% of males with MCS	% of females with MCS
Total age 12 y and over	2.2	1.2%	3.1%
12 to 14 years	0.8	0.6	1.0
15 to 17 years	0.7	0.4	1.0
18 to 19 years	0.9	0.8	0.9
20 to 24 years	0.9	0.5	1.2
25 to 29 years	1.4	1.1	1.7
30 to 34 years	1.6	1.0	2.1
35 to 39 years	1.7	1.2	2.2
40 to 44 years	2.4	1.7	3.0
45 to 49 years	2.9	1.3	4.4
50 to 54 years	3.3	1.7	4.9
55 to 59 years	3.6	1.7	5.5
60 to 64 years	3.6	1.4	5.8
65 to 69 years	3.3	1.8	4.6
70 to 74 years	2.9	1.9	3.8
75 to 79 years	3.2	1.6	4.5
80 years plus	1.9	1.1	2.3

*Target population: citizens aged 12 and over, excluding Canadians living in institutions, native Canadians living on reserves, full time members of the armed forces, and Canadians living in remote regions



Self-reported MCS

- Like almost any medical condition, people may be mildly, moderately or severely affected, and those more mildly affected may not present for medical care. Also, it takes time for educational programs for healthcare professionals to be developed after a relatively newly observed illness has been reported, and so diagnoses may be less frequently made and the condition under-reported. Researchers in three U.S. states therefore also asked randomly selected adults if they thought themselves to be “unusually” or “especially” sensitive and if they felt ill on exposure to low-level everyday chemicals. In California and New Mexico, 16% said yes ([Kreutzer R, Neutra RR, Lashuay N. Prevalence of people reporting sensitivities to chemicals in a population-based survey. Am J Epidemiol 1999, 150:1-12; Voorhees RE. Memorandum from New](#)

Mexico Deputy State Epidemiologist to Joe Thompson, Special counsel, Office of the Governor, 13 March 1998). In North Carolina, 33 % of randomly selected adults, and in Arizona, 33 % of college students answered affirmatively (Meggs WJ, Dunn KA, Bloch Rm et al. Prevalence and nature of allergy and chemical sensitivity in a general population, *Arch Environ Health*, 1996,51:275-82; Bell IR, Schwartz Ge, Peterson JM et al. Self-reported illness from chemical odors in young adults without clinical syndromes or occupational exposures, *Arch Environ Health*, 1993, 48:6-13). High prevalence rates found in workers studied after occupational overexposures were cited in a study funded by the Ontario Ministry of Health (Kutsogiannis DJ, Davidoff AL. A multiple center study of multiple chemical sensitivity syndrome, *Arch Environ Health*, May/June 2001, 56(3):196-207).

- The 2005 National Survey of the Work and Health of Nurses revealed that 3.6% of all Canadian nurses, predominantly women, experienced chemical sensitivities (N=18,676). Of nurses younger than 35 years, 1.4% reported chemical sensitivities, which increased to 3.7% in nurses 35-44 years old, and 4.3% and 4.8% in successive decades (Statistics Canada www.statcan.ca → Publications, electronic format catalogue no. 83-003-XIE; print version 83-003-XPE)..

Poverty Influence

- In the 2002 and 2003 CCHS, MCS prevalence was higher in those of the lowest socioeconomic status, who are known to have higher exposures to hazardous environmental agents, generally poorer nutrition, and more psychosocial stress, all known vulnerability factors for chronic health problems. In addition, these surveys found that 22% of those with MCS were “dependent in instrumental activities of daily living” (Statistics Canada. Canadian Community Health Survey 2003, reported by Park J, Knudson S, Health Reports, Catalogue 82-003, February 2007, 18(1):45).
- Of a random sample of 1,582 individuals from Atlanta, Georgia, 12.6% reported hypersensitivity to common chemicals, and 13.5 % of these (1.8% of the entire sample) reported loss of employment due to their hypersensitivity (Caress SM, Steinemann AC. A review of a two-phase population study of multiple chemical sensitivities, *Environ Health Perspect.* 2003, 111:1490-7).
- **Prevalence in Childhood and Incidence**
The prevalence of MCS in children under age 12 has never been studied, but we at the EHC think there is cause for concern, given that fetuses and children are known to be the most vulnerable to health impacts from exposure to environmental toxins, and exposure during key developmental stages can have lifelong consequences (McKeown D, Toronto Public Health, *Environmental Threats to Children, Understanding the Risks, Enabling Prevention*, September 2005). Certainly, the rapid rise in childhood asthma, learning and neurobehavioural disorders and disabilities has been linked with increased exposure to various environmental chemicals (Canadian Partnership for Children’s Health and the Environment. *Child health and the environment-A primer*, August 2005:33-40; www.healthyenvironmentforkids.ca).
- To our knowledge, no studies of incidence of MCS at any age have yet been published, and so it is unknown if the condition is increasing or not.

- ***Co-morbid Conditions***

Much overlap has been noted in the U.S. between prevalence of allergies and chemical sensitivities (Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. Prevalence and nature of allergy and chemical sensitivity in a general population, Arch Environ Health, 1996, 51:275-82), and between asthma and chemical sensitivities (Caress SM, Steinemann AC. National prevalence of asthma and chemical hypersensitivity: an examination of potential overlap, J Occup Environ Med, 2005, 47:518-22).

- Allergies and asthma commonly overlap with MCS in Canada too, and the prevalence of several other underlying or co-morbid chronic conditions affecting multiple body systems is greater in the MCS population compared to the general Canadian ‘target population’ (Statistics Canada, CCHS, 2005) (Table 4) Medical care for many of the listed chronic conditions on their own is provided in medical specialty clinics, although patients with myalgic encephalomyelitis/chronic fatigue syndrome and some with fibromyalgia are chronically underserved by specialty clinics in Ontario and are commonly referred to the provincial Environmental Health Clinic by their primary care physicians. If specialists are not knowledgeable about how chemical sensitivity reactions can mimic or trigger many of the problems that they treat, patients with ES-MCS who go to such specialists are not likely to receive effective treatment/support, and may even have treatments recommended that are harmful for them, such as non-tolerated medications. Because of stigmatization of ES-MCS, specialists have not been encouraged to study how the condition impacts their specialty scope.

Table 4:

Frequencies of MCS Co-diagnoses for Canadian Target Population*

(From the 2005 Public Use Microdata File of the Canadian Community Health Survey, Statistics Canada.10-10-2007, compiled by Margaret Parlor, BA, LLB, Statistical Analyst)

Chronic condition	% of people with MCS having this additional diagnosis...	% of target population having this diagnosis...
Other allergies (not food)	61.1	26.6
Other back problems (not arthritis or fibromyalgia)	39.7	18.8
Arthritis/rheumatism	38.5	16.4
Food Allergies	27.3	7.2
Migraine headache	26.3	10.5
Asthma	25.7	8.3
High blood pressure	24.5	14.9
Mood disorder	15.9	5.6
Anxiety Disorder	14.5	4.4
Thyroid condition	13.8	5.6
Bowel disorder	13.1	3.9
Bronchitis	11.4	2.5
Fibromyalgia	10.0	1.4
Chronic Fatigue Syndrome	9.9	1.2
Heart disease	9.8	4.7
Cataracts	9.1	4.2
Stomach/Intestinal ulcers	8.9	3.1
Diabetes	6.9	4.9
Glaucoma	3.9	1.5
Effects of stroke	2.5	1.1
Cancer	2.3	1.4
Epilepsy	1.3	0.6

* Target Population: citizens aged 12 and over, excluding Canadians living in institutions, native Canadians living on reserves, full time members of the armed forces, and Canadians living in remote regions.

Diagnosis:

Diagnosis of ES-MCS is accomplished by ruling out or treating other conditions that could account for, or contribute to the presenting symptoms, by assessing each individual's exposures, and determining whether or not the person's pattern of symptoms fits validated clinical consensus criteria. A few tests are helpful in assessing body burden of various chemicals, functional status, co-morbid allergies, and brain hypoperfusion.

 Ruling Out Other Conditions

- Given that there are no definitive objective diagnostic tests for ES-MCS, a practical strategy of 'ruling out' other conditions or factors that could be contributing to each patient's symptoms is used initially via comprehensive clinical history, physical examination, and readily available laboratory tests ([Sears M. The Medical Perspective on Environmental Sensitivities. Canadian Human Rights Commission, 2007](#),

http://www.chrc-ccdp.ca/pdf/envsensitivity_en.pdf). If ES-MCS is suspected, but other conditions or potential contributors are found, they are treated, cautiously, with tolerated treatments, often at lower doses than usual, and the patient's symptoms are re-assessed (Marshall Lynn M., Bested Alison C., Bray Riina I. Poorly understood conditions of the 21st century- Chronic Fatigue Syndrome, Fibromyalgia, and Multiple Chemical Sensitivity, invited paper, Canadian Journal of Diagnosis, July 2003: 65-71, based on a presentation for Family Medicine Forum 2002, Montreal, College of Family Physicians of Canada.

<http://www.stacommunications.com/journals/pdfs/diagnosis/dxjuly03/drmarshallsyndromes%20pd.pdf> and Frequently Asked questions, Poorly understood conditions of the 21st century: Chronic Fatigue syndrome (CFS), Fibromyalgia (FM), and Multiple Chemical Sensitivity:32, and Why do I feel so tired? : 39-42

<http://www.stacommunications.com/journals/pdfs/diagnosis/dxjuly03/wydx.pdf>). If a patient has both ES-MCS and one or more co-morbid conditions, it can be challenging to find tolerable treatments, and medication side effects can obscure links between symptoms and exposure to other environmental agents.

Exposure Assessment

- A systematic method of taking a comprehensive exposure history using a handy mnemonic has been developed (Marshall Lynn, Weir Erica, Abelsohn Alan, Sanborn Margaret D. Identifying and managing adverse environmental health effects: 1. Taking an exposure history. CMAJ Apr. 16, 2002; 166 (8): 1049-55 and Occupational and environmental exposure, response to letter to the editor by Michael Schweigert, CMAJ, Oct. 1, 2002; 167 (7): 744, 746), as well as exposure history forms utilizing this method, which may be downloaded from the Ontario College of Family Physicians website (Marshall Lynn. Taking an Exposure History, 2002, updated 2004 and 2005 after peer review by the provincial Environmental Health Clinic physicians and Ontario College of Family Physicians Environmental Health Committee Members, www.ocfp.ca → Environmental Health Committee and scroll).
- Blood and 24-hour urine tests for some toxic metals are accessible in Ontario and, for the most part, are funded by the Ontario Health Insurance Plan. However, blood or urine tests or fat biopsies for other retained chemicals must be obtained in the United States at patients' expense. Some of these tests are currently being used in Canada in biomonitoring studies (Canadian Health Measures Survey, Maternal-Infant Research on Environmental Chemicals, accessed August 15, 2010, <http://www.chemicalsubstanceschimiques.gc.ca/plan/surveil/bio-initiatives-enquetes-eng.php>)

Ruling In MCS

- If no other explanation is found for a patient's presenting illness, and their symptom pattern follows that specified in the consensus case criteria (Bartha et al. Multiple Chemical Sensitivity: a 1999 consensus. Archives of Environmental Health, May/June 1999; 54(3): 147-9), and if the patient reports having a stronger sense of smell than most people and two of three discriminating neurological symptoms (McKeown-Eyssen GE, Baines CJ, Marshall LM, et al. "Multiple Chemical Sensitivity: Discriminant Validity of Case Definitions." Arch Environ Health, 2001; 56(5):406-12), this is considered to 'rule in' MCS. The Environmental Health Clinic physicians have created a checklist of these criteria and posted them online for the use of practising physicians (www.ocfp.on.ca → Environmental Health Committee and scroll).

Functional Status

- Blood test indicators of various organ functions as well as nutritional status, along with pulmonary function tests and sleep studies are employed to gauge various functions of ES-MCS patients along the severity continuum.
- The physicians in the provincial Environmental Health Clinic in Ontario also assess functional status of patients referred by Ontario physicians using the Short Form-36 questionnaire (Ware JE, Sherbourne CD. *The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection*, Med Care 1992, 30(6):473-83). A chart review of 128 consecutive patients diagnosed by an EHC physician with one or more of MCS, chronic fatigue syndrome or fibromyalgia revealed substantial functional impairment (Lavergne MR, Cole DC, Kerr K, Marshall LM. *Functional impairment in chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity*, Canadian Family Physician, February 2010; 56: e57-65). The results supported findings in the United States (Black DW, Doebbeling BN, Voelker MD, Carke WR, Woolson RF, Barrett DH et al. *Quality of life and health services utilization in a population-based sample of military personnel reporting multiple chemical sensitivities*, J Occup Environ Med, 1999;41(10):928-33; Jason LA, Taylor RR, Kennedy CL. *Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms*, Psychosom Med, 2000; 62(5):655-63).
- EHC physicians in Ontario have developed an Activity Log and Functional Capacity Scale that may be downloaded from the Ontario College of Family Physicians website (Bested AC, Marshall LM. *Activity Log and Functional Capacity Scale*, www.ocfp.on.ca → Environmental Health Committee).

Chemical Provocation Tests

- In our view, there are ethical concerns with chemical provocation inhalation challenges because in a vulnerable population it is hard to determine challenge dosages without potential for harm.
- Das-Munshi et al reviewed heterogeneous studies of chemical provocation, in that various chemicals were used in various doses, sometimes with or without nasal clips or face masks, and sometimes with or without chemical masking agents/placebos that were acknowledged to be potentially active (Das-Munshi J., Rubin G.J., and Wessely S. *Multiple chemical sensitivities: A systematic review of provocation studies*, J Allergy Clin Immunol, December 2006; 118(6):1257-64). In addition, there was an apparent lack of understanding of, and accounting for the confusing impacts on provocation results of habitual versus intermittent exposure to test agents. Coupled with lack of consistent, objective, easily measurable outcomes, it is not surprising to us that results of these studies were inconsistent.

Allergy Tests

- As noted previously (Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. *Prevalence and nature of allergy and chemical sensitivity in a general population*, Arch Environ Health, 1996, 51:275-82; Parlor M. *Frequencies of MCS Co-diagnoses for Canadian Target Population*, CCHS Public Use Microdata File, Statistics Canada, 2005), there is a strong overlap of allergies, to both foods and biological inhalants, such as dust mites, animal danders, pollens and moulds. While blood radioallergosorbent (RAST) tests

may be used to identify antibodies to such allergens, the results do not correlate well with symptoms. Skin prick tests may be helpful to screen for inhalant allergens, less so for foods, but, empirically, can provoke significant exacerbation of symptoms for some patients with ES-MCS.

- Serially diluted intradermal or sublingual tests for inhalants with individual formulation of hyposensitization treatments have been empirically helpful in ES-MCS cases with concomitant allergies ([Wright ST. Diagnosis and management of inhalant allergens,
http://www.utmb.edu/otoref/grnds/Inhalant-allergens-2003-0611/Inhalant-allergens-2003-0611.doc](#)) in Canada, the U.S. and U.K. They were not included in Gibson's U.S. survey. Moreover, since the treatment is unique for each individual, and individuals with ES-MCS are heterogeneous in many respects, they are not amenable to group trials.
- Since skin prick test results for food allergens do not correlate well with symptoms, elimination and re-ingestion challenge tests may be used, except of course if there is a history of known or suspected life-threatening (anaphylactic) reactions. If many foods are suspected to be problematic, rotation of a broader range of foods can help to ferret out intolerances, and then, once discovered, the patient may be able to limit exposure to those foods. In contrast to Das-Munshi et al's interpretation that rotation of foods has "iatrogenic effects" ([Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: review,
Current Opinion in Otolaryngology & Head and Neck Surgery, 2007; 15:277](#)), Taylor et al found that the more the diet was adhered to, the better the nutritional intake and the fewer and less severe the symptoms ([Taylor JP, Krondl MM, Spidel M, Csuma AC. Dietary adequacy of the rotary diversified diet as a treatment for 'environmental illness',
Canadian Journal of Dietetic Practice and Research, Winter 2002; 63\(4\):198-201](#)).

SPECT Scans

- Physicians of the internationally consulted Dallas, Texas Environmental Health Center described specific abnormalities of metabolism in the brains of those with MCS with neurocognitive impairment when imaged with single photon emission computed tomography (SPECT). The recurrent patterns consistent with neurotoxicity included a mismatch in tracer uptake between early- and late-phase imaging, multiple hot and cold foci throughout the cortex, temporal asymmetry and increased tracer uptake into the soft tissues and sometimes the basal ganglia. They had previously noted a similar pattern in patients with acute neurotoxic chemical exposures and breast implants, and indicated: "Affective processes such as depression do not, alone, show this pattern". Further they found that controlled challenges to ambient chemicals induced the same specific changes on SPECT imaging in chemically sensitive patients, and that significant improvement on SPECT brain imaging frequently followed detoxification treatment in these patients. ([Ross GH, Rea W, Johnson AR, Hickey DC, Simon TR. Neurotoxicity in single photon emission computed tomography brain scans of patients reporting chemical sensitivities,
Toxicology and Industrial Health, 1999 April/May;15\(3-4\):415-20](#)).
- However, controlled studies have been difficult to mount due to challenges in finding controls, ethical issues regarding chemical challenges, and cost. Nevertheless, a recent, well-designed and executed study has confirmed empirical reports and the authors concluded, "Chemical exposure caused neurocognitive impairment and SPECT brain dysfunction, particularly in odour processing areas, thereby suggesting a neurogenic origin

of MCS” (Orriols R, Costa R, Cuberas G, Jacas C, Castell J, Sunyer J. Brain dysfunction in multiple chemical sensitivity, *Journal of the Neurological Sciences*, 2009; 287:72-8).

- SPECT scans are very expensive and, while they do provide some objective evidence in MCS, they do not generally impact management more than a careful exposure history. They have been used to bolster legal efforts to obtain benefits or accommodation for those seriously ill with MCS.

Etiological Understanding and Diagnosis

- As understanding of etiological mechanisms improves, it will hopefully become possible to design readily available and affordable objective diagnostic tests for those with ES-MCS, and any subset populations that are discovered that have unique features. Such tests would aid earlier diagnosis and treatment and likely save much cost for the health care system.

Treatment:

Treatment for ES-MCS is based on evidence-informed principles, is individualized, holistic and person-centred. It focuses on assisting patients to reduce their exposures to their unique symptom triggers and hazardous chemicals, optimizing their internal processing and elimination of chemicals, and reducing chemical body burdens when necessary and achievable. If co-morbid allergies are not relieved by environmental controls at home and in the workplace, they may be helped by increased ventilation, filtration, individualized desensitization or symptom-relieving medications. Dysbiosis (imbalanced microflora in the gastrointestinal tract) may be helped by probiotics and stabilization of pH. Patients are encouraged to take control and self-manage their health, planting a “health garden” using a “weed, SEEDS and feed approach”. With the support of their health care professionals, patients learn how to weed out aggravators, and then to institute and nurture elements of good health. [SEEDS is an acronym for Sleep, Exercise (and pacing), Environment, Diet (nutrition), and Support.]

Patients who do not have adequate economic resources to achieve the above measures early in the course of their illnesses, and/or cannot access knowledgeable physicians in safe facilities, and/or who are severely chemically sensitive, and/or have co-morbid infections/other conditions are greatly challenged. For such people, it can be risky to their already compromised health to undertake necessary activities such as shopping in a supermarket or consulting with a physician in an unsafe office, and lack of physician awareness can increase the risk of inappropriate treatment and further deterioration.

Duty to Provide Care

- In the 21st century, physicians and other healthcare professionals are frequently consulted by patients suffering with complex conditions such as ES-MCS, who need immediate and ongoing medical assistance. Despite imperfect knowledge of etiology and mechanisms of conditions, and in the absence of definitive laboratory tests, healthcare professionals nevertheless have a responsibility to provide care. Even if there is a dearth of randomized clinical trial evidence for therapies, physicians are duty bound to “Consider first the well-being of the patient” ([Canadian Medical Association. Code of ethics, Update 2004, http://policybase.cma.ca/PolicyPDF/PD04-06.pdf](http://policybase.cma.ca/PolicyPDF/PD04-06.pdf)). They need to listen to patients’ feedback about their observations and pay attention to their own, and then take the time to advise patients using the *available* evidence and their best clinical judgment, so that patients may make informed choices about the lowest risk, highest potential benefit modalities likely to apply to their individual situations. Such a collaborative working relationship avoids abandoning patients to their own devices.

✚ **Patient-centred Trend in Health Care**

- There has been a shift by Canadian healthcare professionals and policymakers towards “patient centredness” in care, which “may be most commonly understood for what it is not- technology centred, doctor centred, hospital centred, disease centred” (Stewart M. Towards a global definition of patient centred care: The patient should be the judge of patient centred care, BMJ, February 24, 2001; 322, 444-5; Stewart M, Brown JB, Weston WW, McWhinney IR, McWilliam CL, Freeman TR. Patient-centred medicine: Transforming the clinical method, 2nd Edition, 2003, Radcliffe Medical Press Ltd, U.K.).
- In an observational cohort study of 315 patients seen by 39 randomly selected family physicians, patient-centred communication/practice was found to improve health status outcome and decrease health care costs by decreasing diagnostic tests and referrals (Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, Jordan J. The impact of patient-centred care on outcomes, The Journal of Family Practice, July 4, 2000, <http://www.jfponline.com/Pages.asp?AID=2601>).
- An observational study of 865 consecutive patients in the offices of three doctors revealed the key components to patients of a patient-centred model of care (**Table 5**) (Little P, Everitt, H, Williamson I, Warner G, Moore M, Gould C, Ferrier K, Payne S. Preferences of patients for patient centred approach to consultation in primary care: observational study, BMJ, 24 February, 2001; 322:1-7).

Table 5:

Key Components of a Patient Centred Model of Care According to Patients

(Little P, Everitt, H, Williamson I, Warner G, Moore M, Gould C, Ferrier K, Payne S. Preferences of patients for patient centred approach to consultation in primary care: observational study, BMJ, 24 February, 2001; 322:1-7)

<i>“Main domains of model of patient centredness”</i>
“Exploring the experience of disease and illness: patients' ideas about the problem, feelings, expectations for the visit, and effects on function
Understanding the whole person: personal and developmental issues (for example, feeling emotionally understood) and the context (the family and how life has been affected)
Finding common ground (partnership): problems, priorities, goals of treatment, and roles of doctor and patient
Health promotion: health enhancement, risk reduction, early detection of disease
Enhancing the doctor-patient relationship: sharing power, the caring and healing relationship”

- However, as Ball has pointed out, “Politics and power drive the system and the fact is: consumers have no power” (Ball T. Disruptive innovation: Patient/family-focused care, Managing Change, Summer 2010:1-16). He cited Glover: “the principle of individuality creates an interesting problem: a patient-centred system must be inclusive enough to support 34 million personalized health systems that are unique to each Canadian and ultimately managed by him or her”. Glover and the Canadian Association for People-centred Health envision that patients

should be able to select and access the most appropriate providers/coaches and support services they need, and that they are collectively willing to pay for in the Canadian health care system (Glover V. *Journey to wellness: Designing a people-centred health system*; available at www.caph.ca).

- For ES-MCS sufferers the ideal of ‘patient-centred care’ is currently in stark contrast to realities within the health care system. Knowledgeable healthcare professionals and support workers are so few as to be virtually inaccessible most of the time. For moderately or severely chemically sensitive persons, physicians’ offices, clinics and hospitals commonly are unsafe places to wait, consult, or undergo procedures because patients can be exposed to many symptom triggers emitted from furnishings, cleaning and laundry products, disinfectants, and personal care products on staff or other patients, making their conditions worse. Fragrance/scent-free hospital, home care and rehabilitation services are very rarely available, and there are no chemically safe emergency shelters. Consequently, patients with severe chemical sensitivities may avoid seeking care, risking further deterioration and chronicity, thereby being “caught between a rock and a hard place.”
- In this time of health professional shortages and increasing demand by an aging population, it is also difficult to get knowledgeable ongoing medical or surgical care for complex multi-system health problems such as ES-MCS, and patients may still be disbelieved and ignored. The results include poor health outcomes and higher health care costs, both for the patient and for the health care system.
- In addition to aspiring towards truly person-centred individual care, the Environmental Health Clinic team consults with consumer representatives from patient support groups on EHC programs. These representatives attend several EHC staff meetings each year, keep the leaders of relevant support groups informed, and consult them for their opinions on environmental health service issues. The EHC team is constantly hearing from the consumer support organizations how Ontarians with ES-MCS are underserved, and how their ongoing care physicians from across the province find it extremely challenging and time-consuming to address the needs of the population of patients with ES-MCS in their own communities. Clearly, with the current level of funding and staffing, the support that the Ontario EHC team has been able to offer to Ontarians with ES-MCS is inadequate.

Empirical Evidence-informed Approaches

- The team at the provincial Environmental Health Clinic in Ontario believes, as does the staff at the Nova Scotia Environmental Health Centre (NSEHC), “that there is no need to wait for a full understanding of the pathophysiology of these conditions before we should manage them” (Fox RA, Joffres MR, Sampalli T, Casey J. *The impact of a multidisciplinary, holistic approach to management of patients diagnosed with multiple chemical sensitivity on health care utilization costs: An observational study*, *The Journal of Alternative and Complementary Medicine*, 2007; 13(2):223-9). Both clinics assess potential biological, physical environmental, nutritional, psychosocial, and other potential contributors to illness for each patient, and, whenever possible, assist the individual to self manage these factors with their primary care physician's medical support. Our clinical impression, consistent with that of other clinicians, is that generally the earlier actions are taken to address illness factors, the faster and more satisfactory the recovery- and thus the lower the utilization of the health care system.
- In Gibson et al’s study, subjects commented that it was only the combination of treatments that helped them improve. Many reported that it was necessary to do environmental controls, a

correctly tailored program of nutritional supplements, and a number of other interventions that addressed their own unique constellation of symptoms” (Gibson PR, Elms AN-M, Ruding LA. [Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environmental Health Perspectives, September 2003; 111\(12\):1503](#)).

- Such a multi-faceted, individualized approach to care of heterogeneous ES-MCS patients is not conducive to group randomized controlled trials, and so no specific treatment protocol has been assessed by that method.
- Just as ES-MCS patients have been disparaged, so have the practising physicians who first observed and reported ES-MCS, hypothesized pathological mechanisms, and clinically explored what they thought were rational therapeutic responses ([Swoboda DA. Negotiating the diagnostic uncertainty of contested illnesses: physician practices and paradigms, Health \(London\), October, 2008; 12\(4\):453-78](#)). Nevertheless, many of their ideas, including reduction of exposure to triggers and toxins, have stood the test of time. Physicians from family medicine and many medical specialties are now recognizing the importance of environment-health links and information about exposure reduction is being made available to the public (<http://www.newswire.ca/en/releases/archive/March2007/01/c4421.html>; Canadian Liver Foundation, Liver health begins at home; The Lung Association, http://www.lung.ca/protect-protegez/pollution-pollution/indoor-interieur/index_e.php; Reuben SH for the President’s Cancer Panel. Reducing environmental cancer risk- What we can do now. U.S. Department of Health and Human Services, April 2010; http://deainfo.nci.nih.gov/advisory/pcp/annualReports/pcp08-09rpt/PCP_Report_08-09_508.pdf).
- The cornerstones in clinical management of ES-MCS are:
 - reduction of exposure to each person’s unique environmental symptom triggers (e.g. some perfumes, cat dander) and toxins (e.g. formaldehyde emitted from particleboard, pesticides), once identified via exposure history and observation,
 - enhancement of internal processing and elimination of chemicals,
 - reduction in body burden of retained chemicals if necessary,
 - relief of suffering with symptomatic treatments as needed,
 - treatment of co-morbid conditions that can exacerbate or be exacerbated by ES-MCS, and
 - encouragement to make changes in habits that would be likely to prevent further illness and promote health.
- Unlike the provincial EHC in Ontario, the NSEHC provides ongoing treatment, and there is now evidence of reduced healthcare utilization by NSEHC patients after treatment, resulting in significant health care system savings from reduced physician visits both to general practitioners and specialists, as well as reduced emergency room visits and hospital admissions ([Fox RA, Joffres MR, Sampalli T, Casey J. The impact of a multidisciplinary, holistic approach to management of patients diagnosed with multiple chemical sensitivity on health care utilization costs: An observational study, The Journal of Alternative and Complementary Medicine, 2007; 13\(2\):223-9](#)).

Reduction of Exposure to Triggers and Toxins

- By definition, people with MCS have symptoms that “are reproducible with [repeated chemical] exposure” and that “improve or resolve when the incitants are removed” ([Bartha et al. Multiple Chemical Sensitivity: a 1999 consensus. Archives of](#)

[Environmental Health, May/June 1999; 54\(3\): 147-9](#)). Most patients who have noted a few such links between their symptoms and exposure to environmental triggers have already avoided them as best they can by the time they come to medical care, with some improvement in acute, intermittent symptoms. However, they may have chronic symptoms and may not have noticed the symptom-exposure links of substances to which they are exposed very frequently, which may be “masked” due to quasi-persistence in the body. It takes time and expertise for physicians to identify the most likely problematic chemicals via a detailed exposure history and observation, to educate patients about where these chemicals are likely to be encountered, and then how to avoid them or reduce exposures, for example by using less-toxic and/or better-tolerated substitutes.

- Since many of the same triggering agents (e.g. pesticides, paints, and perfumes) are repeatedly reported by those with MCS, it often helps to assist patients to focus on reducing their exposure to these substances as well as to their own unique symptom triggers as a precautionary measure if there is no undue hardship. Gibson et al’s finding of MCS sufferers’ almost universal use and the helpfulness of “chemical avoidance” and “chemical-free living space” is not surprising. Gibson et al also noted that these therapies are “fairly non-invasive and low risk”, as respectively these two strategies were rated to be 119 and 155 times more likely to be helpful than harmful. ([Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environmental Health Perspectives, September 2003; 111\(12\):1498-1504](#)).

- Avoidance strategies have also been reported to be helpful for those with MCS by many other authors (e.g. [Ziem G. Multiple chemical sensitivity: Treatment and follow up with avoidance and control of chemical exposures, Toxicol Ind Health July 1, 1992; 8\(4\):73-86](#); [Lax, M., Henneberger, P. Patients with Multiple Chemical Sensitivities in an Occupational Health Clinic: Presentation and Follow-up, Archives of Environmental Health, 1995; 50\(6\):425-31](#)); [Ashford NA, Miller CS. Chemical exposures, low levels and high stakes, 2nd Edition, John Wiley & Sons Inc., 1998](#); [Canada Mortgage and Housing Corporation. Research House for the environmentally sensitive, 1994, reprinted 1995, 1998, 2002, Cat. No. NH15-90/1994E](#); [Caress S.M., Steinemann A.C. Prevalence of fragrance sensitivity in the American population. Journal of Environmental Health , 2009; 71\(7\): 46-50](#); [National Defence and the Canadian Forces. Environmental sensitivities, Safety Digest, Edition 6/2010, reproduced from the Safety, Emergency and Security Management Division of Treasury Board](#)).

- Sadly, treatment of severely ill patients is often less successful than of those identified in primary care and treated early, when often simple modifications such as avoiding pesticide applications and using low VOC (volatile organic compound) paints and unscented cleaning, laundry and personal care products, possibly with minor dietary changes, are enough to return the person to health. They may still experience symptoms when they encounter such substances elsewhere, but if they can keep away from them in their daily diet, home and work environments, the symptoms triggered elsewhere generally become much milder and shorter lasting. However, avoiding many symptom-triggering exposures in air, food, water, and consumer products is not easy, and much less so if the sufferer has limited financial means ([Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environmental Health Perspectives, September 2003; 111\(12\):1503](#)).

- If people with ES-MCS are not successful in achieving accommodation in the workplace, it can directly impact their income-earning capacity and financial resources. Gibson et al found that the mean annual personal income for their sample of 917 people was \$20,000. 286 (31%) of the 917 had made a worker's compensation claim, 115 had been compensated and 54 were awaiting resolution. Only 211 (23%) were employed outside the home (Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, *Environmental Health Perspectives*, September 2003; 111(12):1499).
- Finding or creating a safe living space, although medically desirable (Canada Mortgage and Housing Corporation. *Research house for the environmentally hypersensitive*, 1994, reprinted 1995, 1998, 2002, and *Building materials for the environmentally hypersensitive* 61089, 1995, revised 2005, www.cmhc-schl.gc.ca/; <http://journals.lww.com/jphmp/toc/2010/09001#-1750774083>, *J of Public Health Management and Practice*, September/October 2010 16 (E-Supplement 5): S1-S93) can be very challenging and can lead to considerable expenditures and possibly the need for stopgap measures. For example, in a 1996 survey, Gibson et al found that 66% of their sample of 305 people with MCS had lived in what they described as "unusual conditions", such as in their vehicles, on porches, or in tents at some time during their illness (Gibson PR, Cleavers J, Warren ML. Multiple chemical sensitivity/environmental illness and life disruption, *Women Ther*, 1996; 19:63-79). In the Canadian climate, such temporary measures are only tenable in mild weather.
- While relatively modest changes at home such as substituting non-fragranced cleaning, laundry and personal care products, de-cluttering, and removing carpets may make significant differences for many of those with ES-MCS, for others, making a truly safe home can involve remodelling/building anew with tolerated building materials or extensive mould remediation. Gibson et al. found that respondents in their 2003 survey had spent a mean of US \$57,000 on such expenses from the onset of their illnesses (Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, *Environmental Health Perspectives*, September 2003; 111(12):1499).
- Homelessness is an extreme, sometimes life-threatening hardship for any person, but especially for someone who is ill. Ontario has no sufficiently environmentally safe emergency shelters, where a person with moderate to severe ES-MCS can get away from acute chemical exposures quickly enough and stay long enough to recover from them in order to avoid health deterioration. The necessary environmental accommodations are not available in the usual continuum of government-supported care and shelter for Ontarians, from urgent to acute to ongoing to assisted living to long term care. Sufficiently environmentally-safe government-supported housing for those with moderate to severe ES-MCS is also as yet virtually unavailable.
- With only a handful of Ontario ES-MCS-knowledgeable physicians, urgent care treatments that have rationales and a long history of empirical benefit, such as intravenous nutrient repletion (Rea W.J. *Chemical sensitivity*, Volume 4, Lewis Publishers, 1997:2438, 2653-66) and oxygen therapy (Rea WJ. *Chemical sensitivity*, Volume 4, CRC Lewis Publishers, 1997:2554-63), are generally not obtainable from hospital emergency rooms.

✚ **Enhancing Internal Processing and Elimination of Chemicals**

- It will never be possible to eliminate all hazardous substances in communities, homes and workplaces. Hence, it is important to take steps to help MCS patients to metabolize and excrete the chemicals they inadvertently absorb, whenever possible.
- Poverty impacts on the ability of the body's defence systems to defend, both directly through increased exposure to environmental chemical and biological hazards, and indirectly through overloading and overwhelming of protective mechanisms. Both direct and indirect impacts can take effect for those with or susceptible to MCS over a prolonged period in poor housing, more so if they do not have access to protective devices such as air and water filters.
- Besides a highly nutritious, preferably organic, diet, which may be difficult and expensive to maintain, if there are many food intolerances, nutritional supplements are often required by sensitive people in order to be able to metabolize and eliminate toxic chemicals to which they are unavoidably exposed ([Burford-Mason A. Nutrition for Docs: Using nutritional supplements in clinical practice, a practical, evidence-based approach, Dalla Lana School of Public Health, University of Toronto, Syllabus, April 17-18, 2010](#)).
- Tolerated targeted supplements may be cost prohibitive, but if patients do not have adequate nutrition, they may accumulate more and more body burden of hazardous substances and become so overloaded that encountering even minute quantities of avoided chemical triggers will initiate severe symptoms which can be debilitating and last for days or longer. In such circumstances, their symptoms often spread to other body systems and the number of triggering substances expands as well. If they are being continually exposed to triggering agents, they may have chronic "masked" symptoms that affect their ability to function and to defend against infectious organisms ([Miller CS. The compelling anomaly of chemical intolerance, Annals of the New York Academy of Sciences, 2001; 933:1-23](#)).
- A high fibre diet is also a well-accepted and common sense method to enhance bowel transit function and elimination of toxins ([Mayo Clinic Staff. Dietary fiber: Essential for a healthy diet, <http://www.mayoclinic.com/health/fiber/NU00033>, updated July 8, 2010; accessed August 17, 2010](#)).
- Since thyroid and other hormonal functioning can be disrupted by many commonly encountered environmental chemicals, sometimes at exceedingly low levels ([Diamanti-Kandarakis E et al \(2009\) Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. *Endocrine Reviews* 30\(4\):293-342](#)), vigilance for deficiencies or imbalances and swift correction with the tolerated medication and dosage is important.
- As noted in the Canadian Community Health Survey 2005 (**Table 4**), there is a strong overlap of MCS and gastrointestinal disorders. Gut inflammation could be related to direct effects on the gut mucosa from ingestion of toxic substances, or altered immune resistance to pathological organisms. "Probiotic therapies have attempted to modify disease expression by favourably altering bacterial composition, immune status and inflammation" ([Tamboli CP, Neut C., Desreumaux P, Colombel JF. Dysbiosis in irritable bowel disorder, *Gut*, January 2004; 53\(1\):1-4; Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC. A randomized, double-blind, placebo-](#)

controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome, *Gut Pathogens* 2009, 1:6, Biomed Central). The Dallas Environmental Health Center has long found that intravenous nutrient repletion has been useful in bypassing inflamed GI tracts with impaired nutrient absorption (Rea W.J. *Chemical sensitivity*, Volume 4, Lewis Publishers, 1997:2438, 2594, 2653-66).

Decreasing Body Burden

- If avoidance of symptom triggers and toxics reduction, along with described enhancement of metabolism and elimination of chemicals are insufficient to provide relief, and there are retained substances that may be prolonging a patient's illness, it is important to assess what could be done to decrease that body burden- e.g. by removing mercury amalgam fillings (Health Canada. The safety of dental amalgam fillings, 1996; http://www.hc-sc.gc.ca/dhp-mpps/md-im/applic-demande/pubs/dent_amalgam-eng.php#a11; Haley B. A study on the release of mercury from dental amalgams..., May, 2007, http://iaomt.org/articles/category_view.asp?intReleaseID=278&month=7&year=2007&catid=36), following a careful protocol (International Academy of Oral Medicine and Toxicology. Safe removal of amalgam fillings, <http://www.iaomt.org/articles/files/files288/Safe%20Removal%20of%20Amalgam%20Fillings.pdf>).
- Some medical specialists are trained in the appropriate application of a careful protocol for chelation of retained heavy metals (Genuis SJ. Elimination of persistent toxicants from the human body, *Hum Exp Toxicol OnlineFirst*, April 16, 2010, doi:10.1177/0960327110368417).
- Increased excretion of some persistent compounds via sweat has been reported using a combination of exercise and sauna while maintaining optimal metabolism and elimination (Rea WJ, Pan Y, Johnson AR, Ross GH, Suyama H, Fenyves EJ. Reduction of chemical sensitivity by means of heat depuration, physical therapy and nutritional supplementation in a controlled environment, *Journal of Nutritional and Environmental Medicine*, 1996; 7:141-8; Dahlgren J, Cecchini M, Takhar H, Paepke O. Persistent organic pollutants in 9/11 world trade center rescue workers: reduction following detoxification, *Chemosphere*, 2007; 69:1320-5; Genuis SJ. Elimination of persistent toxicants from the human body, *Hum Exp Toxicol OnlineFirst*, April 16, 2010, doi: 10.1177/0960327110368417).
- Very recently, clearance of persistent, bioaccumulated perfluorinated compounds via stool has been reported using a bile acid sequestrant cholestyramine, and, although further trials are needed, thus far the method appears to be safe and effective (Genuis SJ, Birkholz D, Ralitsch M, Thibault N. Human detoxification of perfluorinated compounds, *Public Health* 2010;124:367-75; Genuis SJ. Human detoxification of perfluorinated compounds, *Syllabus*, 45th Annual Scientific Assembly, American Academy of Environmental Medicine, 21 October, 2010, La Jolla, CA).

Symptomatic Treatment and Desensitization

- As noted previously, there is a strong overlap of allergies with ES-MCS. Symptomatic treatment with antihistamines, decongestants or analgesics may be tried, usually starting at one quarter to one half the usual dose to assess tolerance. However, medications are often poorly tolerated, and standard dose desensitization with escalation may exacerbate allergy symptoms. Individually formulated desensitization with only needed antigens included in the formula, at the level of sensitivity to that antigen for that patient, with gentle or no

escalation, has repeatedly been reported to be helpful for those with ES-MCS at American Council of Continuing Medical Education-accredited conferences of the American Academy of Environmental Medicine (www.aaemonline.org).

Oxygen

- Baseline and post-chemical challenge brain perfusion decreases have been noted in MCS patients vs controls on single photon emission computed tomography (SPECT) brain scans (Orriols R, Costa R, Cuberas G, Jacas C, Castell J, Sunyer J. Brain dysfunction in multiple chemical sensitivity, *Journal of the Neurological Sciences*, 2009; 287:72-8). This may be why oxygen helps to relieve acute reactions (Rea WJ. *Chemical sensitivity, Volume 4, CRC Lewis Publishers*, 1997:2554-63). Empirically, Rea has also noted that severely ill chemically sensitive patients sometimes respond well to daily oxygen inhaled for two hours over an average of eighteen days. A hypothesized mechanism is that oxygen supplementation enables a microcirculation switch to allow better blood flow, more extraction of oxygen to the tissues and normalization of pH. (von Ardenne M. *Oxygen multistep therapy: Physiological and Technical Foundations*. Trans. Kirby P, Kruger W. New York: Georg Thieme Verlag Stuttgart, 1990: 1-73).

Randomized Controlled Trials of Therapies

- While randomized controlled trials (RCTs) are extremely useful for deciding on the efficacy of a specific treatment such as a medication in comparison with other treatments or placebo, treatments such as desensitization for those with ES-MCS and severe allergies are individualized with respect to antigens, doses and timing, and so are not amenable to group RCTs. Two systematic reviews by the Succinct and Timely Evaluated Evidence Reviews (STEER) group in 2001 and 2003 noted this limitation. STEER was mounted to assist funding decisions in the National Health Service in the United Kingdom.
- In group RCTs, there must be strict subject inclusion and exclusion criteria to reduce the 'noise' of other variables in assessing treatment outcomes. The population of potential ES-MCS subjects is extremely heterogeneous, and so, even if sufficient subjects could be found to meet eligibility criteria, the results would be unlikely to be generalizable to individual patients presenting to their physicians. Outcomes may be heterogeneous and difficult or impossible to quantify.
- We are familiar with the method of critically appraising scientific papers called Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method (Guyatt GH et al, *GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ* 2008; 336: 924-926) as two of us, along with other members of the Environmental Health Committee of the Ontario College of Family Physicians, met with Dr. Gordon Guyatt last year about the possibilities of implementing the method in literature reviews in environmental health. As already discussed, environmental health is an extremely complex area to study.
- Single subject (N-of-1) longitudinal treatment trials with extreme limitation of extraneous exposures in an environmental control unit have been suggested (Spencer TR, Schur PM. *The challenge of multiple chemical sensitivity, Journal of Environmental health*, June 2008; 70(10):24-7), and were successful in relieving symptoms, but with the disadvantage of extreme cost (Ross GH. *History and clinical presentation of the chemically sensitive patient. Toxicol. Ind. Health.* 1992; 8, 21-28).

- In theory, N-of-1 randomized controlled, double blind crossover trials of therapies, although cumbersome, might provide a level of evidence similar to group RCTs and have been tried with a university-based referral service doing N-of-1 trials at the requests of community and academic physicians ([Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: clinical usefulness, our three-year experience, *Annals of Internal Medicine*, February 15, 1990; 112\(4\):293-99.](#) However, their utility was questioned ([Tsapas A, Matthews DR. Using N-of-1 trials in evidence-based clinical practice, *JAMA*, March 11, 2009; 301\(10\),](#) and Montori and Guyatt replied that the method worked best in individuals with a stable condition seeking symptom relief, and that the effect of the intervention should be short-lived ([Montori VM, Guyatt GH. Reply, *JAMA*, March 11, 2009; 301\(10\).](#) Unfortunately, this method may not be applicable to individuals with ES-MCS, given that their condition is chronic and very unstable depending on their daily exposures, and improvement would need to be evaluated over a longer period.

Self-management Strategies

- In addition to reduction of exposure to triggering or toxic agents, individuals with MCS, as with other chronic illnesses, try many therapies to relieve symptoms and to improve quality of life. In the Gibson et al survey, a very wide range of therapies had been tried by a variable number of subjects for variable lengths of time. The therapies tried were perhaps attempts to address various determinants of health, for example nutritional/dietary interventions, physical therapies, medical interventions (e.g. oxygen therapy), psychosocial support therapies, and contemplative therapies. For example, our team has found, as did Gibson et al, that prayer, meditation and other contemplative methods, chosen according to each patient's needs and preferences, are frequently somewhat helpful, often in combination with other therapies listed. They are hypothesized to both dampen the overstimulation of the sympathetic nervous system related to the body's repeated recognition and response to symptom-initiating exposures in MCS, and to assist with coping ([Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, *Environmental Health Perspectives*, September 2003; 111\(12\):1498-1504.](#)
- In attempting to enhance the doctor-patient relationship and to encourage self management, we at the Environmental Health Clinic (EHC) in Ontario have sometimes used a slightly whimsical metaphor, asking patients what they think might be needed in their particular situation to "plant a health garden", so that we could enjoy watching their health slowly grow. Tongue in cheek, we have noted that weeding, seeding and feeding is usually needed to grow a garden, and have asked what unnecessary aggravators they might 'weed' out of their lives, ask them to work with us on the individual components of planting SEEDS of health, and then 'feed' whatever helps. SEEDS is an acronym for Sleep, Exercise (and pacing), Environment, Diet (nutrition), and Support, and provides a framework for self-management that patients seem to find easy to follow. The application of this framework is described in a requested article based on a presentation to physicians at "Saturday at the University" at the University of Toronto ([Marshall LM, Bested AC, Bray RI. Tools to treat Multiple Chemical Sensitivities, Chronic Fatigue Syndrome and Fibromyalgia, *Canadian Journal of CME*, University of Toronto Edition, January, 2004: 56-65\).](#)
- An EHC physician is the primary author of a book with many self-management ideas ([Bested AC, Logan AC, Howe R. Hope and help for chronic fatigue syndrome and fibromyalgia, 2nd Edition, 2008, Cumberland House, Nashville, Tennessee.](#)

- The EHC nurse provides a set of printed resources as well as individualized verbal and written information and web links as appropriate to each patient, and is available to answer questions by telephone. Under her tutelage, University of Toronto nursing students research the literature and develop easily understood posters and pamphlets.
- Das-Munshi et al suggested that “A multifactorial model incorporating behavioural, physiological and sociological approaches may be useful”, but focused on psychological, behavioural and conditioning factors and only suggested treatment in these areas, sometimes in combination with antidepressants ([Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: review, Current Opinion in Otolaryngology & Head and Neck Surgery, 2007; 15:277](#)). The evidence of effectiveness cited by the authors, two psychologists and a psychiatrist, seemed to be largely based on single case reports or small case series. The authors also did not mention that antidepressants were found more likely to harm than help in the Gibson et al survey ([Gibson PR, Elms AN-M, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environmental Health Perspectives, September 2003; 111\(12\):1502](#)).
- The experience of the EHC team and other clinicians in Ontario and the U.S. has been in agreement with Gibson et al’s finding that individuals with MCS often tolerate medications poorly. If prescribed, they commonly require much lower doses than usual, possibly because their capacity to metabolize drugs is compromised. Thus pharmaceuticals in MCS not only may not suppress symptoms, but also may exacerbate them. If symptoms are relieved, the underlying etiology may be obscured. Also, following avoidance of triggering agents, the symptoms in various body systems, including the central nervous system (e.g. emotional and cognitive symptoms), may improve significantly without need for medication.
- In response to a clinic needs assessment, EHC offered group classes to inform EHC patients about indoor air quality, nutrition, exercise and pacing, and the adverse impact of negative thinking on progress.
- In addition, from 1999-2005 (until resources ran out), a psychologist and an EHC physician ran an annual 10-week group psycho-educational program for EHC patients for 2 hours weekly, along with a 1 year follow-up group session for consolidation and evaluation, and a parallel individual counselling program. The program was conducted in a fragrance free environment, stretching and moving around as needed were encouraged, and a “smorgasbord” of strategies was used to meet needs while recognizing fluctuating neurocognitive deficits. The strategies included use of film clips to bridge sensation, affect and cognition, meditative inductions for grounding, relaxation, and symptom relief, education about the General Adaptation Syndrome ([Selye H. The Stress of life, New York: McGraw-Hill, 1956](#)), dealing with stressful situations, creating boundaries, and strengthening the ego, as well as locating new life purpose. Qualitative evaluations one year after completion of each group program repeatedly revealed surprisingly strong and unique uptakes and applications of various features of the program.
- Telemedicine, recently being piloted in the EHC, offers a tantalizing opportunity to serve more Ontarians with complex, chronic conditions with individual clinical consultations

and group programs close to home, as well as with educational programs for patients and health professionals.

Primary Prevention:

Dr. Herbert Needleman, Professor of Psychiatry and Pediatrics at the University of Pittsburgh suggested “We are conducting a vast toxicological experiment in which our children and our children’s children are the experimental subjects” ([Quoted by Dr. Philip Landrigan, Mount Sinai School of Medicine, keynote address to Children’s Environmental Health II: A Global Forum for Action, Washington, DC, September, 2001, CPCHE Primer, August 2005:5](#)). Protective policies have been successfully implemented in the face of some remaining scientific uncertainties in the case of tobacco smoke and pesticides. Reduction of exhaust fumes from vehicle idling, decreased exposure to smoke in public places, and the banning of the use of pesticides for cosmetic purposes have reduced exposure to these harmful substances for the entire population, and have been particularly helpful for the chemically sensitive.

Health Promotion and Partnerships

- Although we at the Environmental Health Clinic work at the individual clinical level through comprehensive assessments and development of individualized treatment plans, we also work, often as volunteers, towards preventing or minimizing environment-associated illnesses at the population level through collaboration with universities, associations, and coalitions of like-minded, multi-sector organizations in research, education and promotion of policy changes. There has been growing public awareness of the impacts of various environmental exposures on health, aided in part by increased media attention and the explosion of information available on the internet. Since internet information is not always trustworthy, more and more patients are asking their most trusted health advisors, their physicians and other healthcare professionals, what actions they should be taking to protect themselves and their families ([Hesse BW, Nelson DE, Kreps GL, Croyle RT, Arora NK, Rimer BK, Viswanath K. Trust and sources of health information, Archives of Internal Medicine, December 12/26 2005; 165:2618-24](#)). This may be particularly so if patients have noticed associations between their symptoms and exposures to environmental substances or locations, or if their symptoms are ongoing and unexplained.
- We think the physicians of tomorrow will need to be very conversant with the latest credible environmental health information. We teach/train a small number of medical and environmental studies students, nurses, residents and graduate physicians in collaboration with the Departments of Family and Community Medicine and Continuing Education and Professional Development at the University of Toronto. As long as clinic resources would permit, we also maintained a series of six annual accredited rounds and a one-year academic Environmental Health Fellowship Program. We also lecture to medical students at the University of Ottawa, University of Western Ontario, Northern Ontario School of Medicine, and to Master of Public Health students at Lakehead University.
- The Environmental Health Clinic Staff Physicians, Nurse Educator, and Community Outreach Coordinator have served on international, national, provincial and local committees and panels to try to influence precautionary, protective policy development- for example, on an international Expert Medical Consensus Panel on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome selected by Health Canada; on Health Canada Committees and in Workshops on Children’s Environmental Health and Impacts of the Environment on Older Adults; on the Canada Mortgage and Housing

Corporation's Task Force on Material Emissions; on the Ontario Ministry of the Environment's Toxics Reduction Scientific Expert Panel; on the Ontario Accessible Built Environment Standards Development Committee; and on the Occupational and Environmental Working Group of the Toronto Cancer Prevention Coalition.

- We have also participated in many reviews of scientific studies, synthesis of the evidence, and translation into papers, reports, primers, brochures, websites, case studies, teaching modules, and presentations for a variety of target groups locally, provincially, nationally, and internationally, in partnership with many different organizations.
- Some of our productive partnerships in environmental health promotion are listed in **Table 6** with websites for more information, and brief descriptions of projects we have, or are collaborating on with the listed organizations.

Table 6:

Examples of Environmental Health Promotion via Partnerships

Staff Physicians, Nurse Educator, and Community Outreach Coordinator of the
provincial Environmental Health Clinic, Ontario, at Women's College Hospital

Canadian Coalition for Green Health Care (www.greenhealthcare.ca)- on an Ontario Trillium Foundation (OTF)-funded project on toxics reduction in health care facilities, fragrance free program/policy development, local food use in hospitals, + active problem solving via listserv.
Canadian Environmental Law Association (www.cela.ca) and the Environmental Health Institute of Canada (www.ehicanada.ca)- on an Ontario Law Foundation-funded project "Making the Links" between pollution, chronic health effects and poverty in six Ontario communities, selected for high prevalence of these and interest in addressing them.
Canadians for a Safe Learning Environment (www.casle.ca)- on "Guidelines to Accommodate Students and Staff with Environmental Sensitivities"
Canadian Institute of Child Health (www.cich.ca)- on Physician Master Training Program to train physicians to adapt World Health Organization modules on Children's Health and the Environment to their communities and to present them in day-long workshops. Five workshops were presented across Ontario in 2009, funded by the Ontario Ministry of the Environment.
Canadian Institutes of Health Research -funded "Toxic metals in Canadians and their environments- Exposures, health effects and physical and public health management standards: A scoping review"- Co-principal investigators Drs. Margaret Sears and Riina Bray; acknowledged consultants Drs. John Molot and Lynn Marshall.
Canadian Partnership for Children's Health and the Environment (CPCHE) www.healthyenvironmentforkids.ca - 12 health, public health, environmental, and child care partner organizations that have worked together on multiple projects since 2001- e.g. collection of training materials and resources, fact sheets and flyers posted on website in English and French including Child Health and Environment: A Primer , and the CPCHE brochure Playing it Safe: Childproofing for Environmental Health , 2005; Playing It Safe: Service Providers Strategies to Reduce Environmental Risks to Preconception, Prenatal and Child Health , 2006; National Policy Consultation in 2007; First Steps in Lifelong Health: A Vision and Strategy for Children's Environmental Health in Canada , 2008; a multi-year "Engage, Enable and Empower (E3)" project, funded by the Public Health Agency of Canada (PHAC) to create local community champions, completed in 2009; Advancing Environmental Health in Child Care Settings: A Checklist for Child Care Practitioners and Public Health

Inspectors, funded by the Ontario Trillium Foundation and Health Canada, 2010. CPCHE and Ontario Chronic Disease Prevention Alliance (www.ocdpa.on.ca)- together on an Ontario Trillium Foundation (OTF)-funded project studying early life exposures and the risk of chronic disease- held day-long evidence/policy workshop on bisphenol A in May, 2010.
Canadian Transportation Agency-on a commissioned report “Air travel and chemical sensitivities”, co-authors Drs. John Molot, Lynn Marshall and Margaret Sears.
Centre for Equality Rights in Accommodation (www.equalityrights.org/cera)- on an OTF-funded “Creating Healthy Housing” project to address the needs of the chemically sensitive.
Community Care Access Centres Ontario- on interactive presentations and resources to improve accessible home care for those with MCS.
Environmental Health Association of Nova Scotia (www.environmentalhealth.ca)- e-mail contact and use of guide to less toxic cleaning, laundry, and personal care products, www.lessstoxicguide.ca.
Environmental Health Association of Ontario (www.ehaontario.ca) provides representative consumer advisors to the Ontario Environmental Health Clinic on an ongoing basis.
Environmental Health Association of Quebec (www.aseq-ehaq.ca)- on simultaneously translated workshops on Children’s Health and the Environment and Complex Chronic Conditions ME/CFS, FM and MCS at Annual Scientific Assembly, November 2009, which had an Environmental Health theme.
Environmental Health Institute of Canada (www.ehicanada.ca)- on the “Making the Links” project with the Canadian Environmental Law Association, the Ontario Trillium Foundation grant on toxics reduction in health care with the Canadian Coalition for Green Health Care, and on the Environmental Health Day to be held in November, 2010.
Healthy Indoors Partnership (www.healthyindoorspartnership.ca)- on development of multi-stakeholder consensus brochures on “Products and Services with Low Chemical Emissions”.
Myalgic Encephalomyelitis Association of Ontario (MEAO) www.meao.ca- provides ongoing consumer advisory service to the Ontario Environmental Health Clinic; worked with National ME/FM Action Network www.mefmaction.net, and Environmental Health Association Ontario (EHAO) www.ehaontario.ca - on International ME/FM/MCS Day, May 12, 2010.
National ME/FM Action Network www.mefmaction.net- on extracting needed data from the public use microdata files of the Canadian Community Health Survey, Statistics Canada.
Nurses’ Environmental Reference Group, now part of the Canadian Nurses’ Association- a teleconference and listserv started by the Environmental Health Clinic nurse after publication of an article in Canadian Nurse (Fraser G. Environmental Health and Nursing, Canadian Nurse, 16 January, 2004). http://www.cna-aiic.ca/CNA/issues/environment/default_e.aspx
Ontario College of Family Physicians www.ocfp.on.ca → Environmental Health Committee- on many projects e.g. on Children’s Environmental Health, Complex Chronic Conditions, Heavy Metals, Outdoor and Indoor Air quality, Uranium Mining, Urban Sprawl etc. Affiliated with Environmental Health Committees of the College of Family Physicians of Canada and the World Organization of Family Doctors, WONCA.
Toronto Cancer Prevention Coalition www.toronto.ca/health/resources/tcpc - on a GTA Cancer Prevention and Screening Network-funded pilot project to increase awareness of environmental links to breast cancer, and spearheaded the establishment of an Environmental Disclosure and Reporting Bylaw in Toronto: the first “community right to know” bylaw in Canada.
Toronto Public Health and South Riverdale Community Health Centre- on updated resource

for prenatal educators, Hidden Exposures: Informing pregnant women and families about harmful environmental exposures http://www.toronto.ca/health/hphe/pdf/hidden_exposures.pdf .
University of Toronto Medical students' 'Determinants of Community Health 2' - on course projects annually- e.g. in 2009-2010 a student interviewed patients and hospital staff for ideas on updating "Environmental Health in Hospitals: Environment-sensitive Care" guidelines, that are posted as a patient/physician resource on www.mcscanadian.org/hospital.html .
U.S. Environmental Protection Agency -funded study of heat depuration/nutrition treatment in chronically ill, chemically sensitive 9/11 rescue workers is underway- co-investigator Dr. Kathleen Kerr, Environmental Health Clinic physician.
Women's College Hospital Green Team - energy conservation, recycling, and toxics reduction, e.g. mercury in medical devices, safer cleaning products, fragrance free program/policy.
Women's Health Matters www.womenshealthmatters.ca - Environmental Health Centre - information and answers to questions from the public.

APPENDIX C

SEEDS of Health

Complex Chronic Conditions Contributors- Gene-Environment Interactions

Genetic Susceptibilities- Family history- a warning about potential hazards

Environmental Factors- Minimize hazard- maximize function

The Weed, SEEDS, and Feed Approach:

Weed out as many stressors as possible.

Plant **SEEDS** of Health: S leep

E xercise

E nvironment

D iet/Drugs

S upport

Feed whatever works!

SEEDS of Health Examples

S leep- Onset, awakenings, restless legs, apnoea, pain or other symptoms

Sleep hygiene, symptom relief, self hypnosis, melatonin, hypnotics if necessary

E xercise- Balance between conditioning and over-exertion

Recognition of physiological limitations, pacing activities with rest, building

E nvironment- **External**- Air quality- outdoors, indoors

Food- pesticides, additives, colourants, allergies, intolerances

Water- chemical contaminants, microbes

Contactants and consumer products- hazardous chemicals, endocrine disruptors

Minimize (avoid) unnecessary exposures that put extra load on body's defence mechanisms

Internal- Imbalances in operation of any/many body systems from environmental overload (influenced by genetic susceptibilities)→ reduced defences against infections, injuries, chemicals, electromagnetic radiation, stressful events
→ chronic inflammation, oxidative stress within cells→ more malfunctioning

Correct imbalances, along with reducing environmental load

Diet and Drugs- Macro and micronutrients intake, absorption, utilization
Medications- effects and side effects

Ensure adequate nutrition to compensate for increased metabolic need

Support- **External**- Family, friends, health care system respect, health care providers, religious communities, financial, safe housing, social services, activities of daily living

Family/friend/caregiver individual or group educational and support meetings

Health provider case conferences

Advocacy for financial, housing and social service support

Internal- Self support- resilience-sustaining thoughts, activities

Encouragement through individual health professional or religious support and/or groups

Marshall Lynn, Bsted Alison- used with permission of authors